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Abstract 
The proper regulation of gene expression is crucial for cell-fate and lineage 
determination of hematopoietic stem cells (HSCs). Dysregulated expression of genes that 
drive haematopoietic differentiation can cause blood disorders, including leukaemia. 
Connecting hematopoietic genes with their regulatory elements is central to correct gene 
regulation, and is orchestrated by chromatin modifiers, including the genome organising 
protein complex, cohesin. 
The developmental transcription factor RUNX1/AML1 is a well-known 
leukaemia-associated gene. Runx1 is an important regulator of haematopoiesis in 
vertebrates; it is crucial for early myeloid differentiation, and plays a vital role in adult 
blood development. Genetic disruptions to the RUNX1 gene are frequently associated 
with Acute Myeloid Leukaemia (AML). 
Despite the well-established role of RUNX1 in haematopoiesis and disease 
contribution, the cis-regulatory mechanisms that modulate RUNX1 require further 
elucidation. Gene regulatory elements, such as enhancers, located in non-coding DNA 
are likely to be important for Runx1 transcription. 
My PhD studies provided insight into mouse Runx1 enhancer functions and 
highlighted the features of conserved human enhancers. I also used circular chromosome 
conformation capture sequencing (4C-seq) to identify DNA interactions with the 
previously identified +24 RUNX1 enhancer, which is essential for HSC expression of 
RUNX1. Using cohesin-deficient K562 leukaemia cells, my work shows that cohesin is 
required for the +24 enhancer (also known as eR1) to anchor an insulated neighbourhood 
that shields RUNX1 from outside influences. Striking results from this work show that 
the +24 Runx1 enhancer is a significant cohesin-dependent organiser of Chromosome 21 
during megakaryocyte differentiation. 
iii 
In summary, my PhD studies identified a bouquet of enhancer-anchored 
connections that regulate RUNX1 transcription in leukaemia cells at steady state and 
during differentiation, and explain why cohesin loss dysregulates the expression of this 
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1 Chapter 1: Introduction  
1.1 Haematopoiesis  
Haematopoiesis is the formation, development and differentiation of all the blood 
cellular components, and is fundamentally conserved throughout vertebrate evolution 
(Davidson et al., 2004). Haematopoietic stem cells (HSCs) are the source of all blood cells that 
are required throughout the lifetime of an organism. HSCs are capable of self-renewal and 
differentiation into progenitor cells, which generate specialised haematopoietic cell lineages 
(Dobrzycki et al., 2020). Haematopoiesis begins in the early stages of embryo development 
(primitive) and carries on into adulthood (definitive) to maintain a steady supply of 
haematopoietic cells over the lifespan of an organism (Orkin et al., 2008). 
Correct spatiotemporal transcription of haematopoietic genes is essential in the 
initiation of embryonic haematopoiesis, as well as in the maintenance of haematopoiesis in 
adults (Dobrzycki et al., 2020). Combinations of regulatory factors (transcription factors, 
enhancers, mediators, cohesins, insulators, silencers) help coordinate differentiation, 
proliferation, ensure survival of haematopoietic cells, and maintain correct levels of 
haematopoietic gene expression throughout life (Peng et al., 2018). Misexpression of crucial 
haematopoietic genes can lead to failure to produce HSCs, or haematopoietic disorders that can 
lead to leukaemia (Wilson et al., 2011). Therefore, understanding the drivers of normal 
haematopoiesis can provide opportunities for intervention when haematopoiesis is 
dysregulated. 
1.1.1 Primitive and definitive haematopoiesis 
In vertebrate embryos, haematopoiesis occurs in two sequential waves: “primitive” and 
“definitive” (Orkin et al., 2008). Each wave occurs in anatomically distinct locations that vary 
throughout development (Figure 1.1). The initial wave, known as primitive haematopoiesis, 
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specifies endothelial to haematopoietic precursors and takes place in the mammalian yolk sac 
(Figure 1.1A) (Davidson et al., 2004; Dzierzak et al., 1998; Ivanovs et al., 2017; Julien et al., 
2016). The primary function of this wave is the production of red blood cells (erythrocytes), 
which enable tissue oxygenation as the embryo undergoes rapid growth (Orkin et al., 2008). 
The primitive wave is transient and rapidly superseded by the adult-type definitive 
haematopoiesis. Definitive haematopoiesis produces multilineage self-renewing HSCs and 
allows for the life-long production of all blood cells (Ciau-Uitz et al., 2014) (Figure 1.2). HSC 
specification begins in cells from an endothelial precursor, termed the hemogenic endothelium 
(HE) (Figure 1.2) (Bonkhofer et al., 2019; Gritz et al., 2016). Expression of the haematopoietic 
gene Runx1 defines the distinct HE population (Gritz et al., 2016; Kalev-Zylinska et al., 2002). 
These cells appear from HE in the aorta-gonad-mesonephros (AGM) region, then subsequently 
colonise the fetal liver (Figure 1.1B) (Bonkhofer et al., 2019; Gritz et al., 2016). Finally, the 
permanent location for HSCs to seed is in the bone marrow (Figure 1.1C) (Julien et al., 2016; 
Martin et al., 2011). In mammals, initial production of B- and T- lymphocytes occurs in bone 
marrow, and then cells migrate to other sites to complete development (Germain, 2002; Loder 
et al., 1999) (Figure 1.1C).  
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Figure 1.1: Schematic of haematopoiesis cell generation locations during human development.  
A) Primitive haematopoiesis occurs in the yolk sac blood island (blue) 16-17 days post conception (pc). B) 
Definitive haematopoiesis begins first in the Aorta-gonad-mesonephros (purple) 4 weeks pc, then in the foetal 
liver (orange) 5 weeks pc. C) Bone marrow (pink) is the lifelong source of adult definitive haematopoiesis from 
12 weeks pc. The thymus (yellow) is the site of T lymphocyte development, whereas the spleen (brown) 
develops B lymphocytes. Figure is from Thomas (2015). 
 
HSCs are required throughout an organism’s life to replenish precursors of multiple 
lineages, as mature haematopoietic cells are predominantly short lived (Orkin et al., 2008). 
HSCs must self-renew to maintain their own population, as well as produce differentiated blood 
cells. In adult humans (Homo sapiens) and mice (Mus musculus), a limited number of HSCs 
reside in the bone marrow and commence the cascade of cell differentiation (Albacker et al., 
2009). HSCs are at the root of progenitor cells which gradually produce mature haematopoietic 
cells; this haematopoietic model is described as a multi-step process with cells becoming more 
lineage-specific at each step (Figure 1.2). In this model, self-renewing HSCs, at the top give 
rise to common progenitors/stem cells for the myeloid and lymphoid lineages. Following this 
first step in lineage-restriction, myeloid stem cells give rise to proerythroblasts, 
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megakaryoblasts, myeloblasts and monoblasts; lymphoid stem cells, on the other hand, give 
rise to B- and T- lymphocytes and large granular lymphocytes (Orkin et al., 2008). 
Proerythroblasts differentiate into erythrocytes, these cells contain haemoglobin and 
transporting oxygen from the lungs to different sites of the body. Erythrocytes make up 40-
45% of blood volume (Popel, 1989). 
White blood cells or leukocytes are generated from both myeloid and lymphoid cell 
types and contribute about ~1% of blood volume. Leukocytes are crucial in protection against 
infection as they form the major part of the innate immune system (Lay et al., 1968; Trinchieri, 
1989). Megakaryoblasts produce megakaryocytes and platelets; during thrombopoiesis, 
megakaryocytes break into fragments to make platelets. Platelets are fundamental to blood 
coagulation and wound healing (Opneja et al., 2019). Myeloblasts generate granulocytes; 
basophils, neutrophils and eosinophils. Neutrophils are transient immediate-responders to 
general infection, while basophils and eosinophils are predominantly connected to allergies 
and inflammation (Ginhoux et al., 2014; van Furth et al., 1972). Monoblasts differentiate into 
circulating monocytes and tissue-resident macrophages (Ginhoux et al., 2014; van Furth et al., 
1972). 
Lymphoid derived T-lymphocytes and B-lymphocytes are crucial to adaptive 
immunity. Large granular lymphocytes are innate cytotoxic cells that target cells that are virally 
infected or cancerous; they target these compromised cells through the occurrence of 




Figure 1.2: Vertebrate primitive and definitive haematopoiesis cell development pathways.  
Primitive haematopoiesis is the initial wave of blood production which is transient and rapidly replaced by the 
adult-type definitive haematopoiesis (Highlighted in grey). Definitive haematopoiesis is the life-long production 
of all blood cells. Haematopoietic stem cells reside in the bone marrow in adult mammals and yield blood 
precursors devoted to unilineage differentiation and production of mature blood cells. HSCs are also capable of 
self-renewal.  
 
1.1.2 Transcription factors involved in haematopoiesis 
 It is well established that a number of transcription factors are required to regulate the 
fate determination of haematopoietic stem cell populations. These transcription factors include 
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(but are not limited to) Tal1, Runx1, Gata1, Gata2, Lmo2, Spi1, Notch and c-Myb in most 
vertebrates (Okuda et al., 2001). 
Primitive haematopoiesis is principally regulated by two factors; Gata1 (erythroid) and 
Spi1 (myeloid) (Cantor et al., 2002). Mesodermal haematopoietic cell-fate specification is 
facilitated by the basic-helix-loop-helix factors (Tal1 and Lmo2) in both haematopoietic waves 
(Kim et al., 2007).  
Erg and Gata2 are required for HSC survival and self-renewal (Ezoe et al., 2002; 
Taoudi et al., 2011). Maintenance of HSCs is also co-ordinated through Notch, Wnt and Hox 
signalling pathway factors. Runx1 is crucial for making HSCs in the AGM and subsequently 
in definitive haematopoiesis Runx1 protein is required for correct megakaryocyte and 
lymphocyte production (Ichikawa et al., 2004; North et al., 1999; North et al., 2004). 
Dysregulation of normal haematopoiesis leads to a diverse range of diseases collectively called 
haematological malignancies.  
1.2 Haematological disorders 
Misexpression of transcription factors can lead to failure to produce HSCs, or 
haematopoietic disorders that can lead to leukaemia (Dobrzycki et al., 2020). There are many 
different types of haematological disorders; including chromic myeloid leukaemia (CML),  
acute myeloid leukaemia, familial platelet disorder, B- or T- cell lymphoblastic leukaemia. 
This thesis will focus on myeloid dysplasias (acute myeloid leukaemia and familial platelet 
disorder) as RUNX1 has a central role in disease progression. 
Disruption of Runx1 leads to the complete loss of definitive haematopoiesis in all 
lineages (Kalev-Zylinska et al., 2002; Okuda et al., 1996; Wang et al., 1996). Somatic 
mutations in the RUNX1 gene are one of the most frequent mutations identified in the patients 
with myeloid malignancies (Harada et al., 2005; Harada et al., 2009; Hayashi et al., 2017). 
RUNX1 (runt-related transcription factor 1) is also known as AML1 (acute myeloid leukaemia 
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1 protein), as it was initially cloned from a chromosomal breakpoint normally associated with 
acute myeloid leukaemia (Meyers et al., 1993; Miyoshi et al., 1991; Okuda et al., 2001). 
RUNX1 mutations can result in familial platelet disorder, an inheritable blood disease, which 
predisposes individuals to acute myeloid leukaemia (Ito et al., 2015).  
1.2.1 Familial platelet disorder 
Familial platelet disorder (FPD) is characterised by inherited platelet defects caused by 
germline mutations in RUNX1 (Luddy et al., 1978; Song et al., 1999). Clinically, patients 
present with mild to moderate thrombocytopenia, platelet dysfunction, bleeding, and an 
increased predisposition of developing acute myeloid leukaemia (around a 35% of patients) 
(Owen et al., 2008). Many RUNX1 variants are reported only in individual families; more than 
70 families with inherited RUNX1 mutations have been identified (Sood et al., 2017). FPD can 
almost exclusively be attributed to RUNX1 mutation or downregulation. RUNX1 mutations in 
FPD generate null, hypomorphic, or dominant-negative alleles (Churpek et al., 2015; Krutein 
et al., 2021; Latger-Cannard et al., 2016; Matheny et al., 2007; Song et al., 1999).  
1.2.2 Acute Myeloid Leukaemia 
Leukaemia is a common name given to cancers that develop in the bone marrow and 
blood cells. Leukaemia occurs due to the dysregulation of a normal cell, which then enables 
one cell type to proliferate in excess. Leukaemia is normally classified according to the original 
cell lineage in which the cancer occurs. i.e., myeloid or lymphoid (Figure 1.2). The leukaemia 
is further distinguished into two types: acute leukaemia, which progresses at a fast pace and 
chronic leukaemia, which develops over a longer time period (Teittinen et al., 2012). 
Therefore, Acute myeloid leukaemia (AML) is a fast developing leukaemia, which 
occurs in the myeloid cell lineage. Whilst found predominantly in individuals over 65, 15-20% 
of AML cases occur in childhood. (O'Donnell et al., 2012).  
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Chromosomal abnormalities such as t(9;21), t(9;11), t(8;21), inv(16), t(15;17) are 
clinically distinctive in AMLs and indicate a genetic basis to leukemogenesis. However, major 
chromosome abnormalities only describe 45% of AML cases (Betz et al., 2010). Unlike other 
adult cancers, AML genomes have fewer somatic mutations, with a total of 23 genes 
significantly mutated (CGARN, 2013). Molecular classification of AMLs can offer prognostic 
information (Betz et al., 2010). Somatic driver mutations in genes have been identified in ~ 
80% of patients across various myeloid malignancies subtypes (Shallis et al., 2018). Within 
the myeloid malignancies, a median of three somatic mutations per patient was observed 
(Shallis et al., 2018). Several studies have detected at least one driver gene mutation in AML 
patients (86%) (Bullinger et al., 2010; CGARN, 2013; Hou et al., 2020a; Papaemmanuil et al., 
2016; Yu et al., 2020). RUNX1 and other mutations (TP53, EZH2, ETV6, ASXL1, SRSF2) 
predict poor overall survival (Yu et al., 2020). The prognostic significance of these mutations 
appears to be maintained irrespective of whether these mutations are early or late events in 
disease progression (Yu et al., 2020).Understanding the mutational profile of malignant cells, 
helps define which treatments will be successful and the likelihood of relapse or achieving 
remission (Assi et al., 2019; Conway O’Brien et al., 2014; Papaemmanuil et al., 2016; Shallis 
et al., 2018; Tyner et al., 2018). 
1.2.3 Leukaemogenesis 
Gilliland et al., 2002 suggested a conventional model of leukaemogenesis, in which 
they proposed that two different types of genetic mutations were necessary for malignant 
transformation of the myeloid precursor (Gilliland et al., 2002; Jordan, 2002). Class I mutations 
are understood to lead to unrestrained cellular proliferation and evasion of apoptosis, whereas 
Class II mutations are associated with preventing differentiation. It is therefore suggested that 
alone, Class I mutations lead to myeloproliferative diseases, however Class II mutations lead 
to the development of myelodysplastic syndromes (Conway O’Brien et al., 2014).  
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Mutations in epigenetic modifier genes including DNA methylation and histone 
modification have been found in a significant proportion of AML (Jaiswal et al., 2019; Shih et 
al., 2012); these mutations do not fit into Class I or II. It is also been proposed that mutations 
have to occur at a particular time in cell development and in a certain order to progress to 
leukaemia (Murati et al., 2012). This evidence indicates that Gilliland’s conventional model is 
an oversimplification of a more complex process. Each novel mutation and its potential roles 
need to be thoroughly evaluated so that updated models of AML development can be defined. 
As healthy individuals age, the haematopoietic cells become burdened with mutations 
typically seen in AML patients (Young et al., 2016; Zink et al., 2017). Abnormal and excessive 
growth of myeloid cells (myeloid neoplasms) develop due to a gradual gain of somatic 
mutations in haematopoietic cells (Kim et al., 2016). Expansion of these myeloid neoplasms 
may lead to a pre-leukaemic state. Pre-leukaemic clones are dynamic and can have several 
founder mutations (Kim et al., 2016); even after treatment, these mutations can persist through 
to complete remission and then lead to relapse with additional secondary mutations (Shlush et 
al., 2014). 
Founder haematopoietic mutations are largely characterised by mutations in genes 
related to epigenetic control of the genome; these mutations are frequently observed in pre-
leukaemic clones (Desai et al., 2018). Chromatin and RNA splicing-associated factor 
mutations can arise later, or alongside epigenetic gene mutations. Additionally, mutations in 
transcription factors, and genes encoding signalling proteins occur as late events leading to 
AML transformation (Papaemmanuil et al., 2016). Desai et al., (2018) studied 188 patients and 
revealed mutations in epigenetic genes and splicing factors were evident up to 9.6 years before 
AML onset; however, mutations in transcription factors were found to be late events tied to the 
onset of AML (Desai et al., 2018). Therefore, AML is characterised by combinatorial 
mutations that are attained in a hierarchical manner.  
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1.2.4 AML patient survival and treatment 
The genetic and epigenetic profile of malignant cells influences the threat of relapse 
and the likelihood of achieving remission (Conway O’Brien et al., 2014). Despite the high 
variability in AML subtypes, the outcome for most is unfavourable. Patients aged 60 and under 
achieve a remission with chemotherapy in approximately 70-80% of cases, whereas for those 
over 60 it is 50% chance of remission (Bower et al., 2016; Burnett et al., 2011; Sweeney et al., 
2019). Despite achieving remission, without ongoing treatment most patients subsequently 
relapse, typically within 6 months, and relapse is coupled with poor prognosis (Goyal et al., 
2016; Sweeney et al., 2019) 
A small number of therapies targeted to mutational events have been developed for 
patients with AML, although the current standard of care remains largely unchanged over the 
past 30–40 years (Tyner et al., 2018). Rigorous chemotherapy is the conventional treatment 
for AML and depending on the cancer’s genetic profile, bone marrow transplantation may also 
be used (Ferrara et al., 2008). The combination of cytotoxic chemotherapy drugs used varies 
depending on the patient’s age and karyotype (Ferrara et al., 2013). Chemotherapy drugs are 
designed to target proliferating cells; however, other cells rapidly divide including those in 
bone marrow, gastrointestinal mucosa, hair follicles and gonads, which results in adverse side 
effects (Corrie, 2008).  
Advanced age in most patients affects their ability to survive the side effects of 
chemotherapy (Ferrara et al., 2008). In addition to improved antibiotic, antifungal, and antiviral 
drugs to reduce infections, developments to improve supportive care include high quality 
platelet transfusions and elimination of post transfusion hepatitis (Ferrara et al., 2013). 
Increased understanding of the different disease mechanisms may detect potential therapeutic 
targets and refine treatment strategies, and consequently improve survival rates. 
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Some targeted therapies for leukaemias exist, such as imatinib mesylate (Gleevec), 
which is a very efficient treatments of Philadelphia chromosome positive chronic myeloid 
leukemia (Kantarjian et al., 2002a; Kantarjian et al., 2002b). AML treatment has expanded to 
include inhibitors for gene mutation-targeted therapies. For example, patients with FLT3-ITD–
mutated AML who were treated with FLT3-inhibitor therapy at diagnosis have demonstrated 
significant survival benefit (Daver et al., 2015; DiNardo et al., 2016; Röllig et al., 2015; Stein, 
2015; Stone et al., 2015).  
AML with mutated transcription factor RUNX1, is considered a biologically distinct 
subgroup due to its distinctive clinico-pathologic features and inferior prognosis (Gaidzik et 
al., 2016). Currently no targeted or specific therapeutic options exist for RUNX1-mutated 
patients, or patients with other high-risk genetic lesions such as chromatin-spliceosome 
(including cohesin subunits) mutations, TP53 mutations, or complex cytogenetics (DiNardo et 
al., 2016). 
Papammanuil et al., (2016) found that 4% of AML patients sequenced contained no 
driver mutations (Papaemmanuil et al., 2016). The molecular events that cause the 
development and pathology of this leukaemia have so far not been completely defined. 
Difficulties arise for clinicians when providing prognoses to AML patients without well-known 
mutations. Changes to the known leukaemia genes by mutation in non-coding regulatory 
regions, which could alter gene regulation; rather than mutations in protein-coding sequence, 
may explain why not all instances of leukaemia harbour mutations in known genes. The cell-
fate of haematopoietic cells from a common progenitor relies upon the differential expression 
of key haematopoietic genes. Mutations in these key genes, such as RUNX1, or changes to gene 
regulation, could consequently alter normal blood development, and lead to the development 
of leukaemia. 
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1.2.5 Cohesin mutation contributes to AML 
Cohesin is a chromosome-associated multiprotein ring complex made up of four major 
subunits: two structural maintenance subunits, Smc1a and Smc3, which form a closed ring 
together with Rad21 and Stag1 or Stag2 (Figure 1.3) (Costantino et al., 2020; Feeney et al., 
2010; Gruber et al., 2003; Nasmyth et al., 2009).This multi-subunit protein complex was 
originally characterised for its crucial role in sister chromatid cohesion, as it ensures accurate 
sister chromatid segregation during mitosis (Downes et al., 1991; Michaelis et al., 1997). 
Cohesin also plays a role in DNA double strand break repair, chromatin loop extrusion and 
regulation of gene expression. Complete loss of cohesin function stops mitosis and thus results 
in cell death. Reductions in cohesin functions alters the development of multiple organ systems 
in humans, indicating that the correct expression of developmental genes are sensitive to 
cohesin dosage (Cuartero et al., 2018b; Deardorff et al., 2020). 
Somatic mutations to cohesin subunits are typically heterozygous, mutually exclusive, 
and  result in loss of function (17% frameshift, 70% missense)(CGARN, 2013). Mutations in 
RAD21, SMC3, and STAG1 subunits are always heterozygous, whereas mutations in the X 
chromosome-located genes SMC1A and STAG2 can result in complete loss of function due to 
male hemizygosity, or wild-type silencing during X-inactivation in females (Kon et al., 2013; 
Thota et al., 2014; Tsai et al., 2017). STAG2 and STAG1 have redundant roles in cell division, 
therefore complete loss of STAG2 is tolerated due to partial compensation by STAG1 (Tsai et 
al., 2017) Nevertheless, STAG1 and STAG2 have non-redundant roles in facilitating three-
dimensional (3D) genome organisation (Kojic et al., 2018). Combined loss of both STAG2 and 
STAG1 is lethal to cells (Benedetti et al., 2017; Van Der Lelij et al., 2017). 
Cohesin proteins are mutated, have reduced function, or are overexpressed in multiple 
cancer types including brain, breast, prostate, bladder, pancreatic, colorectal, Ewing sarcoma, 
and myeloid leukaemia (Balbás-Martínez et al., 2013; Brennan et al., 2013; Brohl et al., 2014; 
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Evers et al., 2014; Guo et al., 2013; Jones et al., 2012; Rhodes et al., 2011; Solomon et al., 
2013; Stephens et al., 2012; Taylor et al., 2014; Welch et al., 2012). STAG2 is one of 12 genes 
that is mutated at significant frequencies in at least four different tumour types (Lawrence et 
al., 2014).  
 
Figure 1.3: Structure of cohesin complex.  
Smc1 (blue), Smc3 (purple), Rad21 (pink) and Stag1 or Stag2 (yellow) form a tripartite ring. Figure is from 
Thomas (2015). 
 
Multiple studies observed cohesin mutations in myeloid malignancies, providing 
evidence of a role for cohesin in pathogenesis (Au et al., 2016; CGARN, 2013; Kon et al., 
2013; Leeke et al., 2014; Lindsley et al., 2015; Papaemmanuil et al., 2016; Rocquain et al., 
2010; Ruffalo et al., 2015; Thol et al., 2014; Wang et al., 2016; Welch et al., 2012; Welch et 
al., 2016). Cohesin insufficiency has been shown to impair differentiation and alter overall 
chromatin accessibility, as well as the transcription of RUNX1 (Mazumdar et al., 2015; 
Mullenders et al., 2015; Viny et al., 2015).  
Cohesin mutant AML is rarely aneuploid, with over half of AML patients exhibiting a 
normal karyotype, demonstrating that mitotic defects are not likely to be involved in 
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leukemogenesis (Kon et al., 2013). AML patients with cohesin mutations do not typically have 
a higher observed presence of chromosomal translocations (Fisher et al., 2017a; Heimbruch et 
al., 2021). Except RAD21 mutations, which have been reported to co-occur with t(8:21) in 
AML patients (Tsai et al., 2017; Wilde et al., 2019), 
Deep sequencing established that mutations in subunits or regulators of the cohesin 
complex occur in 20% of AML samples (CGARN, 2013; Fisher et al., 2017a; Heimbruch et 
al., 2021; Leeke et al., 2014; Losada, 2014). Somatic cohesin defects are found in 12% of 
myeloid malignancy patients and a further 15% of patients had low cohesin expression (Thota 
et al., 2014). Previous research has highlighted that cohesin mutations occur early in 
leukaemogenesis and mainly arise in pre-leukaemic cells (CGARN, 2013; Corces et al., 2017; 
Kon et al., 2013; Thol et al., 2014; Welch et al., 2012). 
Mutations in cohesin subunits occur in other myeloid malignancies, including 
myelodysplastic syndrome (MDS), Down Syndrome acute megakaryoblastic leukaemia (DS-
AMKL), myeloproliferative neoplasms (MPN), chronic myelogenous leukaemia (CML), and 
chronic myelomonocytic leukaemia (CMML) (Kon et al., 2013; Thota et al., 2014; Yoshida et 
al., 2013). Cohesin mutations are recurrent in myeloid malignancies but not in lymphoid 
malignancies, consistant with evidence showing cohesin-deficient cells have myeloid-skewed 
differentiation(Chen et al., 2019; Cuartero et al., 2018b; Viny et al., 2019). Cohesin mutated 
myeloid leukaemia cells have reduced levels of chromatin-bound cohesin components, 
implying a loss of function mechanism (Kon et al., 2013). Cohesin mutations found in patients 
are mutually exclusive, illustrating that a mutation in just one member of the complex is 
sufficient to decrease cohesin activity (Kon et al., 2013; Thota et al., 2014). Patients with 
cohesin mutations have a lower 5 year survival rate of 20% when compared to cohesin-WT 
AML patients (48%) (Heimbruch et al., 2021). Cohesin mutations co-occur with other 
leukaemogenic mutations, indicating cooperation between pathways (Welch et al., 2012).  
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Cohesin mutations have been shown to impair the differentiation of HSPCs in humans 
and mice (Mazumdar et al., 2015; Mullenders et al., 2015; Viny et al., 2019; Viny et al., 2015). 
Stag2 deletion in HSPCs had altered hematopoietic function, increased self-renewal, and 
impaired differentiation. (Viny et al., 2019). Typically increased inflammatory signals in 
HSPCs promotes myeloid differentiation. Chen et al., (2019) demonstrated that HSPCs with 
impaired cohesin function had reduced inflammatory gene expression and increased resistance 
to the differentiation inducing inflammation stimuli (Chen et al., 2019). STAG2 is frequently 
mutated in myeloid malignancies and shows co-mutation patterns with other drivers, including 
RUNX1. Combined loss of Runx1 and Stag2 leads to myeloid-skewed expansion of HSPC and 
MDS in mice (Ochi et al., 2020). Concurrent loss of Stag1 and Stag2 in HSPCs is lethal to 
cells. Alone, Stag2 loss decreases the chromatin accessibility and differentiation gene 
transcription (Viny et al., 2019). Cohesin subunits have dose-dependent consequences which 
alter chromatin structure and HSC function in mice (Viny et al., 2015). Complete loss of Smc3 
induced bone marrow aplasia and mitotic defects, whereas Smc3 haploinsufficiency reduced 
transcriptional capacity (Viny et al., 2015). Haploinsufficiency of Smc3 increased self-renewal 
of cells and when combined with Flt3-ITD mutation could induce acute leukaemia in mice 
(Viny et al., 2015). Chin et al., (2020) highlighted that cohesin mutations are synthetic lethal 
with Wnt pathway stimulation, and suggested that cohesin mutant cells could progress to 
oncogenesis by enhancing their Wnt signaling (Chin et al., 2020). Depletion of Rad21 
enhanced self renewal in HSPCs by derepression of Polycomb Repressive Complex 2 (PRC2) 
target genes (Fisher et al., 2017b). Fisher et al., (2017) showcased that cohesin function is 
crucial for proper PRC2 complex mediated gene silencing, and dysregulation of this epigenetic 
mechanism may underly leukemogenesis in AML patients with cohesin mutations (Fisher et 
al., 2017b).  
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Together these studies provide evidence that cohesin mutations are a causal event in 
acute myeloid leukaemogenesis. Overall cohesin mutations are implicated as a putative genetic 
precursor for development of AML, but how the disease develops from these mutations has 
not been resolved. One possibility is that impairment of cohesin’s regulatory role leads to 
dysregulation of other important leukaemogenic genes. 
1.3 RUNX1 is a leukaemia gene 
RUNX1 belongs to the family of Runx transcription factors (TFs), which are essential 
for lineage-specific gene expression in major developmental pathways.  
Runx genes encode transcription factor proteins defined by the highly-conserved Runt 
DNA-binding domain (Figure 1.4). The conserved Runt domain is a fundamental functional 
component of Runx proteins (Rennert et al., 2003). The Runt domain is required for DNA 
binding and interacting with the conserved non-DNA-binding partner CBFβ (Figure 1.4). Runx 
family members all have important roles during lineage-specifying steps in both embryonic 
and adult developmental processes; they appear to be involved in cell quiescence, proliferation, 
lineage commitment and cell-fate determination in mammals and invertebrates (Coffman, 




Figure 1.4: The Runx protein.  
The Runt domain (dark blue) of the Runx protein (blue) directs binding to the Runx DNA-motif (grey box) near 
the promoter of target genes (black right angled arrow). It also binds with core-binding factor-β (CBF-β) protein 
(purple). The Runx proteins either activate or repress gene transcription through interactions with other 
transcription factors (TFs)(Orange) and co-activators (arrows), or co-repressors (blocked line).  
 
Runx1 is essential for definitive haematopoiesis (Levanon et al., 2004; Li et al., 2002). 
Runx2 is crucial for osteoblast development and proper bone formation (Komori et al., 1997). 
Runx3 is needed for the development of dorsal root ganglia proprioceptive neurons and proper 
control of gastric epithelium growth (Levanon et al., 2002; Li et al., 2002). Because each Runx 
protein has a particular biological function, mutations in Runx genes are often the cause for 
specific diseases. RUNX1 mutations can cause FPD (Ito et al., 2015). Point mutations in the 
runt domain of RUNX2 are reported in cleidocranial dysplasia, in which patients exhibit 
skeletal deformities of the collarbone, teeth and cranium (Ito et al., 2015; Otto et al., 2002). 
Point mutations of RUNX3 are associated with stomach and bladder cancers (Ito et al., 2015). 
Each gene contains P1 (distal promoter) and P2 (proximal promoter) that generate 
alternative Runx isoforms (Levanon et al., 2004; Rennert et al., 2003). A dual promoter 
structure is a characteristic feature of vertebrate Runx genes, as invertebrates only have P2 
(Rennert et al., 2003). Since all vertebrate Runx genes have this conserved dual promoter 
structure, it is likely to be crucial for correct regulation (Rennert et al., 2003). 
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1.3.1 Role of RUNX1 in normal embryonic and adult developmental 
processes 
Runx1 expression is crucial in early myeloid differentiation, as well as playing an 
essential role in adult blood development (Okuda et al., 2001). Runx1-/- mice fail to generate 
haematopoietic cell clusters from the vessel wall and consequentially cannot generate 
haematopoietic stem cells (HSCs), leading to mid-gestation lethality (Okuda et al., 1996; 
Yokomizo et al., 2001). The Runx1 protein initiates transcription of genes that help control the 
development of blood cells. In particular, it plays an important role in the development of 
pluripotent haematopoietic stem cells that have the potential to develop into all types of mature 
blood cells. (Ichikawa et al., 2004; North et al., 1999; North et al., 2004). 
As well as haematopoiesis, RUNX1 plays a role in development of dorsal root ganglia, 
cranial sensory neurons, myofibroblasts and mesenchymal stem cells, regulation of hair follicle 
stem cells, mammary stem cells, gastric stem cells, neural crest stem cells, and some possible 
roles in intestinal stem cells and oral epithelial stem cells (Groner et al., 2017; Inoue et al., 
2008; Kim et al., 2014; Kramer et al., 2006; Theriault et al., 2004). 
1.3.2 Regulation of Runx1 
The dual promoter structure of the Runx genes allows for many different isoforms of 
the gene to be produced (Figure 1.5) (Levanon et al., 2004). The regulation machinery of these 
genes and spatiotemporal regulation of Runx are poorly understood. It is possible that the 
spatial-temporal regulation is driven by different 3D arrangements of the chromosome in 
different cell types.  
In mammals, the dual promoter structure of Runx1 allows for the transcription of at 
least three diverse isoforms (Levanon et al., 2004). Transcription from P2 produces Runx1a 
and Runx1b, whereas transcription from P1 generates Runx1c (Figure 1.5) (Bee et al., 2009b). 
P1 and P2 expression alone is not consistent with Runx1 tissue specificity, suggesting 
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additional enhancer elements are required for correct initiation of runx1 (Marsman et al., 2014). 
The 5’UTR of Runx1c is conserved between mammals and zebrafish, and may be important 
for the regulation of Runx1 expression (Marsman et al., 2014). Lam et al., 2009 showed the 
first exon of P1 transcript was not needed for definitive or primitive haematopoiesis in 
zebrafish (Lam et al., 2009).  
Expression of Runx1-P1 and-P2 isoforms is tightly controlled during haematopoiesis. 
In early mouse haematopoiesis, before the generation of HSCs, expression of the P2 isoforms 
are prominent (Bee et al., 2010; Pozner et al., 2007). Runx1-P1 is expressed shortly after P2, 
its expression is co-ordinated with the generation of HSCs (Bee et al., 2009b; Bee et al., 2010). 
The main isoform in the mouse fetal liver is P1 driven, the liver is the main site of definitive 
HSPC development (Bee et al., 2009b). 
Horsfield et al., 2007 showed that homozygote rad21 cohesin mutants lack cell type 
specific expression of runx1 and runx3, highlighting that cohesin is necessary for correct runx 
expression. Cohesin may provide an additional mechanism by which Runx expression can be 




Figure 1.5: Comparative genomic organisation of the Runx1 locus in human, mouse and zebrafish.  
The exons (grey) are numbered according to Marsman et al., (2014). Untranslated regions are shown as white 
boxes. Distances between promoters (black right-angled arrows) is indicated in kilobases (kb). Figure is from 
Thomas (2015).   
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1.3.3 Role of RUNX1 in AML progression 
The developmental transcription factor RUNX1/AML1 has been identified as a classic 
leukaemia gene (Okuda et al., 2001). Germline mutations to the Runt binding domain result in 
FPD with patients having a predisposition to acute myelogenous leukaemia (Ito et al., 2015). 
Disruptions such as truncations and translocations to RUNX1 are frequently associated with 
AML (Betz et al., 2010; Tighe et al., 1993). 
RUNX1 is important for the differentiation of cells of all haematopoietic lineages,  and 
there are two categories of genetic changes: translocations and somatic mutations (Bellissimo 
et al., 2017). In AML, RUNX1 mutations that occur due to chromosomal translocations have a 
favourable prognosis, compared to somatic mutations which are associated with a poorer 
prognosis (Byrd et al., 2002; Grimwade et al., 1998; Schlenk et al., 2003).  
RUNX1 is altered by chromosomal translocations; these disruptions can generate 
oncogenic fusion proteins like RUNX1-ETO t(8;21) and ETV6-RUNX1 t(12;21) (Figure 1.6).  
10-15% of all AML cases are characterised by the most common translocation t(8;21) 
(Reikvam et al., 2011; Tighe et al., 1993). This translocation creates a chimeric gene of the 5'-
region of the RUNX1 gene fused with the 3'-region of the ETO gene (RUNX1-ETO) (Erickson 
et al., 1992; Miyoshi et al., 1993). RUNX1-ETO protein is predicted to bind to several target 
genes and dysregulate haematopoiesis which results in AML (Ajore et al., 2010; Gardini et al., 
2008). The breakpoints in characterised RUNX1 translocations are often downstream of the 
Runt homology domain (De Braekeleer et al., 2011). ETV6-RUNX1 translocation is the most 
frequent gene fusion (~25%) in paediatric acute lymphoblastic leukemia (ALL)(Sun et al., 
2017). It is important to note that RUNX1 changes can lead to AML as well as to ALL (Sood 
et al., 2017). This is not often the case for other genes involved in haematological malignancies. 
Translocations can also create truncated RUNX1 protein that interfere with the wildtype protein 
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product (Cheng et al., 2018). Chromosomal translocations in RUNX1 often result in 
haematopoietic malignancies, though the molecular mechanisms are not often described.  
 
Figure 1.6: RUNX1 gene common isoforms and leukaemic fusion isoforms.  
The exons are depicted as grey and blue, the runt binding domain is blue. Untranslated regions are shown as 
white boxes. Distances between the two promoters P1 and P2 (black right angled arrows) is indicated in 
kilobases (kb). Straight arrows indicate common chromosomal breakpoints. Isoforms and common leukaemic 
fusion isoforms are depicted.  
 
Cheng et al., 2018 characterised a translocation that disrupts a regulatory element 
between RUNX1 P1 and P2. This regulatory element was shown to “normally” silence RUNX1 
P2 (Cheng et al., 2018). They proposed that the translocation increased P2 transcription and 
may activate P1 expression via a positive feedback loop (Cheng et al., 2018). RUNX1a isoform 
is transcribed from P2 and its overexpression has been previously noted in AML (Liu et al., 
2009). RUNX1a overexpression has also been observed in patients with myelodysplastic 
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syndromes and myeloproliferative neoplasms; interestingly, levels of expression increased as 
the disease progressed (Sakurai et al., 2017).  
Studies have identified breakpoints in similar regions between the distal promoters in 
cases of paediatric AML, B-lineage acute lymphoblastic leukaemia, and FPD (Buijs et al., 
2012; Cheng et al., 2018; Gandemer et al., 2007). The occurrence of DNA double strand breaks 
which underpin translocations have been linked to 3D genome organisation (Cuartero et al., 
2018a). 
Mutations are significantly associated with increasing age and higher platelet counts. 
3% of paediatric and 15% of adult de novo AML patients have somatic RUNX1 point mutations 
(Sood et al., 2017). Further mutations are usually required on top of RUNX1 alteration for the 
progression to leukaemia (Asou, 2003). Molecular mechanisms for haematopoietic 
malignancies include disruption of intron 1, which deregulates promoters and causes RUNX1 
overexpression (Gandemer et al., 2007). Aberrant regulation of RUNX1 promoters was seen in 
the human myeloid leukaemia (HL-60) cell line, implying that promoter dysregulation may 
lead to leukaemogenesis (Marsman et al., 2014). 
These previous studies indicate that progression to AML can occur by disruption of 
RUNX1 regulation. This disruption can be a translocation which alters the genome structure or 
somatic mutations which alter the RUNX1 transcription. Cheng et al., 2018 showcased that 
dysregulation of regulatory elements can produce aberrant RUNX1 and progress 
leukaemogenesis. 
The 3D genome influences the regulation of genes at the transcriptional level 
(Holwerda et al., 2012; Lieberman-Aiden et al., 2009). For instance, 3D folding of chromatin 
provides a mechanism for distal enhancers to interact with target promoters (Deng et al., 2010). 
In cases where no mutation is found in the coding sequence, instead there may be mutations in 
regulatory sequences, such as enhancers (Ng et al., 2010). 
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1.4  Three-dimensional genome structure 
Though the genome is often represented as linear in order to view the annotations of its 
features, the genome is in reality arranged in three-dimensions. The eukaryotic genome is 
tightly packaged to sit within the spatial limits of a cell nucleus; yet it must permit movement, 
remain flexible and allow for access of transcription and regulatory factors to the DNA 
sequence (Deng et al., 2010). 
Genome organisation relies on two mechanisms: compartmentalisation and chromatin 
loop formation. (Nuebler et al., 2018). Nuebler et al., (2018) previously showed that active 
process of loop extrusion counteracts compartmental segregation, which indicates that these 
two mechanisms are mutually exclusive (Nuebler et al., 2018). Genome-wide chromatin 
conformation capture (Hi-C) is a technique used to systematically interrogate interaction 
frequencies between genomic regions. The development of Hi-C technology has demonstrated 
the presence of spatially insulated genomic regions: topologically associated domains (TADs), 
organised by chromatin loop extrusion (Dixon et al., 2012). Hi-C also revealed that each 
genome territory separates into two chromosome compartments (compartmentalisation), 
euchromatic (active) and heterochromatic (inactive) (Lieberman-Aiden et al., 2009).  
Chromatin loop extrusion model uses the cohesin complex and CCCTC binding factor 
(CTCF) to form stable DNA loops, which act as functional barriers between active and inactive 
chromatin. Loop extrusion by cohesin and CTCF is important for the formation of TADs, and 
cohesin and CTCF are enriched at TAD boundaries (Dixon et al., 2012; Rao et al., 2014). Loss 
of CTCF relaxes the global domain structures, which results in increased contacts between 
domains; loss of cohesin mostly affects interactions within domains (Li et al., 2013b; Zuin et 
al., 2014). These observations have led to the chromatin loop extrusion model to describe how 
TADs are formed: in this model, cohesin begins to extrude a chromatin loop until it encounters 
an obstruction associated with the DNA (CTCF). Think of the DNA as a thread being pulled 
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through a needle’s eye (cohesin) to make a loop. The CTCF only functions as a barrier when 
it is bound to the DNA in a specific orientation (Rao et al., 2014); directionality of CTCF sites 
is important for loop formation, as sites that anchor loops are convergent (Merkenschlager et 
al., 2016). 
Compartmentalisation depicts the process in which proteins arrange themselves into 
condensates and act as membrane-less organelles that cluster specific molecules (Hyman et al., 
2014; Shin et al., 2018). In these condensates there are often co-localisation of similar 
transcription factors or polycomb proteins, suggesting that like attracts like. Hence why there 
is euchromatic and heterochromatic compartments (Stadhouders et al., 2019). 
1.4.1 Topologically associated domains (TADs) 
TADs are characterised by an elevated number of chromatin interactions within a 
genomic locality, with fewer interactions to outside regions (Lieberman-Aiden et al., 2009; 
Rao et al., 2014). Genes positioned within the same TAD often have the same histone 
modifications and are co-regulated (Rao et al., 2014). TADs are present in a wide range 
different metazoan phyla, suggesting that they are ancient features of the genome (Harmston 
et al., 2017). TADs have been under intense selective pressure, and act on the same functional 
subset of genes, at least back to the common ancestor of chordates and arthropods (Harmston 
et al., 2017).  
Harmston et al., 2017 propose that chromatin structure is mainly defined by the need 
to regulate important developmental genes. TADs often contain the regulatory elements 
(enhancers, silencers and insulators) required to regulate the genes within that TAD. TADs 
containing clusters of regulatory regions are enriched with conserved CTCF sites when 
compared to TADs without clusters of regulatory regions (Harmston et al., 2017). This 
suggests that these regions are isolated from neighbouring domains. Gómez-Marín et al., 2015 
highlighted that diverging CTCF sites are a signature of TAD borders that are maintained 
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between species, suggesting that specific 3D organisation is highly conserved and under 
intense selection pressure (Gómez-Marín et al., 2015). 
Disruption of TAD boundaries allows erroneous contacts with regulatory elements of 
neighbouring domains, which leads to misexpression of genes, including the activation of 
oncogenes driving cancer progression (Kloetgen et al., 2019; Pope et al., 2014; Taub et al., 
1982; Zhan et al., 2017)(Bohlander, 2000; Look, 1997; Rawat et al., 2004). 
Taub et al., (1982) described t(8;14) translocations in Burkitt's lymphoma which alter 
gene expression through enhancer hijacking (Taub et al., 1982). Rewat et al., (2004) showed 
that in the t(12;13) translocation, overexpression of CDX2 gene is leukaemogenic rather than 
the ETV6-CDX2 fusion(Rawat et al., 2004). Chromosomal translocations like RUNX1-ETO 




Figure 1.7: RUNX1 TAD Hi-C contact map of RUNX1 region in K562 cells.  
Hi-C data generated by Rao et al., (2014) was visualised in 3D genome browser at a 25-kb resolution (Wang et 
al., 2018). Every square is coloured according to the frequency of two regions interacting. The alternating 
yellow and blue bars are predicted TADs. RUNX1 is annotated according to its transcription direction (reverse 
strand). RUNX1 sits within its own isolated TAD. 
 
1.5 Regulators of gene transcription 
Most genes display individual characteristics that determine the site, level, and timing 
of expression throughout development and the cell cycle (Kadauke et al., 2009). Accurate 
spatiotemporal and quantitative gene expression is crucial for normal development and, in 
many cases, is achieved by the interaction of promoters with cis-regulatory elements. In 
addition, the chromatin must be ‘open’ for external factors to facilitate regulatory functions of 
the DNA (Gilbert et al., 2004).  
Genomic regions have been shown to be highly conserved across a diverse set of 
vertebrate species (Abbasi et al., 2007). While some conserved regions correspond to coding 
genes and non-coding RNAs, the remainder are unlikely to produce a functional transcript 
(Rebolledo-Jaramillo et al., 2014). Non-coding DNA can play crucial roles in the regulation of 
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gene expression, as some conserved non-coding regions can contain transcriptional regulatory 
modules, such as enhancers, insulators or silencers (Deng et al., 2010). 
Highly conserved developmental genes are surrounded by clusters of conserved 
regulatory elements. Expression patterns driven by regulatory regions often correlate with the 
function of the closest genes; however, the overlap can be inconsistent with regulatory elements 
controlling expression in genes further afield (Marsman et al., 2014; Smemo et al., 2014; 
Spieler et al., 2014). Long-range chromatin interactions between promoters and regulatory 
elements can be mediated by scaffolding proteins and transcription factors to regulate gene 
expression (Phillips-Cremins et al., 2013). 
The syntenic organisation of clusters of regulatory regions supports the idea that there 
are combinations of regulatory elements controlling the complex expression patterns of 
developmental genes. Synteny is required to retain the regulatory regions in cis with the genes 
under long range interaction (Ritter et al., 2010).  
1.5.1 Cohesin acts with other regulators to determine gene expression 
Cohesin controls a large number of genes, as evidenced by altered expression profiles 
when the multi-subunit protein is knocked down in mouse embryonic stem cells and drosophila 
neuronal cells (Kagey et al., 2010; Schaaf et al., 2009). One of the potential mechanisms by 
which cohesin regulates cell-type specific gene expression is by facilitating long-range 
interactions through the formation of DNA loops. These chromatin loops could connect 
regulatory elements and gene promoters over large distances (Strom et al., 2012). 
Depending on the nature of the regulatory elements, formation of chromatin loops may 
either facilitate or inhibit transcription from the interacting promoter. Cohesin and CTCF act 
together to form regions that isolate enhancers from interacting with inappropriate gene 
promoters (Canela et al., 2017; Phillips-Cremins et al., 2013); this can lead to cell-type and 
gene-type specific transcriptional programmes. Simonis et al., 2006 showed that the mouse β-
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globin locus is active in the fetal liver and inactive in the fetal brain due to CTCF and cohesin 
mediated regulation. CTCF binding motifs sit within the β-globin locus and CTCF binding 
varies depending on the cell type; different CTCF binding patterns change the 3D structure of 
the β-globin locus, consequentially altering regulation in a cell-specific manner (Phillips et al., 
2009; Simonis et al., 2006). In human cells, both CTCF and cohesin were shown to be 
necessary for long-range loop formations that are cell-type specific (Hou et al., 2010). 
Disease-causing mutations are also found in cellular machinery that maintain 3D 
structure, such as cohesin and CTCF. Hnisz et al., (2016) reported leukaemia cell genomes 
with recurrent microdeletions that modified CTCF boundary sites. These mutations were 
sufficient to activate proto-oncogenes (Hnisz et al., 2016). Schierding et al., (2020) highlighted 
that several genes that are coregulated with cohesin loci are themselves intolerant to loss-of-
function mutations. These results emphasised the significance of correct regulation of cohesin 
genes and indicated new pathways of cohesin related disease progression (Schierding et al., 
2020). Mutations in cohesin could inhibit cohesin binding to regulatory elements, thus varying 
interactions with promoters and consequent gene expression. Alternatively, mutations in 
regulatory elements to which cohesin binds could affect the binding of regulatory proteins and 
modify transcription of the regulatory element’s gene target. Katainen et al., (2015) reported 
recurrent mutations to CTCF and cohesin binding sites in cancer samples (Katainen et al., 
2015). 
1.5.2 Cohesin and Runx1 
Tissue-specific regulation of runx1 transcription in zebrafish is reliant on cohesin 
(Horsfield et al., 2007). Horsfield et al., (2007) observed that a null mutation in the rad21 
subunit of cohesin prevented runx1 expression in the haematopoietic mesoderm, but not in 
Rohon-Beard neurons in the developing zebrafish embryo (Horsfield et al., 2007). This study 
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presented the first evidence that the transcriptional role of cohesin is tissue-specific in 
haematopoietic precursors.  
Subsequently, it was established that zebrafish runx1 is directly bound by cohesin and 
CTCF at the promoters and contains an intronic regulatory element between runx1 promoters 
(Marsman et al., 2014). Marsman et al., (2014) showed that depletion of cohesin in zebrafish 
decreased the total amount of runx1 transcript produced overall, but the relative expression of 
P1-regulated runx1 increased. Cohesin depletion in human myelocytic leukaemia (HL-60) cell 
line enhanced RUNX1 transcription, implying that cohesin’s transcriptional role could be 
conserved in humans (Marsman et al., 2014). 
Down’s syndrome patients with acute megakaryoblastic leukaemia (DS-AMKL) 
contain three copies of the RUNX1 gene (owing to trisomy 21), as well as a high frequency of 
cohesin mutation (53% ) (Yoshida et al., 2013). As normal Runx1 expression requires cohesin, 
the elevated rate of cohesin mutations in DS-AMKL patients indicates the strong possibility 
that cohesin mutation is actively contributing to leukaemia progression (Leeke et al., 2014). 
AML patients with mutations in genes regulating RNA splicing, chromatin (cohesin) 
or in the RUNX1 gene have poor prognoses, with the various mutations contributing 
independently and additively to the disease (Papaemmanuil et al., 2016). RUNX1 and cohesin 
mutations co-occur or are enriched in 27-52% of AML samples (Heimbruch et al., 2021). 
Mazumdar et al., (2015) showed that cohesin mutant cell lines with impaired differentiation 
had increased chromatin accessibility and binding of ERG, GATA2 and RUNX1 (Mazumdar 
et al., 2015). 
Recently, Antony et al., (2020) showed that mutation of the STAG2 subunit of cohesin 
in K562 cells disrupted RUNX1 expression during megakaryocyte differentation (Antony et 
al., 2020). In the STAG2 mutant, RUNX1 showed increased chromatin accessibility. This 
research also established that in wildtype K562 cells, RUNX1-P1 had a gradual increase in 
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transcription during phorbol 12-myristate 13-acetate (PMA)-stimulated megakaryocyte 
differentiation. However, STAG2 mutants cells showed an aberrant spike in transcription of 
RUNX1-P2 6-12h post-PMA stimulation (Antony et al., 2020). After 48h stimulation the 
aberrant RUNX1 transcription observed in STAG2 mutant cells had returned to baseline. This 
implies that the initial response to PMA stimulation in cohesin mutant cells (that have increased 
chromatin accessibility at RUNX1), leads to unrestrained transcription (Antony et al., 2020).  
Antony et al., (2020) decreased BRD4 binding and suppressed enhancer-driven 
transcription by using a bromodomain and extra-terminal motif (BET) inhibitor protein called 
JQ1 (Antony et al., 2020). BRD4 is a bromodomain-containing protein that interacts with 
active enhancers (Bhagwat et al., 2016). When wildtype cells were JQ1-treated concurrently 
with PMA, there was reduced RUNX1-P2 and ERG expression in parental cells, and 
dramatically dampened aberrant expression peaks in STAG2 mutant cells. RUNX1-P1 
expression is essential for megakaryocyte development and its transcription was completely 
blocked by JQ1 in both parental and STAG2 mutant cells. These results suggest that STAG2 
depletion deconstrains the chromatin surrounding RUNX1, which produces aberrant enhancer-
amplified transcription in response to differentiation signal. This study also highlighted that 
the correct expression of RUNX1 is enhancer-driven. 
Ochi et al., (2020) observed reduced enhancer–promoter loops in Runx1 and Stag2 
double knockout mouse models. These double knockouts lead to myeloid-skewed expansion 
of hematopoietic stem/progenitor cells (HSPC) and myelodysplastic syndromes (MDS) in 
mice. The reduced loops were associated with genes important for regulation of HSPCs; these 
same genes were downregulated in cohesin-mutated leukaemia samples (Ochi et al., 2020). In 
the absence of Stag2 in HSPCs, Stag1 can still maintain TAD boundaries, however Stag1 
cannot retain intra-TAD interactions, at differentiation genes (Viny et al., 2019). 
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The occurrence of RUNX1 and cohesin dysregulation in AML subtypes and in vitro 
models provides further evidence that these two factors are likely to play important roles in 
normal and abnormal haematopoiesis. Additionally, these studies support previous work that 
suggests cohesin mediates interactions between cis-regulatory elements and the promoters of 
Runx1 (Antony et al., 2020; Marsman, 2016; Marsman et al., 2014; Ochi et al., 2020). 
1.5.3 Regulatory elements 
Crucial to the development of multicellular organisms is the ability of cells to acquire 
new cell-fates. Cell-fate decisions are driven by environmental cues that activate signal 
transduction in the nucleus – the environmental cues initiate transcription factors that define 
the specific gene-expression program for each cell type. Transcription factors take effect by 
binding to defined DNA motifs within gene regulatory elements to control the rates of 
transcription (Griffiths et al., 1999). There are two main types of protein regulated transcription 
elements: enhancers and insulators (Figure 1.8).  
1.5.3.1 Enhancers 
Enhancers are regions characteristically found in non-coding DNA regions that 
positively regulate promoters to stimulate transcription by recruiting specific transcription 
factors, chromatin remodelling proteins, and RNA polymerase II (Marsman et al., 2012). 
Enhancers are generally identified by distinct histone modifications including; histone H3 
lysine 4 monomethylation (H3K4me1), histone H3 lysine 4 dimethylation (H3K4me2) histone 
H3 lysine 4 trimethylation (H3K4me3), histone H3 lysine 9 acetylation (H3K9ac), histone H3 
lysine 36 monomethylation (H3K36me1) and histone H3 lysine 27 acetylation (H3K27ac) 
(Ong et al., 2012; Zentner et al., 2011). These histone marks determine which regions of DNA 
are accessible for transcription factor binding (Gates et al., 2017; Lawrence et al., 2016). The 
pattern of histone marks suggests whether a region is active, inactive, or poised, and 
accordingly whether the enhancer status correlates with gene activity. Active transcription is 
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associated with histone marks such as H3K4me3 and H3K9ac at active promoters, H3K4me1 
and H3K4me2 at active enhancers, and H3K27ac at both active promoters and enhancers. 
Heterochromatic regions are zones of gene inactivation and are associated with H3K27me3 
(Heintzman et al., 2007; Kolovos et al., 2012; Pokholok et al., 2005). Active enhancer 
sequences are characterised by bound RNA polymerase II (RNA Pol II) and can produce 
enhancer RNAs (eRNA) that contribute to gene regulation (Peng et al., 2018). These regions 
are often identifiable by transcription factor binding, acetyltransferase p300, cohesin, and/or 
CTCF (Zentner et al., 2011). In addition, active enhancers usually lack nucleosomes and are 
sensitive to DNase I digestion (Kolovos et al., 2012). Enhancers regulate spatiotemporal gene 
expression, and therefore direct developmental programmes (Ong et al., 2012). 
The location or orientation of an enhancer is independent of its ability to interact with 
a promoter. Enhancers have been traditionally identified based on their ability to drive 
transcription in reporter gene assays (Peng et al., 2018). Enhancers can also be predicted by 
computational methods, including: computational analysis of conserved non-coding sequence 
and transcription factor binding motifs (Pennacchio et al., 2006; Visel et al., 2008; Woolfe et 
al., 2004); analysis of chromatin immunoprecipitation and sequencing (ChIP-seq) to locate 
binding of transcription factors, mediators, and histone modifications at the regions of interest 
(Murakawa et al., 2016; Visel et al., 2009); chromatin accessibility assays to identify areas of 
open chromatin (DNase-seq, ATAC-seq) (Buenrostro et al., 2013; Thurman et al., 2012); 
detection of enhancer RNAs such as cap-analysis gene expression (CAGE) (Andersson et al., 
2014); revealing promoter-enhancer interactions using chromosome conformation capture (3C, 
R3C, 4C, 5C, Hi-C, Promoter capture) (Dekker et al., 2002; Dostie et al., 2006; Lieberman-
Aiden et al., 2009; Simonis et al., 2006); and chromatin interaction analysis using paired-end 
sequencing (ChIA-PET) (Fullwood et al., 2009). 
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1.5.3.2 Silencers and insulators 
Conversely, suppression of gene expression during differentiation and cell cycle 
progression is facilitated by silencers and insulators. Silencers prevent gene expression by 
producing non-coding transcripts that recruit polycomb repressor complexes to target genes 
(Boyer et al., 2006).  
Insulators block the interaction between enhancers and promoters by confining regions 
within repressed or active chromatin boundaries; insulators establish chromatin domains 
(Kolovos et al., 2012; Levine, 2010; Splinter et al., 2006; West et al., 2002). Mutation of 
insulators changes the pattern of gene expression and can lead to developmental defects 
(Feinberg, 2007). 
 
Figure 1.8: Cohesin mediated cis-regulatory DNA elements.  
A) An enhancer (green) is recruited to activate gene expression through a physical interaction with the gene 
promoter (black arrow). Transcription factors (blue) are often present for binding. B) An insulator (orange) 
excludes the enhancer from interacting with the promoter, which prevents expression. CTCF (red) can 
demarcate domains of active and inactive chromatin by binding with cohesin (multi-coloured ring) and forming 
long-range loop formations. Figure is from Thomas (2015).  
 
The three-dimensional genome conformation is crucial for efficient gene regulation. 
CTCF and cohesin help mediate enhancer-promoter, insulator-insulator and insulator-promoter 
interactions (Raab et al., 2010). 
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1.5.4 Techniques to determine three-dimensional conformation 
A significant portion of our understanding of nuclear organisation has been discovered 
through microscopic study of the nucleus, using techniques like fluorescent in situ 
hybridization (FISH)(Dekker et al., 2015). However, as the resolution of these techniques is 
low, it is difficult to reliably distinguish between a looped or linear conformation of two regions 
(Williamson et al., 2014).  
The majority of recent discoveries of sequence-specific chromatin structure have been 
made using chromatin capture techniques which map physical genome interactions (Sanyal et 
al., 2011; Splinter et al., 2011). 3C, 4C, 5C, and Hi-C involve chemical cross-linking of the 
genomes capturing regions that are in close proximity, fragmenting chromatin (by digestion 
with restriction enzymes), religating cross-linked regions, and identifying the interacting 
regions by DNA sequencing (Hakim et al., 2012; Sanyal et al., 2011; Splinter et al., 2011). 
Most of these methods allow the unbiased and genome-wide mapping of interactions without 
prior knowledge of partners, thus permitting the discovery of new interactions. 
Chromosome conformation capture (3C) investigates previously selected regions and 
determines if there is an interaction between them (one versus one)(Dekker et al., 2002). 
Circular chromosome conformation capture (4C), is utilised to investigate all interactions with 
a chosen region, or ‘bait’, and can be detected through the use of next-generation sequencing 
(one versus many)(Simonis et al., 2006; Zhao et al., 2006). 4C is typically used to identify all 
genomic loci that interact with a particular gene or regulatory element. Chromosome 
conformation capture carbon copy (5C) detects all interactions within a genomic region (many 
versus many)(Dostie et al., 2006). Hi-C is determined from a promoter perspective and is used 
to analyse all interactions within a genome (Lieberman-Aiden et al., 2009). Hi-C allows for 
high throughput analysis and genome interaction maps to be created, which is valuable for 
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determining genomic structure. However, detection of specific local interactions is limited by 
its resolution, detection of local interactions is better achieved using 4C. 
1.5.5 Genome structure and disease 
Recent research shows that disrupting the boundaries of TADs severely alters the 
spatial organisation of a locus, which allows ectopic enhancer-promoter interactions and leads 
to aberrant expression of target genes (Gómez-Marín et al., 2015; Lupiáñez et al., 2015). 
Gómez-Marín et al., 2015 demonstrated that vertebrate Six genes share an evolutionarily-
conserved 3D chromatin architecture. When the conserved intergenic region containing the 
TAD border between six3 and six2 was removed, there was a dramatic change to the gene 
expression profile. This research demonstrates that evolutionarily-conserved TAD borders are 
crucial to prevent competition between promoters for enhancers in opposing regulatory 
landscapes (Acemel et al., 2017). This concept has been challenged by Williamson et al., 
(2019) who demonstrated that perturbations to the sonic hedgehog (Shh) TAD structure had 
little or no detectable effect on Shh expression patterns or levels of Shh expression during 
development (Williamson et al., 2019).  
Multiple studies have shown the 3D context of the genome is a key determinant in the 
development and progression of cancer. The probability of 3D contact between two loci 
influences the extent of somatic copy number alterations in cancer cells (Engreitz et al., 2012; 
Fudenberg et al., 2011; Zhang et al., 2012). Physical proximity is a major player of genomic 
rearrangements which result in translocations (Chiarle et al., 2011; Klein et al., 2011). 
Mutations to cohesin and CTCF have been shown to dysregulate 3D organisation of the 
genome and perturb normal development (Anania et al., 2020; Hnisz et al., 2016). 
Hypermethylation of specific CTCF sequences resulted in a loss of CTCF at a domain 
boundary, which caused aberrant expression of an oncogene (Flavahan et al., 2016). 
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Northcott et al., (2014) and Weischenfeldt et al., (2017) describe somatic variants that 
disrupt genome organisation, and result in enhancer jacking in cancer cells (Northcott et al., 
2014; Weischenfeldt et al., 2017). 
Disease-associated variants are found in regulatory elements and in genes with equal 
frequency, making these regions highly relevant to cancer (Ernst et al., 2011). More than 95% 
of genome-wide association studies (GWAS) single nucleotide polymorphisms (SNPs) are 
located in intergenic regions, of which over 75% are associated with open chromatin (DNase I 
HS sites) implying a strong association to regulatory elements (Maurano et al., 2012). A variant 
in a regulatory region may cause differential regulation of a cancer gene, and could be 
functionally equivalent to a mutation in the coding sequence of the cancer gene itself. Recent 
studies have shown alterations to regulatory regions reported in cancers (Zhang et al., 2020). 
It is therefore possible that mutations in enhancers or insulators may change their function, and 
subsequently could lead to altered regulation of key blood development gene(s) and the onset 
of leukaemia (Stranger et al., 2007).  
Understanding the connection between the 3D organisation of the genome and its 
underlying biological function will allow a better interpretation of human pathogenesis. 
1.5.6 Regulatory regions of Runx1 
Both the specific haematopoietic and non-haematopoietic expression of Runx1 appear 
to rely on enhancer elements, as the Runx1 promoters by themselves in vivo are unable to drive 
any Runx1-specific activity (Bee et al., 2009a). Antony et al., (2020) highlighted the enhancer 
regulated activity in aberrant megakaryocytic differentiation (Antony et al., 2020). 
Understanding Runx1 enhancers and how they contribute to Runx1 organisation is imperative 
to understanding the regulatory landscape of Runx1.  
Numerous groups recognised an intronic enhancer of Runx1 specific to haematopoietic 
cells. This mouse regulatory region is variously termed +23/ +24/eR1/RE1 (Bee et al., 2009a; 
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Koh et al., 2015; Markova et al., 2011; Ng et al., 2010; Nottingham et al., 2007). Significantly, 
this enhancer was shown to be active in haemogenic endothelial cells and haematopoietic cell 
clusters in the AGM equivalent region in both mice and zebrafish (Markova et al., 2011; Ng et 
al., 2010; Schütte et al., 2016). Bee et al., (2009) showed the enhancer worked with both 
promoters to drive HSC-specific gene expression (Bee et al., 2009a).  Interestingly, this well-
known enhancer was also described as a silencer in HEK293 cells (Markova et al., 2011). 
Other putative regulatory elements have been identified upstream of Runx1 and 
between the P1 and P2 promoters in humans and mice (Figure 1.9)(Cheng et al., 2018; Gunnell 
et al., 2016; Markova et al., 2011; Marsman, 2016; Marsman et al., 2017; Ng et al., 2010; 
Schütte et al., 2016; Wilson et al., 2016).  
Schütte et al., (2016) and Ng et al., (2010) identified 12 possible regulators of Runx1 
in mice, with some regions functionally validated (Ng et al., 2010; Schütte et al., 2016). My 
previous masters project investigated the functions of the putative regulatory regions described 
by Ng et al., (2010) (Thomas, 2015). Nine further putative regulators were identified because 
they physically interacted with Runx1 P1, P2 or +24 enhancer in mouse hematopoietic 
progenitor cells (Marsman, 2016) (Figure 1.9A). 
In humans, the interactions between RUNX1 promoters and two regulatory regions were 
identified using chromosome conformation capture for two regions (Cheng et al., 2018; 
Markova et al., 2011). Gunnell et al., (2016), characterised the functions of three potential 
RUNX1 regulatory elements (Gunnell et al., 2016) (Figure 1.9B).  
39 
 
Figure 1.9: Identified Runx1 regulatory regions.  
Regulatory elements are annotated with orange circles, grey boxes annotate exons. The blue boxes show the 
exons encoding the Runt binding domain. The two Runx1 promoters are represented by black right angled 
arrows A) Identified Human RUNX1 regulatory elements B) Identified mouse Runx1 regulatory regions. 
However, not all of these elements have been tested for regulatory functionality, nor 
examined for Runx1 promoter-enhancer interactions using chromosome conformation capture. 
Interaction between regulatory elements and promoters of the Runx1 gene cannot be predicted, 
as less than 50% of enhancers contact the nearest gene promoter. Previous research has used 
zebrafish to characterise the functional roles of regulatory elements in vivo and demonstrated 
the value of this animal model for studies of non-coding DNA (Bessa et al., 2009; Marsman et 
al., 2014). 
The spatiotemporal regulation of Runx1 is beginning to be understood; it is possible 
that mutations in regulatory regions may explain AML progression in patients who have no 
known protein-coding mutations, and perhaps in patients who have cohesin mutations. 
1.6 Zebrafish as a model organism 
 The small tropical zebrafish (Danio rerio) is an important model organism for a variety 
of studies. As developmental genes are highly conserved amongst vertebrates, development of 
zebrafish can be compared to that of the mice and humans (Bopp et al., 2006; Kari et al., 2007; 
Lieschke et al., 2007). Advantages of using zebrafish as an animal model for research include 
the zebrafish’s rapid development and ability to lay hundreds of eggs in each mating, allowing 
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for large sample sizes. Additionally, their small size means they are simple and cost-efficient 
to maintain and breed. In contrast to mammals, zebrafish eggs are externally fertilised and the 
resulting embryos develop outside of the mother. The embryos are transparent, which allows 
development to be easily visualised through a microscope (Teittinen et al., 2012).  
Zebrafish develop rapidly, with fish reaching sexual maturity by 3-4 months post-
fertilisation. All major organs are formed by 5 days post-fertilisation (dpf) (Haffter et al., 1996) 
(Figure 1.10). The zygote remains at the one-cell stage for approximately 40 minutes, allowing 
for injections of reporter constructs, which can reveal gene expression in the developing 
embryo. At ten hours post-fertilisation (hpf), somites and organs begin to form (Albacker et 
al., 2009). The zebrafish begin to hatch from their clear chorions at 48 hpf, and they are 
swimming freely by three dpf (Bopp et al., 2006). 
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Figure 1.10: Diagram of normal Danio rerio (zebrafish) development.  
A) 1-cell stage embryo approximately 20 minutes post fertilisation (pf). B) 2-cell stage embryo approximately 
40 minutes pf. C) Zebrafish embryo in clear chorion approximately 36 hours pf. D) Zebrafish embryo hatched 
from chorion approximately 48 hours pf. E) Zebrafish embryo 3-5 days pf. F) Zebrafish reach adulthood at 
approximately 3-4 months pf. Figure is from Thomas (2015).  
 
Although the fish genome is immensely rearranged compared to the human genome, 
several areas of local synteny and larger chromosomal regions are preserved (Martin et al., 
2011). The entire zebrafish genome has been sequenced and 70% of human genes have at least 
one obvious zebrafish orthologue (Howe et al., 2013). 
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1.6.1 Haematopoiesis in zebrafish 
The combination of visualisation, manipulation, and large-scale capabilities of 
zebrafish allows for novel genome-wide studies. Zebrafish are particularly informative for the 
analysis of haematopoietic development as blood circulation begins around 23-26 hpf within 
the transparent embryos (Albacker et al., 2009). Comparable to other vertebrates, 
haematopoiesis in zebrafish occurs in primitive and definitive waves (Paik et al., 2010; 
Rasighaemi et al., 2015). The zebrafish primitive wave of haematopoiesis arises within the 
intermediate cell mass (ICM) and generates primitive erythrocytes and limited myeloid 
populations (Figure 1.11A). The ICM is functionally analogous to the embryonic yolk sac in 
mammals (Davidson et al., 2004). These blood cells are seen in circulation until about four 
dpf. The first definitive HSC markers are seen at 26 hpf, in the ventral wall of the dorsal aorta 
(Figure 1.11B) (Kulkeaw et al., 2012; Orkin et al., 2008). The ventral wall of the dorsal aorta 
of zebrafish is the equivalent of the AGM in mammals (Martin et al., 2011). HSCs emerge by 
endothelial-to-haematopoietic transition in the dorsal aorta in zebrafish (Julien et al., 2016). 
Finally, in zebrafish the permanent niche of HSCs is the kidney marrow (Figure 1.11C), 
however in mammals, the permanent location for HSCs to seed is in the bone marrow 
(Albacker et al., 2009). 
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Figure 1.11: Schematic of haematopoiesis cell generation locations during zebrafish development.  
A) Primitive haematopoiesis occurs in the intermediate cell mass (blue) 12 hours post fertilisation (pf). B) 
Definitive haematopoiesis begins first in the ventral wall of the dorsal aorta (purple) 26 hours pf, then in the 
caudal haematopoietic tissue (orange) 2 days pf and finally in the kidney marrow (pink) 4 days pf. C) Kidney 
marrow (pink) is the life-long source of adult definitive haematopoiesis. Figure is from Thomas (2015). 
 
1.7 Overall hypothesis and aims of this PhD 
Runx1 has differing isoforms which are crucial to distinctive developmental and cell 
cycle processes. Runx1 is essential for definitive haematopoiesis and dysregulations of RUNX1 
are frequently associated with AML progression. Despite the well-established role of RUNX1 
in haematopoiesis and disease contribution, there is limited understanding of the regulatory 
mechanisms that drive cell-specific expression. 
Previous identification of the +24 Runx1 regulatory element as an enhancer in 
haematopoietic cells in zebrafish and mice, as well as dysregulation of a RUNX1 silencer 
element in a leukaemia patient has highlighted the importance of regulatory elements in driving 
correct RUNX1 expression. RUNX1-P1 expression is essential for megakaryocyte development 
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and is driven by enhancers. Investigating 3D structure of RUNX1 and functions of possible 
regulatory elements may reveal important regulatory connections and provide rationale for 
disease progressions. 
Cohesin is crucial in correct genome organisation and gene regulation, and enhancer-
promoter interactions. Cohesin mutations are frequently seen in myeloid malignancies and in 
several solid tumour types. The occurrence of RUNX1 and cohesin dysregulation in AML 
subtypes and in vitro models suggests these two factors are likely to play important roles in 
normal and abnormal haematopoiesis.  
The overall aim of my study is to explore the potential of regulatory regions and cohesin 
to modulate the transcription of Runx1.  
I hypothesise that regions that interact with Runx1 promoters and Runx1 +24  enhancer 
may have enhancer capabilities, and some may be conserved in humans. Furthermore, I predict 
RUNX1 +24 is an important regulator of RUNX1 expression during megakaryocyte 
differentiation, and coupled with reduced cohesin the correct genomic organisation cannot be 
maintained. 
To examine this hypothesis, first, I analysed the putative Runx1 regions 
bioinformatically, to establish genomic characteristics and conservation, in order to determine 
enhancer potential. I subsequently tested regions identified by 4C for functional ability and 
cell-type specific regulation using zebrafish reporter assays (Chapter 3).  
Second, I investigated RUNX1 +24 structural and genomic characteristics. I then 
identified the significant 3D connections of RUNX1 +24 using chromosome conformation 
capture (Chapter 4).  
Third, to elucidate important connections of RUNX1 +24 during normal megakaryocyte 
differentiation, I used chromosome conformation capture of megakaryocyte differentiation 
time points and compared them to the baseline RUNX1 +24 interactions. To understand how 
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cohesin and 3D chromosome organisation influences RUNX1 transcription and impacts disease 
progression, I compared the wild type differentiation interaction profiles to STAG2 mutant 
cells at the same time points of PMA stimulation (Chapter 5).  
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2 Chapter 2: Methods 
2.1 Ethics consent and protocol approval 
2.1.1 Zebrafish 
The University of Otago Animal Ethics Committee approved all zebrafish work (AEC 
#95/14). University of Otago Animal Welfare Office Animal Ethics Training was undertaken 
and any manipulations involved larvae no older than 30 days. Relevant work with transgenic 
Zebrafish was approved by IBSC/EPA (GMC100225, GMD101727). 
2.1.2 Escherichia coli (E. coli)  
All E.coli work was undertaken under the approval codes GMC100216, GMC100219, 
GMD101715, GMD101717. 
2.1.3 Cell culture 
All work with human cell lines was carried out under approval codes GMC100228, 
GMD101730. Animal cell line work was  performed under approval codes GMC100227, 
GMD101729. 
2.2 Materials 
All materials, solutions and buffers used in this study are listed in Appendix I.  
2.3 Molecular biology techniques 
The mouse regulatory elements were previously identified in Ng et al., (2010) and in 
Judith Marsman’s PhD (Marsman, 2016). 
2.3.1 Plasmids and reporter constructs 
Plasmids used in this project are listed in Table 2.1.  
To determine the regulatory potential of selected mouse regulatory regions in vivo, 
Zebrafish enhancer detector vector (ZED) and pGL4.23-GW reporter constructs were used. 
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mouse regulatory elements were previously cloned into ZED and pGL4.23-GW(Marsman, 
2016; Thomas, 2015). 
Maps of all plasmids are shown in Appendix II. 
 












across somites as 
internal control. 
Cell-specific GFP 
expression when an 
enhancer is cloned 
into vector.  
Ampicillin José Bessa lab, Institute 
for Molecular and Cell 
Biology, Portugal (Bessa 
et al., 2009) 
Zebrafish mRNA plasmid 
pCS-TP  Tol2 mRNA plasmid 
for integration of 
enhancer DNA into 
zebrafish 
Ampicillin (Kawakami, 2005) 
Cell Culture enhancer reporter plasmid 
pGL4.23-GW  Luciferase assay 
reporter construct 
Ampicillin Jorge Ferrer lab, 
Imperial Centre for 
Translational and 
Experimental Medicine, 
Imperial College London 
(Pasquali et al., 2014) 
Cell culture Luciferase control plasmid 











Quantity and quality of plasmid DNA, genomic DNA or RNA was measured by 
spectrophotometry, using a Nanodrop ND-1000, version 3.81 Spectrophotometer. 1 µL of 
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DNA or RNA was added to the well to measure sample purity and concentration by the 
absorbance spectrum of UV-visible light.  
2.3.3 Agarose gel electrophoresis 
To determine if the production of PCR, mRNA or a restriction digest was successful, 
products were run on an agarose gel. Unless otherwise stated 2 µL of PCR, mRNA or restriction 
digest product was mixed with 8 µL of 1x loading dye and loaded onto a 60mL 1% agarose 
gel, with 1x SYBR Green I (ThermoFisher) added before the gel set. A 1 kb plus DNA ladder  
(Invitrogen) was used as a marker of band sizes. Gels were run at 100 Volts for 1 hour, then 
visualised and photographed using a BioRad UV light transilluminator. 
2.3.4 Primer design 
To determine the best primers, the online program Primer3 was employed (Koressaar 
et al., 2007; Untergasser et al., 2012). Primers were selected based on optimised efficiency (i.e. 
Primer GC%, 18-13 bp length) and ordered from Integrated DNA Technologies. 
2.3.5 Sequence confirmation and alignment 
All sequence confirmations were carried out by Genetic Analysis Services (Department 
of Anatomy, University of Otago) according to their protocol using a capillary ABI 3730xl 
DNA Analyser. 200 ng of plasmid DNA was supplied for sequencing. Primer list is provided 
in Appendix III. 
To align sequences to their appropriate reference genome the sequences BLAST-like 
alignment tool (BLAT) was applied (Kent, 2002). Sequences were viewed using 4Peaks 
(Griekspoor et al., 2005). Ambiguous base calls were examined by eye and manually corrected 
if necessary.  
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2.3.6 Measuring Runx1 +24 enhancer G-quadruplexes  
To test the if Runx1 +24 enhancer contains G-quadruplex structures Circular dichroism 
(CD) photospectrometer was used.  
2.3.6.1 Runx1 +24 enhancer G-quadruplexes Oligo design 
The G-quadruplex oligos were designed directly from the mouse Runx1 +24 predicted 
G-quadruplexes (Appendix IV). A negative control Runx1 +24 oligo was also designed. The 
negative oligo should not be able to function as a G-quadruplex.  
Oligos (100 nM) were commercially synthesised (Integrated DNA Technologies, 
Singapore), and reconstituted in nuclease-free H2O. 
 
Table 2.2: Runx1 +24 enhancer G-quadruplexes Oligo 
Oligo Sequence 
Runx1 +24 G-quadruplexes Oligo GGTGGGGGTGGG 
Runx1 +24 negative Oligo GGTGTGTGTGGG 
 
 
2.3.6.2 CD Spectrophotometer protocol 
To determine if the predicted G-quadruplexes Runx1 +24 enhancer are present in vitro, 
CD spectrometer readings were used to measure ellipticity. 
4 µM of each oligonucleotide was heated to 95 °C for 10 minutes then left to cool 
(slowly in the heating block) to room temperature (22 °C) overnight for CD analyses the 
following day. CD experiments were carried out in different buffers: 100 mM KCl pH 7 
(positive control buffers) 100 mM NaCl, and 100 mM LiCl (negative control buffer). The 
desired buffer pH was adjusted by relative quantities of Na2H2PO4 /Na2HPO4.H20 and 
determined using a pH meter.  
CD measurements were performed on a CD Spectrophotometer (Department of 
Biochemistry, University of Otago) with a 1 mm path length quartz curvette (approx. 8000 
µL). CD spectra were collected across 340 nm to 220 nm in 1 nm increments (continuous 
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scanning) and the reported spectra corresponded to the average of at least two scans. An 
appropriate buffer blank correction was used for all spectra. The scanning speed of 200 
nm/minute was used for preliminary investigations, with a response of 1 second and a band 
width of 1 nm. 
CD melting studies were performed to measure if there was a change in ellipticity as a 
function of temperature across all wavelengths. Temperature was increased from 25 °C to 95 
°C at a rate of 0.25°C min-1.  
2.3.7 Site-Directed Mutagenesis of Runx1 +24 enhancer 
To test whether the G-quadruplexes were functionally important for Runx1 +24 
enhancer capability, pGL4.23-Runx1+24 G-quadruplex sites were mutated. Quikchange II 
Site-Directed Mutagenesis Kit (Agilent Technology) was used to mutagenise the Runx1+24 
enhancer within the pGL4.23-Runx1+24. 
2.3.7.1 Runx1 +24 enhancer Site-Directed Mutagenesis primer design 
Primers were designed using the online program QuikChange Primer Design 
(https://www.agilent.com/store/primerDesignProgram.jsp) to ensure the desired mutation 
(deletion or insertion) were in the middle of the primer with ~10-15 bases of correct sequence 
on both sides and had a minimum GC content of 40%. The list of primers is available in 
Appendix III. 
2.3.7.2 Mutant Strand Synthesis Reaction (Thermal Cycling) 
To generate point mutations in pGL4.23-Runx1+24, the mutant strand synthesis 
reaction was PCR amplified. PCR amplification was performed in an Applied Biosystem 
Thermal Cycler 2.08 as follows: 95 °C for 30 seconds; 12 cycles of 95 °C for 30 seconds, 55 
°C for 1 minute, 68 °C for 4 minutes, finally 72 °C for 2 minutes. Following temperature 
cycling, the reaction was cooled on ice for 2 minutes. 
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Table 2.3: Mutant strand synthesis reaction 
Ligation components Amount per 50µL (reaction 
volume) 
PfuUltra HF DNA polymerase reaction buffer (10x) 5 µL 
pGL4.23-Runx1+24 50 ng 
Oligonucleotide primer 2 125 ng 
Oligonucleotide primer 2 125n g 
dNTP mix 1 µL 
nuclease-free H2O to 50 µL 
PfuUltra HF DNA polymerase (2.5U/µL) 1 µL 
 
2.3.7.3 DnpI Digestion of the Mutant Strand Amplification Products 
1 µL DpnI (10U/µL) was added to the amplification reactions and incubated at 37 °C for 1 
hour to digest any nonmutated supercoiled template dsDNA. Plasmids were then transformed 
into competent cells (Section 2.3.8). 
2.3.8 Transformation of plasmids in competent cells 
All bacterial work was carried out using standard aseptic techniques. 
Competent Escherichia coli (E. coli) STABLE3 (One Shot) and XL1 Blue (One Shot) 
cells were used for transformation procedures. STABLE3 and XL1 Blue competent cells were 
prepared in house.  
pUC19 was used as a positive control for all transformations. All plasmid 
transformations were carried out with a LacZ recombination positive control and MilliQ H2O 
negative recombination control.  
1 µL plasmid DNA was added to a vial of E. coli competent cells and mixed gently and 
incubated on ice for 15 minutes. Samples were transferred to a water bath at 42°C for 30 
seconds before placing on ice. 250 µL prewarmed Luria Broth (LB) was added and cells were 
incubated at 37 °C for 1 hour with shaking (200 rpm). 
After transformation, cells were spread on agar plates containing appropriate antibiotic, 
Ampicillin (Sigma-Aldrich). The plates for the LacZ transformation control contained 50 µL 
of 20 mg/mL X-gal (Sigma-Aldrich). 50 µL of competent cell mixture was spread on the first 
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half of the prewarmed plate, before cells were pelleted by centrifugation. Most of the 
supernatant was discarded, and all remaining cells were resuspended in the remaining 
supernatant and spread on the other half of the selective plate. Plates were incubated at 37 °C 
overnight. 
Recombination efficiency was identified by the blue/white colony ratio on the LacZ 
plate. 2-4 individual colonies from successful transformations were picked with a wire loop. 
Bacteria were then incubated at 37 °C overnight with shaking (200 rpm) in starter culture (4 
mL LB containing 100 µg/mL of the appropriate antibiotic). 
To prepare a large amount of plasmid, 1 mL of starter culture was added to 99 mL of 
LB containing 100 µg/mL of the appropriate antibiotic, this was incubated at 37 °C overnight 
with shaking (200 rpm). 
To establish glycerol stocks of each successful transformation, 750 µL of the starter 
culture was combined with 250 µL of glycerol (VMR Prolabo) and stored at -80°C. 
2.3.9 Plasmid purification preparation 
After glycerol stocks were made, the remaining bacterial culture was centrifuged at 
13,300 g for 1 minute and the supernatant was discarded. Plasmids were prepared using the 
Qiagen plasmid Miniprep kit for initial restriction enzyme digestion or sequencing 
confirmation. Preparation of plasmids for experiments used the Macherey-Nagel maxi prep kit; 
both were executed according to manufacturer’s manual. Plasmid DNA was eluted in 40 µL or 
500 µL of elution buffer (5 mM Tris-HCl pH 8.5)  respectively and stored at -20 °C.  
2.3.10 Tol2 transposase mRNA synthesis 
Tol2 sites permit transposon-mediated integration into the zebrafish genome with high 
efficiency in the presence of Tol2 transposase mRNA (Kawakami, 2005). In order to 
successfully integrate ZED reporter construct into zebrafish host genome, Tol2 mRNA is 
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required (Bessa et al., 2009). Ambion mMESSAGE mMACHINE® kit was used for in vitro 
synthesis of large amounts of capped mRNA. To confirm successful mRNA synthesis the 
product was run on a 1% agarose gel according to section 2.3.3. 
2.4 In vivo Zebrafish approaches 
Feeding, maintenance and breeding were performed according to the Otago Zebrafish 
Facility Standard Operating Procedures.  
2.4.1 Zebrafish strains 
The strains of Zebrafish used in this project were wild-type (WT) AB/PS, and (WT) 
WIK. AB/PS is an in-house line, previously created by outcrossing an AB fish with a pet-shop 
fish. Transgenic lines created in this project were outcrossed onto Tübingen long fin (TL) fish 
for easy differentiation between the transgenic and WT lines. 
2.4.2 Maintenance 
Zebrafish (Danio rerio) were housed in the Otago Zebrafish Facility (OZF), Pathology 
Department, University of Otago, Dunedin. Each tank was kept at a temperature of 24-30 °C, 
pH of 6.5-8.5 and a conductivity of 200-1000 µS. Water in the facility was purified using 
ZebTEC system (Techniplast) of biological filters and UV light. Stocking density was 
maintained at or below the maximum number of fish per 3.5 L tank; 15-20 adults or 20-30 
younger fish (5-40 days old).  
2.4.3 Feeding 
Zebrafish were fed three times a day; two dry feedings and one live feeding. The dry 
feed (ZM Ltd) was given morning and evening. The live feed was given to adult Zebrafish in 
the afternoon and consisted of artemia (brine shrimp). Younger fish were given rotifers, as they 
are smaller than artemia.  
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2.4.4 Breeding and embryo collection 
Wild type Zebrafish breeding pairs were set up in specialised breeding tanks the 
afternoon prior to embryo collection. The tanks contain a false bottom and a removable barrier 
to separate male and females. The false bottom allows the eggs to fall through once they are 
laid to prevent the parents consuming them. The natural internal breeding cue is light. The OZF 
has automated lighting; from 10 pm until 8 am it is dark. Removal of barriers allows the 
zebrafish to mate. To regulate breeding, barriers are removed from the tank just prior to 
collection. 
Embryos are collected through a fine sieve 10 minutes after laying, washed twice with 
system water and transferred to a petri dish with E3 embryo medium. E3 medium promotes 
growth and survival. Methylene blue (Sigma-Aldrich) is also added as it acts as an anti-fungal 
agent, as zebrafish eggs are prone to fungal infection. 
2.4.5 Growing embryos 
Embryos are grown in a petri dish in E3 medium at 28.5 °C for normal development or 
22.5 °C for slower development. The embryos hatch naturally at 2-3 days post fertilisation or 
the chorion can be removed earlier using #55 Dumont Forceps. When the chorions are 
discarded the media is changed to E3 without methylene blue. 
2.5 Zebrafish microinjection  
2.5.1 Needle pulling and calibration 
A 1.0 mm OD borosilicate glass capillary (Harvard Apparatus) was pulled to form 2 
needles using pulling programme 6 (P= 500, Heat= 600, Pull= 50, Vel = 75, Time= 120) on a 
Sutter p-97 Flaming/Brown glass micropipette puller. 
Injection solutions were well mixed and 2 µL loaded with a microloader pipette into 
the needle. The needle was placed in the needle holder of an air-pressure MPPI3 system. 10 
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µL of Halocarbon oil 27 (Sigma-Aldrich) was pipetted onto a stage micrometre calibration 
slide. Pressing the injection pedal released a droplet of injected solution, which floated on the 
oil. The drop was measured to ensure it was 1 nl (Figure 2.1). Clean forceps were used to trim 
needle tip and pulse duration was adjusted to change drop size when necessary. The pulse 
duration of the pressure injector was set between 4.5 and 6.5 to minimise needle breakage and 
embryo damage. 
 
Figure 2.1: Calibration slide with close up of 1 mm scale, each division is 0.01 mm. 




Injections were achieved by lining embryos up on a ridged plate and, under 
magnification of a Leica M80 microscope, guiding the needle tip through the chorion to pierce 
the yolk sac. 
ZED injections were optimised and the following concentrations were injected 30ng/µL 
ZED vector DNA, 120 ng/µL Tol2 transposase mRNA and Ultrapure DNase – RNase free 
distilled H20. 
The vector solutions were directly injected into the yolk sac at the one cell stage, to 
ensure the dividing cell could uptake and integrate the plasmid into the host genome. For each 
injected group, uninjected controls of the same batch were kept to observe normal development 
and death rates. 
2.5.3 Microscopy 
In order to screen embryos for fluorescence, embryos were anaesthetised in 0.5ng/µL 
tricaine and placed on a microscope slide. GFP3 and dsRED2 filters were applied to view 
fluorescence.  
If fluorescence was observed, samples were removed from E3 tricaine solution and 
embryos were mounted in 3% methylcellulose (Sigma-Aldrich). The dechorionated embryos 
were orientated with anterior on the left and dorsal at the top. Embryos were first imaged with 
bright field, and then filters were employed to photograph the fluorescence.  
Images were taken using a Leica M205 fluorescence microscope on the Leica 
Application software.  
2.6 Transgenic zebrafish analysis 
To find out the function of the putative enhancers identified by Dr. Judith Marsman 
ZED zebrafish reporter assays were used. DNA sequences of the putative enhancers were 
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previously cloned into ZED reporter constructs, then injected into the first cell of zebrafish 
embryos. The enhancer test vectors contain Tol2 transposon sites which allow the reporter gene 
constructs to be integrated into the gDNA. Transient expression of assays can be analysed in 
F0; however, the F1 generation contain a germ line integration of the constructs, to avoid the 
problem of a mosaic expression pattern seen in F0.  
2.6.1 Zebrafish enhancer assay 
ZED F0 embryos were dechorionated  then imaged at 20-24 hours post fertilisation (hpf) 
or 40 hpf using a Leica M205FA stereomicroscope and were imaged with a DFC490 camera 
and LAS software (Leica Microsystems), images were processed using Adobe Photoshop. 
ZED F1 embryos were also viewed at 20-24 hpf or 40 hpf 72 hpf and embryos with  
were examined for GFP.  
2.7 In vitro Cell culture and maintenance of cell lines 
2.7.1 Cell lines  
Cell lines were stored in a Thermo Scientific liquid nitrogen dewar. All cells were 
maintained at 37 °C in a humidified environment with 5% CO2 incubator 
HPC7 cell line was cultured in Isocove’s Modified Dulbecco’s Media (IMDM) 
containing 10% fetal bovine serum (FBS) (Gibco, Life Technology) and 10% stem cell factor 
(SCF) conditioned media, 1% Penicillin Streptomycin (P/S), 1.5x 10-4 M monothiolglycerol 
(MTG).  
BHK/MKL was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 
10% FBS. These cells contain a mouse SCF expression vector and the media collected from 
these cell lines was used to produce SCF used for HPC7 media.  
PNX and NIH/3T3 were cultured in DMEM containing 10% FBS.  
K562 and K562 cell line variations were cultured in IMDM containing 10% FBS. 
Differentiation to megakaryocytes was induced using 30 nM of phorbol 12- myristate 13-
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acetate (Kuvardina et al., 2015)(PMA, Sigma-Aldrich). Control treatment of K562 cell line 
variations used Dimethyl Sulfoxide (DMSO)(Sigma-Aldrich), which was prepared in the same 
way as PMA. 
Table 2.4: Cell lines used in this study 




IMDM  + 10% 
fetal bovine 
serum (FBS). 
Sourced originally from 
ATCC (p10) 
(Lozzio et al., 1975) 
K562 STAG2 
R614* -/- 
IMDM + 10% 
FBS 
Generated by Dr. Jisha 
Antony, a Postdoc in the 
Horsfield lab (p20) 
(Antony et al., 2020) 
PNX (Phoenix 
cells)  
DMEM + 10% 
FBS 
Sourced originally from 
Braithwaite lab 
(Pathology department, 
University of Otago, 
Dunedin, New Zealand) 





SCF + 10% 
FBS + 1% P/S, 
1.5x 10-4 M 
MTG 
Sourced originally from 
Kathy Knezevic (Lowy 
Cancer Research centre, 
Sydney, Australia) 




DMEM + 10% 
FBS 
Sourced originally from 
Kathy Knezevic (Lowy 
Cancer Research centre, 
Sydney, Australia) 




DMEM + 10% 
FBS 
Sourced originally from 
Braithwaite lab (p15) 
(Pathology department, 
University of Otago, 
Dunedin, New Zealand) 
(Todaro et al., 1963) 
 
2.7.2 Reviving cells from liquid nitrogen stocks 
Cell vials were removed from liquid nitrogen stocks and transferred on ice to 37 °C 
water bath. Vials were rapidly thawed and the cell suspension added to 10 mL of pre-warmed 
media in 15 mL falcon tube. Cells were pelleted by centrifugation (250 g for 5 minutes) and 
supernatant was aspirated. Cells were resuspended in 10 mL of fresh media and plated in a 
medium culture flask. 
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2.7.3 Splitting cells for new passage 
2.7.3.1 Adherent cells (PNX, BHK/MKL, NIH/3T3) 
The cells were allowed to form a monolayer and reach 70-90% confluence before 
splitting for a new passage. The media was carefully aspirated and adherent cells were washed 
with phosphate buffered saline (PBS). 0.005% trypsin (Life Technologies) was added and flask 
was then incubated at 37 °C for 3-5 minutes. Media was added to flask to deactivate trypsin. 
Cells were gently pipetted up and down to create a single cell suspension. Cells were spun at 
250 g for 5 minutes and media was removed. The pellet was resuspended in fresh media to 
create single cell suspension. 1 mL of cell suspension was added to a new culture flask with 10 
mL fresh media to make a new passage. 1 mL of suspension was collected for cell counting 
(Figure 2.2). Number of cells/mL was determined using a haemocytometer slide on a 
microscope stage or Luna automatic cell counter.  
2.7.3.2 Suspension cells (K562, HPC7) 
Cells were observed every day for signs of growth. 1 mL of cell suspension was counted 
each day to determine growth patterns and when the cell density reaches 0.7-0.8x106 cells/mL 
the culture was split to approximately 0.4x106 cells/mL with fresh media. Number of cells/mL 
was determined using a haemocytometer slide on a microscope stage. Cells were spun at 250 
g for 5 minutes and media was removed and the pellet was resuspended in fresh media. 
2.7.3.3 K562 STAG2 R614-/- mutant lines 
Cells were semi-adherent so were grown in suspension cell flasks and treated as 
suspension cells (Section 2.7.3.2). 
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Figure 2.2: Haemocytometer slide used for counting cells, each shaded grid is 1 mm2.. 
The black circles represent cells in the grid. The number of cells in each shaded grid is counted. The average is 
determined by dividing the total by 5. The number of cells/mL is calculated by grid averaged dilution factor (2)x 
10 000 
 
2.7.4 Freezing cells for liquid nitrogen storage 
Single cell suspension (2.7.3) cells were centrifuged for 5 minutes at 250 g and 
supernatant removed. The pellet was gently suspended in equal parts media and cryoprotectant 
(20% DMSO in FBS), 500 µl of each per intended vial of frozen cells except for K562 and 
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K562 cell line variations which were suspended in media and 5% DMSO 1 mL per intended 
vial. The cell suspension was aliquoted into each cryovial and then transferred to Nalgene Mr 
Frosty. Mr Frosty was stored at -80 °C overnight then transferred to the liquid nitrogen dewar. 
2.8 Expression analysis 
2.8.1 Total RNA purification 
To examine gene expression in cell lines, RNA was extracted from K562 and K562 
STAG2 R614* mutant cell lines. Cells (5x105) were collected by centrifugation. The extraction 
procedure was carried out in accordance with the RNA purification method described in 
Macherey-Nagel user manual. Concentration and purity of RNA was determined by Nanodrop 
technique described in section 2.3.2. RNA was eluted in 40 µL Ultrapure DNase – RNase 
free distilled H2O (Life Technology) and stored at -80 °C until required.  
2.8.2 cDNA synthesis 
Complementary DNA (cDNA) was synthesised from the RNA extracted in section 
2.8.1 using 4 µL of qScript  cDNA SuperMix (Quantabio), 500 ng of total RNA and RNase-
free H2O in a 20 µL reaction. Reverse transcription was performed in an Applied Biosystem 
Thermal Cycler 2.08, at 25°C for 5 minutes, 42 °C for 30 minutes and finally 85 °C for 5 
minutes. cDNA products were stored at -20 °C until required.  
2.8.3 Quantitative reverse-transcriptase PCR (qRT-PCR) 
qRT-PCR is a technique that quantitatively measures RNA following cDNA 
conversion. This is achieved through real-time PCR. qRT-PCR was used to measure 
endogenous ERG, KLF1, P1-/P2- generated, and total RUNX1 expression in K567 and K562 




Figure 2.3: Quantitative PCR primer locations at human RUNX1.  
Schematic of human RUNX1 gene and transcripts are shown with exons in boxes and the 5’ and 3’ untranslated 
regions in white. P1 and P2 promoters are indicated with a black hooked arrow. Primers used for analysis of P1, 
P2 and total RUNX1 transcript expression by quantitative PCR are indicated with black arrowheads.  
 
Relative gene expression was normalised to reference genes H-CYCLOPHILIN and 
GAPDH. Dr. Jisha Antony previously validated each primer for 80-100% efficiency, with an 
external standard curve, generated by serial dilutions of the cDNA. A list of primers is available 
in Appendix III. 
qRT-PCR mix was made for each primer set, in each cell line (Table 2.5).  
Table 2.5: qRT-PCR reaction mix 
Reagent Amount per 20µL (reaction volume) 
cDNA (500 ng) 1 µL 
3µM Forward primer 1 µL 
3µM Reverse primer 1 µL 
SYBR  Green (2x)  10 µL 




qRT-PCR was performed using LightCycler® 480 Instrument II (Roche Life Science) 
using the following programme: 95 °C for 30 seconds and 40 cycles of 95 °C for 5 seconds, 60 
°C for 30 seconds.  
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Analysis was carried out using qBase software, which utilised the ∆∆CT method. Graphs were 
created using Prism 7 (GraphPad). 
2.8.4 pGL4.23 Transfection  
To determine the ability of the Runx1 +24 G-quadruplex to act as an enhancer in mouse 
cells lines, NIH/3T3 cells were transfected with the pGL4.23 +24, pGL4.23 +24 g->t ,  
pGL4.23 +24 t->a. Cultures were plated in a 96-well plate at 8x 103 cells per well, and cells 
were 30-50% confluent at time of transfection. Cells were transfected using Lipofectamine 
3000 (Invitrogen) according to the manufacturer’s instructions. Plates were incubated at 37 °C 
for 48 hours. A Renilla luciferase reporter construct was co-transfected with the mouse 
regulatory elements pGL4 reporter constructs. Firefly and Renilla luciferases have distinct 
evolutionary origins and dissimilar enzyme structures and substrate requirements. Renilla acts 
as a transfection control.  
Table 2.6: Transfection components per well 
Component per well  Amount per well 
 Adherent cells 8x103 cells 
Lipofectamine 3000 
dilution 
Opti-MEM Media (Gibco, Life 
Technology) 
5 µL 
Lipofectamine 3000  0.2 µL 
Master Mix 
 
Opti-MEM Media 5 µL 
Plasmid DNA  50 ng 
P3000 Reagent 0.2 µL 
Renilla 20 ng 
 
 
2.8.5 pGL4.23 Transfection analysis 
If pGL4.23-GW contains an enhancer there should be an increase in expression of 
luciferase, which can be determined with a luminometer. Dual-Glo Luciferase Assay System 
(Invitrogen) was used according to manufacturer’s instructions to measure luminescence. 
Dual-Glo Reagent was added in equal parts to the volume of culture medium and mixed well. 
Firefly luminescence was measured by Victor X3 plate reader after 10 minutes. Dual-Glo 
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Stop & Glo Reagent, equal to the original culture medium, was added to each well and mixed. 
After 10 minutes Renilla luminescence was measured by Victor X3 plate reader.  
2.8.6 Statistical analysis of luciferase assays 
All analyses were performed in Prism 6. Significance of the differences observed was 
assessed using ANOVA. 
2.9 In silico approaches for Enhancer analysis  
Genomic sequences surrounding the Runx1 locus for human (Homo sapiens) and mouse 
(Mus musculus) were obtained from publicly available genome assemblies [human 
(GRCh38/hg38 and GRCh37/hg19) assembly, and mouse (mm9 and mm10) assembly] on the 
UCSC genome browser (Kent et al., 2002; Waterston et al., 2002). All genome alignments 
were performed in accordance with previous Ng et al., 2010 alignments (Ng et al., 2010).  
2.9.1 Epigenetic analyses using ENCODE data 
ENCODE is the Encyclopaedia of DNA elements, a publicly available database of 
functional protein, RNA and DNA elements in the human and mouse genomes, including 
epigenetic marks and regulatory factors. Numerous other genomes are available for analysis 
(Rosenbloom et al., 2013), but were not used in this study. To identify any patterns in 
functionally validated regulatory elements as enhancers, various haematopoietic cell lines were 
selected for analysis (Table 2.7). The ENCODE datasets were used to detect the presence of 
various histone modifications, DNase I hypersensitivity sites, transcription factors and cohesin 
binding sites (Table 2.8) (Barski et al., 2007; Raney et al., 2014; Rosenbloom et al., 2013; 
Wilson et al., 2016). Analysis of ENCODE annotations was carried out using data submitted 
by Stanford, Yale, University of Washington (UW) and Ludwig Institute for Cancer Research 
(LICR).  
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In order to visualise the combined ENCODE cell line data, all sequences were 
annotated using Geneious, program version R8.0.4 (Biomatters) (Kearse et al., 2012). 
To determine the enhancer locations in different genome assemblies UCSC ‘liftOver’ 
tool was utilised to convert coordinates within a species (Rosenbloom et al., 2013). 
To determine the human genome co-ordinates for functionally validated Runx1 
enhancers, the identified enhancer sequences were searched using UCSC BLAT tool and NCBI 
BLAST tool (Altschul et al., 1990; Kent, 2002). More genomic features of the conserved 
enhancer regions were deduced by analysing the human coordinates using FANTOM 5 
(Andersson et al., 2014; Lizio et al., 2015) and UCSC Genome Browser (Table 2.8).  
ENCODE also has Chromatin State predictions (ChromHMM) for K562 cells (Kellis 
et al., 2017). ChromHMM annotates the data based on epigenetic information. The predicted 
chromatin states are active promoter, promoter flanking, inactive promoter, candidate strong 
enhancer, candidate weak enhancer, distal CTCF/candidate insulator, transcription associated, 
low activity proximal to active states, polycomb repressed, and heterochromatin /repetitive 
/copy number variation. Transcription associated refers to transcriptional transition or 
elongation (Ernst et al., 2010; Ernst et al., 2011). 
Further regulatory markers for K562 cells were uploaded into UCSC genome browser 
including; super-enhancers (Khan et al., 2016), silencers (Pang et al., 2020), cohesin mediated 
chromatin accessibility (Antony et al., 2020). 
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Table 2.7: Analysed cell lines 
Cell line Origin 
K562 Human Chronic Myelogeneous 
Leukaemia cells 
 
Table 2.8: Analysed ENCODE annotations 
Regulatory association ENCODE annotation 
Open chromatin DNase I hypersensitivity (HS) 
Transcription initiation RNA Pol II (phosphorylated at serine 
5) 
Cohesin (subunit) RAD21, SMC3 
CTCF binding sites CTCF 
Histone acetyltransferase that is recruited to 
transcriptionally active enhancers (an 
increase in the expression of target genes) 
p300 
H3K4me1/2 demethylase (mediates 
transcriptional repression) 
LSD1 
Super-enhancer previously annotated by 
Khan et al., (2016) 
K562 Super-enhancers  
Silencer previously annotated by Peng et 
al., (2020) 
Silencers  
Cohesin mediated chromatin accessibility 
previously annotated by Antony et al., 
(2020) 
Chromatin sites that show increased 
accessibility in the absence of cohesin  
Chromatin State  ChromHMM 
Enhancer Enhancer-associated 
histone methylation or 
acetylation marks 
H3K27ac, H3K4me1, H3K4me2 
Active promoters H3K27ac, H3K9ac, H3K4me3 




Erythroid development GATA1 
Haematopoietic SPI1 
Blood/ Stem progenitors TAL1,GATA2  
 
2.9.2 Comparative analysis of cancer genomic datasets 
To assess whether any AML patients had mutations in the conserved regulatory 
elements regions, publicly available cancer genomic datasets were explored. Online tools were 
used to categorise publicly available patient information, into different tumour types for 
analysis. Sequence data at the RUNX1 locus was downloaded from all available AML cases.  
The large-scale cancer genomics datasets were retrieved from International Cancer 
Genome Consortium (ICGC) Data Portal [human Feb. 2009 (GRCh37/ hg19) assembly] 
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(Hudson et al., 2014; Zhang et al., 2011), The c-BioPortal for Cancer Genomics [human Feb. 
2009 (GRCh37/ hg19) assembly] (Cerami et al., 2012; Gao et al., 2013) and The Cancer 
Genome Atlas (TCGA) Data Portal [human Mar. 2006 (NCBI36/ hg18) assembly](CGARN, 
2013).  
2.9.3  Single nucleotide polymorphism (SNP) analysis 
To deduce if there were any reported SNPs in each region GWAS catalog 
(GRCh38/hg38) (Buniello et al., 2019), HaploReg v4.1 (GRCh37/hg19)(Ward et al., 2016) 
were used. GWAS catalog shows SNPs chromosome locations and highlights any publications 
that report on the function of that SNP. HaploReg v4.1 displays the genome characteristics and 
transcription factor binding  data for each SNP and predicts  regulatory motif changes.  
To establish if any SNPs had a minor allele frequency (MAF) of >1% Genotype-Tissue 
Expression (GTEx) portal v8 (GRCh38/hg38) (https://gtexportal.org/home/) was used. 
gnomAD browser (Karczewski et al., 2020) v2 1.1 (GRCh37/hg19) and v3 (GRCh38/hg38) 
reviewed SNPs with MAF >1% for any ClinVar associations and/ or publications.  
To identify which genes a SNP physically interacts with, the CoDeS3D pipeline 
(Fadason et al., 2017) was used to interrogate Hi-C chromatin interaction libraries. This 
pipeline identifies interactions across the genome with the SNPs, and then identifies SNPs 
where the genetic variant correlates with the expression level of the spatially associated partner 
gene [the SNP is an expression quantitative trait locus (eQTL)]. 
2.10  Circular Chromatin Conformation Capture (4C) 
Circular chromatin conformation capture (4C) was used to elucidate the all interactions 
with a chosen region or ‘bait’ (Figure 2.4). 4C sequencing libraries were prepared from 4C 
material, each containing PCR products amplified by bait-specific primer pairs. Chromatin 




Figure 2.4: Schematic outline of 4C process.  
Chromatin in close contact is cross-linked using formaldehyde (1), then digested with the 1st Restriction Enzyme 
(RE) (2). Chromatin is ligated  to fuse the RE cut ends of DNA fragments (3). Chromatin is reverse cross-linked 
using heat (4), then digested by a 2nd RE (5). DNA fragments are then ligated to form small circles, then regions 
of interest are PCR amplified using bait specific primers (6). Regions of interest are then deep-sequenced (7). 
2.10.1 4C Design 
To determine the best primers for the chosen 4C bait regions (P1-RUNX1, P2-RUNX1, 
RUNX1+24, ERG+85), the sequences for each bait were searched for possible restriction 
enzyme digest sites. An appropriate primary restriction enzyme would leave a bait fragment of 
>500 bp for 4-bp cutters or >1500 for 6-bp cutters. An appropriate secondary enzyme would 
chop the bait to be ideally >250 bp long. Once appropriate enzymes were selected, the online 
program Primer3 was employed (Koressaar et al., 2007; Untergasser et al., 2012). All primers 
were aligned to the genome using BLAST and BLAT. Primers were selected based on 
optimised efficiency (i.e. Primer GC%, 18-13 bp length, shortest length to the restriction 
enzyme site) and ordered from Integrated DNA Technologies. Primers are listed in Appendix 
III. 
2.10.2 Cross-linking of K562 cells 
37% fomaldehyde was heated up to 65 °C for 15 minutes whilst vortexing every five 
minutes then left to cool to room temperature. Two million cells in 20 mL petri dish were cross-
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linked in 2% formaldehyde by addition of 1.1 mL of 37% formaldehyde to media, and mixed 
into media with gentle swirling. Cells were then incubated with gentle rocking in a hybe oven 
at 21 °C for 10 minutes. To stop cross-linking activity, 1 mL of 2.5 M glycine was added to 
media with gentle swirling and then incubated for 5 minutes on ice with occasional swirling. 
Cells were scraped off the dish and into a 50 mL falcon tube. Cells were spun at 250 g for 8 
minutes at 4 °C. The supernatant was decanted, cells were washed (not resuspended) with 10 
mL ice-cold 1x PBS and centrifuged at 250 g for 8 minutes at 4 °C. The supernatant was 
decanted, cells were resuspended with 10 mL ice-cold 1x PBS and centrifuged at 250 g for 8 
minutes at 4 °C. The supernatant was removed with a 10 mL pipette and the remaining volume 
was removed with a p200 pipette. Pellets were stored at -80 °C.  
2.10.3 Isolation of nuclei 
Frozen pellets were resuspended in 10 mL lysis buffer (Appendix I) (1 mL first) and 
incubated on ice for 30 minutes. Cells were Dounce homogenised 10 times up and down, then 
centrifuged at 600 g for 5 minutes at 4 °C. The supernatant was removed and the pellet was 
resuspended in 1 mL of ice-cold PBS and transferred to 1.5 mL Eppendorf tube. Cells were 
centrifuged at 600 g for 5 minutes at 4 °C. The supernatant was decanted and the remaining 
volume removed using a p200 pipette.  
2.10.4 First Digestion 
The pellets from 1.11.3 contain 2 million cells. Pellets of the same samples were 
combined for a total of 4 million cells. Four million nuclei were resuspended in 76 µL 
Ultrapure DNase – RNase free distilled H20 and 4 µL 10% sodium dodecyl sulfate (SDS) 
and incubated at 60 °C for 10 minutes. SDS was neutralised by addition of 26.72 µL 15% 
Triton X-100 and 245.28 µL Ultrapure DNase – RNase free distilled H20, then incubated at 
37 °C for 20 minutes. Any aggregate was broken up every 5 minutes. 16 µL of sample was 
taken out as undigested control and stored at -20 °C. 80 µL restriction buffer and 14 µL DpnII 
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restriction enzyme (50,000U/mL) (for 4 million cells; increased proportionally for more cells) 
were added and the total volume was made up to 800 µL with Ultrapure DNase – RNase free 
distilled H20. Samples were digested with tubes placed horizontally at 37 °C for 4 hours without 
shaking. Every 10 minutes for the first hour and every 30 minutes after that samples were 
gently mixed by inverting the tube. Lids were sealed with parafilm to prevent evaporation. 
After digestion, 32 µL of sample was taken out as the digested control and stored at -20°C. 
To analyse digestion success, undigested and digested controls were treated with 
Proteinase K (Invitrogen). The undigested sample had 2.5 µL of 10 mg/mL Proteinase K and 
70 µL of 10 mM Tris-HCl pH 7.5 added. The digested sample had 5 µL of 10 mg/mL Proteinase 
K and 58 µL of 10 mM Tris-HCl pH 7.5 added, and both samples were incubated at 65 °C for 
1 hour. 20 µl of each sample was run on 0.6% agarose gel for 1 hour at 100 Volts.  
2.10.5 First restriction enzyme inactivation  
The first restriction enzyme was heat inactivated at 65 °C for 20 minutes 
2.10.6 Ligation 
Two 15 mL Falcon tubes were prepared for ligation; one for ligated sample and one for 
non-ligated sample. Both the samples had 2336 µL of Ultrapure DNase – RNase free distilled 
H20 800 µL ligase buffer, 40 µL adenosine triphosphate (ATP) and 784 µL of sample added. 
For the ligated sample, 40 µL Invitrogen T4 DNA ligase (500 U at 1 U/µL). For the non-ligated 
sample 40 µL of Ultrapure DNase – RNase free distilled H20 was added. Samples were 
incubated at 16 °C overnight while shaking vertically at 30 rpm. After incubation at 16 °C, 
samples were incubated at room temperature for 30 minutes. After ligation, 90 µL of sample 
was taken out as ligated and non-ligated controls and stored at -20 °C. 
To check ligation efficiency, ligated and non-ligated controls were treated with  5 µL 
of 10mg/mL Proteinase K at 65 °C for 1 hour. 40 µL of ligated and non-ligated controls were 
run alongside 20 µL of digested control on 0.6% agarose gel for 1 hour at 100 Volts.  
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2.10.7 Reverse cross-linking and DNA purification 
To reverse crosslink samples, 75 µg (7.5 µL of 10 mg/mL) of Proteinase K was added 
to ligated and non-ligated samples and incubated overnight at 65 °C. For samples that were 
treated with PMA for 72 hours, 150 µg of Proteinase K was added and samples were incubated 
overnight at 65 °C.  
RNA was degraded by addition of 75 µg (7.5 µL of 10 mg/mL) RNaseA to samples 
and incubation at 37 °C for 45 minutes. 
DNA was purified by phenol/chloroform extraction. An equal volume of 
Phenol:Chloroform:Isoamyl Alcohol 25:24:1 (Sigma-Aldrich) was added to the samples. 
Samples were vortexed for 30 seconds and spun at 4000 g (maximum speed) for 15 minutes at 
room temperature. The aqueous phase was transferred to 15 mL Falcon tubes.  
DNA was ethanol precipitated by adding 3 M NaOAC pH 5.6 to a concentration of 240 
mM and 2.5 volumes absolute ethanol (Scharlab). Samples were vortexed and incubated at -80 
°C for 1.5 hours or until frozen solid. Samples were centrifuged at 4000 g for 1 hour at 4 °C. 
The supernatant was discarded and 5 mL of 70% ethanol was added. Samples were spun at 
4000 g for 15 minutes at room temperature. The supernatant was discarded and tubes were re-
spun to collect any residual solution. Residual supernatant was removed using a p200 pipette. 
Pellets were air-dried for around 10 minutes at room temperature and resuspended in 400 µL 
of 10 mM Tris-HCl pH 7.5. 
To check DNA purification of the undigested and digested sample, 60 µL of the sample 
was taken out, 20 µL of which was run on 0.6% agarose gel for 1 hour at 100 Volts.  
2.10.8 Second digestion 
Samples were transferred to 1.5 mL tubes for digestion with CviQI. 40 µL of 10x 
Buffer, 340 μL of sample and 80 U (8 μL) of 10000 U/mL CviQI and 12 µL of Ultrapure 
DNase – RNase free distilled H20 (for a total of 400 µL), were digested overnight at 25 °C 
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while shaking with tubes placed horizontally at 30 rpm. Lids were sealed with parafilm to 
prevent evaporation. After digestion, 10 µL of each sample was taken out as digested control 
and combined with 100 µL 10 mM Tris-HCl pH 7.5 and stored at -20 °C. 
To analyse digestion success, 20 μL of digested samples were run on a 0.6% agarose 
gel for 1 hour at 100 Volts alongside purified ligated samples (Section 2.10.6). 
2.10.9 Removal of second restriction enzyme 
As CviQI cannot be heat inactivated, phenol:chloroform extraction was used to remove 
restriction enzyme. Total volume was made up to 400 µL with Ultrapure DNase – RNase 
free distilled H20, then an equal volume of phenol:chloroform was added to samples. Samples 
were vortexed for 30 seconds, then centrifuged at 15000 rpm (max speed) for 10 minutes at 
room temperature. The aqueous phase was transferred to 2 mL tube.  
DNA was ethanol precipitated by adding 3 M NaOAC pH 5.6 to a concentration of 240 
mM and 2.5 volumes absolute ethanol. Samples were vortexed and incubated at -80 °C for 1.5 
hours or until frozen solid. Samples were centrifuged at 15000 rpm for 20 minutes at 4 °C. 
Supernatant was removed and 1 mL of 70% ethanol was added. Samples were spun at 15000 
rpm for 5 minutes at room temperature. The supernatant was removed and tubes were re-spun 
to collect any residual solution. Residual supernatant was removed using a p200 pipette. Pellets 
were air-dried for around 5-10 minutes at room temperature and resuspended in 400 µL of 10 
mM Tris-HCl pH 7.5. 
To check DNA purification, 10 µL of the sample was taken out, of which 2.5 µL was 
run on 0.6% agarose gel for 1 hour at 100 Volts with the digested sample. 
2.10.10  Second Ligation 
Samples were transferred to 50 mL falcon tubes for ligation. To each sample, 1120 µL 
ligation buffer, 56 µL of ATP and 40 µL ligase was added and the total volume was made up 
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to 5600 µL with Ultrapure DNase – RNase free distilled H20. Samples were incubated at 
16°C overnight at 30rpm. 
To check ligation, 80 µL of sample was taken out. 20 µL was run on 0.6% agarose gel 
for 1 hour at 100 Volts with the purified digested sample. 
2.10.11  DNA purification with linear polyacrylamide (LPA) 
DNA was purified by adding 22.4 µL 20µg/mL linear polyacrylamide (LPA), NaOAC 
to a final concentration of 240 mM, and 2 volumes of Ethanol to the samples. Samples were 
incubated at -80 °C for 1.5 hours. Samples were then centrifuged at 4000 rpm (max speed) for 
1 hour at 4 °C. The supernatant was removed and 5 mL 70% ethanol was added. Samples were 
centrifuged at 4000 rpm for 15 minutes at room temperature. The supernatant was removed 
and tubes were re-spun to collect any residual solution. Residual supernatant was removed 
using a p200 pipette. Pellets were air-dried for around 5-10 minutes at room temperature and 
resuspended in 160 µL of 10 mM Tris-HCl pH 7.5. 
The concentration of samples was measured using the Qubit® 3.0 Fluorometer (Life 
Technologies) and Qubit® double-stranded DNA (dsDNA) High Sensitivity Assay kit (Life 
Technologies) according to the manufacturer’s instructions. Samples were stored at -20 °C. 
2.10.12  4C Polymerase Chain Reaction 
A total of 344 ng of DNA per bait was amplified by Polymerase Chain Reaction (PCR) 
using Q5® Hot Start High-Fidelity 2x Master mix (New England Biolabs). For the final 4C-
PCR reactions a no-template control was used to control for DNA contamination. PCR reaction 
conditions are listed below. Optimised amplification conditions, per primer set, are listed in 
Table 2.10. Primer sequences are listed in Appendix III. Amplified products were run on 1.5% 
agarose gel for 45 minutes. 
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Table 2.9:  4C-PCR reagents 
Reagent Amount per 25µL (reaction volume) 
Q5®  High-Fidelity 2x Master Mix  12.5 µL 
10 µM Forward primer 1.25 µL 
10 µM Reverse primer 1.25 µL 
Template DNA 86 ng 
nuclease-free H2O to 25 µL 
 
The PCR protocol was optimised by varying the temperature of annealing phase (63.2 
°C-67.8 °C). Amplification was performed in an Applied Biosystem Thermal Cycler 2.08 as 
follows: 98°C for 30 seconds; 30 cycles of 98 °C for 10 seconds, 63.2 °C-67.8 °C for 15 
seconds, 72 °C for 2 minutes, finally 72 °C for 2 minutes, 4 °C for ∞. 
Table 2.10:  Optimised PCR conditions for 4C-PCR primers 
Primer set Annealing temperature (°C) 
RUNX1 P1  64.7 °C 
RUNX1 P2 67.8 °C 
RUNX1 +24 63.2 °C 
ERG +85 64.2 °C 
 
2.11  4C-seq Library preparation 
2.11.1 PCR purification 
PCR products were cleaned up using the QIAquick PCR purification kit (Qiagen) 
according to the manufacturer’s instructions. For each 4C-PCR, one column was used (the 
maximum binding capacity of a column is 10 µg). DNA from column was eluted in a total of 
30 µL elution buffer (5 mM Tris-HCl pH 8.5).  
The concentration of samples was measured using the Qubit® 3.0 Fluorometer (Life 
Technologies) and Qubit® double-stranded DNA (dsDNA) High Sensitivity Assay kit (Life 
Technologies) according to the manufacturer’s instructions and samples were stored at -20 °C. 
2.11.2 Adaptor ligation 
Adapter ligation was performed by Dr. Jisha Antony (Horsfield lab, University of Otago). 
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Libraries were prepared using TruSeq® DNA PCR-Free preparation kit (Illumina) 
according to the manufacturer’s instructions for Low Sample preparation. Based on the lowest 
DNA concentration, 29 ng from each bait were pooled according to sample and the total 
volume was made up to 50 µL with Ultrapure DNase – RNase free distilled H20.  
Purified amplicon concentration was measured by Qubit® Fluorometer using dsDNA 
High Sensitivity assay kit and average size of PCR products was measured on a 2100 
Bioanalyser (Agilent Technologies) using a High Sensitivity DNA Kit (Agilent Technologies) 
according to the manufacturer’s instructions. Bioanalyser data was analysed using 2100 Expert 
software (Agilent Technologies).  
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WT_12_DMSO_1 UDI0001 CCGCGGTT UDI0001 AGCGCTAG 
WT_12_DMSO_2 UDI0002 TTATAACC UDI0002 GATATCGA 
WT_12_DMSO_3 UDI0003 GGACTTGG UDI0003 CGCAGACG 
WT_12_DMSO_no_ligase UDI0004 AAGTCCAA UDI0004 TATGAGTA 
WT_12_PMA_1 UDI0005 ATCCACTG UDI0005 AGGTGCGT 
WT_12_PMA_2 UDI0006 GCTTGTCA UDI0006 GAACATAC 
WT_12_PMA_3 UDI0007 CAAGCTAG UDI0007 ACATAGCG 
WT_72_PMA_1 UDI0024 ATGAGGCC UDI0024 GTTAATTG 
WT_72_PMA_2 UDI0009 AGTTCAGG UDI0009 CCAACAGA 
WT_72_PMA_3 UDI0010 GACCTGAA UDI0010 TTGGTGAG 
WT_72_PMA_no_ligase UDI0012 CTCTCGTC UDI0012 TATAACCT 
ST37_12_DMSO_1 UDI0021 GGTACCTT UDI0021 AAGACGTC 
ST37_12_DMSO_2 UDI0022 AACGTTCC UDI0022 GGAGTACT 
ST37_12_DMSO_3 UDI0015 GGCTTAAG UDI0015 TCGTGACC 
ST37_12_DMSO_no_ligase UDI0016 AATCCGGA UDI0016 CTACAGTT 
ST37_12_PMA_1 UDI0017 TAATACAG UDI0017 ATATTCAC 
ST37_12_PMA_2 UDI0018 CGGCGTGA UDI0018 GCGCCTGT 
ST37_12_PMA_3 UDI0019 ATGTAAGT UDI0019 ACTCTATG 
ST37_72_PMA_1 UDI0020 GCACGGAC UDI0020 GTCTCGCA 
ST37_72_PMA_2 UDI0013 CCAAGTCT UDI0013 AAGGATGA 
ST37_72_PMA_3 UDI0014 TTGGACTC UDI0014 GGAAGCAG 
ST37_72_PMA_no _ligase UDI0023 GCAGAATT UDI0023 ACCGGCCA 
 
2.11.3 Library purification 
Library purification was performed by Dr. Jisha Antony (Horsfield lab, University of Otago). 
Libraries were purified by removing fragments above 1 kb using Agencourt® 
AMPure® XP beads (Beckman Coulter). The total volume was made up to 50 µL with 
Ultrapure DNase – RNase free distilled H20. Beads were equilibrated at RT for at least 30 
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minutes and vortexed briefly before use. 0.5x of magnetic beads was added per sample and 
mixed at 1800 rpm at room temperature on the thermomixer for 1 minute and then incubated 
at room temperature for further 5 minutes. Samples were spun at 300 g for 1 minute at room 
temperature. Beads were separated using a magnet until solution was clear (around 5 minutes) 
and supernatant was removed. Beads were washed twice with 200 µL of 70-80% ethanol 
(freshly made). Tubes were air dried at room temperature for 5 minutes. The magnet was 
removed and 20 µL of TruSeq® DNA PCR-Free Resuspension buffer was added and mixed 
until homogeneous. Solutions were incubated for 5 minutes at room temperature. The magnet 
was applied until solution was clear (1-2 minutes). Eluates were transferred to DNA low-bind 
0.2 mL tubes (Eppendorf). 
2.11.4 Equal mixing of baits 
Purified amplicon concentration was measured by Qubit® Fluorometer using dsDNA 
High Sensitivity assay kit and average size of PCR products was measured on a 2100 
Bioanalyser (Agilent Technologies) using a High Sensitivity DNA Kit (Agilent Technologies) 
according to the manufacturer’s instructions. Bioanalyser data was analysed using 2100 Expert 
software (Agilent Technologies).  
2.11.4.1 MiSeq library  
Samples were pooled by Dr. Jisha Antony (Horsfield lab, University of Otago) based 
on average fragment size: 1 µL for libraries with average size of <1.5 kb and 2 µL for libraries 
with average size of >1.5 kb. After pooling, samples were vacuum dried to reduce volume to 
10 µL. 1 µL was run on the Bioanalyser. 
2.11.4.2 HiSeq Library 
Baits were mixed equimolarly based on concentration and average fragment size bait 
mixed and adjusted based on the percentage of demultiplexed 4C baits obtained from an initial 
MiSeq run.  
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2.11.5 Next generation sequencing 
Final libraries were sequenced as 100 bp single-reads on an IlluminaTM HiSeq 2500 by 
Otago Genomics Facility (OGF). Because the 4C-seq libraries have low diversity, they were 
combined with 15% PhiX control (v/v). A trial library (PCR comparison) was sequenced as 
151 bp reads on an IlluminaTM MiSeq by Dr. Rob Day (Cancer Genetics, Department of 
Biochemistry, University of Otago). 
2.12  Processing of sequenced reads 
All code used and generated for this project can be found in Github: 
(https://github.com/thoam810/4C_analysis). 
2.12.1 Generating read counts and data quality reports 
Quality and number of initial reads and demultiplexed reads were checked using: 
https://github.com/thoam810/4C_analysis/blob/master/FASTQC_analysis_bash. Quality of 
reads was assessed using FastQC software (Andrews, 2010), for each bait within the libraries 
before and after demultiplexing.  
2.12.2 Demultiplexing of libraries based on indexed adaptors 
Libraries were demultiplexed based on 8 base index barcodes (see Table 2.11). For the 
HiSeq run, libraries were demultiplexed by OGF (see Appendix V for report); for MiSeq runs, 
libraries were demultiplexed automatically after the run. 
2.12.3 Trimming of adaptors 
Adaptor sequences were removed from bait demultiplexed reads by Sequencing 
providers (HiSeq - OGF) and (MiSeq - Dr. Rob Day). 
2.12.4 Demultiplexing of baits based on 4C primers 
Baits were demultiplexed by Dr. William Schierding (University of Auckland). 
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2.12.4.1 HiSeq 
Samples were sequenced using HiSeq2500 100 bp single end reads on two lanes. To 
join reads for the different lanes samples files were concatenated 
(https://github.com/thoam810/4C_analysis/blob/master/Concatenate_seq_bash). Baits were 
demultiplexed based on 4C primers up to and including the restriction site, as listed in Table 
2.12 (https://github.com/thoam810/4C_analysis/blob/master/demux_4C_hiseq.sl). Only reads 
that had the forward and reverse primer and bait sequences in the correct orientation were 
selected. No mismatches were allowed. Primer sequences were not removed from the reads. 
2.12.4.2 MiSeq 
Sequences used for demultiplexing of baits are 4C primers up to and including the 
restriction site (no mismatches were allowed) as listed in Table 2.12.  
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Table 2.12:  Primer sequences and lengths used for demultiplexing of 4C baits 
Primer Sequence Length (bp) 
RUNX1 P1 F AACCAAGTCTGTCAGTCTCCTGTAC 25 
RUNX1 P1 R GCTAACAAGCAGAGGAAGCAATATTTGTATAGAAT
AACAGAAAAAAAAGATC 
52 
RUNX1 P2 F GCCGGCTCCTGGAATTGGCCCGCGCGCCCCCGCCG
CCGCGCCGCGCGCTACTGTAC 
56 
RUNX1 P2 R AGGATGTGCGTGCGTGTGTAACCCGAGCCGCCCGA
TC 
37 
RUNX1 +24 F ACGTGTCCACATTTTTCAGAAGTTGAATGGTTTTGT
GTAATGGTAC 
46 
RUNX1 +24 R CAGTTACTTCGCCCATTGCTTTTTCTAAAGGATC 34 
ERG +85 F CTCGCTGCTTAGGTGTAGTCCTTAGGAATGAAAATC
TGAACGTAGTAC 
48 
ERG +85 R TGGGGGAGACTGACAAATAGATC 23 
 
2.13  Mapping of sequenced reads 
Mapping of sequenced reads was carried out on Linex Server according to 4Cker 
(Raviram et al., 2016). 
2.13.1 Generating restriction enzyme digestion of Human Genome (hg19) 
4C-Seq reads are usually mapped to a reduced genome which consists of unique 
sequence fragments adjacent to the primary restriction enzyme sites in the genome. Mapping 
to a reduced genome helps to remove inauthentic ligation events that do not result from 
crosslinking. 
The 4Cker script created a custom reduced genome using oligoMatch (Kent et al., 
2002) and fastaFromBed (Bedtools).  
The fragment length should be longer than the length of the sequenced read (100 bp) 
minus the size of adapter barcode (8 bp) and primer including the restriction enzyme (RE) 
sequence (various bp see Table 2.11 and 2.12). As the longest sequence read was 69 bp 
therefore, 70 bp fragment length for digestion was chosen. 
In order to map reads to regions of Homo sapiens hg19 reference genome, the Human 
genome file (Broad Institute) was digested into 70 bp fragments using an edited 4Cker script 
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and primary RE DpnII file (4Cker). 
(https://github.com/thoam810/4C_analysis/blob/master/RE_digest_genome).  
Table 2.13:  Length of sequenced reads after trimming  
Primer Sequenced read length after trimming (bp) 
RUNX1 P1 F 67 
RUNX1 P1 R 40 
RUNX1 P2 F 36 
RUNX1 P2 R 55 
RUNX1 +24 F 46 
RUNX1 +24 R 58 
ERG +85 F 44 
ERG +85 R 69 
 
2.13.2 Generate Bowtie2 reference files of RE digested genome. 
The DpnII reduced genome was used to map 4C-Seq single-end reads using Bowtie2 
(Langmead et al., 2012) 
Bowtie2 requires specific index files which were created using the reduced genome 
files: https://github.com/thoam810/4C_analysis/blob/master/bowtie2_build.  
2.13.3 Mapping of reads 
The 4C-seq single-end reads were aligned to the Bowtie2 DpnII reduced genome using: 
https://github.com/thoam810/4C_analysis/blob/master/Alignment_bowtie. This generates 
Sequence Alignment/Map (SAM) files of aligned and unaligned reads. 
The sequenced reads were trimmed from the 5’ end based on the adapter sequence 
length and bait primer sequence including the RE length. The 3’ end was trimmed by 5bp based 
on the demultiplexed quality reports.  
2.13.4 Creating a counts file from mapped data 
The SAM output from bowtie2 reads (Section 2.13.2) were used to create a counts file 
(.bedGraph) with number of reads per RE fragment using: 
https://github.com/thoam810/4C_analysis/blob/master/mapped_data_counts_bedGraph. This 
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generates a tabulated bedGraph file with 4 columns: Chromosome number, location start of 
fragment, location end of fragment, count. 
2.13.5 Removing self-ligated and undigested reads 
The self-ligated and undigested fragments were removed from the count files before 
analysing 4C interactions using: 
https://github.com/thoam810/4C_analysis/blob/master/remove_self_ligated_undigested.  
To remove the self-ligated and undigested fragments for each bait, the coordinates for 
the primer sequences (not including RE sequence) were found in the human reference 
genome. Following this the sequence before and after the primer sequence were found. The 
fragments that match the coordinates for the fragments before, after and including the primer 
were removed. 
2.13.6 Removal of background noise 
Fragments that had reads in controls are considered background noise and these reads 
were removed from the statistically significant interactions using: 
https://github.com/thoam810/4C_analysis/blob/master/remove_controls.  
Reads at fragments 10 kb up- and downstream of the bait were removed using: 
https://github.com/thoam810/4C_analysis/blob/master/remove_bait_10kb.  
2.14  Analysing 4C interactions 
4C interaction analyses were done in R on a Linux server. 
The interactions of a bait across the genome will differ depending on proximity to bait, 
with closer interactions (near-bait) occurring at a higher frequency, followed by cis interaction 
then trans interactions having the least amount of interaction with the bait region. 4Cker 
provides different analyses for near-bait, cis and trans interactions.  
4Cker interaction analysis checks if each samples passes quality control (QC) criteria. 
To pass 4Cker QC, samples must have more than 1 million reads, more than 40% of reads on 
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the cis chromosome and more than 40% coverage in the 200 kb region near the bait. Krijger et 
al., 2020 state that 50,000-100,000 reads are sufficient to generate 4C profiles that correlate to 
the 4C profile of 1 million reads (Krijger et al., 2020). For this 4C, samples with more than 
400,000 reads with more that 40% reads in cis and >30% reads in near-bait would be allowed 
in analysis. 
When checking RUNX1 P1, RUNX1 P2 and ERG +85 baits they did not pass the quality 
control criteria, so these reads were not processed further.  
2.14.1 Identification of statistically significant interactions per condition 
To determine significant interactions, 4Cker reduces bias of PCR artifacts as fragments 
with counts greater than  the 75th quantile within a given window by trimming to this value.  
As 4C signal is generally higher around the bait region and decreases in far-cis and 
trans, different adaptive window sizes were used for read normalisation and creating smooth 
spline in each data set. 
Adaptive windows were used to obtain an analogous number of observed fragments for 
each window. Window size is determined by the amount of signal detected in the region. This 
results in small windows near the bait and regions where there is high coverage and larger 
windows further away from the bait where there is low coverage.  
The smooth spline (with a smoothing parameter of 0.75) is fitted to the window sizes 
separately for each analysis. Significant interactions are determined by what read counts in 
domains are called by all replicates, and are greater than the 90th quantile of the adaptive 
window.  
The value of 'k' determines the size of the adaptive windows. The following k values 
were optimised based on comparison of raw reads to the normalised reads and analysed reads. 
For the analysis near the bait k = 3, entire bait chromosome analysis k = 3 and trans analysis 
used k = 15. 
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Significant 4C interactions for each condition were determined using; 
https://github.com/thoam810/4C_analysis/blob/master/Analysing_4C_interactions.  
2.14.2 Generation of ggplots 
To plot the 4C profiles for all the conditions ggplot was utilised 
(https://github.com/thoam810/4C_analysis/blob/master/4C_ggplots).  
2.14.3 Differential interactions using DESeq2 
Differential analysis was carried out between two conditions on the windows that are 
interacting with the bait in at least 2 conditions. 4Cker has optimised this analysis for near-bait 
and cis interactions. Significantly different domains were determined with a p-value of 0.05 
using (https://github.com/thoam810/4C_analysis/blob/master/DESeq_diff_analysis). 
2.14.4 Overlap of significant interactions with genes 
Significant interactions were overlapped with UCSC K562 reference gene list using 
(https://github.com/thoam810/4C_analysis/blob/master/map_gene_list). 
2.14.5 Overlap of significant interactions with protein binding sites and 
enhancer characteristics 
See section 2.9.1 
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3 Chapter 3: Functional analysis of Runx1 enhancers 
Some of the results from this chapter contributed to Marsman, J., Thomas, A., Osato, 
M., O'Sullivan, J. M., & Horsfield, J. A. (2017). A DNA contact map for the mouse Runx1 
gene identifies novel haematopoietic enhancers. Scientific Reports, 7, 13347 (Appendix VI). 
3.1 Runx1 enhancers 
The precise spatiotemporal expression of Runx1 requires the activity of cis-regulatory 
elements, the majority of which have not been defined. In AML and other myeloid 
malignancies where no mutation is found in the coding sequence, there may instead be 
mutations in regulatory sequences that affect gene function (Cornish et al., 2019).  
Understanding the regulatory landscape of RUNX1 will further increase understanding 
of haematopoiesis as well as identify potential new regions for driver mutations in myeloid 
malignancies. Recent studies have identified recurrent mutations in regulatory elements of 
genes associated with oncogenesis, such in as the TAL1, ETV1, and PAX5 enhancers 
(Mansour et al., 2014; Orlando et al., 2018; Puente et al., 2015), highlighting the importance 
for determining functionality of non-coding elements.  
Regulatory regions can be highly tissue-specific, are often spread over across the 
chromatin, and only a small proportion of distal enhancers target the nearest transcript (Javierre 
et al., 2016; Mifsud et al., 2015). 
3.1.1 Previously identified enhancers of Runx1 
Cis-regulatory elements (CREs), such as enhancers are able to control the expression 
of genes by long-range chromatin interactions (Marsman et al., 2012).  
Several research groups identified an important intronic Runx1 enhancer in mice: 
Runx1 +23/+24/eR1/RE1 mouse conserved non-coding element (Bee et al., 2009a; Ng et al., 
2010; Nottingham et al., 2007) (Table 3.1). The naming of the element refers to the kilobases 
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(kb) downstream of each group’s reference point. The inconsistency of enhancer naming 
between groups is because Ng et al., (2010) uses the transcriptional start site (TSS), +1 as the 
reference point, whilst the other groups refer to this enhancer being 23.5 kb downstream from 
the ATG of exon 1. The term eR1 proposed by Koh et al., (2015) refers to enhancer of Runx1 
(Koh et al., 2015), whereas Tang et al., (2019) named it regulatory element 1 (RE1) (Tang et 
al., 2018). Throughout this thesis, this previously described intronic enhancer will be referred 
to as +24.  
The +24 enhancer is responsible for the activation of Runx1 expression in 
hematopoietic stem/progenitor cells (HSPCs) (Ng et al., 2010; Nottingham et al., 2007). Most 
enhancers evolve rapidly and are rarely conserved at the DNA sequence level among species 
due to positive evolutionary selection (Villar et al., 2015). Runx1 +24 is highly conserved in 
eukaryotes, indicating an essential role in gene regulation. The discovery of +24 regulatory 
element as a haemogenic endothelial cell-specific enhancer in mouse and zebrafish embryos 
provided an insight into a mechanism for the targeted transcriptional regulation of Runx1 
(Markova et al., 2011; Ng et al., 2010; Schütte et al., 2016). 







Identification methods Functional validation 
Mouse and 
Human Runx1 
relative to P1  
+23/ +24/ 
eR1/RE1 
+24 In silico conservation 
(interspecies DNA 
sequence homology) 
and DNase I 
hypersensitive sites 
(Markova et al., 2011; 
Ng et al., 2010; 
Nottingham et al., 
2007). 
Haematopoietic enhancer activity 
during mouse and zebrafish 
development. Luciferase enhancer 
activity in 416B, K562 and Jurkat 
haematopoietic cell lines. Thought to 
be a silencer in HEK293 cells 
(Markova et al., 2011; Marsman et 
al., 2017; Ng et al., 2010; Schütte et 
al., 2016) 
 
This chapter will focus on the other candidate regulatory regions for Runx1, while 
Chapter 4 provides a detailed analysis of the Runx1 +24 enhancer.  
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In this thesis enhancers are labelled according to sequence origin, and location relative 
to Runx1 transcriptional start site (TSS): + means downstream from the Runx1 TSS at the P1 
promoter, whereas – refers to upstream e.g. +62 is 62 kilobases (kb) downstream, from Runx1 
TSS. If the sequence for the Runx1 regulatory element was discovered in mice, (m) is used 
before the location label, human is unlabelled e.g. +62 sequence information is from humans 
and m+110 is from mice. 
In mice, Schütte et al., (2016) and Ng et al., (2010) used a combination of techniques 
to identify 12 possible regulators of Runx1 with some functional identification (Table 3.2). My 
previous masters project investigated the functions of the putative mouse regulatory regions 
described by Ng et al., (2010). 
Markova et al., (2011), Gunnell et al., (2010), Wang et al., (2014), Cheng et al., (2018), 
and Nie et al., (2019) characterised the functions of potential human RUNX1 regulatory 
elements. Some of these discoveries included identifying long-range interactions with RUNX1 
promoters (Table 3.3). 
Enhancers were predicted by several different methods including; computational 
analysis of non-coding sequence for inter-species conservation, predicted transcription factor 
binding motifs; analysis of chromatin immunoprecipitation sequencing (ChIP-seq) to locate 
binding of transcription factors, mediators, and histone modifications at the regions of interest; 
revealing promoter-enhancer interactions using chromosome conformation capture (4C, Hi-C) 
and chromatin interaction analysis using paired-end sequencing (ChIA-PET). 
In this Chapter I describe the conservation and features of previously identified and 
novel Runx1 CREs, and identify the functional enhancer capability of regions previously 
identified by 4C. This information will provide a deeper understanding of the regulation of 
Runx1 transcription, with implications for causality and treatment of leukaemias with RUNX1 
dysregulation.  
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Table 3.2: Identified mouse Runx1 regulatory regions with available classifications 
Regulatory region location 
(kb) 
Name in this thesis Identification methods Functional validation 
-368 m-368 In silico Conservation (interspecies 
DNA sequence homology) and 
transcription factor binding motif 
analysis of sequences (Ng et al., 2010) 
Potential enhancer activity within 
hematopoietic cells/tissues in 20-24 
hpf zebrafish embryos (Thomas, 2015) 
-328 m-328 ChIP-seq analysis of haematopoietic 
TFs (ERG, FLI1, GATA2, GFI1B, 
LYL1, MEIS1, SPI1, RUNX1 and 
TAL1) and H3K27ac (Schütte et al., 
2016). 
No enhancer activity observed in mice 
(Schütte et al., 2016). 
-322 m-322 ChIP-seq analysis of haematopoietic 
TFs (ERG, FLI1, GATA2, GFI1B, 
LYL1, MEIS1, SPI1, RUNX1 and 
TAL1) and H3K27ac (Schütte et al., 
2016). 
Identified, but not tested for enhancer 
activity (Schütte et al., 2016). 
-101 m-101 In silico Conservation (interspecies 
DNA sequence homology) and 
transcription factor binding motif 
analysis of sequences (Ng et al., 2010) 
Potential enhancer activity within 
hematopoietic cells in 20-24 hpf 
zebrafish embryos (Thomas, 2015) 
-59 m-59 ChIP-seq analysis of haematopoietic 
TFs (ERG, FLI1, GATA2, GFI1B, 
LYL1, MEIS1, SPI1, RUNX1 and 
TAL1) and H3K27ac (Schütte et al., 
2016).. 
Haematopoietic enhancer activity in 
E11.5 transgenic mice and luciferase 
enhancer activity in 416B cells 
(Schütte et al., 2016). 
-43 m-43 ChIP-seq analysis of haematopoietic 
TFs (ERG, FLI1, GATA2, GFI1B, 
LYL1, MEIS1, SPI1, RUNX1 and 
TAL1) and H3K27ac (Schütte et al., 
2016). 
No enhancer activity observed in mice 
(Schütte et al., 2016). 
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Regulatory region location 
(kb) 
Name in this thesis Identification methods Functional validation 
-42 m-42 ChIP-seq analysis of haematopoietic 
TFs (ERG, FLI1, GATA2, GFI1B, 
LYL1, MEIS1, SPI1, RUNX1 and 
TAL1) and H3K27ac (Schütte et al., 
2016). 
No enhancer activity in observed mice 
(Schütte et al., 2016). 
+1 m+1 ChIP-seq analysis of haematopoietic 
TFs (ERG, FLI1, GATA2, GFI1B, 
LYL1, MEIS1, SPI1, RUNX1 and 
TAL1) and H3K27ac (Schütte et al., 
2016). 
Identified, but not tested for enhancer 
activity (Schütte et al., 2016). 
+3 m+3 ChIP-seq analysis of haematopoietic 
TFs (ERG, FLI1, GATA2, GFI1B, 
LYL1, MEIS1, SPI1, RUNX1 and 
TAL1) and H3K27ac (Schütte et al., 
2016).. 
Haematopoietic enhancer activity in 
E11.5 transgenic mice and luciferase 
enhancer activity in 416B cells 
(Schütte et al., 2016).  
+110 m+110 In silico Conservation (interspecies 
DNA sequence homology) and 
transcription factor binding motif 
analysis of sequences (Ng et al., 2010) 
Haematopoietic enhancer activity in 
E11.5 transgenic mice, potential 
enhancer activity within hematopoietic 
cells in 20-24 hpf zebrafish embryos 
and luciferase enhancer activity in 
416B and Hela cell lines (Schütte et 
al., 2016; Thomas, 2015). 
+181 m+181 ChIP-seq analysis of haematopoietic 
TFs (ERG, FLI1, GATA2, GFI1B, 
LYL1, MEIS1, SPI1, RUNX1 and 
TAL1) and H3K27ac (Schütte et al., 
2016). 
No enhancer activity in observed mice 
(Schütte et al., 2016). 
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Regulatory region location 
(kb) 
Name in this thesis Identification methods Functional validation 
+204 m+204 ChIP-seq analysis of haematopoietic 
TFs (ERG, FLI1, GATA2, GFI1B, 
LYL1, MEIS1, SPI1, RUNX1 and 
TAL1) and H3K27ac (Schütte et al., 
2016).. 
Haematopoietic enhancer activity in 
E11.5 transgenic mice and luciferase 
enhancer activity in 416B cells 
(Schütte et al., 2016). 
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Table 3.3: Identified human RUNX1 regulatory regions with available classifications 
Regulatory region location 
(kb) 
Name in this thesis Identification methods Functional validation 
-139 / E1 -139 ChIP-seq analysis of EBNA2 (Gunnell 
et al., 2016). 
Luciferase enhancer activity in 
GM12878 and EBV positive Burkitt’s 
Lymphoma cell lines (Gunnell et al., 
2016). 
-188/ E4 -188 ChIP-seq analysis of EBNA2 (Gunnell 
et al., 2016). 
Alone drives a 4.3 fold increase in 
luciferase enhancer activity in 
GM12878 and EBV positive Burkitt’s 
Lymphoma cell lines. When combined 
with -139 and -250 it drives a five-fold 
increase in enhancer activity (Gunnell 
et al., 2016). 
-250/ E6 -250 ChIP-seq analysis of EBNA2 (Gunnell 
et al., 2016). 
Luciferase enhancer activity in 
GM12878 and EBV positive Burkitt’s 
Lymphoma cell lines (Gunnell et al., 
2016). 
+62 +62 ChIA-PET (RNA polymerase II) and 
DNase I hypersensitive sites and 
conserved binding sites for the SNAG 
repressors GFI1/GFI1B and SNAI1 
(Cheng et al., 2018). 
Silencer activity in K562, OCl-AML3, 
U937 cell lines (Cheng et al., 2018). 
Intron 5.2/RE2 intron 5.2 In silico Conservation (interspecies 
DNA sequence homology) and DNase 
I hypersensitive sites (Markova et al., 
2011). 
No enhancer or silencer activity 
observed in K562, Jurkat and HEK293 
cell lines (Markova et al., 2011). 
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3.1.2 Previously identified long-range interactions with Runx1 
promoters 
Interaction between predicted CREs and promoters of the Runx1 gene cannot be 
assumed, as fewer than 50% of enhancers contact the nearest gene promoter (Li et al., 2012). 
In order to determine the long-range interaction between Runx1 promoters and its CREs, Dr. 
Judith Marsman performed circular chromosome conformation capture (4C) (Marsman, 2016) 
in the mouse haematopoietic progenitor cell line, HPC7. 4C detects interactions with chosen 
regions or “baits” through use of next-generation sequencing. HPC7 cells resemble early 
haematopoietic progenitors (Kolterud et al., 1998) and were chosen because Runx1 expression 
is crucial for the development of definitive haematopoietic stem- and progenitor cells (Cai et 
al., 2011; Growney et al., 2005; Ichikawa et al., 2004; Okuda et al., 1996; Wang et al., 1996).  
Quantitative PCR (qPCR) analysis showed that in HPC7 cells, the Runx1 P1 isoform is highly 
expressed, whereas the Runx1 P2 isoform is not (Marsman, 2016).  
Dr. Marsman’s selected baits for Runx1 4C, situated at the Runx1 P1 and Runx1 P2 
promoters and at the Runx1 +24 enhancer. For each of these regions, one bait was located at 
the core region, and another bait was located at a nearby (1.5-2 kb away) cohesin/CTCF binding 
site.  
Cohesin/CTCF binding sites upstream of Runx1 P1 and downstream of the Runx1 +24 
enhancer are present in CH12, MEL and HPC7 cells, whereas cohesin/CTCF binding sites 
upstream of Runx1 P2 are not present in HPC7 cells (Wilson et al., 2016). 4C analysis with 
baits at the Runx1 -P1 and -P2 promoters allows for comparison of interactions between the 
active Runx1 -P1 promoter and inactive -P2 promoter. 
Runx1 P1 interacted with seven regions, as well as with the Runx1 +24 enhancer (Table 
3.4). Each regulatory element recruits multiple blood transcription factors in HPC7 cells, 
suggesting they function as haematopoietic-specific enhancers. They are named according to 
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their distance from the Runx1 P1 transcriptional start site: -371, -354, -327, -321, -303, -58, -
48, and +110.  
Of these putative enhancers, two had been previously described; conserved Runx1 m-
368, m+110 (Ng et al., 2010; Thomas, 2015). 
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Table 3.4: Identified long range interactions with putative mouse Runx1 regulatory regions. 
Regulatory region 
location (kb) 
Name in this thesis Identification methods Interactions identified Functional validation 
-371 m-371 3D interaction with Runx1 
Promoters described by 4C 
and transcription factor 
binding motif analysis 
(Marsman, 2016). 
Interacts with +24 and P1 in 
HPC7 cells identified by 4C 
(Marsman, 2016). 
Not investigated. 
-368 m-368 Conservation and 
transcription factor binding 
motif analysis (Ng et al., 
2010) 
Interacts with +24 and P1 in 
HPC7 identified by 4C 
(Marsman, 2016). 
Interacts with P1 in HPC-7 
cells identified by Capture 
Hi-C (Wilson et al., 2016). 
Potential enhancer activity 
within hematopoietic 
cells/tissue in 20-24 hpf 
zebrafish embryos (Thomas, 
2015) 
-354 m-354 3D interaction with Runx1 
Promoters described by 4C 
and transcription factor 
binding motif analysis 
(Marsman, 2016). 
Interacts with +24 and P1 in 
HPC7 cells identified by 4C 
(Marsman, 2016). 
Interacts with P1 in HPC-7 
cells identified by Capture 
Hi-C (Wilson et al., 2016). 
Not investigated. 
-327 m-327 3D interaction with Runx1 
Promoters described by 4C 
and transcription factor 
binding motif analysis 
(Marsman, 2016). 
Interacts with +24 and P1 in 
HPC7 cells identified by 4C 
(Marsman, 2016). 
Interacts with P1 in HPC-7 
cells identified by Capture 
Hi-C (Wilson et al., 2016). 
Not investigated. 
-321 m-321 3D interaction with Runx1 
Promoters described by 4C 
and transcription factor 
binding motif analysis 
(Marsman, 2016). 
Interacts with +24 and P1 in 






Name in this thesis Identification methods Interactions identified Functional validation 
Interacts with P1 in HPC-7 
cells identified by Capture 
Hi-C (Wilson et al., 2016). 
-303 m-303 3D interaction with Runx1 
Promoters described by 4C 
and transcription factor 
binding motif analysis 
(Marsman, 2016). 
Interacts with +24 and P2 in 
HPC7 cells identified by 4C 
(Marsman, 2016). 
Interacts with P1 in HPC-7 
cells identified by Capture 
Hi-C (Wilson et al., 2016). 
Not investigated. 
-58 m-58 3D interaction with Runx1 
Promoters described by 4C 
and transcription factor 
binding motif analysis 
(Marsman, 2016). 
Interacts with +24 and P1 in 
HPC7 cells identified by 4C 
(Marsman, 2016). 
Not investigated. 
-48 m-48 3D interaction with Runx1 
Promoters described by 4C 
and transcription factor 
binding motif analysis 
(Marsman, 2016). 
Interacts with +24 and P1 in 
HPC7 cells identified by 4C 
(Marsman, 2016). 
Not investigated. 
+110 m+110 Conservation and 
transcription factor binding 
motif analysis (Ng et al., 
2010) 
Interacts with P1 in HPC7 
cells identified by 4C 
(Marsman, 2016). 
Haematopoietic enhancer 
activity in E11.5 transgenic 
mice, potential enhancer 
activity in hematopoietic 
sites in 20-24 hpf zebrafish 
embryos and luciferase 
enhancer activity in 416B 
and Hela cell lines (Schütte 
et al., 2016; Thomas, 2015). 
96 
4C data identified new cis elements bound by TFs, that could have regulatory functions. 
The Runx1 +24 enhancer interacted with all of the putative elements, except m+110. Runx1 P1 
connected to all the identified regions excluding m-303. Conversely, the Runx1 P2 promoter 
showed fewer interactions with enhancer clusters, but did interact with the putative regulatory 
sites m-303, m-48 and m+24.  
 
Figure 3.1: Schematic overview of the mouse Runx1 locus (chromosome 16:93,220,074-92,589,466).  
Previously identified regulatory regions are annotated with orange circles, novel regions detected by 4C  
(Marsman, 2016) are represented by yellow circles, grey boxes annotate exons. The blue boxes show the exons 
encoding the Runt binding domain. The two Runx1 promoters are represented by black right angled arrows. 
 
In humans, the interactions between RUNX1 promoters and regulatory regions were 
identified using 3C for two regions, +62 and intron 5.2. +62 interacts with RUNX1 -P2 in K562 
and OCl-AML3 cell lines (Cheng et al., 2018). Intron 5.2 Interacts with RUNX1 -P1 and P2 in 




Figure 3.2: Schematic overview of human RUNX1 locus (chromosome 21: 36,148,773-36,872,777).  
Each human RUNX1 regulatory region is annotated with orange circles, grey boxes annotate exons. The blue 
boxes show the exons encoding the Runt binding domain. The two RUNX1 promoters are represented by black 
right angled arrows. 
 
3.1.3 Functional enhancer characterisation assays 
In order to determine the enhancer function of these identified regions, enhancer assays 
can be used. Luciferase assays show the ability of a regulatory element to drive expression of 
the firefly luciferase reporter gene Luc2 in cell lines. If the luciferase vector contains an 
enhancer, there should be an increase in expression of luciferase, which can be determined with 
a luminometer.  
Zebrafish reporter assays can identify cell-type specific gene expression driven by 
putative enhancers. If the zebrafish vector contains an enhancer there should be expression of 
green fluorescent protein (GFP) in the cells that can respond to that enhancer. This is 
determined by viewing zebrafish embryos during development under a fluorescent microscope. 
The zebrafish enhancer assay vectors contain integration sites so that the reporter gene 
constructs can be incorporated into the host genome. The Horsfield lab currently utilises three 
reporter assays; ISceI-pBSII SK+ which integrates using I-Sce I sites, and Tol2Gata2 and ZED 
which use Tol2 sites. Transient expression can be analysed in F0, however the F1 generation 
contain a germ line integration of the constructs, to avoid the problem of a mosaic expression 
pattern seen in F0.  
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By using zebrafish enhancer assays I can define whether these putative regulatory 
elements influence any cell- and/or stage-specific Runx1 haematopoietic expression. It is 
possible that mutations or defects in the regulation of in such elements may explain AML 
progression in patients who have no known protein-coding mutations or perhaps patients who 
have cohesin mutations. It is also necessary to determine whether the identified mouse 
enhancers are conserved in humans. 
3.2 Hypothesis 
I hypothesise that the regions identified by Runx1 4C have enhancer capabilities and 
some of them may be conserved in humans. As most enhancers rapidly evolve and are rarely 
conserved at a sequence level between species, any regions that are conserved may have an 
essential roles in RUNX1 gene regulation. Understanding the regulatory mechanisms that drive 
cell-specific expression of RUNX1 in haematopoiesis will have implications for causality and 
treatment of leukaemias with RUNX1 dysregulation. 
3.3 Aims 
1) Elucidate conservation and genomic characteristics of previously identified and 
novel Runx1 cis-regulatory elements using bioinformatic tools. 
2) Identify the enhancer ability of putative cis-regulatory elements previously 
identified by 4C, using zebrafish reporter assays. 
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3.4 Characteristics of previously identified regulatory regions 
In order to understand the overall contributions of regulatory regions to Runx1 
haematopoietic expression and their potential to be dysregulated in myeloid malignancies, in 
silico analyses were carried out. Bioinformatic tools can be used to determine conservation of 
a regulatory regions, which cells these regions are active in and what transcription factors bind 
to them. 
3.4.1 Epigenetic and conservation analyses using ENCODE data 
ENCODE project data from RUNX1-dependent Human Chronic Myelogenous 
Leukaemia cells (K562) were analysed at each conserved locus (Barski et al., 2007; Raney et 
al., 2014; Rosenbloom et al., 2013; Wilson et al., 2016) using the UCSC Genome Browser. 
Elements included in the search for regulatory features were transcription factor 
binding sites (TFBS), open chromatin (DNase I hypersensitivity), histone modifications, CTCF 
binding sites, RNA polymerase II (Pol II), cohesin (RAD21 and SMC3 subunits) binding sites 
(Table 3.5). 
ENCODE also has Chromatin State predictions (ChromHMM) for K562 cells (Kellis 
et al., 2017). ChromHMM annotates the data based on epigenetic information. The predicted 
chromatin states are active promoter, promoter flanking, inactive promoter, candidate strong 
enhancer, candidate weak enhancer, distal CTCF/candidate insulator, transcription associated, 
polycomb repressed and heterochromatin/repetitive/copy number variation. Transcription 
associated refers to transcriptional transition or elongation (Ernst et al., 2010; Ernst et al., 
2011). 
Further gene regulatory markers for K562 cells were uploaded into UCSC genome 
browser including; super-enhancers from dbSUPER (Khan et al., 2016), silencers annotated 
by Pang et al., (2020) (Pang et al., 2020), cohesin-mediated chromatin accessibility (Antony 
et al., 2020). 
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Conservation analysis identifies whether these regions could be important for human 
haematopoiesis. The UCSC BLAT tool (Kent, 2002) and NCBI BLAST tool (Altschul et al., 
1990) were used to determine the human co-ordinates of mouse (m) Runx1 -368, -327, -321, -
58, -43, -42, +3, +1, +110, +181, +204. Mouse Runx1 m-368, m-368, m-327, m-58, m-43, 
m+3, m+110 and m+204 were all found to be conserved in humans (Table 3.6). Runx1 m+204 
sequence sits within the previously described RUNX1 intron 5.2. 
When gathering sequence information about these regulatory regions I noted that three 
regions identified by Dr. Judith Marsman corresponded to the regions described by Schütte et 
al., (2016); Marsman’s m-327 is Schütte’s m-328, Marsman’s m-321 is Schütte’s m-322 and 
Marsman’s m-58 is Schütte’s m-59. These will be referred to from now as m-327, m-321 and 
m-58. 
To convert coordinates within a species UCSC ‘liftOver’ tool was utilised (Rosenbloom 
et al., 2013). Appendix VII contains the Hg38 locations of Runx1 regulatory regions. 
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Table 3.5: Analysed ENCODE annotations 
Regulatory association ENCODE annotation 
Open chromatin DNase I hypersensitivity (HS) 
Transcription initiation RNA Pol II (phosphorylated at serine 
5) 
Cohesin (subunit) RAD21, SMC3 
CTCF binding sites CTCF 
Histone acetyltransferase that is recruited to 
transcriptionally active enhancers (an 
increase in the expression of target genes) 
p300 
H3K4me1/2 demethylase (mediates 
transcriptional repression) 
LSD1 
Super-enhancer previously annotated by 
Khan et al., (2016) 
K562 Super-enhancers  
Silencer previously annotated by Pang et 
al., (2020) 
Silencers  
Cohesin mediated chromatin accessibility 
previously annotated by Antony et al., 
(2020) 
Chromatin sites that show increased 
accessibility in the absence of cohesin 
(STAG2)  
Chromatin State  ChromHMM 
Enhancer Enhancer-associated 
histone methylation or 
acetylation marks 
H3K27ac, H3K4me1, H3K4me2 
Active promoters H3K27ac, H3K9ac, H3K4me3 




Erythroid development GATA1 
Haematopoietic SPI1 
Blood/ Stem progenitors TAL1, GATA2  



























































N/A N/A N/A 
-250 chr21:366697
12-36670621  
RNA Pol II, p300, 
LSD1, H3K9me3, 
H3K27me3 
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m+3 chr21:364184
72-36418744 






No change in 
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H3K4me1H3K9ac, 















DNase I HS, RNA Pol 
II, CTCF, p300, LSD1, 
H3K27ac, 
H3K4me1H3K9ac, 









Based on the ChromHMM data it appears that the in RUNX1-dependent K562 line m-
368, m-58, m+110 are all operating as strong enhancers, whilst -139, m-43, and +62 are 
functioning as weak enhancers. Remarkably, +62 a known silencer in K562, also has enhancer-
associated histone methylation marks. Intron 5.2, m-101 and m+3 show the same regulatory 
104 
associations as the enhancers, however, they are labelled as transcription associated. 
ChromHMM also reported -139 and -188 as transcription associated. Transcription associated 
annotation could be due to their close proximity with exons when compared to the regions 
annotated as enhancers, or it may indicate that these regions are producing RNA, such as 
enhancer RNA (eRNA). Intron 5.2 and m+110 had increased accessibility in cohesin mutant 
K562 cells. Antony et al., (2020) found that sites of increased accessibility were enriched for 
motifs of enhancer-regulating bZIP or AP-1 factors (Antony et al., 2020). These regulatory 
regions did not overlap with any known K562 super-enhancers or silencers. Interestingly, m-368 
and m-327 are both within LOC100506403 an uncharacterised non-coding RNA and may 
therefore play a role in its regulation as well.  
m-368, -250, m-101, m-58, m-43, m+3, +62, m+110 and intron 5.2 were all bound by 
LSD1 a mediator of transcriptional repression usually seen in silencers. SPI1 a haematopoietic 
transcription factor was only bound to -139 and -188. Blood stem progenitor transcription 
factor TAL1 and GATA2, as well as, GATA1 a marker of erythroid development were found 
to bind m+110 and m-58. 
These annotations provide a good overview of the likeliness of a region to be regulatory. 
However, the analysis is limited to the types of cell lines that have been used for ChiP-seq by 
previous groups, as well as which transcription factors were chosen. This may explain why no 
consistent expression patterns could be observed in the available K562 data. 
To further determine enhancer expression, FANTOM 5 data was considered. Rather 
than assessing enhancers via chromatin accessibility and transcription factor binding, 
FANTOM 5 detects enhancer RNAs using cap-analysis gene expression (CAGE). The 
FANTOM 5 dataset is a compilation of many cell types and RNA transcription across the 
genome. It can predict enhancer activity status based on whether short segments of RNA are 
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transcribed from the regulatory region. By understanding which cell types enhancers are 
transcribed in, a pattern of enhancer arrangement may become apparent.  
The FANTOM 5 data showed that not all regulatory regions produced enhancer RNA 
(eRNA) in the cells available types for analysis. Regions m-368, -188, m-58, m-101 did not 
have any eRNA expression. Although eRNA is typically used for enhancer identification, not 
all active enhancers produce detectable eRNA (Mikhaylichenko et al., 2018; Sartorelli et al., 
2020). It remains unclear whether these enhancers produce low levels of eRNAs that are not 
easily detectable with current methods. 
All other regions expressed RNA in haematopoietic cells, however there was no 
consistent expression patterns in other tissues (Table 3.7). 
Table 3.7: Cell types with regulatory region RNA expression 
Regulatory 
region location 
relative to P1 
(kb) 
Cell type expressing regulatory region RNA 
m-368 Not expressed 
m-327 Skin, Liver, Brain, Lung, Haematopoiesis, Stomach, Oesophagus, 
Colon, Gall Bladder, Mesenchymal  
-250 Prostate, Brain, Haematopoiesis, Colon, Gall Bladder, Mesenchymal 
-188 Not expressed 
-139 Liver, Breast, Brain, Lung, Haematopoiesis, Oesophagus, 
m-101 Not expressed 




relative to P1 
(kb) 
Cell type expressing regulatory region RNA 
m-43 Brain, Lung, Haematopoiesis, 
m+3 Haematopoiesis, Mesenchymal, Kidney 
+62 Skin, Prostate, Liver, Breast, Brain, Lung, Haematopoiesis, Ovary, 
Oesophagus, Colon, Mesenchymal, Kidney 
m+110 Prostate, Haematopoiesis 
Intron 5.2  
 
Skin, Prostate, Brain, Lung, Haematopoiesis, Stomach, Colon, 
Mesenchymal, Kidney 
 
Single nucleotide polymorphism (SNP) analysis 
Ernst. et al., (2011) highlighted that disease variants, such as single nucleotide polymorphisms 
(SNPs) in genome-wide association studies (GWAS) frequently overlapped with enhancer 
elements relevant to the disease cell type (Ernst et al., 2011). To determine if there were any 
SNPs in each regulatory region, GWAS catalog (Buniello et al., 2019) and HaploReg v4.1 
(Ward et al., 2016) were used. SNPs were also analysed to ensure they had a minor allele 
frequency (MAF) of >1 % using the Genotype-Tissue Expression (GTEx) portal v8 
(https://gtexportal.org/home/). gnomAD browser v2 1.1 and v3 (Koch, 2020) were used to 
review SNPs with MAF >1 % for any ClinVar associations and/or publications. Some of the 
SNPs identified in this research (Table 3.8) were linked to SNP variants with r2 values of >= 
0.8 and r2 >= 1. As this was a preliminary investigation these linked SNPs were not investigated 
further. 
Multiple SNPs were identified in all of the regulatory regions except m-101. m-368, 
m+110 and intron 5.2 contained SNPs that have functional effects in haematopoietic cells 
(Table 3.8). Therefore, mutations in these regulatory regions have the potential to alter TF 
107 
binding sites and affect the regulatory activity of that region of DNA. Some of the other SNPs 
may be functional, but have not yet been investigated. 
 
 






SNP name Predicted changes SNP function 
m-368 3 rs11695144
1 
not predicted to 
change any motifs 
Not investigated 
rs16993221 A to T change of 
rs16993221 alters 2 
regulatory motifs 
BATF and IRF 
which work 
together in immune 
response.  
Related to white blood 
cell count a crucial 
marker which 
contributes to chronic 
inflammation (p value: 
2E-8)(Kong et al., 
2013). 
rs909143 The A to G change 
in rs909143 is 
predicted to affect 
3 regulatory motifs 
Has an eQTL with 
oesophagus and is 




in peripheral blood 
monocytes (p value: 
1.84E-06)(Zeller et al., 
2010). 
m-327 2 rs4817723 not predicted to 
change any motifs.  
Not investigated 
rs12106380 T to G change of 





-250 3  rs57911917 not predicted to 
change any motifs 
Not investigated 
rs2834885 C to A change of 










SNP name Predicted changes SNP function 
rs61607093 T to C change of 
rs61607093 alters 
20 binding motifs 
including GATA3, 
Nanog, SPI1, Pax5 
and p300 
Not investigated 
-188 1 rs35526434 C to T change 
alters 12 regulatory 
motifs including 





T to G change 





TTA to T change 




rs2834825 G to A change 
alters 19 motifs 
including Pou2f2.  
Not investigated 
m-101 0 Not 
applicable 
Not applicable Not applicable 
m-58 13 rs2834768 G to A change of 
rs2834768 alters 13 
regulatory motifs 
including MYC, 
TAL1 and multiple 
GATA sites. 
Not investigated 
rs2834769  C to T alters 3 
binding motifs. 
Not investigated 
rs13049322  not predicted to 
change any motifs 
Not investigated 
rs73374626 G to A change 
alters 5 motifs 
including MYC 
Not investigated 
rs9984842 C to T is predicted 
to alter 12 motifs 
including KLF4, 








SNP name Predicted changes SNP function 
rs11322166
2 






rs66840558 2 altered motifs. Not investigated 
rs14464130
5 
contains a change 
from AAG to A 
and is predicted to 





rs1883063 not predicted to 
change any motifs 
Not investigated 
rs8129889 not predicted to 
change any motifs 
Not investigated 
rs2834770 A to G change 
alters CEBPβ site 
and Hdx (brain 
related). 
Not investigated 









Has eQTLs reported 
with skin and thyroid 





m-43 2 rs73902837 C to G predicted to 
change 2 regulatory 
regions 
Not investigated 
rs2834756 T to C change 









SNP name Predicted changes SNP function 
m+3 1 rs9978978 T to C change to 
change 1 regulatory 
motif 
Not investigated 
+62 2 rs933131 G to A change 
alters 4 regulatory 
motifs including 
Pax5 and Pax8. 
Not investigated 
rs2834716. not predicted to 
alter any regulatory 
motifs 
Not investigated 
m+110 2 rs73900579 T to C change 
alters 2 regulatory 
motifs CEBPα and 
Pax4. 
Has an eQTL with 
brain related to red cell 
distribution width 
(Kichaev et al., 2019). 
rs20170885
7 
A to AG change is 
predicted to alter 
20 regulatory 
motifs including 
CEBPA, SP1 and 
Pou2f2. 
Not investigated 
Intron 5.2  
 
3 rs2268276 (G major - A 
minor) alters 2 
regulatory motifs.  
These two SNPs 
(rs2268276 and 
Rs2249650) were 
found to be associated 
with acute myeloid 
leukaemia 
susceptibility. The 
different SNPs are in 
LD and change the 
ability of the enhancer. 
A (rs2249650) G 
(rs2268276) bases and 
AA have more 
enhancer capability 
that GA and GG. GA 
has the most reduced 
enhancer capability. 
The SNPs also affect 
SPI1 binding 
capability; AG has 
strong SPI1 binding, 
GA has weak SPI1 
binding, whereas AA 
and GG have medium 
SPI1 binding capability 
(Xu et al., 2016)  
Rs2249650 (G major- A minor) 










SNP name Predicted changes SNP function 
rs8130772 A to G alters 5 
binding motifs 




To determine a potential regulatory relationship, Dr. William Schierding and I 
identified which genes a SNP physically interacts with and whether that SNP-gene interaction 
is supported by an allele-specific change in gene expression (CoDeS3D pipeline (Fadason et 
al., 2018)). First, CoDeS3D interrogates 70 Hi-C chromatin interaction libraries (from a diverse 
set of human cell lines) to identify interactions across the genome with the SNPs. Next, each 
SNP is tested for an allele-specific association to the expression level of the spatially associated 
partner gene (the SNP is an expression quantitative trait locus (eQTL).  
Despite finding many regulatory spatial interactions between RUNX1 regulatory region 
SNPs and RUNX1, none of them were supported by a significant eQTL interaction (FDR< 
0.05). One reason for this lack of significance is that the CoDeS3D pipeline uses the GTEx 
portal for eQTL outputs, which only can test 54 tissues sampled from healthy older individuals. 
GTEx also only measures whole blood, rather than individual cell types, so cell type- or 
disease-specific effects may not be detected. 
3.4.2 Comparative analysis of cancer genomic datasets 
To assess whether any AML patients had mutations in the conserved regulatory regions, 
publicly available cancer genomic datasets were explored. Online tools were used to categorise 
publicly available patient information into different tumour types for analysis.  
The large-scale cancer genomics datasets were retrieved from International Cancer 
Genome Consortium (ICGC) Data Portal (Hudson et al., 2014; Zhang et al., 2011), the c-
BioPortal for Cancer Genomics (Cerami et al., 2012; Gao et al., 2013) and the Cancer Genome 
Atlas (TCGA) Data Portal (CGARN, 2013).  
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International Cancer Genome Consortium (ICGC) was the only database that allowed 
for analysis of non-coding regions. RUNX1 regulatory regions  (as defined in Table 3.6) were 
analysed for mutations in cancer datasets, with 237 mutations found (Table 3.9). The number 
of mutations observed in the different RUNX1 regulatory regions in haematopoietic- related 
cancers was relatively low (6.75%). The majority of mutations in these regions occurred in 
skin-related cancers (39.24%) (Table 3.9). However it is worth noting that even normal skin 
has a high mutational load relative to other tissues (García-Nieto et al., 2019; Martincorena et 
al., 2015). 
Table 3.9: Spread of 237 Runx1 regulatory region mutations that were found in ICGC dataset represented 
in a range of primary tissue sites. 
Primary site of mutation Representation of found mutations (%) 










Gall Bladder 2.53% 
Mesenchymal 1.69% 






The regulatory regions showed different frequencies of mutations in this dataset (Figure 
3.3). m-58 had the highest frequency of mutations with 81 incidences, followed by intron 5.2 
(41) and then m-327 (27). m-58 also showed the highest incidence of mutation in 
haematopoietic cancers (4). Each enhancer had a relatively diverse profile of primary mutations 
sites (Figure 3.3) 
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 Figure 3.3: Proportions of cancerous primary site mutations of regulatory regions.  
Each of the regulatory regions displayed diverse cancerous primary site profiles. Primary site profiles are colour 
coded. Key is at the bottom of the figure. Total number of mutations excluding skin in each regulatory region 
shown at top of each bar. As normal skin has a high mutational load relative to other tissues it was not included 
in this diagram. 
 
Some of the regulatory region SNPs (from Section 3.4.2) were reported in patients: an 
oesophageal adenocarcinoma patient had the m-327 T>G rs12106380 SNP, another 
oesophageal adenocarcinoma sample had the same G to A change reported in m-58 rs8129889 
SNP. Three patients had -250 SNP rs2834885, two with acute myeloid leukaemia and one with 
oesophageal adenocarcinoma. Four patients with malignant lymphoma had m-58 mutations 
chr21:g.36480715C>A (rs199811665), chr21:g.36480761A>C and chr21:g.36481470C>T 
(rs1440069314). None of these SNPs were reported in the GTEx portal. Two SNPs in +62 were 
found in patients with acute myeloid leukaemia rs933131 and rs2834716. Interestingly, the 
patient with rs2834716 also had the intron 5.2 SNPs (rs2268276 and rs2249650) which have 
been previously associated with acute myeloid leukaemia susceptibility (Xu et al., 2016). 
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Intron 5.2 SNP rs2268276 was also found in a patient with lung cancer. Three other patients 
also reported intron 5.2 SNP rs2249650, two with lung cancer, one with paediatric brain 
tumour.  
The genomic data in the ICGC Data portal contains multiple mutations per patient. The 
analyses of these regions shows that some of the reported SNPs are found in AML patients, 
however, it is unknown whether many of these SNP have a functional impact in these patients. 
As was done for the analysis of intron 5.2 SNPs (Xu et al., 2016), there is a need to analyse 
each of these SNPs for functional capability. Interestingly, the majority of cancers reported 
with mutations in RUNX1 regulatory regions were not blood-specific, instead reflecting the 
roles of RUNX1 in other tissues (Groner et al., 2017). The tissues highlighted as expressing 
regulatory regions in FANTOM 5 data (Table 3.7) were the same primary sites of mutation in 
ICGC data (Table 3.9, Figure 3.3). 
3.5 Zebrafish enhancer reporter assays 
To understand the tissue-specific activity of Runx1 regions that directly interact with Runx1 -
P1, -P2 and +24 (Marsman, 2016), zebrafish reporter assays were used. 
DNA sequences of the putative enhancers were amplified from mouse gDNA then 
cloned into zebrafish enhancer detector assay reporter constructs (Figure 3.4), and injected into 




Figure 3.4: Schematic representation of ZED assay vector.  
This vector contains two cassettes, the first cassette consists of cardiac actin promoter (blue) upstream of Red 
Fluorescent Protein (red). The second cassette contains the gateway cassette (yellow), which is immediately 
downstream of the gata2 promoter (blue), downstream of the green fluorescent protein (green). The second 
cassette is protected by insulator sequence (purple). Purple dotted line indicates the insulated sequence, which 
prevents positional effects from surrounding DNA, following integration. Tol2 sites (orange) allow for 
integration of vector into zebrafish genome. The vector contains two excision cassettes, one targeted by Flip-
recombinase (FRT sites) and the other by Cre-recombinase (LoxP sites). Figure from Thomas (2015). 
 
The zebrafish enhancer detector assay (ZED) is designed to have two different 
cassettes; one to test enhancer activity of the regulatory element in a cell type specific manner 
and a second cassette which functions as a an internal control for assessing injection efficiency 
and a transgenic marker. If the regulatory region acts as an enhancer it will cooperate with the 
gata2 promoter to drive cell-specific GFP expression. The enhancer detection cassette is 
bordered by two insulator sequences which prevent interaction between the two cassettes. The 
two insulator sequences also prevent position effects from the surrounding DNA following 
integration, eliminating false positives. LoxP and FRT sites allow for deletion of either cassette 
using Flipase or Cre recombinase. The internal control cassette utilises the cardiac actin 
promoter (pCarA) to drive, Red Fluorescent Protein (RFP) expression in the somites, which 
serves as a marker for successful transgene integration. The second cassette designed to test 
the cell-type specific functional ability of a putative enhancer contains; a gateway entry site for 
the putative enhancer, a gata2 minimal promoter and the enhanced GFP reporter gene.  
Tol2 sites permit transposon-mediated integration into the zebrafish genome with high 
efficiency in the presence of Tol2 transposase mRNA (Kawakami, 2005). Germline integration 
into the host genome allows for expression of the ZED cassette in subsequent generations. If 
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vector is successfully integrated, non-mosaic expression patterns are seen. Unsuccessful or 
partial integration can lead to inconsistent and mosaic expression.  
3.5.1 Zebrafish Enhancer assay F0: 
All putative mouse Runx1 enhancer regions identified by Dr. Marsman’s 4C (ZED 
m+110, m-48, m-58, m-303, m-321, m-327, m-354, m-368 and m-371) and ZED +24 were 
tested for enhancer activity in a zebrafish enhancer assay (Figure 3.4).  
Runx1 +24 was used as a positive control and empty ZED assay vector was utilised as 
a negative control. (Figure 3.5 A). Runx1 +24 drove GFP expression specifically in the 
intermediate cell mass (ICM) and posterior blood island, which are sites of hematopoietic 
progenitor cell production, at 20-24 hours post-fertilisation (hpf) (de Jong et al., 2005). 
Eight of the nine putative enhancer regions ZED m+110, m-48, m-58, m-303, m-321, 
m-354, m-368 and m-371, showed similar expression patterns to +24 (Figure 3.5 B). These 8 
regions functioned as hematopoietic-specific enhancers in zebrafish, indicating that their 
enhancer activity is conserved. 
ZED m-303 also showed expression in the keratinocytes at 20-24 hours post 
fertilisation (hpf) and 48 hpf as well as haematopoietic activity at 20-24 hpf (Figure 3.5 C). 
ZED empty and ZED m-327 had no observed enhancer activity at these timepoints (Figure 3.5 
A,B).  
Further analysis of these Runx1 enhancers highlighted that each region had individual 
expression patterns (Figure 3.6). Of the enhancer patterns +24, and m-368 had similar patterns 
with the highest expression in the dorsal aorta (DA), followed by expression in the intermediate 
cell mass (ICM). ICM is the site of the primitive wave of haematopoiesis and it generates 
primitive erythrocytes and limited myeloid populations. The DA is a main axial vessel, which 
carries blood away from the heart, towards the tail. The first wave of definitive haematopoiesis 
arises in the ventral wall of the DA. 
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The m-371, m-354, -m-321, m-58 and m-48 enhancers drove the highest expression in 
the ICM. m+110 produced even expression in the DA and ICM as well as in the tail bud of the 
zebrafish. m-303 produced the highest expression keratinocytes in the tail lining, followed by 
DA expression. High DA expression suggests m-371, m-368, m-354 and m+110 have the 





Figure 3.5: Putative mouse enhancers are active in hematopoietic regions in zebrafish.  
Whole mount representative lateral images of zebrafish embryos (20-24 hpf [A, B] and ~48 hpf [C]) that were 
injected with enhancer-GFP plasmids at the one-cell stage; left hand panels are merges with bright field, right 
hand panels are GFP fluorescence. (A) negative control ZED plasmid shows zero (image) or non-specific 
fluorescence, while positive control (+24) shows GFP expression in hematopoietic cells of the posterior blood 
island (red arrows) and intermediate cell mass (yellow arrows). (B) enhancer activity of m+110, m-48, m-58, m-
303, m-321, m-327, m-354, m-368, m-371. (C) The m-303 enhancer also expressed GFP in keratinocytes (white 
arrow). The numbers in the right hand panels represent the number exhibiting the representative phenotype out 
of the total number of fluorescent embryos analysed. Figure originally used in Marsman et al., (2017) (Marsman 
et al., 2017) This image is used with permission under Creative Commons CC BY license.  
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Figure 3.6: . Quantitative summary of GFP expression patterns generated by putative mouse enhancers in 
zebrafish.  
For each enhancer construct (m+110, m- 48, m-58, m-303, m-321, m-327, m-354, m-368, -m371) and the 
negative (ZED) and positive (+24) controls, GFP expression data in different tissues is shown. Diagrams 
represent pooled expression from at least 5 photographed embryos per putative enhancer (20-24 hpf), displayed 
on illustrations of a 24 hpf zebrafish embryo. Categories of expression zones are colour-coded: key is at the 
bottom of the Figure. Bar graphs display the percentage of the total number of GFP-expressing embryos that 
show expression in each tissue category for each putative enhancer. The total number of expressing embryos 
analysed per construct is displayed in the top right corner of each graph. Figure originally used in Marsman et 
al., (2017) (Marsman et al., 2017) This image is used with permission under Creative Commons CC BY license.   
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The expression of enhancer assays in injected generation of zebrafish (F0) is mosaic 
(not expressed in every cell), however this still provides information about tissue specific 
activities for the identified enhancers. F1 fish can be grown and used for further analysis.  
3.5.2 Zebrafish Enhancer assay F1: 
Although strong enhancers were detected using transient GFP expression in zebrafish 
reporter assays, it is more informative to analyse the F1 fluorescence, as each embryo should 
have complete integration of the construct in all cells (Bessa et al., 2009). Cell-specific GFP 
expression through development would reveal more precisely tissue-specific spatiotemporal 
activity of the enhancer. 
The injected generation, F0, which presented complete fluorescence in the somites of 
embryos were selected to produce transgenic lines. When the F0 were sexually mature they 
were out-crossed with wild type fish in order to determine the individual integration success of 
the assay into the gametes. F1 fish can be grown and used for further analysis.  
Ute Zellhuber-McMillan and I bred all the fish lines to try establish stable F1 lines. 
Together we bred 11 different fish enhancer lines, from which over 140 fish were paired for 
breeding and 116 fish produced embryos. The fish produced 15,314 embryos which were 
screened for green fluorescence (20-24 hpf) and red fluorescence (48 hpf), however no 
embryos showed any control somite RFP or enhancer GFP.  
Lack of fluorescence does not appear to be a Tol2 mRNA issue, as others lines in the 
lab have made successful F1 lines from the same Tol2 mRNA (Ketharnathan et al., 2018). It is 
unlikely that the lack of fluorescence is due to injection technique as I clearly observed 
fluorescence in F0, and have completed successful double injections for other projects during 
my PhD (Meier et al., 2018). This could be a blood enhancer specific issue, as none of the 
different plasmids used have produced successfully integrated F1 lines (I previously have used 
ZED, SCE, Tol2Gata2). Personal communication with the Zon lab indicated that other 
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researchers have been unsuccessful in making haematopoietic specific enhancer F1 lines using 
assays that contained the zebrafish gata2 promoter. It has been proposed that due to the delicate 
nature of haematopoiesis, if the plasmid DNA is integrated into the zebrafish genome, it is 
actively repressed to maintain the correct haematopoiesis. As the plasmid insert is repressed 
there is no RFP or GFP expressed in F1 fish.  
3.6 Genomic characteristics of 4C identified functional novel 
enhancers 
To understand if there was a rationale to the cell type patterns observed in the zebrafish 
enhancer assays (Figure 3.6), Dr. Judith Marsman analysed the Runx1 4C identified regulatory 
regions (Table 3.4) (Runx1 m+24, m+110, m-48, m-58, m-303, m-321, m-327, m-354, m-368 
and m-371) in the available mouse haematopoietic progenitor cells (HPC7) ENCODE data. No 
consistent patterns could be observed. Runx1 -327 had similar transcription factor binding to 
other observed enhancers but no observed enhancer activity in zebrafish embryos. Interestingly 
the Runx1 -368 does not bind any transcription factors, shows no sign of open chromatin 
(DNase I HS site) and therefore does not appear to have a regulatory function in developing 
haematopoietic cells. 
Of the Runx1 4C identified regulatory regions, m-371, m-354, m-303 and m-48 were 
novel. As noted in section 3.1.1 m-368, m-327, m-321, m-58 and m+110 were identified by 
other groups (Ng et al., 2010; Schütte et al., 2016).  
In order to further understand the novel Runx1 enhancers identified by Judith Marsman 
(m-371, m-354, m-303 and m-48), I carried out the same in silico analysis used to define the 
previously identified Runx1 regions (Section 3.4).  
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3.6.1 Conservation and epigenetic analysis 
The only novel Runx1 enhancer that is conserved in humans is m-371 (Table 3.10). 
This region shows transcription factor binding sites and chromatin modifications similar to that 
found at m-58 and m+110. ChromHMM annotates this region as a strong enhancer like m-368, 
m-58 and m+110. The m-371 enhancer region sits within the same uncharacterised non-coding 
RNA LOC100506403 as m-368 and m-327. 
m-354, m-303 and m-48 are mouse specific novel Runx1 enhancers.  
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N/A N/A N/A 
 
3.6.2 Single nucleotide polymorphism (SNP) analysis 
The FANTOM 5 data showed that m-371 RNA was actively expressed in skin and 
prostate cells. SNP analysis of m-371 showed that one of the two SNPs in this region is related 
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to Kynurenine 3-monooxygenase (KMO) expression in peripheral blood monocytes (Table 
3.11) identical to m-368 SNP rs909143. KMO is typically researched in a neurological context, 
as high KMO expression leads to neurodegeneration (Breton et al., 2000). 
The 3D spatial interactions found by CoDeS3D pipeline between RUNX1 m-371 SNPs 
and RUNX1, were not supported by any significant eQTL interactions. 
 






SNP name Predicted changes SNP function 
m-371 2 rs2834944 The T to C change 
alters 4 regulatory 
motifs. 
Not investigated 
rs2834945 The T to C change 
is predicted to 
affect 11 regulatory 
motifs including 
GATA2 and PAX3 
and PAX5. 
Has an eQTL with 
oesophagus and is 
related to Gene 
expression of KMO in 
peripheral blood 
monocytes (p value: 




3.6.3 Comparative analysis of cancer genomic datasets 
The majority of m-371 mutations (n=23) presented with skin as the primary site 
(40.90%), followed by prostate, liver and breast primary sites (13.63% each). m-371 also 
presented in oesophagus (9.09%), pancreas (4.54%) and ovary (4.54%). 
The FANTOM5 expression of m-371 in skin and prostate cells overlaps with the 
primary tissues that contain m-371 mutations. This suggests that m-371 is an enhancer in skin 
and prostate cells, as it is producing eRNA. Mutations in this enhancer, in skin and prostate 
tissues may alter normal cell development. 
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3.7 Chapter summary 
This work identified conservation of 9 out of the 16 mouse Runx1 regulatory regions 
from mouse to human (m-371, m-368, m-327, m-101, m-58, m-43, m+3, m+110, m+204 ). m-
354, m-321, m-303, m-48, m-42, m+1 and m+181 are not conserved in human.  
In K562 cells ChromHMM annotates m-368, m-58, m+110 -139, m-43, and +62 as 
enhancers. Intron 5.2, m-101 and m+3 show the same regulatory associations as the enhancers, 
however, they are instead labelled as transcription associated. This could be due to their close 
proximity with exons when compared to the regions annotated as enhancers. ChromHMM also 
reported -139 and -188 as transcription associated. m-371, m-368 and m-327 all sit within 
LOC100506403, an uncharacterised non-coding RNA.  
m-368, -250, m-101, m-58, m-43, m+3, +62, m+110 and intron 5.2 were all bound by 
LSD1, a mediator of transcriptional repression usually seen in silencers. SPI1, a haematopoietic 
transcription factor was only bound to -139 and -188. Blood stem progenitor transcription 
factors TAL1 and GATA2, as well as GATA1, a marker of erythroid development, were found 
to bind m-371, m+110 and m-58. 
Cheng et al., (2018) characterised +62 as a silencer of RUNX1 P2 in K562, OCI-AML3 
and U937 cells (Cheng et al., 2018). However in K562 cells +62 has ENCODE and 
ChromHMM annotations associated with enhancer activity.  
Intron 5.2, m+110 and m-371 regions were annotated as differentially opened 
chromatin in the ATAC-seq of the cohesin mutant (Antony et al., 2020). This suggests these 
enhancers’ interactions could be dependent on cohesin. In this chapter, I observed a 
coincidence of cohesin subunit Rad21 binding in the absence of CTCF with +110 enhancer, 
and CTCF binding with m-371, m-58, m-43, m+3, +62 and intron 5.2. This suggests that CTCF 
and cohesin could independently mediate a subset of enhancer-promoter looping in 
combination with transcription factors.  
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Nine of the 13 conserved RUNX1 regulatory regions produced eRNA in human 
haematopoietic cells. SNP analysis identified SNPs in each of the conserved regulatory regions 
except m-101. Of the 35 SNPs 5 had previously reported functional effects in haematopoietic 
cells. The available AML genomic data is relatively limited because the majority of analyses 
were done with exome sequencing data rather than whole genome sequencing data.  
I functionally characterised novel Runx1 enhancers m-371, m-354, m-303 and m-48 
using zebrafish enhancer assays. I also characterised previously identified m+110, -58, -321, -
327, -368 showing that all of these have enhancer capability except m-327. Despite the lack of 
activity seen in embryos expressing m-327, this region spatially connects to the active promoter 
Runx1 P1 and +24 in HPC7 cells so it may have another regulatory role in this hub. My analysis 
showed enhancer activity in haematopoietic tissues of developing zebrafish embryos, 
highlighting that they appear to be important in both primitive and definitive waves of 
haematopoiesis.  
After I functionally analysed the mouse enhancers using zebrafish reporter assays, Zhu 
et al., (2020) further characterised m-371 using single cell (sc) ATAC-seq and scRNA-seq 
from developing mice. m-371 is only accessible in pre- haemogenic endothelial (HE) cells and 
in the intra -arterial clusters (IAC) in mice. This suggested it could initiate Runx1 P1 in pre-
HEs and contribute to expression of P1 in IACs (Zhu et al., 2020). 
Of the enhancers functionally identified, all except +110 interacted with Runx1 +24 
(Marsman, 2016), suggesting that +24 could be anchoring an enhancer hub. These CREs are 
conserved between mice and humans suggesting they are fundamental for the correct regulation 
of RUNX1.  
This chapter has provided an insight into mouse Runx1 enhancer functions and 
highlighted the features of conserved human enhancers. As shown in Dr. Judith Marsman’s 4C 
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analysis +24 is a central hub that binds most active Runx1 enhancers in HPC7s. +24 may also 
be the organiser of correct enhancer-promoter interactions for Runx1 regulation.  
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4 Chapter 4: Three-dimensional (3D) connections of 
Runx1 +24 
4.1 Introduction 
The three-dimensional (3D) organisation of the genome is non-random (Holwerda et 
al., 2012; Lieberman-Aiden et al., 2009). The genome is organised into topologically 
associated domains (TADs), formed by an elevated number of chromatin interactions within a 
genomic locality, with fewer interactions to outside regions (Lieberman-Aiden et al., 2009; 
Rao et al., 2014). Genes located within the same TAD often have the same histone 
modifications and are co-regulated (Rao et al., 2014). The borders of domains are enriched for 
cohesin and CTCF binding sites, housekeeping genes, short interspersed element (SINE) 
retrotransposons and transfer RNAs (Dixon 2012). Loss of CTCF relaxes the global domain 
structures, which increases contacts between domains, whereas loss of cohesin mostly affects 
interactions within domains (Li et al., 2013b; Zuin et al., 2014). 3D connections of the genome 
are predominantly detected by Hi-C and Promoter Capture sequencing, allowing for high 
throughput analysis and subsequently the creation of genome interaction maps (example shown 
in Figure 4.1).  
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Figure 4.1: Hi-C contact map of the RUNX1 region in K562 cells.  
Hi-C data generated by Rao et al., (2014) from chromosome 21 was visualised in 3D genome browser 
(http://3dgenome.fsm.northwestern.edu/view.php) at a 25-kb resolution (Wang et al., 2018). Every square is 
coloured according to the frequency of two regions interacting. The alternating yellow and blue bars are 
predicted TADs. The dark red bars are DNase I hypersensitive sites (DHS) in the same cell type. Locations of 
genes are annotated according to their transcription direction, forward strand (black) and reverse strand (blue).  
 
In Chapter 3 I described the characterisation and function of Runx1 regulatory regions. 
The majority of functional haematopoietic-specific Runx1 enhancers interacted with +24 in 
mouse hematopoietic progenitor (HPC7) cells (Marsman, 2016). Runx1 +24, a well 
characterised enhancer, interacts with promoters (P1 and P2) of Runx1 (Markova et al., 2011; 
Marsman, 2016). I hypothesise that Runx1 +24 may nucleate an enhancer hub, thereby 
controlling Runx1 connections and contributing to the overall Runx1 organisation and 
expression.  
Previous work from Dr. Antony described RUNX1 transcription in normal and cohesin 
deficient megakaryocytic differentiation (Antony et al., 2020). Runx1 +24 is crucial to 
hemogenic endothelial cells in mouse and zebrafish (Markova et al., 2011; Marsman et al., 
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2017; Ng et al., 2010; Schütte et al., 2016). Interestingly this well-known enhancer was also 
described as a silencer in the non-haematopoietic cell line, HEK293 (Markova et al., 2011). 
Understanding where in the genome Runx1 +24 connects to and how it contributes to Runx1 
organisation is imperative to understanding the transcriptional regulatory landscape of Runx1.  
4.1.1 Secondary structure of DNA 
G-quadruplexes are secondary structures that are often present in telomeres and also 
gene promoters; however, their function remains elusive. Previous studies on G-quadruplexes 
indicate possible roles for them in controlling gene expression (Du et al., 2007; Eddy et al., 
2008; Zhao et al., 2007). 
4.1.1.1 Secondary structure of Runx1 +24 
In my previous Master’s work, a possible G-quadruplex (G4) structure was identified 
in the Runx1 +24 mouse cis-regulatory element (CRE). Despite multiple attempts and different 
primers, the mCRE was never sequenced the full way through using Sanger sequencing. When 
compared back to the mouse (mm9) +24 mCRE sequence sent by Professor Motomi Osato, it 
was noted that the sequences stopped in the same place every time. The online tool QGRS 
mapper was used to predict if there was a G-quadruplex structure (Kikin et al., 2006). 
Two predicted quadruplex structures sit either side of the +24 region that could not be 
sequenced. One was in the sense direction and the other was in the antisense direction. 
Sequences can be found in Appendix IV. Each predicted structure has the potential to form a 
four-stranded structure stabilised by G-quartets (Figure 4.2). G-quadruplex structures derive 
stability from hydrogen bonding between guanines and stacking of G-quartets (Maizels et al., 
2013). Due to time constraints I have not investigated to see if this structure is predicted in the 
human sequence.  
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Figure 4.2: Schematic representation of mouse +24 individual G-quadruplex.  
Four guanines form a G-quartet, a planar ring around a central channel (represented by each grey rectangle). G-
quadruplex structures derive stability from hydrogen bonding between guanines and stacking of G-quartets . 
 
In the work described in this Chapter, I sought to understand how Runx1 +24 influences 
the 3D structure and connectivity of the Runx1 locus. To understand how the formation of the 
G-quadruplexes influences transcription, I measured the predicted mouse Runx1 G-quadruplex 
3D structure integrity using a Circular Dichroism (CD) photospectrometer. I then determined 
whether G-quadruplex structure impacts on enhancer capability by using luciferase assays in 
mouse fibroblast (NIH/3T3) cells. 
I used circular chromatin conformation capture (4C) to identify DNA-DNA interactions 
with the RUNX1 +24 enhancer region. 4C is an unbiased approach that detects genome-wide 
interactions with a chosen region or “bait” by using next generation sequencing of captured 
fragments (van de Werken et al., 2012a). Identification of RUNX1 +24-anchored interactions 
has potential to further elucidate the role of this enhancer by measuring its genomic 
connectivity. 4C was performed in the K562 (chronic myelogenous leukaemia) cell line. In 
K562, RUNX1 P1 expression was previously shown to have a key role in megakaryocyte 
lineage determination (Draper et al., 2017). K562 cells can be induced to differentiate to the 
megakaryocytic lineage (Kuvardina et al., 2015; Pencovich et al., 2011). 
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Majority of 3D chromatin mapping has been done in steady state cells. Cohesin 
depletion has been shown to alter, and in some cases result in the complete collapse of TADs 
(Waldman, 2020). Cuartero et al., (2018) and Antony et al., (2020) have recently shown upon 
differentiation stimulation, the gene expression changes are more distinct in cohesin depleted 
cells (Antony et al., 2020; Cuartero et al., 2018b). To determine the influence of cohesin and 
enhancer specific connections in lineage specific regulation, the chromatin architecture should 
be investigated before, during and after the differentiation process. 
To understand the role of cohesin in enhancer connections and leukemic gene 
regulation, K562 cells with CRISPR-CAS9 engineered STAG2 mutations were used to 
determine the connectivity of RUNX1 +24. K562 cells were induced to differentiate to the 
megakaryocytic lineage, using phorbol 12-myristate 13-acetate (PMA), so the role of RUNX1 
+24 could be further understood. K562 lines with patient-specific STAG2 R614* mutation (-/-
) were previously generated by Dr. Antony. 
Antony et al., (2020) highlighted the altered phenotype of K562 cells with STAG2 
mutation using RNA seq (Antony et al., 2020). Using ATAC-seq Dr. Antony also noted altered 
chromatin accessibility in K562 cells with STAG2 mutation. The RNA seq and ATAC seq 
revealed that the gene expression changes observed are associated with altered chromatin 
accessibility at regulatory regions and super-enhancers in STAG2 mutants (Antony et al., 
2020). 
K562 cells are labelled as wild-type (WT) cells with the treatment condition (PMA or 
DMSO) and timeframe also included in the nomenclature. STAG2 refers to the STAG2-mutant 
K562 cells that were CRISPR edited to contain R614*  mutation in the STAG2 subunit (Antony 
et al., 2020). The baseline treatment condition was collected after 12 hours (h) of DMSO 
treatment (12 DMSO). Cells were collected after 12 h of PMA treatment (12 PMA) and 72 h 
of PMA treatment (72 PMA). 12 h of PMA treatment was chosen based on the aberrant RUNX1 
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and ERG expression spikes seen in STAG2 mutants at this timepoint (Antony et al., 2020) and 
72 h is the time point when the aberrant expression spikes of RUNX1 seen in STAG2 mutants 
return to non-PMA stimulated levels (Antony et al., 2020).  
I chose RUNX1 +24 as a ‘bait’ to capture chromatin interactions because it is a strong 
and well-characterised enhancer of RUNX1 transcription and therefore is likely to make 
important regulatory contacts during haematopoietic cell differentiation. Identifying the +24 
contacts in leukaemia cells may enhance our understanding of haematopoiesis and the 
development of leukaemia.  
4.2 Hypothesis 
I hypothesise that RUNX1 +24 makes 3D genomic contacts that are important in the 
regulation of RUNX1 expression. 
4.3 Aims 
1) Identify enhancer characteristics of RUNX1 +24 using bioinformatic tools. 
2) Characterise a possible G-quadruplex structure in the mouse Runx1 +24 enhancer. 
3) Identify the 3D connections of human RUNX1 +24 using 4C in K562 cells. 




4.4 Enhancer characteristics of RUNX1 +24 
RUNX1 +24 was analysed in the same manner as the other Runx1 regulatory regions 
(Section 3.5).  
4.4.1 Epigenetic analysis 
The +24 region shows similar haematopoietic transcription factor binding sites and 
chromatin modifications to m-371 m-58 and m+110. However, +24 has additional cohesin 
(SMC3) and SPI1 binding. ChromHMM annotates this region as a strong enhancer, similar to 
m-371, m-368, m-58 and m+110. Interestingly, +24 showed no change in chromatin 
accessibility in K562 cohesin-mutant cells relative to wild type K562. 
















DNase I HS, RNA Pol 




GATA1, SPI1, TAL1, 
GATA2 





4.4.2 Single nucleotide polymorphism (SNP) analysis 
FANTOM5 data showed that +24 eRNA is actively expressed in haematopoietic cells. 
No SNPs with a minor allele frequency (MAF) of >1% were detected in this region. 
Consequently, 3D spatial interactions were not detected by the CoDeS3D pipeline due to the 
lack of SNPs. 
4.4.3 Comparative analysis of cancer genomic datasets 
The International Cancer Genome Consortium (ICGC) reports 5 mutations in this 
region from 5 donors. Primary sites of +24 mutations presented evenly with ovary, prostate, 
breast, lung and haematopoietic cells (20%) in ICGC database. There is only one 
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haematopoietic mutation chr21:g.36399191A>T reported in a malignant lymphoma. The 
FANTOM5 expression of +24 in haematopoietic cells overlaps with the primary ICGC tissues 
that contained +24 mutations. The low number of mutations and lack of SNPs may suggest this 
area is important for haematopoesis and a mutation may prevent normal development.  
4.5 Characterising Runx1 +24 G-quadruplex structure 
4.5.1 CD spectroscopy 
G-quadruplexes (G4s) are generally classified according to strand orientation, loop 
location and the number of strands involved in formation. To verify if the G4s predicted can 
form in vitro, preliminary CD spectrometer readings were taken.  
The predicted G4 structure GGTGGGGGTGGG, within the Runx1 +24 sequence is 
made up of two G-quartets (Appendix IV) . Mutated G4 GGTGTGTGTGGG was generated as 
a negative control with two Ts so that only one quartet can form, one quartet should be 
insufficient for this structure to function as a G-quadruplex (Figure 4.3).  
 
Figure 4.3: Predicted representation of Runx1 +24 mCRE G-quadruplex and mutated +24 mCRE.  
A) Predicted Runx1 +24 mCRE G-quadruplex structure with two G-quartets (Grey rectangles). B) Predicted 
mutated Runx1 +24 mCRE structure. Blue Ts show the mutated base pairs so only one quartet can form. 
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CD experiments are carried out in different buffers: 100 mM KCl pH 7 (positive control 
buffers); 100 mM NaCl, and 100 mM LiCl (negative control buffer). It is expected that G4s 
will form in the KCl buffer because the buffer provides the K+ cation required to stabilise the 
quartet. Both NaCl and LiCl donate fewer stable cations so the G4 should be less prominent; 
at 95 °C, NaCl and LiCl should not support formation of the G4 structure. 
Preliminary scans showed that at 25 °C the predicted +24 mCRE G-quadruplex was 
forming a parallel stranded G4 formation (Figure 4.4A-C and Figure 4.5A). The mutated G-
quadruplex was unable to form any secondary structure because the DNA is in a parallel 
formation (Figure 4.5B). The increase of temperature to 95 °C significantly decreased 
structural stability in all buffers except for KCl (Figure 4.4D-F).  
 
 
Figure 4.4: CD spectroscopy of wild-type and mutant +24 G4s.  
Molar ellipticity (deg.cm2.dmol-1) is on the vertical axis and wavelength (nm) is on the horizontal axis. The 
blue line represents the CD spectra for the wild-type sequence and the orange line represents CD spectra for the 
mutant sequence. CD spectra of +24 G4 and mutant at A) 25 °C in the presence of 100 mM KCl. B) 25 °C in the 
presence of 100 mM NaCl. C) 25 °C in the presence of 100 mM LiCl. D) 95 °C in the presence of 100 mM KCl. 
E) 95 °C in the presence of 100 mM NaCl. F) 95 °C in the presence of 100 mM LiCl.  
 
These preliminary scans indicate that a parallel G4 forms in vitro for the native 
sequence. Based on the CD Spectra, the +24 G4 presents a positive peak at 260 nm and a 
negative peak at 240 nm. This specific spectroscopic signature is representative of a parallel 
G4, which suggests the strands are orientated in the same direction (Gattuso et al., 2016). 
Figure 4.5 shows a schematic representation of the normal and mutated G4.  
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Figure 4.5: Schematic representation of the predicted Runx1+24 mCRE G-quadruplex in parallel 
conformation and when base subsitutions are made at the +24 mCRE.  
A) Predicted Runx1 +24 mCRE G-quadruplex structure in parallel formation with two G-quartets, based on CD 
spectrometer results (grey rectangles). Red arrows indicate 5’-3’ DNA arrangement B) Predicted mutated Runx1 
+24 mCRE structure. Blue Ts show the mutated base pairs, preventing the formation of parallel quartets. 
 
4.5.2 Runx1 +24 G-quadruplex Luciferase reporter assay 
In order to determine whether an intact G-quadruplex is required for the functional 
enhancer capability of the Runx1 +24 enhancer, luciferase reporter assays with mutated and 
normal G-quadruplexes were used. The relative ability of constructs to drive expression of the 
firefly luciferase reporter gene Luc2 (Phoinus pyralis) was determined. Luc2 was previously 
cloned into the eukaryotic reporter gene vector pGL4.23-GW (Figure 4.6) (Pasquali et al., 
2014). A functional enhancer cloned into the Gateway site of pGL4.23-GW will increase 




Figure 4.6: Diagram of Luciferase reporter construct pGL4.23-GW.  
This 4283 bp vector contains Gateway cassette (yellow) immediately upstream of the minimal promoter (blue). 
The minimal promoter (minP), a TATA-box promoter element, drives low basal expression, which allows for 
sensitive responses to promoterless regions of interest. The minP sits immediately upstream of the Luciferase 
reporter gene Luc2 (green) (Paguio et al., 2005). Figure from Thomas et al., (2015). 
 
Runx1 +24 and modified +24 were cloned into the pGL4.23-GW (pGL4) vector (Figure 
4.7) . The empty pGL4 plasmid was included to monitor background luciferase activity of the 
reporter construct and acted as a negative control.  
Runx1 +24 pGL4 has previously shown enhancer activity (Thomas, 2015). If the G-
quadruplex influences enhancer activity, we would expect the G to T mutation (g->t) in Runx1 
+24 pGL4 to alter luciferase activity (Figure 4.7B). This g->t mutation is the same as the G4 
mutant analysed in the CD analysis, so we know the G4 is unable to form. A control mutant, 
Runx1 +24 pGL4 t->a (Figure 4.7 C) that alters base pairs in the loop region without affecting 
the overall G4 structure was also generated.  
I generated Runx1 +24 pGL4 g->t and t->a G4 mutants using site-directed mutagenesis. 
This allowed for targeted base pairs to be altered efficiently. Mutations were confirmed by 




Figure 4.7: Schematic representation of pGL4 Runx1+24 mCRE G-quadruplex in parallel conformation 
and mutated +24 mCREs.  
A) Predicted Runx1 +24 mCRE G-quadruplex structure in parallel formation with two G-quartets (grey 
rectangles). B) Mutated g->t Runx1 +24 mCRE structure. Blue Ts show the mutated base pairs and no quartets 
form in parallel formation. C) Mutated t->a Runx1 +24 mCRE structure. Blue As show the mutated base pairs 
and two quartets still form in parallel formation. 
 
A Renilla luciferase reporter construct was co-transfected with the Runx1 +24 or +24 
modified pGL4 reporter constructs. Firefly and Renilla luciferases have distinct evolutionary 
origins, dissimilar enzyme structures and substrate requirements. These features allow these 
two distinct luciferases to be used as dual reporters when co-transfected in a single well (Sherf 
et al., 1996). Renilla was used as an internal control, to which the measurement of the pGL4 
construct variants could be normalised.  
The luminescence emitted was measured 48 h after transfection. To calculate the 
relative luciferase units (RLU) of each reporter construct, the pGL4 luciferase value was 
normalised to Renilla value to account for variations in transfection efficiency associated with 
inter-sample variation. Results were expressed as Luciferase/Renilla ratios with vectors 
carrying putative enhancers relative to the ratio of empty pGL4.23 vector (control).  
In my previous Master’s project, NIH/3T3 (mouse fibroblast) cells showed a significant 
upregulation of Runx1 +24 which indicates that +24 operates as an enhancer in this cell line. 
NIH/3T3 cells express Runx1 P1, Runx1 P2 and total Runx1 at similar levels to the reference 
genes (Thomas, 2015). 
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NIH/3T3 cell lines were co-transfected with the normal and mutated +24 pGL4 
constructs (Figure 4.7) and Renilla, then assayed for their relative luciferase activity. Six 
individual replicates were executed for each construct, and three biological repeats were 
performed (Figure 4.8). 
 
Figure 4.8: Luciferase activity in response to the various +24 mCREs in the NIH/3T3 cell line.  
The data show enhancer activity of normal and mutated +24 pGL4 constructs compared to empty pGL4.23-GW 
plasmid in NIH/3T3 cells, p value <0.05 (*) <0.001(****). Mutated G-quadruplex g->t had significantly less 
enhancer activity than mutated t->a +24. However, there was no significant difference in enhancer expression 
when the unaltered Runx1 +24 was compared to the mutated +24s enhancer expression. The data were analysed 
by ANOVA using GraphPad Prism 6 and are represented as mean +/- standard error of mean (S.E.M) of at least 
three experiments (n=3). pGL4 luciferase value was normalised to Renilla value and expressed as relative 
luciferase units (RLU). 
 
In the NIH/3T3 cell line, significant enhancement of luciferase activity was caused by 
the Runx1 enhancer +24 mCRE (p <0.001) (Figure 4.8). The mutated Runx1 +24 G-
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quadruplexes showed similar enhancement profiles to the normal Runx1+24 (p <0.001). The 
non G4 forming mutant (g->t) showed significantly reduced expression when compared to the 
control G4 mutant (t->a) (p <0.05). There was no significant difference between the unaltered 
Runx1 +24 and the mutated Runx1 +24. Runx1 +24 g->t exhibited a minor decrease in enhancer 
expression, whereas Runx1 +24 t->a showed a slight increase in enhancer expression when 
compared to the unaltered Runx1 +24. This suggests that alterations to the loop regions of the 
G4 could alter enhancer capability. However, the altered enhancement shown in the mutants is 
modest, and was not statistically significant when compared to the normal Runx1 +24 G4. 
G-quadruplexes are also capable of producing their own RNA, which have functional 
roles (Beltran et al., 2019; Wang et al., 2017). This was not investigated in this research project. 
4.6 Circular Chromatin Conformation Capture (4C) of 
Human RUNX1 +24 
Circular chromatin conformation capture (4C) was used to elucidate the connectivity 
of the RUNX1 +24 enhancer region. The 4C sequencing libraries were prepared from 4C 
material, each containing PCR products amplified by bait-specific primer pairs. The processing 
of the sequencing data is available in Appendix VIII. 
The guideline for the amount of mapped reads required for successful calling of 4C 
data is 1 million, but identification of interactions can be done with less than 300,000 reads 
(van de Werken et al., 2012a). A recent study has shown that 50,000–100,000 cis-mapped 4C 
reads are sufficient to generate reproducible 4C profiles (Krijger et al., 2020). The number of 
mapped reads for RUNX1 +24 bait in K562 and STAG2 mutant cells, in each library is shown 
in Figure 4.9.  
WT 12 PMA replicate 2 and WT 72 PMA replicate 2 had very low mapped reads, (1172 
and 58721 respectively), however the rest of the libraries each had over 370,000 reads. This is 
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sufficient for successful interaction identification. Controls were cells that went through the 4C 
process without the ligation steps. 
 
Figure 4.9: RUNX1 +24 Mapped read count.  
The number of mapped reads (millions) is shown for the individual conditions in replicate 1, 2, 3 or control. 
 
4.6.1 Quality check of 4C data 
Mapped reads were assigned to restriction fragments resulting in a read count per 
fragment. To determine whether my Runx1 +24 4C data is of good quality and comparable to 
other published 4C studies, I assessed the distribution of reads across fragments and correlation 
of read counts between replicates. 
The quality is measured by the proportion of reads on the same chromosome as the bait 
(cis) and the proportion of reads around the bait viewpoint (near-bait:1 megabase either side of 
the bait) (van de Werken et al., 2012a). The majority of the reads should be in close proximity 
to the bait, captured and represented in the read count (van de Werken et al., 2012a). A high 
number of reads on different chromosomes (trans) would indicate that the data originated from 
random ligation events and therefore the data is of low quality. The general guideline of good 
quality 4C data should have approximately 40% of reads in cis and at least 40% coverage in 
142 
the near-bait  (Raviram et al., 2016; van de Werken et al., 2012a). For each condition, the 
coverage of reads in cis and near-bait was calculated for all 3 replicates (Figure 4.10). The 
majority of conditions had over 40% reads in cis and over 40% of fragments covered in the 
near-bait. The STAG2 72 PMA replicate 1 had more than 40% coverage of fragments in near-
bait, but percentage of reads in cis was lower than 40% (31%). A low proportion of reads in 
cis can indicate fixing conditions of the chromatin are not optimal, as more trans interactions 
are detected, or that the bait forms a large number of trans interactions for structural or 
regulatory purposes. Dr. Marsman previously allowed the +24 bait to be analysed in HPC7 
cells with lower than 40% coverage in cis. The same parameter was extended to this analysis. 
WT 12 PMA replicate 2 and WT 72 PMA replicate 2 had less than 40% reads in the near-bait 
(14% and 39%). This factor combined with their low read count meant they were excluded 




Figure 4.10: RUNX1 +24 4C quality evaluation. 
 The coverage of fragments that had more than one read present within 0.1 megabases (Mb) on either side of the 
bait was plotted against the percentage of reads in cis over total. 4C data of WT 12 DMSO (light blue), WT 12 
PMA (blue), WT 72 PMA (dark blue), STAG2 12 DMSO (yellow), STAG2 12 PMA (orange), STAG2 72 PMA 
(red) is plotted. Three points, corresponding to replicate 1, 2 and 3 are presented for each condition. Grey dotted 
lines indicate cut-off point for good quality data.  
 
All samples that passed quality control were analysed using 4Cker, a bioinformatics 
pipeline developed to analyse 4C and determine significant interactions (Raviram et al., 2016).  
4.6.2 Detection of significant interactions 
The interactions of a bait across the genome will differ depending on proximity to bait, 
with closer interactions (near-bait) occurring at a higher frequency, followed by cis interaction 
then trans interactions having the least amount of interaction with the bait region. 4Cker 
provides different analyses for near-bait, cis and trans interactions. 
Near-bait analysis was carried out for 1 Mb either side of the +24 bait (within the 
RUNX1 domain). Cis analysis is carried out across chromosome 21, but excluded the near-bait 
region. Trans analysis is carried out across all chromosomes except 21. 
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Statistically significant interactions were detected using the 4Cker package (Raviram 
et al., 2016) using an adaptive window size of 3 fragments. Because the 4C signal is generally 
higher around the bait region and decreases in far-cis and trans, different adaptive window 
sizes were used for read normalisation and creating smooth spline in each data set. Adaptive 
windows were used to obtain an analogous number of observed fragments for each window. 
Window size is determined by the amount of signal detected in the region. 
Fragments in close proximity to 4C baits have a higher read count compared to 
fragments further away and when examined with the cis 4C analysis near-bait interactions 
would be statistically significantly enriched. For this reason, cis interactions and near-bait 
interactions were analysed separately, with near-bait analysis requiring a higher p-value to be 
determined statistically significant by the 4Cker programme than the p-values of cis 
interactions (Raviram et al., 2016). Significant interactions were visualised in the UCSC 
browser.  
To reduce errors due to mis-priming, fragments that had one or more reads in the control 
samples were removed from the matching cell type and condition. Additionally, fragments 
located 10 kb either side of RUNX1 +24 were removed. Fragments within 10 kb of the bait are 
not informative because bait-proximal fragments have a high read count regardless of whether 
there is a true interaction present or not. 4Cker combined the processed read counts per 
fragment by normalising to the total number of reads in each replicate (Raviram et al., 2016). 
Differential analysis between conditions was carried out between two conditions on the 
windows that are interacting with the bait in at least 2 conditions. 4Cker has optimised this 
analysis for near-bait and cis interactions. Significantly different domains were determined 
with a p-value of 0.05. 
This Chapter will interpret the RUNX1 +24 connections in normal K562 cells (WT 12 
DMSO). Analysis of the other conditions is described in further detail in Chapter 5. 
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4.7 Identification and Genomic Characteristics of Human 
RUNX1 +24 3D Connections 
4.7.1 Visualisation of significant cis interactions 
The mean normalised read count of all three WT 12 h DMSO replicates was plotted 
across chromosome 21 locations using ggplot (Wickham et al., 2007) to generate the cis profile 
of RUNX1 +24 connections in baseline K562 cells (Figure 4.11). Reads had a high coverage 
around the +24 (5 megabases (Mb) surrounding the bait). Figure 4.11 reveals that RUNX1 +24 
makes DNA-DNA contacts across the entire chromosome 21. The large normalised read peak 
that shows an interaction around 45,000,000 (*) with PDE9A and BC033260. 
Phosphodiesterase 9A (PDE9A) mRNA is detected throughout the body, but predominately in 
the brain, whereas BC033260 is an uncharacterised long non-coding RNA (Harms et al., 2019; 
Patel et al., 2018).  
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Figure 4.11: RUNX1 +24 cis 4C profile (chr21) in K562 cells (WT 12 DMSO).  
Ggplot of the cis 4C profile, normalised read count of all WT 12 DMSO replicates is on the vertical axis and 
position on chromosome 21 is on the horizontal axis. * shows the large normalised read peak around 45,000,000 
with PDE9A and BC033260. 
 
WT 12 DMSO showed 115 significant cis interactions across the long arm of 
chromosome 21. Once the overlap of the near-bait region is removed, there are 31 significant 
cis interactions (Appendix IX) (Figure 4.12). These interactions extended across the known 
TADs and ranging from chr21:16193679 to chr21:45164775. These interactions were further 





Figure 4.12: RUNX1 +24 significant cis interactions.  
Chromosome 21 with RUNX1 +24 interactions represented by black arches. Each interaction is colour-coded 
according to its ChromHMM profile: key is at the bottom left of the figure. Super-enhancers were determined 
from dbSuper. Chromosome is aligned to the K562 Hi-C contact map. Yellow and blue bands show the 
predicted K562 TADs.  
 
The majority of the interactions were with ChromHMM annotated regulatory elements 
(enhancers and insulators) (Figure 4.13). Some regions that interact with RUNX1 +24 exhibit 
multiple ChromHMM annotations, for example, location chr21:16193679-16290033 
contained both insulator and strong enhancer regions. The region was also identified as 
containing super-enhancers as determined by dbSUPER (Khan et al., 2016). The main 
proportion of RUNX1 +24 interactions were to enhancer regions (58%), followed by 
interactions to active promoters and insulators (both 32%). It also connects with some super-
enhancers so may be facilitating or restricting their 3D connections. Interestingly the +24 
enhancer also interacted with regions of polycomb repressed chromatin (29%). This indicates 
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that +24 is not just acting as an enhancer hub (as previously described in Section 3.7); it may 
also be holding regions of chromosome 21 to ensure that the chromatin is correctly organised 
into inactive and active domains.  
 
 
Figure 4.13: Profile of RUNX1 +24 significant cis interactions.  
Percentage of interactions is on the vertical axis. Horizontal axis shows the ChromHMM annotations. Individual 
interactions can have multiple annotations. 
 
4.7.2 Overview of significant near-bait interactions 
Near-bait analysis considers the interaction 1 Mb either side of the bait (Raviram et al., 
2016). The mean normalised read count of all three WT 12 h DMSO replicates was plotted 
across chromosome 21 near-bait locations using ggplot (Wickham et al., 2007) (Figure 4.14). 
Domains are formed by high proportions of chromatin interactions in a genomic region, and 
less to outside regions. Domain boundaries can be predicted by a decrease in read count 
between two neighbouring regions. The TAD domain boundaries have already been reported 
for K562 cells and were determined by Hi-C (Rao et al., 2014). In most human cell lines, 
RUNX1 P1 and P2 promoters form TAD domain boundaries (Marsman, 2016). 
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When visualising the near-bait normalised read counts, the majority of reads are located 
within 5 Mb surrounding the bait (Figure 4.14). Figure 4.14 indicates the near-bait genomic 
interactions RUNX1 +24 is involved in.  
 
Figure 4.14: RUNX1 +24 near-bait 4C profile.  
Ggplot of the near-bait 4C profile, normalised read count is on the vertical axis and position on chromosome 21 
is on the horizontal axis. Rao et al., (2014) K562 domain boundaries are shown in grey dotted lines. Domain 
locations in K562 cells were obtained from Rao et al., (2014) (Rao et al., 2014). Black arrows represent the 
RUNX1 promoters. RUNX1 is transcribed telomere to centromere implied by the direction of the black arrows of 
the RUNX1 promoters. * shows the large normalised read peak at human equivalent region of RUNX1 m -368. 
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When the K562 TAD domain boundaries are overlapped with the normalised WT 12 
DMSO +24 reads we see RUNX1 +24 connections are primarily contained within the TAD 
domain. However the interactions are not constrained by the upstream boundary, as there is a 
similar read count between two neighbouring regions.  
Interestingly the large normalised read peak (*) between 36,500,000 and 37,000,000 
reflects an interaction with human equivalent region of RUNX1 m -368. 
WT 12 DMSO showed 143 significant near-bait interactions (Appendix IX) (Figure 
4.16). The majority of these interactions were upstream of RUNX1 P1. Similar to the cis 
connections, most interactions connect to regions within genes or in intronic regions, implying 
RUNX1 +24 connects with regulatory regions.  
Genes within domains are potentially co-expressed and co-regulated with RUNX1. Dr. 
Marsman defined the genes at the domain boundaries of K562 cells as CBR1, CLIC6, KCNE2 
and SMIM11 (Marsman, 2016). These genes were determined to be involved in cellular 
homeostasis and likely to have uniform expression in most cell types. Dixon et al., (2012) 
hypothesised that genes with consistent transcription are frequently present at domain 





Figure 4.15: RUNX1 +24 significant near-bait interactions (chr21:34999764-37572609).  
Chromosome 21 with positional zoom shown by the black box. RUNX1 is transcribed telomere to centromere 
implied by the direction of the black arrows of the RUNX1 promoters. In near-bait black box RUNX1 +24 
interactions represented by black arches. RUNX1 +24 is represented by the yellow line. RUNX1 promoters are 
represented by blue lines and interactions to these promoters are shown in blue. RUNX1 regulatory regions are 
represented by orange lines and interactions to these regions are shown in orange. Chromosome is aligned to the 
UCSC K562 gene list and annotations. Dotted grey lines show Rao et al., (2014) K562 domain boundaries. 
 
4.7.3 Significant interactions with known RUNX1 regulators 
As demonstrated in the previous chapter RUNX1 has multiple different regulatory 
regions that lie in the intronic and intergenic regions of RUNX1. I investigated whether RUNX1 
+24 interacted with any of the characterised RUNX1 regulatory regions in K562 cells. Based 
on the steady increase of RUNX1 P1 transcription after PMA stimulation (megakaryocyte 
differentiation) in K562s (Antony et al., 2020), it was predicted that the RUNX1 +24 would 
connect to multiple enhancers, as well as connecting with P1. Curiously the only RUNX1 
promoter that +24 connected to in WT 12 DMSO was P2. RUNX1 +24 interacts with some of 
the characterized human RUNX1 regulators examined in the previous chapter; m-368, m-101, 
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m-58, +62, m+110. RUNX1 +24 also interacted with the gene encoding the lncRNA RUNXOR. 
Of note, there were a plethora of identified RUNX1 regulatory regions that were not connected 
to RUNX1 +24, which is different to the Runx1 +24 connections seen in HPC7 cells. This 
further supports the notion that different RUNX1 enhancers are used depending on cell type. It 
is important to note that as this 4C only captures interactions from the +24 viewpoint. Other 
enhancers may play important roles in RUNX1 regulation and connect directly with the RUNX1 
promoters, without a RUNX1+24 interaction.  
4.7.4 Significant interactions with other genes 
To investigate which genes may be co-regulated with RUNX1, interactions occurring 
with other genes were identified. Across Chromosome 21 RUNX1 +24 interacted with 63 genes 
(Table 4.2). Gene interaction analysis identifies a connection with an overlap in the same 
genomic region as a gene and does not necessarily reflect an interaction with a promoter or 
exon of a gene. As seen in the ChromHMM analysis, the majority of interactions were with 
regulatory regions (enhancers and insulators) across the chromosome (Figure 4.13).  
The majority of genes that +24 interacts with are protein-coding genes (43%). However, 
the other 57% of connections are to non-coding RNAs. A large proportion of these RNAs are 
uncharacterised.  
Non-coding RNAs have been shown to be involved in many biological processes, 
including regulating transcription, cell-fate programming and maintaining genome 3D 
organisation (Flynn et al., 2014; Geisler et al., 2013; Holoch et al., 2015; Li et al., 2019; 
Nozawa et al., 2019; Sun et al., 2018). In particular, long non-coding RNAs have been shown 
to activate or suppress transcriptional activity by interacting with chromatin modulating 
proteins (Fan et al., 2015; Han et al., 2014; Jain et al., 2016; Prensner et al., 2013; Scarola et 
al., 2015). In WT 12 DMSO, the connections to these RNAs may be important in maintaining 
the chromatin states, to ensure correct gene regulation and overall maintenance of this cell type.  
153 
Table 4.2: Type and name of genes that interact with RUNX1 +24 
Type Name 
Protein-coding genes AP000322.53, BACE2, BRWD1, CBR1, CLIC6, DSCR3, DSCR4, ERG, 
GRIK1, HLCS, HMGN1, IFNAR2, IL10RB, LCA5L, PDE9A, PDXK, 
PKNOX1, PRDM15, PSMG1, RCAN1, RIPK4, SCAF4, SETD4, 
SMIM11A, SMIM11B, USP25, WRB 
Pseudogene GAPDHP16, METTL21AP1, POLR2CP1, RAD23BLP, RBMX2P1, 
RBPMSLP, RNF6P1, RPL34P3, TIMM9P2 
Antisense RNA AL773572.7, AP000688.11, AP001412.1, AP001626.2, AP001630.5, 




AF127936.3, AF127936.5, AF127936.7, AF015720.3, AP000318.2, 
AP000255.6, LINC00159, LINC01671, LINC01426, LOC100506403 




Sense intronic RNA AP000688.14 
Sense overlapping RNA BRWD1-IT1, RUNXOR 




When comparing the expression of the gene list with Antony et al., (2020)’s RNA seq 
expression analysis of K562s, there were no consistent patterns (expressed or not expressed) 
of the connected genes in WT. Notably this supports the theory that the RUNX1 +24 is helping 
to organise different domains across the chromosome into active and inactive domains.  
Gene ontology analysis of genes that interact with RUNX1 +24 was not appropriate as 
these genes were not consistently on or off. However, there was an exciting connection to ERG 
Promoter 3. ERG is crucial to haematopoietic cell specific gene regulation and is also inactive 
in WT 12 DMSO. ERG is a transcription factor involved in the differentiation and maturation 
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of megakaryocyte cells. ERG dysregulation is associated with several haematopoietic tumour 
types including AML (Reddy et al., 1987; Shimizu et al., 1993). Dr. Marsman also found that 
Runx1 +24 interacted with ERG in HPC7 cells (Marsman, 2016) (Table 4.3).  
Altered +24 activity or connections may therefore contribute to haematopoietic 
dysregulation.  
The connections between Runx1 +24 and genes; Brwd1, Clic6, Dscr3, Erg, Hlcs, 
Hmgn1 are seen in both HPC7 and K562 WT 12 DMSO cells  (Table 4.3).Unlike in HPC7 
cells +24 does not interact with TIAM1 in WT 12 DMSO cells (Table 4.3). TIAM1 is involved 
in cell adhesion and migration and is dysregulated in haematopoietic cancers (Habets et al., 
1995; Ives et al., 1998). 
Table 4.3: Name of genes that interact with Runx1 +24 in HPC7s  
 Gene name 
Interactions observed with both 
HPC7 Runx1 +24 4C and K562 
RUNX1 +24 4C 
Brwd1, Clic6, Dscr3, Erg, Hlcs, Hmgn1 
Interactions only observed in HPC7 
Runx1 +24 4C 
Atp5o, B3galt5, Cbr3, Chaf1b, Cldn14, Cryzl1, 
Dopey2, GM10785, Itsn1, Kcnj6, Kcnj15, Morc3, 




4.7.5 Overall significant RUNX1 +24 cis and near-bait interactions 
The cis connections showed significant interactions with ERG P3 and super-enhancer 
regulatory regions between SAMSN1 and NRIP1 genes (Figure 4.17). The WT 12 D RUNX1 
+24 connects with the known enhancers m-368, m-101, m-58, m+62, m+110. It also interacts 
with known RUNX1 regulators long non-coding RNA RUNXOR and RUNX1 P2. Within the 
near-bait connections, RUNX1 +24 connected with RUNX1 Exon 3. RUNX1 +24 also 
connected to three previously undescribed regions +89, -96 and a regulatory region near 
SLC5A3 Exon 2 and a MRPS6 intron (Figure 4.16). 
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Figure 4.16: RUNX1 +24 chromatin hub.  
Yellow boxes represent UCSC annotated gene promoters and/or exons. Blue boxes show described RUNX1 
regulators. Orange boxes annotate novel putative regulators. 
 
The novel connections were further analysed using the same in silico approach (Chapter 
3) to describe other regulatory regions. These annotations are described in Table 4.4. 
ERG P3 is described by ChromHMM as an insulator and transcription-associated 
region. Transcription-associated refers to transcriptional transition or elongation (Ernst et al., 
2010; Ernst et al., 2011). This region has both cohesin and CTCF binding as well as 
haematopoietic transcription factor binding (SPI1, TAL1, GATA2). This region shows no 
change in chromatin accessibility in cohesin mutant K562 cells. 
The novel RUNX1 regulatory regions -96 and +89 are both annotated as weak enhancers 
with transcription association. Intriguingly neither site is shown as open as there are no DNase 
HS sites. +89 binds RNA Pol II, whereas -96 does not. These regions show no change in 
chromatin accessibility in K562 cohesin  mutant cells.  
156 
The novel regulatory region near SLC5A3 Exon 2 and a MRPS6 intron was annotated 
by ChromHMM as containing both strong and weak enhancer regions. These regions showed 
comparable transcription factor binding sites and chromatin modifications to known RUNX1 
enhancers m-371, m-58 and m+110. This region also had increased accessibility in the cohesin 
mutant K562 cells. 
The cis connection and super-enhancer regulatory region between SAMSN1 and NRIP1 
was annotated as containing strong enhancers, weak enhancers and insulators. This region has 
both cohesin and CTCF binding as well as haematopoietic transcription factor binding of SPI1 
and TAL1. This region showed decreased chromatin accessibility in cohesin mutant K562 
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4.7.6 Trans interactions 
The trans interactions of RUNX1 +24 could not be significantly investigated using 
4Cker. The 4Cker analysis mapped the trans interactions to broad areas across various 
chromosomes (Appendix X). This may be because when the software annotates regions as 
significant, it does so based on the average of reads across the inputted window. As there were 
low read numbers across most chromosomes, the software combined the reads across the 
chromosome. This meant there were large (10,000 bp+) “interactions” called which spanned 
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across the different chromosomes. This gave no clear overview of sequencing read peaks hence 
trans interactions were unable to be interpreted.  
This 4C was designed to understand the cis and near-bait with the use of a 4 bp cutter. 
Raviram et al., (2016) highlight in their experiment that 6 bp cutters are optimal for detecting 
trans interactions (Raviram et al., 2016). The genome is cut more frequently with 4 bp cutters 
and this increases resolution by over tenfold compared to 6 bp cutters (Raviram et al., 2016; 
Van De Werken et al., 2012b).  
To understand the trans interactions that could be detected, I looked at the raw read 
peaks across the genome after control reads were removed (Appendix X). Based on peaks that 
contained reads in 2 or more replicates I detected three trans interactions (Table 4.5). All peaks 
were in intergenic regions and contained minimal ENCODE annotations.  
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HPC7 cells had one trans interaction between RUNX1 +24 and the overlapping 
mitochondrial genes Gu332589 and Ak018753, however this was not seen in K562 cells. 
159 
RUNX1 is often translocated in AML and is usually with Chromosome 3 (EVI1), 8 
(ETO), 16 (CBFB) and 12 (ETV6) (Sood et al., 2017). The RUNX1 +24 trans interactions do 
not overlap with these frequent RUNX1 translocation points. The trans interaction on 
chromosome 3 is over 4,782,000 bp away from EVI1.  
It should be noted however that the K562 cells are unlikely to have a completely normal 
karyotype and already carry BCR-ABL translocation. The BCR gene is normally on 
chromosome number 22, ABL gene is normally on chromosome number 9 (McGahon et al., 
1997). Because the trans interactions were not able to be subjected to the same stringency as 
cis and near-bait interactions, analysis of these interactions was not pursued further.  
4.8 Chapter summary 
4.8.1 RUNX1 +24 characteristics 
RUNX1 +24 showed strong enhancer characteristics and active binding of 
haematopoietic transcription factors. The FANTOM5 data showed that there is active 
production of the +24 enhancer RNA (eRNA) in haematopoietic cell types.  
Several studies have reported functional roles of eRNAs that foster enhancer-promoter 
looping formation, promote transcription factor and co-regulator binding and support target 
gene transcription (Bose et al., 2017; Hou et al., 2020b; Lai et al., 2013; Lam et al., 2013; Li 
et al., 2013a; Melo et al., 2013; Panigrahi et al., 2018; Rahnamoun et al., 2018; Sigova et al., 
2015; Tsai et al., 2018). Enhancer RNA can also assist pause-release of RNA Pol II which 
facilitates transcription elongation (Schaukowitch et al., 2014). 
There are no SNPs with a MAF of >1%  reported in RUNX1 +24 region. This could be 
an underestimation, due to the limitations in identifying significant SNPs in haematopoietic 
cells reported in the previous chapter (Section 3.4.2). The available AML genomic data 
reported a low number (5) of mutations. 
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CRISPR/Cas9 editing of RUNX1 +24 (by targeting the whole intron) showed reduced 
RUNX1 expression in OCI-AML5 cells (Mill et al., 2019). The majority of edited cells were 
eradicated via apoptosis, while the viable edited cells had significantly decreased RUNX1 
expression and inhibited growth (Mill et al., 2019). This research shows the importance of the 
P1-P2 intron, which contains multiple RUNX1 regulatory elements. 
The CD analysis showed that the G-quadruplexes observed in the mouse +24 element 
are capable of forming parallel G-quadruplexes. G-quadruplex RNA is capable of targeting and 
removing Polycomb repressive complex 2 from genes and allowing RNA-mediated regulation 
(Beltran et al., 2019; Wang et al., 2017). 
Luciferase assays showed that the mutations of G-quadruplex or mouse Runx1 +24 had 
no significant effect on enhancer function. Given the overall organisational role of RUNX1 +24 
seen in the 4C and possibility of G-quadruplex RNA, this assay is restricted in its ability to 
assess the functional nature of this G-quadruplex, because it doesn’t take non-
transcriptional/structural roles into account. Therefore, luciferase assays may not capture the 
changes in capability when the +24 G-quadruplex is mutated. Furthermore, the G-quadruplex 
analysis was specific to the mouse sequence, so it may not recapitulate the function of the 
human sequence. If the human sequence contains a G-quadruplex, CD analysis should be 
repeated to determine the type of G-quadruplex, or its functional capacity. 
It would be interesting to further investigate the possible functional roles of RUNX1 
+24 eRNA and +24 G-quadruplex RNA. This could be done using precision run-on sequencing 
(PRO-seq) and rapid amplification of cDNA ends (RACE). Pro-seq can define the position, 
amount, and orientation of transcriptionally active RNA polymerases in the genome to a single-
nucleotide resolution (Hou et al., 2020b). RACE can map eRNAs by identifying the 5′ and 3′ 
ends of RNA and RT-qPCR can determine the expression levels of these eRNAs (Hou et al., 
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2020b). The eRNAs could also be knocked down using small interfering RNA (siRNA) or 
mutated using CRISPR/Cas9 (Hou et al., 2020b). 
If the G-quadruplex was capable of forming RNA it would be fascinating to investigate 
its targets or ability to bind to Runx1 protein. Previously Fukunaga et al., (2020) showed the 
ability of a G-quadruplex RNA to bind to the ETO and dissociate the leukemic RUNX1-ETO 
fusion protein from DNA (Fukunaga et al., 2020). This suggests that some G-quadruplex RNA 
may serve as potential therapeutic agents for leukaemia.  
4.8.2 RUNX1 +24 interactions 
In K562 cells, RUNX1 +24 interactions occurred across the whole of Chromosome 21. 
Previously, Hi-C and promoter capture-C showed conservative interactions of promoters 
within TADs. Unexpectedly, the +24 enhancer interacted across the whole chromosome and 
was not limited to the reported domain structure.  
The majority of RUNX1 +24 interactions were with regulatory regions, however it is 
connected to both active and inactive chromatin. This unexpected finding suggests that RUNX1 
+24 is playing a role in the organisation of chromosome 21 in K562s, rather than a traditional 
enhancer role.  
The RUNX1 +24 connections were predominantly with non-coding RNAs, whose 
expression profiles cannot be determined by the existing RNA-seq data. Antony et al., (2020) 
RNA-seq data was unstranded and poly A+ enriched. Often non-coding RNA overlaps with 
genes, if this applies to these non-coding RNAs, they would not get annotated by this data set. 
The connections from RUNX1 +24 to non-coding RNAs, imply that RUNX1 +24 may be 
providing connections across the chromatin to ensure correct transcription and repression for 
maintenance of K562 cells. As non-coding RNAs are important for correct enhancer-promoter 
looping, 3D genome organisation, and cell-fate processes, the +24 may be safeguarding the 
chromatin structure and gene expression.  
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In HPC7 cells Runx1 +24 connected to the active P1 and inactive P2 Runx1 promoters 
and connected to 7 Runx1 regulatory regions (m-371, m-368, m-354, m-327, m-321, m-303, 
m-58, m-48). RUNX1 +24 in K562 cells connected to only one RUNX1 promoter (P2) which 
is active as well as a small number of identified RUNX1 regulatory regions (m-368, m-101, m-
58, +62, and m+110). This reinforces the notion of different enhancer recruitment in order to 
produce different cell types and generation of different RUNX1 isoforms.  
There were some novel interactions identified; RUNXOR, ERG P3 and putative 
regulatory regions -96, +89, SLC5A3 Exon 2 MRPS6 intron and a super-enhancer region 
between SAMSN1 and NRIP1. These putative regulatory regions could be investigated further 
for functional roles in K562 cells by using enhancer and insulator assays, including analysing 
the combinatory roles of the regions.  
RUNX1 +24 could be important for overall organisation and 3D structure of 
chromosome 21. RUNX1 +24 interacts with coding genes, non-coding RNA, super-enhancers 
and regulatory elements, and may be maintaining these connections to prevent transcription, 
rather than the expected enhancer role. Further investigation to define the RNA-DNA 
interactions proposed by this research could determine the importance of RUNX1+24 eRNAs, 
possible G-quadruplex RNA and non-coding RNA connections seen in K562s. This could be 
carried out by utilising previously generated RNA-DNA interactomes for K562s cells such as 
Red-C from Gavrilov et al., (2020) (Gavrilov et al., 2020). 
Some other questions arising from this research include: are there other well established 
enhancers that connect across the chromosome? If so, are they significant for  genome 
organisation? Are there equivalents of RUNX1 +24 on different chromosomes? These could be 
further discovered by using enhancers as baits for 4C experiments or establishing an equivalent 
of Capture-C for enhancers.  
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This chapter describes my work determining how RUNX1 +24 interacts with other 
DNA regions in steady-state K562 cells. However, enhancers become active when cells are 
subjected to various stimuli, such as in differentiation. Cohesin insufficiency has been shown 
to impair differentiation, alter overall chromatin accessibility, as well as the transcription of 
RUNX1 (Mazumdar et al., 2015; Mullenders et al., 2015; Viny et al., 2015). RUNX1 P1 is 
crucial for megakaryocyte differentiation and it is predicted that enhancers play key roles in 
inducing the correct RUNX1 promoters. The following chapter describes experiments in which 
the K562 cells were induced to differentiate to the megakaryocytic lineage, so the role of 
RUNX1 +24 could be further understood. It also details how cohesin insufficiency affects the 
RUNX1 +24 connections. 
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5 Chapter 5: Cohesin insulates 3D connections of RUNX1 
+24 during megakaryocyte differentiation 
5.1 Introduction 
The previous chapter established the connectivity of the RUNX1 +24 enhancer and 
suggests that this region connects to multiple DNA regions spanning chromosome 21 in K562 
cells. RUNX1 P1 is crucial for megakaryocyte differentiation and it is predicted that enhancers 
play key roles in selecting and inducing the correct RUNX1 promoters. Dr. Antony discovered 
that enhancer activity is altered during megakaryocytic differentiation in cohesin-mutant cells 
(Antony et al., 2020). Cohesin insufficiency impairs HSC differentiation, alters overall 
chromatin accessibility, as well as the transcription of RUNX1 (Mazumdar et al., 2015; 
Mullenders et al., 2015; Viny et al., 2015) 
Overall, cohesin mutations are implicated as a putative genetic pathway for 
development of AML, but how the disease arises from these mutations has not been 
determined. Cohesin mutations co-occur with other mutations in leukaemogenic genes 
indicating cooperation between pathways (Welch et al., 2012). One possibility is that 
impairment of cohesin’s regulatory role leads to dysregulation of other important 
leukaemogenic genes. The gene encoding cohesin subunit STAG2 is the most frequently 
mutated of the cohesin genes (Van Der Lelij et al., 2017). STAG2 mutation can lead to complete 
loss of STAG2 function due to mosaic inactivation of the X-linked wild type allele. Several 
studies have shown STAG2 preferentially occupies enhancers and promoters, and promotes 
cell-type-specific transcription, a function that is not compensated by cohesin-STAG1 (Arruda 
et al., 2020; Cuadrado et al., 2019; De Koninck et al., 2020; Kojic et al., 2018; Viny et al., 
2019).  
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K562 cells with a patient-specific STAG2 R614* null mutation were previously 
generated by Dr. Antony. Wild type (WT) and STAG2 mutant R614* K562 cells were 
previously subjected to RNA-seq, revealing genome-wide gene expression changes. Using 
ATAC-seq, Dr. Antony also noted altered chromatin accessibility in K562 cells with STAG2 
mutation. The RNA-seq and ATAC-seq revealed that the gene expression changes observed 
are associated with altered chromatin accessibility at regulatory regions and super-enhancers 
in STAG2 mutants (Antony et al., 2020). 
RUNX1 and ERG are important for HSC differentiation and both have intergenic 
regions that are distinguished as super-enhancers in CD34+ cells (Khan et al., 2016). In Dr. 
Antony’s dataset, ERG was the top differentially upregulated super-enhancer-associated gene 
in the STAG2-/- mutant, while RUNX1 was one the genes that showed differential chromatin 
accessibility.  
K562 cells can be induced to differentiate towards the megakaryocyte lineage using 
phorbol 12-myristate 13-acetate (PMA). Antony et al., (2020) used quantitative PCR (qPCR) 
to measure specific gene expression changes over 72 hours (h) of PMA stimulation. WT cells 
undergoing normal megakaryocyte differentiation had a gradual increase in transcription of 
RUNX1 from its P1 promoter: RUNX1-P1  and ERG. However, STAG2-deficient cells showed 
an aberrant spike in transcription of RUNX1 from its P2 promoter: RUNX1-P2 and ERG 6-12h 
post-PMA stimulation (Antony et al., 2020).. 
Dr. Antony showed that by 48 h post-stimulation, aberrant RUNX1 and ERG 
transcription had returned to baseline in STAG2-deficient cells. This implies that PMA 
stimulation of STAG2-deficient cells, which at baseline have increased chromatin accessibility 
at RUNX1 and ERG, leads to transient unrestrained transcription (Antony et al., 2020).  
Antony et al., (2020) used a bromodomain and extra-terminal motif (BET) inhibitor 
protein called JQ1, to decrease BRD4 binding and suppress enhancer-driven transcription 
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(Antony et al., 2020). BRD4 is a bromodomain-containing protein that interacts with active 
enhancers (Bhagwat et al., 2016). When K562 cells were treated with JQ1 concurrently with 
PMA, there was reduced RUNX1-P2 and ERG expression in WT cells, and dramatically 
dampened aberrant expression peaks in STAG2-deficient cells (Antony et al., 2020). . RUNX1-
P1 transcription was completely blocked by JQ1 in both WT and STAG2-deficient cells 
(Antony et al., 2020). These results suggest that STAG2 depletion de-constrains the chromatin 
surrounding RUNX1 and ERG, which produces aberrant enhancer-amplified transcription in 
response to differentiation signal. 
This Chapter describes the results of my research on: 1) the role of RUNX1 +24 in 
megakaryocyte differentiation and 2) how cohesin insufficiency affects spatial connections 
initiated by the RUNX1 +24 enhancer. For the first objective, K562 cells were induced with 
PMA to differentiate towards the megakaryocytic lineage, so that the spatial connections 
initiated by RUNX1 +24 during the differentiation process could be determined. For the second 
objective, K562 cells with the STAG2 R614* null mutation were differentiated in parallel to 
understand how cohesin deficiency affects +24 enhancer connections.  
This experiment highlighted how the connectivity changes upon cohesin depletion and 
may provide a mechanism for how cohesin mutations can lead to haematopoietic dysregulated 
RUNX1 expression. 
5.2 Hypothesis 
I hypothesise that RUNX1+24 connections will alter during megakaryocyte 
differentiation and without STAG2 these connections will not be maintained. 
5.3 Aims 
3) Elucidate connections of RUNX1 +24 during normal megakaryocyte differentiation. 
4) Determine the change in significant chromatin interactions in STAG2-deficient 
cells after PMA stimulation.   
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5.4 RUNX1 +24 significant interactions during normal 
megakaryocyte differentiation. 
The conditions chosen for this 4C were based on the gene expression analyses shown 
by Antony et al., (2020). Differentiation to megakaryocytes was induced using PMA 
(Kuvardina et al., 2015). Control treatment of K562 (WT) and STAG2-deficient cell lines used 
Dimethyl Sulfoxide (DMSO), as the solvent in place of PMA. 12 h was chosen based on 
abnormal transcription observed at this time in STAG2-deficient mutants. An end timepoint of 
72 h was chosen because by this time, WT cells displayed differentiation markers and gene 
transcription profiles consistent with megakaryocytes (Antony et al., 2020). 
4Cker differential analysis was carried out on the windows that interact with the 
RUNX1 +24 bait in at least 2 conditions, using DESeq2 (Love et al., 2014; Raviram et al., 
2016). This analysis only works for near-bait and cis interactions. A plot of significant 
interactions was generated with a p-value of 0.05, however, to tease out true differences in 
interactions, a more stringent cut-off for significance utilised an adjusted p value of 0.01. 
Hereafter all p values refer to each interaction’s adjusted p value.  
Significantly altered interactions and their log fold changes were visualised in the 
UCSC browser.  
5.4.1 Visualisation of significant interactions during normal 
megakaryocyte differentiation. 
The normalised read count for all WT conditions (WT 12 DMSO (control), WT 12 
PMA, WT 72 PMA) was plotted across chromosome 21 using ggplot (Wickham et al., 2007) 
to generate the cis profile of Runx1 +24 connections in unedited K562 cells (Figure 5.1). Reads 
had a high coverage around the +24 bait. The profile remains relatively similar during 
megakaryocyte differentiation; however, the number of normalised reads was reduced post-
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stimulation. The large normalised read peak that shows an interaction around 45,000,000 (*) 
with PDE9A and BC033260 in WT 12 DMSO dramatically decreased during differentiation. 
 
Figure 5.1: Megakaryocyte differentiation with PMA stimulation RUNX1 +24 WT cis 4C profiles.  
ggplots of the cis 4C profiles for WT DMSO 1, WT PMA 12 h and WT PMA 72 h.  Normalised read count is 
on the vertical axis and position on chromosome 21 is on the horizontal axis. * large peak at PDE9A and 
BC033260 in WT 12 DMSO. 
 
5.4.2 Overview of significant changes in interactions during normal 
megakaryocyte differentiation. 
Significantly altered interactions and their log fold changes were visualised in the 
UCSC browser. Synonymous with WT 12 DMSO; the WT 12 PMA and WT 72 PMA profiles 
showed that significant cis interactions spanned across the long arm of chromosome 21 (Figure 
5.2). A list of all the statistically significant changes between conditions is available in 
Appendix XI. 
Over the differentiation time course RUNX1 +24 loses connections with a number of 
regions across the chromatin. The significant cis differences between WT 12 DMSO and WT 
12 PMA was loss of connection to ERG Promoter 3 (P3) with a Log2 fold change of -7.84 (p 
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value =0.0097) and regulatory region between SAMSN1 and NRIP1 (Log2 fold change of -
8.01, p value =0.0049) (Figure 5.2). 
ERG is repressed in WT 12 DMSO control K562 cells. However, during differentiation 
ERG expression slowly increases (Antony et al., 2020). ERG has three known promoters, and 
can positively regulate its own expression (Thoms et al., 2011). The data suggest that the 
RUNX1 +24 connection in WT 12 DMSO control K562 cells might constrain ERG expression, 
and upon PMA treatment, ERG’s P3 is released to facilitate the expression of ERG. 
When comparing the WT 12 DMSO and WT 72 PMA there are 12 lost interactions 
(Log2 fold change ranges from -5.78 to -8.6, p values range from 0.0017 to 0.0081), including 
loss of connections to ERG P3 and the regulatory region between SAMSN1 and NRIP1 (see 
Appendix XI). Overall, megakaryocyte differentiation of K562 cells causes the RUNX1+24 
enhancer to lose cis-interactions along chromosome 21. 
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Figure 5.2: Differentiation-induced changes to the RUNX1 +24 WT cis interactions.  
Cis 4C profiles for WT DMSO 1, WT PMA 12 h and WT PMA 72 h. Chromosome 21 with WT DMSO 12 h 
RUNX1 +24 interactions represented by grey arches. Green arches show gained interactions compared to 
baseline (WT DMSO 12 h). Blue arches underneath the chromosome sketches highlight lost interactions 
compared to baseline. Each interaction is colour-coded according to its ChromHMM profile: key is at the 
bottom left of the figure. Super-enhancers were determined from dbSuper.  
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The ChromHMM annotations do not necessarily reflect the nature of these elements 
during differentiation. The annotations were determined in steady-state K562 cells and 
represent the baseline (WT 12 DMSO); therefore, the chromatin composition could be altered 
after PMA stimulation.  
The super-enhancers were identified regardless of the chromatin status as they were 
from the collection of cells in dbSUPER (Khan et al., 2016). In WT 12 DMSO 16% (n= 5/31) 
of the cis connections were with super-enhancers. In Chapter 4 I noted that RUNX1 +24 
interactions with super-enhancers may be facilitating or restricting their 3D connections. There 
is a decrease in super-enhancer cis-connections during differentiation (10.3%) (n= 3/29) (WT 
12 PMA), the proportion of interactions with super-enhancers increases to 13.6% (n= 3/22) 
after megakaryocyte differentiation at WT 72 PMA (Figure 5.3). 
 
Figure 5.3: Differentiation-induced changes in the number of RUNX1 +24 significant cis interactions with 
super-enhancers in WT K562 cells.  
Percentage of interactions is on the vertical axis. Horizontal axis shows the treatment conditions WT DMSO (D) 
12h, WT PMA (P) 12h and WT PMA 72h 
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5.4.3 Visualisation of significant  near-bait interactions during normal 
megakaryocyte differentiation. 
The normalised read counts of all three time points in WT cells were plotted across 
chromosome 21 near-bait locations using ggplot (Wickham et al., 2007) (Figure 5.4). The 
majority of reads are located within specific regions surrounding RUNX1 +24 in WT 12 
DMSO. Resembling the cis WT profiles, the number of normalised reads decreases as the cells 
differentiate. Interestingly, the large normalised read peak which highlighted an interaction 
with RUNX1 m -368 (*) and the surrounding area decreases in comparison to the baseline WT 
12 DMSO connections (Figure 5.4). Overall, megakaryocyte differentiation of K562 cells 
causes the RUNX1+24 enhancer to lose interactions within the RUNX1 TAD. 
 
Figure 5.4: Megakaryocyte differentiation with PMA stimulation RUNX1 +24 WT near-bait 4C profile.  
ggplot of the near-bait 4C profiles for WT DMSO 12 h, WT PMA 12 h and WT PMA 72 h, normalised read 
count is on the vertical axis and position on chromosome 21 is on the horizontal axis. The asterisk shows the 
large normalised read peak at human equivalent region of RUNX1 m -368. 
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5.4.4 Overview of significant changes in near-bait interactions during 
normal megakaryocyte differentiation. 
Similar to the cis results RUNX1 +24 progressively lost connections during 
megakaryocyte differentiation. However, unlike cis interactions WT 12 PMA and WT 72 PMA 
near-bait also showed some significantly increased connections (Figure 5.5). The statistically 
significant changes between conditions is available in Appendix XII. 
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Figure 5.5: Differentiation-induced changes to the RUNX1 +24 WT near-bait interactions.  
Near-bait 4C profiles for WT DMSO 12 h, WT PMA 12 h and WT PMA 72 h. Chromosome 21 with WT 
DMSO 12 h RUNX1 +24 interactions represented by grey arches. Green arches show gained interactions 
compared to baseline (WT DMSO 12 h). Blue arches underneath the diagrams highlight lost interactions 
compared to baseline. RUNX1 +24 is represented by the yellow line. RUNX1 promoters are represented by blue 
lines and interactions to these promoters are shown in blue. RUNX1 regulatory regions are represented by 
orange lines and interactions to these regions are shown in orange. Near-bait region is aligned to the UCSC 
K562 gene list and annotations. Dotted grey lines show Rao et al., (2014) K562 domain boundaries. 
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The previous chapter demonstrated the multiple near-bait connections surrounding 
RUNX1 +24. The near-bait interactions observed during megakaryocyte differentiation reflect 
the overall trend of a decrease in connections to RUNX1 +24. When assessing the WT 12 
DMSO and WT 12 PMA there were 3 lost connections; -96, +89 and the SLC5A3 Exon 2 
MRPS6 intron region (Log2 fold changes of -7.81,-7.62 and -8.94 and p values of 0.0034, 
0.0015, 0.0014 respectively), connections that were previously described in Chapter 4.  
Despite the overall loss of connections, after 12 h of PMA treatment there were some 
significantly increased interactions with RUNX1 +24 (Log2 fold change ranges from 6.77 to 
8.25, p values range from 5.3E-7 to 0.0020) see Appendix XII. These include some possible 
regulatory regions +14, +54, +68, +142 between RUNX1 P1 and P2 (Table 5.1). RUNX1-IT1, 
RUNX1 promoter 1, RUNX1 exon 1 and 2 are also recruited to the RUNX1 +24 hub (Figure 
5.6). RUNX1-IT1 is a long non coding RNA which has been previously correlated with RUNX1. 
(Liu et al., 2020). Expression of the RUNX1-IT1 enhanced RUNX1 transcription in pancreatic 
cancer cells (Liu et al., 2020). Connections with m-368, m-58, RUNXOR, m+3, +62, m+11, 
RUNX1 P2 and exon 3 remain stable with RUNX1 +24 during megakaryocyte differentiation. 
The RUNX1 protein is capable regulating its own gene transcription (Martinez et al., 
2016). RUNX1 P1-driven expression is important for megakaryocyte differentiation (Draper et 
al., 2017). During megakaryocyte differentiation RUNX1 P1-driven expression of RUNX1 
gradually increases (Antony et al., 2020). In baseline K562 cells (WT 12 DMSO), RUNX1 P1 
is not connected to RUNX1 +24 and the RUNX1 P1 driven expression is repressed (Chapter 4). 
However, after PMA simulation RUNX1 P1 is recruited to RUNX1 +24 along with other 
possible enhancers (Figure 5.6). In contrast, RUNX1 P2 transcript is stably expressed 
throughout differentiation (Antony et al., 2020). Consistent with this, the connection between 
RUNX1 P2 to RUNX1 +24 remains unchanged throughout differentiation.  
176 
After differentiating to megakaryocytes (WT 72 PMA) more near-bait connections are 
lost (Log2 fold change ranges from -3.93 to -12.36, p values range from 1.4E-35 to 0.0095). 
Contacts with some of the of the possible regulatory regions that were significant at 12 h after 
PMA treatment +14, +54, +68, +142 are lost in differentiated cells. Interactions with RUNXOR, 
RUNX1-IT1, RUNX1 P1, RUNX1 exon 1 and 2 are also lost. The only connection gained at 72 
h of differentiation was with m-371 (Log2 fold changes of 5.95, p value of 0.0069).  
Chromatin status at the near-bait regions with significantly increased connections was 
analysed using ENCODE data as for Chapter 3 and 4 (Table 5.1).  
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5.4.5 Significant interactions with other genes 
Connections with genes were identified using the same methods as Section 4.7.4 and 
are listed in Appendix XIII. The number of gene connections changes during differentiation 
(Table 5.2). Interestingly the number of connected genes increased from 64 in the baseline to 
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154 (12 PMA) and then decreased to 140 (72 PMA). This is opposite to the trend of connections 
which decreases overall. These connections need further investigation to determine gene type, 
establish their expression level, as well as ascertain if there are any patterns in the type of gene. 
However, as the gene interaction reflects an overlap with the region of a gene rather than a 
promoter or exon of a gene, it may not be appropriate to assume the gene’s expression is 
controlled by RUNX1 +24.  
Table 5.2: Number of genes connected to RUNX1 +24 in WT cells 
 WT 12 DMSO WT 12 PMA WT 72 PMA 
Number of genes 
connected to 
RUNX1 +24 
64 154 140 
 
5.4.6 Overall significant RUNX1 +24 and near-bait interactions in K562 
cells during megakaryocyte differentiation 
During PMA treatment there is an overall loss of connections to RUNX1 +24, however 
as the cells are differentiating there are some significant changes in the near-bait. RUNX1 +24 
maintains connections with the known enhancers m-368, m-58, m+3, +62, m+110 during 
differentiation (Figure 5.6). It also sustains connections with RUNX1 P2 and RUNX1 exon 3. 
However, the novel connections determined in Chapter 4 to -96, +89, SLC5A3 Exon 2 MRPS6 
intron and super-enhancer regulatory regions between SAMSN1 and NRIP1 are lost during 
differentiation. The connections to known RUNX1 regulator long non-coding RNA RUNXOR, 
and ERG P3 are also lost during differentiation (Figure 5.6).  
During differentiation (12 h post PMA treatment) The +24 enhancer makes some novel 
connections to putative regulatory elements +14, +54, +68, +142 (Figure 5.6, Table 5.1) 
RUNX1 +24 also gains connections with the RUNX1 promoter 1, exon 1 and 2.  
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After differentiation RUNX1 +24 loses the novel connections gained at 12 h of PMA 
treatment (+14, +54, +68, +142), and with the long non-coding RNA RUNX1-IT1, RUNX1 P1, 
exons 1 and 2. At 72 h once differentiation has occurred, there is a significant increase in the 
interaction between RUNX1 +24 and m-371. m-371 is an important haematopoietic enhancer 
in developing zebrafish and mice.  
179 
 
Figure 5.6: Changes to the RUNX1 +24-anchored chromatin hub during megakaryocyte differentiation of 
K562 cells.  
Yellow boxes represent UCSC annotated gene promoters and/or exons. Blue boxes show described RUNX1 
regulators. Orange boxes annotate novel putative RUNX1 regulators.  
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5.5 The effect of STAG2 deficiency on RUNX1 +24 significant 
interactions during differentiation of K562 cells 
The STAG2 mutants 4C data was prepared in the same way as WT (STAG2 12 DMSO, 
STAG2 12 PMA, STAG2 72 PMA). STAG2 mutants were compared to WT equivalent 
condition and timepoint.  
5.5.1 Visualisation of significant interactions during cohesin impaired 
“differentiation” 
The normalised read count of all WT conditions (WT 12 DMSO, WT 12 PMA, WT 72 
PMA) and STAG2 mutant conditions (STAG2 12 DMSO, STAG2 12 PMA, STAG2 72 PMA) 
were plotted across chromosome 21 using ggplot (Wickham et al., 2007) to generate the cis 
profile of Runx1 +24 connections in baseline K562 cells and cohesin mutants (Figure 5.7). The 
STAG2 mutant cells have a dramatic increase in connections across chromosome 21. Reads 
had a high coverage around the +24 bait.  
A comparison of the +24-mediated connections in WT 12 DMSO versus STAG2 12 
DMSO show a similarly high number of reads around the RUNX1 +24 bait. However, the read 
coverage across chromosome 21 is higher in STAG2 12 DMSO cells.  
During PMA-induced differentiation, WT K562 cells lose connections overall. In 
contrast, STAG2 mutants generally retained, or even gained, connections following stimulation 
with PMA. After 12 h of PMA stimulation the pattern of connections in STAG2 mutants 
approximates the wild type, but with a higher read and more distant connections. After 72 h of 
PMA stimulation there was a dramatic increase in connections across chromosome 21 in 




Figure 5.7: Time course of PMA stimulation of all RUNX1 +24 cis 4C profiles.  
ggplots of the cis 4C profiles for WT DMSO 1, WT PMA 12 h, WT PMA 72 h, STAG2 DMSO 12 h, STAG2 
PMA 12 h and STAG2 PMA 72 h.  Normalised read count is on the vertical axis and position on chromosome 
21 is on the horizontal axis 
 
5.5.2 The effect of STAG2 deficiency on interactions during 
differentiation of K562 cells 
Similar to the baseline WT cells, the baseline STAG2 mutant cells (STAG2 12 DMSO) 
had significant cis interactions spanning the long arm of chromosome 21 (Figure 5.8). A list of 
all the statistically significant changes between conditions is available in Appendix XI. 
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When comparing the WT 12 DMSO and STAG2 12 DMSO, there are 4 interactions 
that are not present in the cohesin mutant baseline (Log2 fold change ranges from -6.66 to 5.15, 
p values range from 0.0003 to 0.0078) including the super-enhancer regulatory region between 
SAMSN1 and NRIP1 (Log2 fold change of -5.64, p value of 0.0047) (Appendix XI). However, 
there are 20 regions interacting with RUNX1 +24 in STAG2 12 DMSO (Log2 fold change 
ranges from 3.85 to 6.04, p values range from 0.0002 to 0.0097) that are not present in WT 12 
DMSO (Figure 5.8). Overall, STAG2 deficiency causes the RUNX1+24 enhancer to make more 




Figure 5.8: Significant changes to the RUNX1 +24 cis baseline (12 DMSO) interactions due to cohesin 
deficiency.  
Cis 4C profiles for K562 STAG2 mutant DMSO 12h cells on Chromosome 21 with K562 WT DMSO 12h  
RUNX1 +24 interactions represented by grey arches. Green arches show a gained interaction compared to WT. 
Blue arches underneath the diagrams highlight lost interactions in STAG2 mutant cells compared to WT. Each 
interaction is colour-coded according to its ChromHMM profile: key is at the bottom left of the figure. Super-
enhancers were determined from dbSuper. 
 
These interactions were further categorised based on the K562 chromatin 
characteristics using ChromHMM and dbSUPER annotations. Some regions that interact with 
RUNX1 +24 exhibit multiple ChromHMM annotations (Figure 5.9). 
Compared to WT cells, STAG2 mutant cells RUNX1 +24 have slightly fewer 
interactions with enhancer regions (WT = 58%, STAG2 = 50%), active promoters (WT = 32%, 
STAG2 = 28%), heterochromatin (WT = 10%, STAG2 = 7%), and polycomb repressed (WT 
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= 29%, STAG2 = 28%) regions. Interactions between RUNX1+24 and insulators increased 
(WT = 32%, STAG2 = 48%). Poised promoters (WT = 16%, STAG2 = 22%) and super-




Figure 5.9: Features of RUNX1 +24 significant cis interactions in WT baseline and STAG2 baseline cells 
(12 DMSO). 
 Percentage of interactions is on the vertical axis. Horizontal axis shows the ChromHMM annotations. 
Individual interactions can have multiple annotations. 
 
During megakaryocyte differentiation of WT K562 cells (12 h post PMA stimulation), 
the RUNX1 +24 enhancer lost 2 cis connections to ERG Promoter 3 (P3) and the regulatory 
region between SAMSN1 and NRIP1. STAG2 12 PMA also lost the connection to ERG P3. 
The connection to regulatory region between SAMSN1 and NRIP1 was not present in STAG2 
12 DMSO, and this loss was maintained in STAG2 12 PMA (Figure 5.10). Most connections 
observed in WT cells were conserved in the cohesin STAG2 mutant. However, one additional 
cis connection was observed in STAG2 12 PMA (Log2 fold change of 8.83, p value of 0.0023) 
(Appendix XI).  
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The overall similarity between RUNX1 +24 enhancer-mediated connections formed in 
WT 12 PMA and STAG2 12 PMA was somewhat surprising based on the presence of 




Figure 5.10: Significant changes to the RUNX1 +24 12h PMA treatment cis interactions due to cohesin 
deficiency.  
Cis 4C profiles for STAG2 mutant PMA 12h Chromosome 21 with time matched K562 WT PMA 12h RUNX1 
+24 interactions represented by grey arches (WT 12 PMA). Green arches show a gained interaction compared to 
WT. Blue arches underneath the diagrams highlight lost interactions in STAG2 mutant cells compared to WT 
baseline. Each interaction is colour-coded according to its ChromHMM profile: key is at the bottom left of the 
figure. Super-enhancers were determined from dbSuper. 
 
After 72 h of PMA treatment, the WT cells significantly lost connections across the 
chromosome. In contrast, 72 h of PMA stimulation in STAG2 mutant cells led to the RUNX1 
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+24 enhancer dramatically gaining cis connections when compared to the WT treatment 
condition (Figure 5.11).  
There are 35 significantly increased cis connections in STAG2 72 h PMA cells (Log2 
fold change ranges from 4.75 to 10.09, p values range from 3.5E-5 to 0.0094) see Appendix 




Figure 5.11: Significant changes to the RUNX1 +24 72h PMA treatment cis interactions due to cohesin 
deficiency.  
Cis 4C profiles for STAG2 mutant PMA 72h Chromosome 21 with time matched K562 WT PMA 72h RUNX1 
+24 interactions represented by grey arches (WT 72 PMA). Green arches show an interaction that has been 
significantly gained compared to time matched WT condition. WT blue arches underneath the diagram show 
lost interactions compared to WT baseline. The STAG2 blue arch underneath the diagram shows an interaction 
that has been lost when compared to WT 72 PMA. Each interaction is colour-coded according to its 
ChromHMM profile: key is at the bottom left of the figure. Super-enhancers were determined from dbSuper. 
 
All interactions observed across PMA treatment and cell line were further categorised 
using super-enhancer annotations derived from dbSUPER (Khan et al., 2016). dbSUPER 
annotations extend across multiple different cell-types. Compared to WT cells, in STAG2 
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mutant cells the RUNX1 +24 enhancer forms more interactions with super-enhancer regions 
(Figure 5.12).  
At the WT baseline (WT 12 DMSO) 16% (n= 5/31) of the connections RUNX1 +24 
makes are with super-enhancers; this is increased in STAG2-deficient cells (STAG2 12 
DMSO) to 24% (n= 11/46). During PMA-induced differentiation (12 h) the RUNX1+24 
enhancer forms similar interactions in both WT and STAG2 mutant cells; 10% of the 
connections are with super-enhancers (n= 3/29 and n= 3/30 respectively). 72 h after PMA 
treatment, 14% (n= 3/22) of the connections to RUNX1 +24 are with super-enhancers in WT 
cells. In contrast, in STAG2 mutant cells the percentage of interactions between RUNX1 +24 
and super-enhancers is 22% (n= 12/55)(Figure 5.12). 
 
Figure 5.12: Profile of RUNX1 +24 significant cis interactions with super-enhancers during megakaryocyte 
differentiation with PMA stimulation in WT and STAG2 mutant cells.  
Percentage of interactions is on the vertical axis. Horizontal axis shows the K562 cells treatment conditions WT 
DMSO (D) 12h, WT PMA (P) 12h and WT PMA 72h in green and STAG2 mutant STAG2 DMSO (D) 12h, 




5.5.3 The effect of STAG2 deficiency on near-bait interactions during 
differentiation of K562 cells  
The normalised read count of all WT conditions (WT 12 DMSO, WT 12 PMA, WT 72 
PMA) and STAG2 mutant conditions (STAG2 12 DMSO, STAG2 12 PMA, STAG2 72 PMA)  
were plotted across chromosome 21 near-bait locations using ggplot (Wickham et al., 2007) 
(Figure 5.13). During differentiation of WT cells, the majority of reads are located within 
specific regions surrounding the RUNX1 +24 enhancer, and read count decreases as the cells 
differentiate. However, RUNX1 +24-mediated interactions in STAG2 mutant cells give rise to 
distinctly different interaction profiles.   
Compared with WT cells, STAG2 12 DMSO lacks the peak around RUNX1 +24 and 
has a higher level of background reads compared to WT 12 DMSO. During differentiation, 
after 12 h of PMA treatment the RUNX1 +24-mediated interactions in STAG2 12 PMA 
resembles the pattern of normalised reads seen in the WT 12 PMA. After 72 h there is a 
dramatic increase in connections across the near-bait region in STAG2 72 PMA compared to 
WT 72 PMA. The normalised read count profiles reflect the gain of connections in STAG2 
mutants seen in the cis profiles.
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Figure 5.13: Time course PMA stimulation of all RUNX1 +24 near-bait 4C profiles.  
ggplot of the near-bait 4C profiles for WT DMSO 1, WT PMA 12 h, WT PMA 72 h, STAG2 DMSO 12 h, 
STAG2 PMA 12 h and STAG2 PMA 72 h.  Normalised read count is on the vertical axis and position on 
chromosome 21 is on the horizontal axis. 
 
5.5.4 Significant changes in near-bait interactions caused by 
STAG2 deficiency 
When comparing the WT 12 DMSO and STAG2 12 DMSO there are 176 interactions 
present in WT cells that are not present in the cohesin mutant baseline (Log2 fold change ranges 
192 
from -10.69 to -2.62, p values range from 2.9E-17 to 0.0087). The statistically significant 
changes between conditions is available in Appendix XII. These are within the 5 Mb region 
surrounding the bait (Figure 5.14) The connections that decreased include RUNXOR, m+3, 
+62, m+110, RUNX1 exon 3 and RUNX1 P2. However, in the STAG2 12 DMSO there are 83 
regions interacting with RUNX1 +24 that are not present in WT 12 DMSO (Log2 fold change 




Figure 5.14: Significant changes to the RUNX1 +24 baseline (12 DMSO) of near-bait interactions due to 
cohesin deficiency.  
Near-bait 4C profiles for STAG2 mutant DMSO 12h Chromosome 21 with time matched K562 WT DMSO 12h 
RUNX1 +24 interactions represented by grey arches. Green arches show a gained interaction compared to time 
matched WT condition. Blue arches underneath the diagram represent lost interactions when compared to WT 
DMSO 12h. RUNX1 +24 is represented by the yellow line. RUNX1 promoters are represented by blue lines and 
interactions to these promoters are shown in blue. RUNX1 regulatory regions are represented by orange lines 
and interactions to these regions are shown in orange. Near-bait region is aligned to the UCSC K562 gene list 
and annotations. Dotted grey lines show Rao et al., (2014) K562 domain boundaries. 
 
During megakaryocyte differentiation (12h post PMA stimulation) the WT cells 
RUNX1 +24 significantly lost connections to -96, +89 and the SLC5A3 Exon 2 MRPS6 intron 
region. STAG2 12 PMA maintains the connection with -96 and the SLC5A3 Exon 2 MRPS6 
intron region (Log2 fold changes of 8.07 and 8.888, p values of 0.0053 and 0.0003 
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respectively). STAG2 12 PMA has one decreased connection when compared to WT 12 PMA 
(Log2 fold change of -7.10, p value of 0.0033) see Appendix XII. In contrast to the DMSO 
baseline, the cohesin mutant STAG2 12 PMA showed very similar connections to WT (Figure 
5.15).  
 
Figure 5.15: Significant changes to the RUNX1 +24 near-bait interactions after 12h PMA treatment due to 
cohesin deficiency.  
Near-bait 4C profiles for STAG2 mutant PMA 12h Chromosome 21 with time matched K562 WT PMA 12h 
RUNX1 +24 interactions represented by grey arches. WT green arches show gained interactions compared to 
WT DMSO 12h. The STAG2 green arch shows an interaction that has been significantly gained compared to 
time matched WT condition. WT blue arches beneath the diagram highlight lost interactions compared to WT 
baseline. The STAG2 blue arch beneath the diagram shows a lost interaction compared to WT 12 PMA. RUNX1 
+24 is represented by the yellow line. RUNX1 promoters are represented by blue lines and interactions to these 
promoters are shown in blue. RUNX1 regulatory regions are represented by orange lines and interactions to 
these regions are shown in orange. Near-bait region is aligned to the UCSC K562 gene list and annotations. 
Dotted grey lines show Rao et al., (2014) K562 domain boundaries. 
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WT 72 PMA RUNX1 +24 had decreased interactions with +14, +54, +68, +142 regions, 
RUNXOR, RUNX1 P1, as well as RUNX1 exon 1 and 2 and an increased connection with m-
371. STAG2 72 PMA also lost connections with +14, +54, +68, +142 regions, RUNX1 P1, and 
RUNX1 exon 1, exon 2. However, RUNX1 +24 STAG2 72 PMA maintained connections with 
RUNXOR and RUNX1-IT1 (Log2 fold changes of 8.28 and 4.15, p values of 2.0E-5 and 0.0096 
respectively). RUNX1 +24 had a decreased connection with RUNX1 exon 3, m+3 and m-371 
when compared with its WT counterpart (Log2 fold changes ranges from -6.05 to -7.37, p 
values range from 3.6E-6 to 0.0003) There was a dramatic increase in the number of 
connections to RUNX1 +24 however these regions require further investigation (Figure 5.16).  
The connections are different between the STAG2 12 DMSO condition and STAG2 72 
PMA as shown in Appendix XIV. These were not analysed further than looking at the adjusted 
p value and Log2 fold change. Although these conditions have different profiles they do show 
a similar trend; When compared to the equivalent WT condition, there is a decrease in the near-
bait connections 5 Mb either side of the bait and a dramatic increase in connections to RUNX1 




Figure 5.16: Significant changes to the RUNX1 +24 near-bait interactions after 72h PMA treatment due to 
cohesin deficiency.  
Near-bait 4C profiles for STAG2 mutant PMA 72 h Chromosome 21 with time matched K562 WT PMA 72h 
RUNX1 +24 interactions represented by grey arches. WT green arches show gained interactions compared to 
WT DMSO 12 h. STAG2 green arches show gained interactions compared to time matched WT condition. WT 
blue arches beneath the diagram highlight lost interactions compared to WT baseline. STAG2 blue arches 
beneath the diagram highlight lost interactions compared to WT 72 PMA. RUNX1 +24 is represented by the 
yellow line. RUNX1 promoters are represented by blue lines and interactions to these promoters are shown in 
blue. RUNX1 regulatory regions are represented by orange lines and interactions to these regions are shown in 
orange. Near-bait region is aligned to the UCSC K562 gene list and annotations. Dotted grey lines show Rao et 
al., (2014) K562 domain boundaries. 
 
5.5.5 Significant interactions with other genes 
Connections with genes were identified using the same methods as Section 5.4.5 and 
the resulting output is listed in Appendix XIII. The number of gene connections in STAG2 
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mutants is different to WT connections. STAG2 has almost double the number of gene 
connections (121) at baseline compared to WT (64). The number of associated genes decreased 
as the cells were treated with PMA (Table 5.3). Interestingly, despite the similar connection 
profiles of +24 in WT and STAG2 mutant cells after 12 h of PMA treatment, the number of 
gene connections varies between mutant and wild type, with fewer genes connected in the 
STAG2 mutant cells. Surprisingly, even though the overall numbers of connections increased 
in STAG2 mutants during differentiation compared with WT, the number of connections that 
were associated with genes decreased. This may be because the gain in connections is to 
intronic and intergenic regions, and/or there are multiple connections within the same gene. It 
may also reflect the inability of STAG2 mutant cells to differentiate, as genes involved in 
differentiation are not being recruited. These results are inconclusive without further 
investigation as mentioned in Section 5.4.5.  
Table 5.3: Number of genes connected to RUNX1 +24 in WT cells 

















64 154 140 121 37 47 
 
5.5.6 Overall changes in and near-bait interactions mediated by RUNX1 
+24 interactions during differentiation of K562 cells, WT versus 
STAG2-deficient 
After 72 h PMA treatment, WT K562 cells have features consistent with 
megakaryocyte identity. During megakaryocyte differentiation in WT K562 cells, there is an 
overall loss of connections to the RUNX1 +24 enhancer, but a gain in connected genes. In 
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contrast, the RUNX1 +24 enhancer gains extra connections in STAG2 mutants, but loses 
connections to other genes.   
Figure 5.17 compares the baseline (12 DMSO) WT and STAG2 RUNX1 +24 
connections with regions that may be important for megakaryocyte differentiation. WT 12 
DMSO maintains connections with m-368, -96, m-58, m+3, m+62, +89, m+110, SLC5A3 Exon 
2 MRPS6 intron, RUNXOR, RUNX1 P2, RUNX1 exon 3, ERG P3 and super-enhancer 
regulatory regions between SAMSN1 and NRIP1. STAG2 12 DMSO maintains connections 
with m-368, -96, m-58, +89, SLC5A3 Exon 2 MRPS6 intron, RUNX1 P2 and ERG P3. 
However, it loses connections with m+3, m+62, m+110, RUNXOR, RUNX1 exon 3 and super-
enhancer regulatory regions between SAMSN1 and NRIP1. 
 
 
Figure 5.17: The effect of cohesin deficiency on the RUNX1 +24 enhancer-anchored chromatin hub in 
baseline (12 DMSO) conditions in K562 cells.  
Yellow boxes represent UCSC annotated gene promoters and/or exons. Blue boxes show described RUNX1 
regulators. Orange boxes annotate novel putative RUNX1 regulators. 
 
In WT K562 cells, during differentiation (12 h PMA) the RUNX1 +24 enhancer gains 
connections to +14, +54, +68, +142, RUNX1-IT1, RUNX1 promoter 1, exon 1 and 2. RUNX1 
+24 maintains connections seen in WT 12 DMSO with m-368, m-58, m+3, m+62, m+110, 
RUNXOR, RUNX1 P2, RUNX1 exon 3. In WT K562 cells, RUNX1 +24 decreased interactions 
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with -96, +89, SLC5A3 Exon 2 MRPS6 intron region, ERG P3 and super-enhancer regulatory 
regions between SAMSN1 and NRIP1. The RUNX1 +24 enhancer in STAG2-deficient cells (12 
h PMA) has a similar interaction landscape as WT 12 PMA, the obvious differences being that 
STAG2 12 PMA RUNX1 +24 further maintains the interaction with -96 and SLC5A3 Exon 2 
MRPS6 intron region, which are lost in the WT (Figure 5.18). 
 
 
Figure 5.18: The effect of cohesin deficiency on the RUNX1 +24 enhancer-anchored chromatin hub in mid-
differentiation (12 PMA) conditions in K562 cells.  
Yellow boxes represent UCSC annotated gene promoters and/or exons. Blue boxes show described RUNX1 
regulators. Orange boxes annotate novel putative RUNX1 regulators. 
 
In WT K562 cells, after differentiation (72 h PMA) the RUNX1 +24 enhancer interacts 
with m-371, m-368, m-58, m+3, +62, m+110, RUNX1 P2 and exon 3. The RUNX1 +24 
enhancer loses connections with +14, +54, +68, +142, RUNX1-IT1, RUNXOR , RUNX1 
promoter 1, exon1 and 2. In STAG2-deficient cells (72 h PMA) RUNX1 +24 interacts with m-
368, m-58, +62, m+110, RUNX1 P2, RUNX1-IT1, RUNXOR. The RUNX1 +24 enhancer loses 
connections with m-371, m+3, and RUNX1 exon 3 when compared to the WT (Figure 5.19) 
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Figure 5.19: The effect of cohesin deficiency on the RUNX1 +24 enhancer-anchored chromatin hub in post-
differentiation (72 PMA) conditions in K562 cells.  
Yellow boxes represent UCSC annotated gene promoters and/or exons. Blue boxes show described RUNX1 
regulators. Orange boxes annotate novel putative RUNX1 regulators. 
 
Figure 5.17, 5.18 and 5.19 give an overview of the changes to the WT identified 
connections mediated by the RUNX1 +24 enhancer. However, these summaries do not illustrate 
the gained connections in STAG2 mutant cells. The regions that have increased interactions 
with the RUNX1 +24 enhancer in STAG2 mutant cells require further analysis to determine 
their functional relevance. 
5.6 Chapter summary 
5.6.1 RUNX1 +24 enhancer connections during K562 differentiation to 
megakaryocytes 
5.6.1.1 Distant connections 
The RUNX1 +24 enhancer makes connections spanning chromosome 21 during 
megakaryocyte differentiation. As differentiation occurs, there is a steady decrease of 
interactions across the chromosome, including loss of the connection between RUNX1 +24 and 
ERG P3. Because ERG expression slowly increases during differentiation, it is possible that 
the interaction between the RUNX1 +24 enhancer and ERG P3 inhibits transcription from this 
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promoter in baseline conditions. During the onset of differentiation, the loss of ERG P3 
connection with RUNX1 +24 may in turn allow ERG P3 initiate expression of ERG.  
5.6.1.2 Connections within the RUNX1 TAD 
During megakaryocyte differentiation, the RUNX1 +24 enhancer displays a dynamic 
interaction landscape in WT K562 cells. Upon PMA treatment, RUNX1+24 connects with 
possible regulatory elements -96, +14, +54, +68, +89, +142 and known regulator m-371. 
Interactions between RUNX1 +24 and +14, +54, +68 and +142 were only observed during 
differentiation (12h PMA). All of these regions were annotated in by ChromHMM as enhancers 
in steady-state K562 cells. RUNX1 +24 maintains contact with a cluster of regulatory regions 
m-368, m-58, m+3, +62 and m+110. Previously m-368, m-58, m+3 and m+110 had only been 
described as enhancers in mice but were shown to be conserved in humans in Chapter 3.  
Upon stimulation with PMA, K562 cells start to transcribe RUNX1 from the P1 
promoter. P1-driven transcription of RUNX1 is essential for megakaryocyte differentiation. 
Consistent with the idea that the interaction between RUNX1 +24 and RUNX1 P1 stimulates 
P1-driven transcription, the connection between RUNX1 +24 and RUNX1 P1 increases during 
differentiation (12h PMA). In contrast, RUNX1 P2 transcript is minimally expressed 
throughout differentiation. The connection between RUNX1 P2 to RUNX1 +24 remains 
unchanged throughout differentiation. After differentiation there is an increase in the 
connection between RUNX1 +24 and m-371.  
5.6.2 RUNX1 +24 enhancer connections during PMA treatment in 
STAG2 mutants 
5.6.2.1 Baseline conditions: 
In contrast to WT K562 cells, in STAG2-deficient cells the RUNX1 +24 enhancer 
makes many more connections across chromosome 21. Increased connections corresponded 
with regions that are annotated as insulators and poised promoters. Despite the overall increase 
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in interactions, some connections that are present in WT K562 cells are lost. RUNX1 +24 loses 
connections with m+3, m+62, m+110, RUNXOR, RUNX1 exon 3 and super-enhancer 
regulatory regions between SAMSN1 and NRIP1. 
5.6.2.2 Mid-differentiation 
In STAG2-deficient K562 cells, transcription of RUNX1 from the P1 promoter fails to 
be activated by PMA stimulation, and instead, there is ectopic expression from the P2 
promoter. From this finding (and from the baseline connectivity) the expectation was that after 
12 h of PMA treatment the RUNX1 +24 enhancer would have a vastly different interaction 
profile in STAG2 mutants compared to WT. Surprisingly, the RUNX1 +24 enhancer forms 
similar connections after 12 h PMA treatment in both WT and STAG2-deficient cells. The 
RUNX1 +24 enhancer maintains the interaction with -96 and SLC5A3 Exon 2 MRPS6 intron 
region, which are lost in the WT, in STAG2 mutants. Although ERG P3 is released upon PMA 
stimulation in STAG2 mutant cells, just as it is in WT, expression of ERG is inappropriately 
sensitised in STAG2 mutant cells. Further investigation is required to determine how ERG 
becomes ectopically activated. 
5.6.2.3 Post-differentiation 
STAG2 mutant cells retained stem cell-like properties and failed to activate 
megakaryocyte markers (Antony et al., 2020). After 72 h PMA treatment of STAG2 mutant 
cells, interactions mediated by the RUNX1 +24 enhancer no longer resembles the WT profile. 
The RUNX1 +24 enhancer mediates a vastly increased number of connections, and the profiles 
of normalised read counts are chaotic when compared to the profiles of the WT RUNX1 +24 
connections (Figure 5.7 and 5.14). After 72 h PMA treatment of STAG2 mutant cells, the 
RUNX1 +24 enhancer maintains connections with RUNX1-IT1, RUNXOR, which are lost in 
WT K562. The RUNX1 +24 enhancer lost interaction with m-371, m+3, and RUNX1 exon 3 in 
STAG2 mutant cells; connections that are maintained in WT K562 (Figure 5.19).  
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The RUNX1 +24 enhancer contacted more super-enhancer regions in STAG2 mutant 
cells compared to WT K562. 
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6 Chapter 6: Discussions and Conclusions 
Runx1 is a transcription factor that is crucial for definitive haematopoiesis (Okuda et 
al., 1996; Wang et al., 1996). RUNX1 has a significant role in the development to myeloid 
malignancies, especially in Acute Myeloid Leukaemia (AML) (Ichikawa et al., 2013; Okuda 
et al., 1996). runx1 expression in haematopoietic progenitor cells in zebrafish is reliant on 
cohesin (Horsfield et al., 2007). Cohesin mutations have been recurrently identified in AML 
and other myeloid malignancies (Leeke et al., 2014). Because karyotypically normal cells are 
found with cohesin mutations, the mechanism by which cohesin mutation leads to leukaemia 
is thought to be by dysregulation of target genes rather than mitotic defects (Thol et al., 2014). 
Cohesin insufficiency impairs differentiation, alters overall chromatin accessibility, as well as 
the transcription of RUNX1 (Mazumdar et al., 2015; Mullenders et al., 2015; Viny et al., 2015). 
Cohesin regulates Runx1 expression, and RUNX1 plays a central role in the development of 
myeloid malignancies, therefore cohesin-dependent RUNX1 expression may represent an 
underlying mechanism that leads to myeloid malignancies (Leeke et al., 2014). The precise 
spatiotemporal expression of Runx1 requires cis-regulatory elements, the majority of which 
have not been defined. 
In my PhD project, I set out to investigate the regulatory potential of Runx1 4C-
identified regions, and determine conservation of mouse Runx1 regulators in humans. This 
work has provided an insight into mouse Runx1 enhancer functions and highlighted the features 
of conserved human enhancers. Runx1 +24 was identified as an important intronic Runx1 
enhancer in mice, and is crucial for the activation of Runx1 expression in hematopoietic 
stem/progenitor cells (HSPCs) (Ng et al., 2010; Nottingham et al., 2007). Runx1 +24 is highly 
conserved in eukaryotes, indicating an essential role in gene regulation. Runx1 +24 binds most 
active Runx1 enhancers in mice HPCs and may anchor a regulatory hub that organises the 
correct enhancer-promoter interactions for Runx1 regulation. Suppression of enhancers by BET 
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inhibitor proteins alters the expression of RUNX1 in haematopoietic cells (Antony et al., 2020). 
I hypothesised that the RUNX1 +24 enhancer anchors an enhancer hub in human cells and is 
important for correct RUNX1 expression, which may be disrupted in AML.  
Chromatin conformation capture techniques were used in this project to understand the 
role of RUNX1 +24 enhancer in 3D chromatin connections, and as a hub for functional 
regulatory regions. The RUNX1 +24 enhancer connected across chromosome 21, defying 
known TADs. It interacted with coding genes, non-coding RNA loci, super-enhancers and 
regulatory elements, and may be maintaining these connections to prevent transcription, rather 
than have a traditional enhancer role. The data suggests that the RUNX1 +24 enhancer could 
be important for overall organisation and 3D structure of chromosome 21. 
The results from my project highlighted the dynamic changes in the RUNX1 +24 hub 
connections with RUNX1 and ERG, genes central in correct megakaryocyte development, 
during differentiation of the chronic myeloid leukaemia cell line K562. Chromatin interaction 
data identified putative RUNX1 regulators and demonstrated how cohesin insufficiency affects 
the RUNX1 +24 enhancer connections. In cohesin-deficient cells, the number of RUNX1 +24 
connections dramatically increased across chromosome 21. This suggests that cohesin STAG2 
mutation leads to a de-constrained chromatin environment. Loss of insulation of chromatin 
domains in STAG2 mutants enables aberrant enhancer-amplified transcription and may 
contribute to the pathogenesis of AML. 
6.1 Regulators of Runx1 
6.1.1 Mouse Runx1 enhancers 
This thesis describes the functional characterisation of novel Runx1 enhancers m-371, 
m-354, m-303 and m-48, as well as the previously identified m+110, m-58, m-321, m-327, m-
368. The data show that all these elements have enhancer capability except m-327. Despite the 
lack of activity seen in zebrafish embryos expressing m-327, this putative regulatory region 
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spatially connects to the active (P1) promoter of Runx1 and the Runx1 +24 enhancer in mouse 
HPC7 cells, so it may have another regulatory role in this hub. All enhancers except m+110 
interacted with the Runx1 +24 enhancer (Marsman, 2016), suggesting that the Runx1 +24 
enhancer could be anchoring an enhancer hub in mouse HPC7 cells. 
My analysis of these enhancers in haematopoietic tissues of developing zebrafish 
embryos shows that they appear to be active during the primitive wave of haematopoiesis. A 
complete summary of the spatiotemporal activity of the mouse Runx1 regulatory regions in 
zebrafish is difficult to interpret, because zebrafish embryos were not continuously observed 
throughout development. Some of the putative enhancer regions may drive cell-specific gene 
expression at developmental periods not observed.   
Recent research has demonstrated the potential of zebrafish models to assess the 
function of human and mouse cis-regulatory elements, regardless of their sequence 
conservation in zebrafish (Bhatia et al., 2013; Bhatia et al., 2014; Chahal et al., 2019; 
Ketharnathan et al., 2018; Rainger et al., 2014; Ravi et al., 2013; Yuan et al., 2018). The 
transcription factors (TFs) required by cis-regulatory elements for their function are still 
present and utilised in the appropriate cell and tissue types (Bessa et al., 2009; Mann et al., 
2019). Enhancer assays highlight the value of the zebrafish model as a way to determine 
functionality of regulatory sequences from other species. 
6.1.2 Conserved human RUNX1 regulators 
I found that 9 out of the 16 mouse Runx1 regulatory regions are conserved in human 
(based on sequence analysis and ENCODE annotations), increasing the number of ‘known’ 
putative human RUNX1 regulatory regions from 6 to 14 (Figure 6.1). Conservation between 
mice and humans suggests that these regulatory regions are fundamental for the correct 




Figure 6.1:Schematic overview of human RUNX1 locus (hg19: chromosome 21: 36,148,773-36,872,777).  
Black text annotates the previously identified human RUNX1 regulatory regions. Blue text highlights the 
conserved mouse regulatory regions. Each regulatory region is annotated with orange circles, grey boxes 
annotate exons. The blue boxes show the exons encoding the Runt binding domain. The two RUNX1 promoters 
are represented by black right angled arrows. 
 
Bioinformatic analysis of RUNX1 regulatory regions showed that not all of them appear 
to be active in K562 cells (Table 6.1). ChromHMM annotates m-327 and -250 as repressed, 
and m-368, m-58, m+110 -139, m-43, +24, +62 as active enhancers. Intron 5.2, m-101 and 
m+3 show chromatin features of enhancers; however, they are labelled as transcription-
associated alongside -139 and -188. Transcription-associated annotation may be due to their 
close proximity with exons when compared to the regions annotated as enhancers or it may 
indicate that these regions are producing RNA, for instance enhancer RNA (eRNA).  
The RUNX1 +24 enhancer has strong enhancer characteristics and recruits 
haematopoietic transcription factors SP1, TAL1, GATA1 and GATA2. SPI also located to -
139 and -188. Haematopoietic transcription factors TAL1, GATA1 and GATA2 bind to m-
371, m-58 and m+110. These regions showed transcription factor binding sites and chromatin 
modifications similar to that found at the RUNX1 +24 enhancer. 
The RUNX1 +24 enhancer also recruits LSD1, a mediator of transcriptional repression 
usually seen in silencers. Interestingly, nine other regulatory regions (m-371, m-368, -250, m-
101, m-58, m+3, +62, m+110 and intron 5.2) had LSD1 binding in K562 cells. Cheng et al., 
(2018) treated haematopoietic cells (chronic myelogenous leukaemia (K562), acute myeloid 
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leukaemia (OCI-AML3) and histiocytic lymphoma (U937)) with a LSD1 inhibitor and 
observed upregulation of RUNX1, which implicates the role of LSD1 in repression of RUNX1 
(Cheng et al., 2018). Kerenyi et al., (2013) previously showed Lsd1 is a crucial epigenetic 
regulator of haematopoiesis in mice, because it represses key hematopoietic stem cell genes 
including Runx1 (Kerenyi et al., 2013).  
Cheng et al., (2018) characterised +62 as a silencer of RUNX1 P2 by measuring the 
repressive effect of various deletion/mutant +62 luciferase constructs on transcription from the 
P2 promoter. This functional assay was carried out in K562, OCI-AML3 and U937 cells 
(Cheng et al., 2018). However, in K562 cells +62 has ENCODE and ChromHMM annotations 
associated with enhancer activity. These regions with enhancer and silencer annotations may 
have multiple roles depending on combinations of connections being made with the region 
(promoters and other regulatory regions) and the cell type. 
ATAC-seq (Antony et al., 2020) showed that intron 5.2, m+110 and m-371 regions 
were in differentially open chromatin regions in STAG2 mutant K562 cells. This suggests that 
cohesin influences the accessibility of these enhancers. I observed a coincidence of cohesin 
subunit Rad21 binding in the absence of CTCF with m+110 enhancer, and CTCF binding with 
m-371, m-58, m-43, m+3, +62 and intron 5.2. This suggested that CTCF and cohesin could 
independently mediate a subset of enhancer-promoter looping in combination with 
transcription factors.  
6.1.3 G-quadruplex 
The Circular Dichroism (CD) analysis showed that the predicted G-quadruplexes 
observed in the mouse +24 element are capable of forming parallel G-quadruplexes in vitro. 
The G-quadruplex analysis was specific to the mouse sequence so it may not reflect the human 
sequence, the type of G-quadruplex, or its functional capacity. Luciferase assays showed that 
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the mutations of G-quadruplex in mouse Runx1 +24 had no significant effect on enhancer 
function when tested in isolation in mouse fibroblast (NIH/3T3) cells.  
6.1.4 Regulatory RNAs 
Non-coding RNAs are involved in many biological processes, including transcription 
regulation, cell-fate programming and genome 3D organisation (Beltran et al., 2019; Flynn et 
al., 2014; Geisler et al., 2013; Holoch et al., 2015; Li et al., 2019; Nozawa et al., 2019; Sun et 
al., 2018; Wang et al., 2017). Types of non-coding RNA include enhancer RNA (eRNA), Long 
non-coding RNAs (LncRNAs) as well as G-quadruplex RNA.  
6.1.4.1 Enhancer RNA (eRNA) 
eRNA has been shown to be involved in functional roles including; assisting enhancer-
promoter looping formation, supporting pause-release of RNA Pol II which facilitates 
transcription elongation, promoting transcription factor and co-regulator binding and aiding 
target gene transcription (Bose et al., 2017; Hou et al., 2020b; Lai et al., 2013; Lam et al., 
2013; Li et al., 2013a; Melo et al., 2013; Panigrahi et al., 2018; Rahnamoun et al., 2018; 
Schaukowitch et al., 2014; Sigova et al., 2015; Tsai et al., 2018). FANTOM5 data showed ten 
of the 14 RUNX1 regulatory regions (m-371, m-327, -250, -139, m-43, m+3, +24, +62, m+110 
and intron 5.2) produced eRNA in haematopoietic cells. Although eRNA is typically used for 
enhancer identification, not all active enhancers produce detectable eRNA (Mikhaylichenko et 
al., 2018; Sartorelli et al., 2020). It remains unclear whether these enhancers produce low levels 
of eRNAs that are not easily detectable with current methods. ChromHMM labelled -188, -
139, m-101, m+3 and intron 5.2 as transcription-associated. This may be attributed to enhancer 
RNA transcription, as m-139, m+3 and intron 5.2 all produce eRNAs. It remains to be 
investigated whether the transcription association observed in m-188 and m-101 may also due 
to enhancer RNA production. 
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6.1.4.2 Long non-coding RNAs 
Long non-coding RNAs (LncRNAs) have been shown to activate or suppress 
transcriptional activity by interacting with chromatin modulating proteins (Fan et al., 2015; 
Han et al., 2014; Jain et al., 2016; Prensner et al., 2013; Scarola et al., 2015). RUNX1-IT1 and 
RUNXOR LncRNAs have been shown to regulate RUNX1. Relatively little is known about 
RUNX1-IT1, a long non-coding RNA expressed from in between m+3 and RUNX1 +24. 
However, Liu et al., (2020) found RUNX1-IT1 enhanced the transcription of the RUNX1 gene 
in pancreatic cancer cells (Liu et al., 2020).  
Previous studies show RUNXOR, a long non-coding RNAs 3.8kb upstream of RUNX1 
has the ability to regulate the RUNX1 P1 promoter (Nie et al., 2019; Wang et al., 2014). 
RUNXOR activates P1 and causes a shift to P1 RUNX1c isoform expression. The binding of 
RUNXOR lncRNA elicits DNA demethylation and induces active histone modification markers 
in the P1 CpG island. Therefore RUNXOR could be essential for the P1/P2 switch during 
normal haematopoiesis and potential tumorigenesis (Nie et al., 2019). 
m-371, m-368 and m-327 all sit within an uncharacterised non-coding RNA 
LOC100506403. Like RUNX1-IT1 and RUNXOR, this long non-coding RNA could also play 
a role in regulating RUNX1, with these regions helping to determine its expression. My 4C data 
showed that in baseline conditions (12 DMSO), wild type K562 cells had a dramatic peak of 
normalised reads that indicates a connection to m-368. Which may indicate an essential role of 
LOC100506403 in WT 12 DMSO cells.  
6.1.4.3 G-Quadruplex RNAs 
G-quadruplex RNA is capable of targeting and removing the Polycomb repressive 
complex 2 from genes and allowing RNA-mediated regulation (Beltran et al., 2019; Wang et 
al., 2017). Because part of the mouse Runx1 +24 enhancer is capable of forming a G-
quadruplex, it is possible that the Runx1 +24 enhancer RNA may also form a G-quadruplex. 
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Previously Fukunaga et al., (2020) showed that G-quadruplex RNA binds the ETO protein and 
dissociates the leukemic RUNX1-ETO fusion protein from DNA (Fukunaga et al., 2020). This 
suggests that some G-quadruplex RNAs may have potential as therapeutic agents for 
leukaemia. 
6.1.5 Could mutational load in regulatory elements also contribute to 
disease progression?  
Single nucleotide polymorphisms (SNPs) are present in each of the human RUNX1 conserved 
regulatory regions, except +24 and m-101. m-371, m-368, m-58, m+110 and intron 5.2 SNPs 
were reported in haematopoietic, brain, thyroid, skin and oesophagus cells. SNP frequency 
could be an underestimate because of the scarcity of whole genome sequence in individual 
haematopoietic cell types, AML, and other myeloid malignancy samples; this limits the ability 
to identify significant SNPs and mutations in haematopoietic cells. The GTEx portal annotates 
SNPs with MAF >1%, as well as eQTL outputs. The GTEx portal contains 54 tissues sampled 
from healthy older individuals, and also only measures whole blood, rather than individual cell 
types, so cell type- or disease-specific effects may not be detected.   
There were no SNPS with MAF of >1% present in the RUNX1 +24 enhancer. This 
suggests that there is strong selection pressure to prevent mutation of the RUNX1 +24 enhancer. 
Consistent with this, functional studies suggest that the region containing RUNX1 +24 enhancer 
is functionally important in haematopoietic cells. To determine the importance of the RUNX1 
+24 enhancer for RUNX1 expression and function, Mill et al., (2019) CRISPR/Cas9 edited the 
whole intron between RUNX1 P1 and P2 in OCI-AML5 cells (Mill et al., 2019). The majority 
of the edited cells were eradicated via apoptosis, and the viable edited cells had significantly 
decreased RUNX1 expression and slower growth (Mill et al., 2019). It is not clear whether the 
observed phenotypes correspond uniquely to deletion of the RUNX1 +24 enhancer since the 
entire P1-P2 intron was removed. Rather, this research shows the P1-P2 intronic region, which 
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contains multiple RUNX1 regulatory elements, is important for cell survival and RUNX1 
expression. 
Of the 35 SNPs identified in the conserved RUNX1 regulatory regions, 6 had previously 
reported functional effects in haematopoietic cells. m-371 contains rs2834945, a T to C change 
that is predicted to affect 11 regulatory motifs including GATA2. rs2834945 is related to 
expression of Kynurenine 3-monooxygenase (KMO) in peripheral blood monocytes (Zeller et 
al., 2010). KMO encodes a mitochondrion outer membrane protein that catalyses the 
hydroxylation of L-tryptophan metabolite, L-kynurenine, to form L-3-hydroxykynurenine 
(Alberati-Giani et al., 1997). KMO is typically investigated in a neurological context, as high 
KMO expression leads to neurodegeneration (Breton et al., 2000).  
m-368 harbours two functional SNPs: rs16993221 and rs909143. rs16993221 is related 
to white blood cell count; it is a crucial marker that contributes to chronic inflammation (Kong 
et al., 2013). The A to T change in rs16993221 alters two regulatory motifs, BATF and IRF, 
which work together in immune response. The A to G change in rs909143 is also related to 
expression of KMO in peripheral blood monocytes (Zeller et al., 2010) and is predicted to 
affect two regulatory motifs (NR3C1, POU2F2).  
Within m+110 sits rs73900579, a T to C change that alters two regulatory motifs and 
is related to red cell distribution width (Kichaev et al., 2019). 
Intron 5.2 contains two functional SNPS, rs2249650 and rs2268276; both are associated 
with AML susceptibility. The different SNPs are in linkage disequilibrium (LD) and change 
the ability of intron 5.2 to act as an enhancer. A (rs2249650) G (rs2268276) bases and AA have 
more enhancer capability that GA and GG. GA has the most reduced enhancer capability. The 
SNPs also affect SPI1 binding capability; AG has strong SPI1 binding, GA has weak SPI1 
binding, whereas AA and GG have medium SPI1 binding capability (Xu et al., 2016). 
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Although not all SNPs found in this project have been functionally analysed, some of 
the regulatory region SNPs were reported in patients with acute myeloid leukaemia. Two AML 
patients had -250 SNP rs2834885, and two SNPs in +62 (rs933131 and rs2834716) were  also 
found in patients with AML. Interestingly, the patient with +62 rs2834716 also had the intron 
5.2 SNPs (rs2268276 and rs2249650) which were previously associated with AML 
susceptibility (Xu et al., 2016). 
Five patients with malignant lymphoma reported mutations within regulatory regions 
m-58 and +24 that are not reported as SNPs with a MAF of >1%. Four patients had m-58 
mutations chr21:g.36480715C>A (rs199811665), chr21:g.36480761A>C and 
chr21:g.36481470C>T (rs1440069314). One case of malignant myeloma reported a mutation 
within +24, chr21:g.36399191A>T. 
The available AML genomic data is relatively limited because the majority of analyses 
were performed with exome sequencing data, rather than whole genome sequencing data. Lack 
of whole genome data and individual SNP significance could lead to an underestimate of the 
functional contribution of enhancer-region mutations to myeloproliferative disorders. 
Xu et al., (2016)’s analysis of intron 5.2 SNPs showing that SNPs are functionally 
relevant to leukaemia suggests a need to analyse each of the SNPs within regulatory regions 
for functional capability. Determining and categorising SNPs may help us understand each 
patient’s disease progression, individual responses to drugs, or susceptibility to relapse. Some 
patients had SNPs with previously described functional effects on haematopoietic cells. 
However, the SNP data for myeloproliferative disorders lacks significance because the 
majority of SNP eQTL information comes from analysis of whole blood, rather than each 
specific cell type.  
There is good evidence suggesting that RUNX1 regulatory regions intron 5.2 and +62 
are directly involved in disease progression, so further investigation of these regulatory regions 
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is necessary. Intron 5.2 contains SNPs that are associated with AML susceptibility, and in 
addition, this regulatory region is the site of translocation in t(8;21) found in AML patients in 
which RUNX and ETO genes recombine. Schnake et al., (2019) identified a long non-coding 
RNA in intron 5.2, at a site of these frequent chromosomal translocations. This long non-coding 
RNA results in a more relaxed chromatin organisation at intron 5.2 (at the location of the 
breakpoint). Consequently, it is possible that this feature acts as a determinant of a higher 
probability of double stranded breakages in myeloid cells, resulting in translocations (Schnake 
et al., 2019). 
The discovery of RUNX1 silencer +62 resulted from characterisation of a novel 
t(5;21)(q13;q22) translocation involving RUNX1 that was acquired during the progression of 
myelodysplastic syndrome to AML in a paediatric patient (Cheng et al., 2018). This 
translocation did not generate RUNX1 fusion, but rather it aberrantly upregulated the P2 
isoform of RUNX1. The authors state that the translocation facilitated upregulation of RUNX1 
P2 because the silencer at +62 was removed.  
Several groups have described chromatin rearrangements that lead to “enhancer 
hijacking”, whereby enhancers from somewhere else in the genome are rearranged next to 
genes leading to overexpression (Bohlander, 2000; Gröschel et al., 2014; Look, 1997; 
Northcott et al., 2014; Peifer et al., 2015; Taub et al., 1982; Zhang et al., 2020). Taub et al., 
(1982) described t(8;14) translocations in Burkitt's lymphoma which alter gene expression 
through enhancer hijacking (Taub et al., 1982). Rewat et al., (2004) showed that in the t(12;13) 
translocation, overexpression of CDX2 gene is leukaemogenic rather than the ETV6-CDX2 
fusion(Rawat et al., 2004). 
The majority of translocations occur between RUNX1 P1 and P2; while the disruption 



























Mutations seen in 
haematopoietic 
cells in cancer 
patients 
m-371 Strong Enhancer ✓ ✓ ✗ ✓ Increased 2 1 ✗ 
m-368 Strong Enhancer ✗ ✓ ✗ ✗ No change 3 2 ✓ 
m-327 Repressed ✓ ✗ ✗ ✗ No change 2 0 ✗ 
-250 Repressed ✓ ✓ ✗ ✗ No change 3 0 ✓ 
-188 Transcription 
Associated 
✗ ✓ ✗ ✗ No change 1 0 ✗ 
-139 Weak enhancer, 
Transcription 
Associated 






✗ ✗ No change 0 0 ✗ 
m-58 Strong Enhancer ✗ ✓ ✗ ✓ No change 13 0 ✓ 
m-43 Weak Enhancer ✓ No 
available 
data 































Mutations seen in 
haematopoietic 
cells in cancer 
patients 
+24 Strong enhancer ✓ ✓ ✓ ✓ No change 0 0 ✓ 
+62 Weak Enhancer ✓ No 
available 
data 
✗ ✓ No change 2 0 ✓ 






✓ ✓ ✗ ✓ Increased 3 2 ✓ 
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6.2 Organisational role of the RUNX1 +24 enhancer  
The mouse Runx1 +24 enhancer binds most other active Runx1 enhancers in murine 
HPCs, and enhancer suppression in K562 results in altered RUNX1 expression. Therefore, I 
hypothesised that the RUNX1 +24 enhancer organises a chromatin hub in human cells that is 
crucial for correct RUNX1 expression. Circular chromosome conformation capture (4C) is a 
technique that can be used to determine 3D chromatin interactions from a given viewpoint, or 
‘bait’ (van de Werken et al., 2012a). I used the RUNX1 +24 enhancer as ‘bait’ in a 4C 
experiment to determine the interacting DNA partners of this enhancer in K562 cells.  
The majority of RUNX1 +24 interactions were with other regulatory regions that 
include both active and inactive chromatin. The connections between the RUNX1 +24 enhancer 
and other genes were predominantly with loci encoding non-coding RNAs.  
Within the RUNX1 TAD, the RUNX1 +24 enhancer connects with other RUNX1 
regulatory regions (m-368, m-101, m-58, and m+110) that had previously only been described 
in mice, but have been shown in this thesis to be conserved in humans. RUNX1 +24 connected 
to only one RUNX1 promoter (P2) and the previously identified +62 enhancer. RUNX1 +24 
does not connect to all RUNX1 regulatory regions, consistent with the idea that different 
enhancer recruitment occurs in diverse cell types to generate different RUNX1 isoforms. There 
were some novel interactions identified; RUNXOR, ERG P3 and putative regulatory regions -
96, +89, SLC5A3 Exon 2 MRPS6 intron and a super-enhancer region between SAMSN1 and 
NRIP1.  
My 4C analysis shows that in K562 cells, the RUNX1 +24 enhancer makes multiple 
connections within the RUNX1 TAD (‘near-bait’) and further afield on chromosome 21 (‘cis’). 
The chromatin conformation methods, Hi-C and promoter Capture-C, show that gene 
promoters usually form interactions within their own TADs. Due to the high resolution of 4C 
interactions, it is apparent that the RUNX1 +24 enhancer was not constrained to within-TAD 
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interactions, but also formed connections across the whole of chromosome 21. These 
interactions outside of TAD also altered with differentiation, so they are unlikely to be artifacts 
of the 4C technique. This surprising finding suggests that the RUNX1 +24 enhancer possibly 
organises a chromatin hub in K562 cells that involves much of chromosome 21. This implies 
that the RUNX1 +24 enhancer forms a chromatin hub that ensures correct regulation of 
transcription of several chromosome 21-linked loci in K562 cells. 
6.3 RUNX1 +24 enhancer connections during megakaryocyte 
differentiation 
My 4C analysis in K562 cells shows that the RUNX1 +24 enhancer makes multiple 
connections across chromosome 21. During megakaryocyte differentiation, transcription 
factors are induced to initiate gene expression consistent with megakaryocyte development. Do 
these transcription factors alter connections made by the RUNX1 +24 enhancer? To determine 
differences in connections, I used the RUNX1 +24 enhancer as ‘bait’ in a 4C experiment in 
K562 cells undergoing PMA-induced differentiation, sampled at mid-point (12 h) and end-
point (72 h) stages. I found that as differentiation occurs, there is a steady decrease in 
interactions mediated by the RUNX1 +24 enhancer across chromosome 21, including a 
decrease in strength of connection between RUNX1 +24 and ERG P3.  
ERG expression slowly increases during megakaryocyte differentiation. ERG P3 is 
constrained in the baseline K562 cells (12 DMSO) and shows insulator annotations. Following 
PMA treatment, ERG P3 has a weakened connection with RUNX1 +24. This may be to allow 
ERG P3 to activate and facilitate the expression of ERG. In steady-state K562 cells, the RUNX1 
+24 enhancer could be safeguarding chromatin structure, including the insulation of regions to 
prevent transcription e.g., at ERG P3 or at loci encoding non-coding RNA. Once the cell has 
begun the differentiation process, RUNX1 +24 “releases” these regions to allow for their 
domain specific regulation and/or expression as the cells differentiate to megakaryocytes. 
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The dynamic interaction landscape of the RUNX1 +24 enhancer during differentiation 
of K562 cells highlights the need to further understand the roles of regulatory regions in 
different cell types. During PMA treatment, the RUNX1 +24 enhancer forms new connections 
with possible regulatory elements +14, +54, +68, +142 and known regulator m-371. 
Interactions between the RUNX1 +24 enhancer and +14, +54, +68 and +142 and RUNX1-IT1 
were only observed during differentiation (12 h PMA). These interactions were not observed 
in steady-state K562 cells. Therefore, these regulatory regions may be important for RUNX1 
regulation during megakaryocyte differentiation. All of these regions were annotated by 
ChromHMM as enhancers in steady-state K562 cells, but this chromatin signature may not 
reflect the nature of these elements during differentiation. The RUNX1 +24 enhancer maintains 
existing contacts with regulatory regions m-368, m-58, m+3, +62 and m+110 throughout 
differentiation.  
The RUNX1 P2 transcript is minimally expressed throughout differentiation. The 
connection between RUNX1 P2 to the RUNX1 +24 enhancer remains unchanged throughout 
differentiation. Previously, +62 was shown to be a silencer of RUNX1 P2. RUNX1 +24 could 
act to mediate the silencer interaction between P2 and +62. In contrast, interaction between the 
RUNX1 +24 enhancer and RUNX1 P1 is increased during differentiation (12h PMA). 
Transcription of RUNX1 from its P1 promoter is crucial for megakaryocyte differentiation 
(Draper et al., 2017). Consistent with this, K562 cells had a gradual increase in transcription 
of the P1 isoform of RUNX1 during PMA-induced differentiation (Antony et al., 2020). 
In the presence of enhancer suppressor JQ1, RUNX1 P1 expression is suppressed, 
suggesting that P1 expression in these cells is enhancer-driven (Antony et al., 2020). Since the 
RUNX1 +24 enhancer recruits P1 during differentiation, its enhancer activity could be the target 
of JQ1-mediated suppression of RUNX1 transcription. 
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Connection between RUNX1 +24, RUNX1 P1, and known RUNX1 regulatory RNAs 
RUNXOR and RUNX1 -IT1 all decrease after differentiation. I speculate that it is likely, 
following activation of RUNX1 P1 transcript during differentiation, that the RUNX1 +24 
enhancer releases connections to regions that are crucial for the RUNX1 P1 switch because 
they are no longer required.  
After differentiation (72 h PMA), there is an increase in frequency of the connection 
between RUNX1 +24 and m-371. This region was shown to act as a primitive haematopoietic-
specific enhancer in developing zebrafish (Chapter 3) and activates RUNX1 P1 in developing 
mice (Zhu et al., 2020). The increase in connection of the RUNX1 +24 enhancer with m-371 
in differentiated K562 megakaryocyte cells may indicate a role for m-371 in megakaryocyte 
identity. m-371 also sits within LOC100506403 – this long non-coding RNA could also play a 
similar role to RUNX1-IT1 and RUNXOR in regulating RUNX1, with the connection to m-371 
helping to determine its expression. 
Although the RUNX1 promoters dynamically interact with the RUNX1 +24 enhancer, 
the 4C analysis is unable to determine what other regulatory elements the promoters connect 
to. This is because the 4C analysis used only the bait within the RUNX1 +24 enhancer as the 
viewpoint for 3D interactions. The combination of regulators used to control transcription of 
RUNX1 appears to be very dynamic, but also suggest cell type dependency. For example, 
despite previous evidence of intron 5.2 and the -250, -188 and -139 cluster acting as RUNX1 
regulators, these regions did not interact with the RUNX1 +24 enhancer upon megakaryocyte 
differentiation. They could instead interact directly with the promoter(s) or act in another cell 
type.  
Vukadin et al., (2020) describe SON protein as a negative regulator of RUNX1 and 
inhibitor of megakaryocyte differentiation in chronic myeloid leukaemia cells. They showed 
that SON obstructs megakaryocytic differentiation by directly binding to RUNX1 P2 and two 
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enhancer regions (the RUNX1 +24 enhancer and a “novel” +139 enhancer) (Vukadin et al., 
2020). +139 overlaps with m+110, suggesting that they represent the same human RUNX1 
enhancer. This research supports the idea that the maintained connection of +m110/+139 with 
the RUNX1 +24 enhancer during megakaryocyte differentiation is crucial for correct RUNX1 
expression. 
6.4 Cohesin/STAG2 dependency of RUNX1 +24 enhancer 
connections in K562 cells 
The cohesin complex mediates tissue-specific enhancer-promoter and enhancer-
enhancer communication (Canela et al., 2017; Phillips-Cremins et al., 2013; Strom et al., 
2012). Furthermore, evidence from our group shows convincingly that cohesin is required for 
the normal transcription of Runx1 in developmental contexts (Antony et al., 2020; Horsfield et 
al., 2007; Marsman et al., 2014). However, the exact mechanism of how cohesin regulates 
Runx1 transcription is still unknown. It is possible that cohesin may influence the connections 
between the Runx1 gene and its regulatory elements, and regulate Runx1 transcription in this 
manner. To uncover potential mechanisms, I sought to determine how cohesin STAG2 mutation 
affects connections formed by the RUNX1 +24 enhancer in steady-state K562 cells, and those 
responding to a signal to undergo megakaryocyte differentiation.  
In steady-state K562 cells, STAG2 mutation dramatically increased the number of 
connections formed by the RUNX1 +24 enhancer in comparison to unedited wild type cells. 
The new connections formed by the RUNX1 +24 enhancer in STAG2-deficient cells included  
regions annotated by ChromHMM and dbSUPER as insulators, poised promoters and super-
enhancers; however, it is possible that these regions do not have the same chromatin features 
in STAG2 mutant cells as they do in wild type. STAG2 mutant K562 cells have differentially 
altered chromatin accessibility, including increased accessibility at super-enhancers and 
decreased accessibility at CTCF sites (Antony et al., 2020). 
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ChromHMM annotates a region as an insulator based on a high frequency of CTCF 
protein binding sites, CTCF motifs, and/or a higher frequency of H3K4me1 (Ernst et al., 2010). 
CTCF sites are frequently found in TAD boundary regions or within super-enhancers (Shin, 
2019). The STAG2 paralogue, STAG1, preferentially locates to CTCF sites and TAD 
boundaries (Arruda et al., 2020), while STAG2 is normally found at enhancers, promoters, and 
Polycomb-repressed domains (Arruda et al., 2020). Absence of STAG2 is tolerated because 
STAG1 can substitute for many of STAG2’s functions in the cohesin complex (Benedetti et 
al., 2017; Van Der Lelij et al., 2017). Increase in interactions of the RUNX1 +24 enhancer with 
insulators and super-enhancers upon STAG2-deficiency raises the possibility that STAG1-
cohesin mediates new contacts at CTCF sites.  
Chromatin organisation relies on two mechanisms: compartmentalisation and 
chromatin loop  extrusion, which are often considered to be counteracting each other (Nuebler 
et al., 2018). In the chromatin loop extrusion model, cohesin and CTCF form stable loops that 
act as functional barriers between active and inactive chromatin. Loop extrusion by cohesin is 
crucial for the formation of TADs, and correct transcription relies on the insulated 
neighbourhoods of TADs, including the constraint of enhancers to their gene targets (Dixon et 
al., 2012; Nuebler et al., 2018; Rao et al., 2014). Compartmentalisation describes the process 
in which proteins (including chromatin proteins) self-organise into phase-separated 
condensates and act as membrane-less organelles that cluster specific molecules. Co-
localisation of transcription factors or polycomb group proteins are frequently observed, 
suggesting like attracts like (Hyman et al., 2014; Shin et al., 2018; Stadhouders et al., 2019). 
These membrane-less organelles have been suggested to carry out crucial roles in a range of 
cellular processes (Boeynaems et al., 2018). 
I hypothesise that increased interactions in STAG2-deficient K562 cells reflect a 
scenario where compromised loop extrusion may not properly balance compartmentalisation. 
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Without STAG2, cohesin’s functions in domain organisation are compromised. As a result, 
TAD boundaries may be destabilised, allowing the RUNX1 +24 enhancer to connect more 
broadly across chromosome 21. Upon STAG2 depletion, compartmentalisation is the dominant 
mechanism used to organise chromatin. This may explain the increase in connections from the 
RUNX1 +24 enhancer to super-enhancers.  
Super-enhancers are described as regions that specify cell identity, are densely bound 
by mediators, chromatin factors and lineage-regulating master TFs, such as GATA1 and TAL1 
in K562 cells (Hnisz et al., 2013; Huang et al., 2018; Khan et al., 2018; Parker et al., 2013; 
Wang et al., 2019; Whyte et al., 2013). Super-enhancers contain a significantly higher 
frequency of chromatin interactions compared to regular enhancers (Huang et al., 2018; Wang 
et al., 2019). These characteristics indicate that RUNX1 +24 is acting as a super-enhancer in 
K562 cells. 
Wang et al., (2019) highlighted super-enhancers capability to attract the formation of 
phase-separated condensates, and capacity to generate 3D genome structures that specifically 
initiate the super-enhancer’s target genes (Wang et al., 2019). Sebari et al., (2018) provided 
evidence that transcriptional coactivators such as BRD4 are components of the phase-separated 
condensate, and that these condensates co-localise with super-enhancers (Sabari et al., 2018). 
BRD4 recruitment required for transcription is known to occur independent of enhancer-
promoter connections (Crump et al., 2021). Together, these studies provide an explanation for 
the surprisingly, similar connections forming, during differentiation (12 PMA) in STAG2 
mutant cells and wild type.  
The transcription factors that respond to PMA induction may be able to mediate correct 
RUNX1 +24 connections regardless of cohesin deficiency. Transcription-specific 3D structure 
could reflect phase-separated condensates formation , which are used to specifically initiate the 
super-enhancer’s target genes. However, when transcription induction stops (72 PMA), 
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connections go back to being abnormal. This also reflects the observations of Antony et al., 
(2020); who found that the use of BET inhibitor, JQ1 to reduce BRD4 binding and dampens 
super-enhancer driven transcription, prevented the aberrant RUNX1 and ERG signal-induced 
transcription in STAG2 mutant cells (Antony et al., 2020). 
6.4.1 K562 Limitations 
This thesis used K562 cells to determine RUNX1 +24 connectivity. K562 are a chronic 
myelogenous leukaemic (CML) cell line which expresses the BCR-ABL fusion gene 
(McGahon et al., 1997). Previous research has highlighted that cohesin mutations occur early 
in leukaemogenesis and mainly arise in pre-leukaemic cells (CGARN, 2013; Corces et al., 
2017; Kon et al., 2013; Thol et al., 2014; Welch et al., 2012). The CRISPR/Cas9 edited STAG2 
subunit is an additional mutation, which sequentially occurred after leukaemogenesis, as such, 
changes observed may be due to compounding effect of existing K562 mutational profile. 
Cohesin mutations are more frequently observed in AML samples than CML, so interactions 
may not reflect AML samples.  
Observing RUNX1 +24 connections in other cell lines would be needed to see which of 
the extensive connections are replicated. However, the K562 and STAG2 mutant K562 cell 
lines were effective for understanding dynamic 3D connections during differentiation, and 
highlighting possible cis-regulatory regions.  
6.5 Future directions 
The hypothesis of my study was that Runx1 expression is regulated by regulatory 
elements that connect with super-enhancer Runx1 +24, and that these connections are 
dependent on cohesin. Although my results did identify some functional enhancers and their 
conservation in human genome, it would be worthwhile investigating the other functional roles 
of these regions, their combinatory effects, and which other cell types utilise these regions. 
Some putative regulatory regions had dynamic interactions with the RUNX1 +24 enhancer 
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depending on the stage of differentiation and presence of STAG2-cohesin. However, these 
regions have no functional data so require further analysis. 
6.5.1 RUNX1 +24 G-quadruplex 
The Runx1 +24 G-quadruplex analysis was specific to the mouse sequence so it may 
not reflect the human sequence, the type of G-quadruplex, or its functional capacity. The CD 
analysis should be repeated with the human RUNX1 +24 G-quadruplexes. 
G-quadruplexes can be selectively targeted by small binding ligands that can disrupt 
translation (Bugaut et al., 2012). This has initiated a new approach in RNA-directed drug 
design. If the G-quadruplex is present and functional in the human +24 region, further research 
is required to validate it as a drug target. If there is dysregulation of the RUNX1 +24 enhancer 
region, targeting of the G-quadruplexes may prove effective. 
6.5.2 Functional analysis of RUNX1 regulatory regions 
I only tested the functional enhancer capability of mouse Runx1 regulatory regions 
identified in HPC7 cells by 4C. However, it would be worthwhile to further characterise the 
enhancer capabilities of previously identified RUNX1 regulators; -250, -188, -139, m-101, m-
43, +62, and 4C identified regions; -96, +14, +54, +68, +89, +142, SLC5A3 Exon 2 MRPS6 
intron and super-enhancer region between SAMSN1 and NRIP1. 
When determining the enhancer potential of regulatory regions, it would be useful to 
investigate other developmental time-points in more detail to analyse the different waves of 
haematopoiesis. Primitive haematopoiesis occurs in zebrafish 12 hpf; definitive 
haematopoiesis begins first in the ventral wall of the dorsal aorta from 36 hpf, then in the caudal 
haematopoietic tissue 2 dpf, and finally in the kidney marrow 4 dpf. Viewing embryos during 
these important time-points may provide further insight into Runx1 regulation. A semi- 
automated imaging technique could be used to efficiently analyse more time-points (Romano 
et al., 2014).  
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To determine the cell type-specific enhancer properties an alternative cell-specific 
enhancer reporter without a gata2 promoter could be used, so that the plasmids can be 
successfully integrated into F1 lines. As the enhancer reporter plasmids contain fluorescent 
markers, fluorescence-activated cell sorting (FACs) can be used to find which zebrafish 
haematopoietic cells contain GFP expression driven by the putative enhancers. This method 
can be used to determine which haematopoietic cells have transcriptional machinery that 
recognizes the enhancers based upon the fluorescent characteristics of each cell. 
Expression patterns of these enhancers show no distinct patterns of collaboration, or 
independence of roles between the enhancers. Enhancers could be working in combinations or 
may be functionally redundant. It would be interesting to analyse enhancer function further 
with combinations of candidates and/or CRISPR/Cas9 edited candidates in reporter assays. 
Interestingly regulatory regions (m-368, -250, m-101, -96, m-58, m+3, +14, +54, +62, 
+68, +89 m+110, +142, intron 5.2 and SLC5A3 Exon 2 MRPS6 intron) showed histone 
demethylase  LSD1 binding in K562 cells indicating they have potential to be epigenetically 
regulated (repressed or activated). I have tested, their enhancer potential but  It would be useful 
to functionally test all regions for silencer  activity to provide further clarity about the 
regulatory capability of these regions. Silencer activity could be determined by measuring the 
repressive effect of various deletion/mutant regulatory region luciferase constructs on RUNX1 
promoters. Silencer activity could also be measured by using an insulator assay vector (INS) 
in zebrafish; this vector expresses GFP across somites as internal control, and there is GFP 
expression variance when an insulator is cloned into vector (Bessa et al., 2009; Marsman et 
al., 2014). 
6.5.3 RUNX1 +24 connections with genes 
Although RUNX1 P1 and P2 promoters dynamically interact with the RUNX1 +24 
enhancer, the 4C analysis could not determine what other DNA regions the P1 and P2 
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promoters independently connect to during megakaryocyte differentiation. Another 4C that 
uses RUNX1 P1 and P2 as baits throughout differentiation would determine what connections 
these promoters make independently of the RUNX1 +24 enhancer. 
Future RNA-seq to determine gene expression levels during megakaryocyte 
differentiation would be informative and subsequent integration with the current 4C data would 
be useful on determining whether the RUNX1 +24 enhancer connections to genes are the 
scaffolds for transcription.  
The connection and subsequent release of silenced ERG P3 may be crucial for correct 
ERG transcription regulation. The role of the P3 promoter in ERG expression and isoform-
specific transcription could be analysed further to understand the dynamic role of the RUNX1 
+24 enhancer in ERG regulation. 
6.5.4 Roles of non-coding RNA in RUNX1 regulation 
It is possible that non-coding RNA elements including long non-coding RNA, eRNA, 
and G-quadruplex RNA could influence RUNX1 regulation. However, more research is 
required to determine the individual functional contributions of these RNAs in RUNX1 
expression. 
Chapter 3 described evidence that eRNA is expressed at most RUNX1 regulatory 
regions. It would be informative to analyse the functional capability of these eRNAs, their 
interactions, and their influence on RUNX1 regulation. It would be especially exciting to further 
investigate the possible functional roles of the RUNX1 +24 enhancer eRNA and possible +24 
G-quadruplex RNA. This could be done using precision run-on sequencing (PRO-seq) and 
rapid amplification of cDNA ends (RACE). Pro-seq can define the position, amount, and 
orientation of transcriptionally active RNA polymerases in the genome to a single-nucleotide 
resolution (Hou et al., 2020b). RACE can map eRNAs by identifying the 5′ and 3′ ends of 
RNA, and RT-qPCR can determine the expression levels of these eRNAs (Hou et al., 2020b). 
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eRNA targets could be analysed using RNA‐guided Chromatin Conformation Capture (R3C) 
as demonstrated by Wang et al., (2014). Functionality could be analysed by eRNA knock down 
using small interfering RNA (siRNA) or mutated using CRISPR/Cas9 (Hou et al., 2020b). 
If the G-quadruplex is capable of forming RNA, it would be fascinating to investigate 
its targets or ability to bind to RUNX1 protein. This could be carried out by isolating sequences 
that bind to given targets with high affinity and specificity, using systematic evolution of 
ligands by exponential enrichment (SELEX) (Ellington et al., 1990; Tuerk et al., 1990). 
The results of this research also indicate a possible role for uncharacterised non-coding 
RNA LOC10050640 in RUNX1 regulation. Regulatory regions m-371, m-368 and m-327 all 
sit within LOC10050640 and may be involved in the regulation of this long non-coding RNA. 
The role of RUNX1–IT1 in haematopoietic cells is currently unknown. More broadly, research 
is also needed to determine the roles of other uncharacterised non-coding RNAs that the 
RUNX1 +24 enhancer also makes connections with. Further investigation to define the RNA-
DNA interactions proposed by this research could determine the importance of the RUNX1 +24 
enhancer eRNAs, possible G-quadruplex RNA and non-coding RNA connections seen in K562 
cells. This could be carried out by utilising previously generated RNA-DNA interactomes for 
K562 cells such as Red-C from Gavrilov et al., (2020) (Gavrilov et al., 2020). 
6.5.5 Further questions proposed by this research 
Several questions from this research remain unanswered, for example: are there other 
strong enhancers that, like the RUNX1 +24 enhancer, connect across an entire chromosome? If 
so, are they significant for genome organisation? Are there equivalents of the RUNX1 +24 
enhancer on different chromosomes? These could be further discovered by using enhancers as 
baits for 4C experiments, or by establishing an equivalent of Capture-C for enhancers.  
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6.5.6 Clinical significance 
Tumour sequencing studies are helpful, but to have medical benefits to the patient, the 
mechanisms of disease must be understood beyond a statistical correlation. Analysis of 
available SNP and cancer mutation databases identified SNPs and mutations in RUNX1-
associated regulatory regions. It would be informative to carry out the same analysis on the 
putative regulatory regions identified by the 4C. 
Other than +62 and intron 5.2, the relevance of mutations to these regions to the 
progression of AML is unknown. My study sets the scene for functional analyses to precisely 
determine how RUNX1 is regulated, including CRISPR/Cas9-mediated interference with 
enhancer activity. The results of my research also provide a rationale for screening patients 
with mutations in enhancer regions. By analysing deep sequencing of AML patient samples 
that have no identifiable mutations in the RUNX1 coding region or in other leukaemia genes, 
mutations in regulatory regions that lead to dysregulated RUNX1 expression may be 
discovered. Sequencing analyses that identify enhancer mutations could not only explain a 
patient’s AML progression, they could provide future therapeutic targets. 
6.6 Overall conclusions 
The precise spatiotemporal expression of Runx1 requires cis-regulatory elements, the 
majority of which have not been previously defined. In this PhD thesis, I describe research that 
provides insight into mouse Runx1 enhancer functions, and highlights the features of conserved 
human enhancers. My study identifies the regulatory regions that interact with the RUNX1 +24 
enhancer and that are potentially crucial for megakaryocyte differentiation. 
One of the more exciting findings to emerge from this study is that the RUNX1 +24 
enhancer forms DNA contacts across chromosome 21, defying the boundaries of known TADs. 
The RUNX1 +24 enhancer interacts with coding genes, non-coding RNA, super-enhancers and 
regulatory elements, and may also maintain connections that prevent transcription as well as 
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enhance it. The findings suggest that the RUNX1 +24 enhancer could be important for overall 
organisation and 3D structure of chromosome 21.  
The results of my investigation show that cohesin STAG2-depletion de-constrains the 
chromatin, allowing increased connections to the RUNX1 +24 enhancer hub and increased 
super-enhancer interactions. This may result in aberrant enhancer-amplified transcription in 
response to differentiation signals.  
Overall, my study identified novel mechanisms for RUNX1 regulation, demonstrated 
the role of the RUNX1 +24 enhancer in megakaryocyte differentiation, and the effect of cohesin 
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Appendix I: Materials 
All solutions were made using sterile milli-Q water unless otherwise stated. The pH 
adjustments were made using 1 M Hydrochloric acid (HCl) (BDH Prolabo) or Sodium 
Hydroxide (NaOH) (VMR Prolabo). All primers were synthesized by ‘Integrated DNA 
technologies’ [(IDT), Custom Science, NZ] unless otherwise specified. 
Chemical reagents and consumables used in this project 
Chemical (Abbreviation) Manufacturer  
Agar Bacteriological Oxoid Ltd, UK 
Ampicillin  Sigma-Aldrich, USA 
Adenosine Triphosphate (ATP) Sigma-Aldrich, USA 
Agencourt® AMPure® XP beads  Beckman Coulter 
Bacto Tryptone Bectone Dickinson and Co, USA 
Bgl II restriction enzyme mix  New England Biolabs, UK 
Calcium Chloride VMR Prolabo, UK 
Chloramphenicol Sigma-Aldrich, USA 
CviQI restriction enzyme New England Biolabs, UK 
CviQI reaction 10x Buffer New England Biolabs, UK 
D-(+)-Glucose Sigma-Aldrich, USA 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, USA 
DNase Roche Applied Science, 
Germany 
DMEM Gibco, Life Technology, USA 
DMSO Sigma-Aldrich, USA 
DpnI restriction enzyme New England Biolabs, UK 
DpnI reaction 10x buffer New England Biolabs, UK 
DpnII restriction enzyme  New England Biolabs, UK 
DpnII reaction 10x buffer New England Biolabs, UK 
Dual-Glo® Luciferase Assay System Invitrogen, USA 
Eco RI restriction enzyme New England Biolabs, UK 
Eco RI reaction 10x buffer New England Biolabs, UK 
Ethanol  Scharlab, Spain 
Ethyl 3-aminobenzoate methanesulfonate salt  Sigma-Aldrich, USA 
Ethylene diamine tetracetic acid (EDTA) Fisher Scientific, USA 
Fetal bovine serum (FBS), NZ origin Gibco, Life Technology, USA 
Formaldehyde Sigma-Aldrich, USA 
Gateway LR Clonase II enzyme mix Invitrogen, USA 
Glacial acetic acid Analar Normapur, NZ 
Glycerol VMR Prolabo, UK 
Glycine Sigma-Aldrich, USA 
Halocarbon oil 27 Sigma-Aldrich, USA 
Hydrochloric acid BDH Prolabo, UK 
IMDM Gibco, Life Technology, USA 
T4 DNA ligase Invitrogen, USA 
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Chemical (Abbreviation) Manufacturer  
Ligase Buffer Invitrogen, USA 
Linear Polyacrylamide (LPA) Invitrogen, USA 
Lipofectamine 3000  Invitrogen, USA 
Lithium Chloride Sigma-Aldrich, USA 
Magnesium Sulfate Sigma-Aldrich, USA 
Meganuclease I-Sce I enzyme mix Roche Applied Science, 
Germany 
Methylcellulose Sigma-Aldrich, USA 
Methylene Blue Sigma-Aldrich, USA 
Na2HPO4.H20 Merck, Germany 
Na2H2PO4  Merck, Germany 
OPTI-MEM reduced serum media Gibco, Life Technology, USA 
Phosphate buffer saline (PBS) solution Gibco, Life Technology, USA 
pCR8/GW/TOPO TA Cloning kit Life Technology, USA 
Penicillin Streptomycin Gibco, Life Technology, USA 
PfuUltra HF DNA polymerase  Agilent Technologies, USA 
PfuUltra HF DNA polymerase reaction 10x 
buffer  
Agilent Technologies, USA 
Phenol:Chloroform:Isoamyl Alcohol 25:24:1  Sigma-Aldrich, USA 
Platinum Taq Polymerase Life Technology, USA 
PMA Sigma-Aldrich, USA 
Potassium Chloride BDH Prolabo, UK 
Proteinase K Invitrogen, USA 
P3000 Life Technology, USA 
qScript  cDNA SuperMix Quanta BioSciences, USA 
Q5® Hot Start High-Fidelity 2x Master mix New England Biolabs 
RNaseA ThermoFisher, USA 
Sodium Bicarbonate Sigma-Aldrich, USA 
Sodium Chloride VMR Prolabo, UK 
Sodium Dodecyl Sulfate Sigma-Aldrich, USA 
Sodium Hydroxide VMR Prolabo, UK 
Spectinomycin Sigma-Aldrich, USA 
SYBR ® Green ThermoFisher, USA 
Triton X-100 Sigma-Aldrich, USA 
Trypan blue stain Sigma-Aldrich, USA 
Trypsin-EDTA (0.5%), No phenol red Gibco, Life Technology, USA 
Ultrapure Agarose Life Technology, USA 
Ultrapure DNase – RNase free distilled water Life Technology, USA 
X-gal Sigma-Aldrich, USA 
Yeast extract Oxoid Ltd, UK 
1 kb Plus DNA ladder Invitrogen, USA 
1 M Tris (pH 8) J.T Baker, USA 
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Chemical (Abbreviation) Manufacturer  
10x Transcription Buffer Roche Applied Science, 
Germany 
10 mM dNTPs Invitrogen, USA 
 
Solutions and buffers 
 
Luria-Broth (LB) Medium 10 g Bacto Tryptone (Becton 
Dickinson and Co), 5 g Yeast extract 
(Oxoid Ltd), 10 g Sodium Chloride 
(NaCl) (VMR Prolabo), make up to 1 
litre with milli Q water. Sterilise by 
autoclaving. 
LB agar Pre- autoclave LB medium with 1.5 % 
Agar Bacteriologial (Oxoid Ltd). Sterilise 
by autoclaving. 
70% Ethanol Absolute ethanol dissolved in ddH2O at a 
final concentration of 70%  
1x Tris-Acetate-EDTA (TAE) buffer 1 M TRIS (pH 8) (J.T Baker), Glacial 
acetic acid and 0.5 M (Analar Normapur) 
Ethylene diamine tetracetic acid (EDTA) 
(Fisher Scientific) (pH 8) added to milli 
Q H2O at a final concentration of 40 mM, 
20 mM and 1 mM, respectively 
1 % Agarose Gel 1 % Ultrapure Agarose (Life 
Technology) in 1 x TAE. For a 60 ml gel 
1 x E3 (5 mM Sodium Chloride (NaCl) (VMR 
Prolabo), 0.17 mM Potassium Chloride 
(KCl) (BDH Prolabo), 0.33 mM CaCl2  
(VMR Prolabo), 0.33 mM Magnesium 
Sulfate (MgSO4) (Sigma-Aldrich), 10 % 
(v/v) Methylene Blue (Sigma-Aldrich)) 
Tricaine 400 mg Tricaine powder (Ethyl 3-
aminobenzoate methanesulfonate salt) 
(Sigma-Aldrich), 97.9 ml ddH2O, ~2.1 
ml 1 M Tris pH 9. Adjust to pH 7. Store 
in freezer. 
3 % Methylcellulose 3 % Methylcellulose (Sigma-Aldrich) in 
1 x E3 solution. 
Cyroprotectant Solution 20 % DMSO in FBS. 
Lysis buffer (10mL) 100 µL of 1 M Tris-HCl (pH 8.0), 20 µL 
of 5 M NaCl, 200 µL of 20 % of NP-40, 
1 tablet of protease inhibitors (Roche 
Diagnostics) 
3 M NaOAC pH 5.6 246.1g  sodium acetate (NaOAC), make 
up to 1 litre with milli Q water. Adjust to 





2.5 M glycine 75 g glycine ), make up to 1 litre with 
milli Q water. Filter sterilise the solution. 
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Appendix II: Plasmid maps  
Plasmid maps of constructs used in this study are presented below. Map of Zebrafish 
enhancer detector vector (ZED) was obtained from Bessa et al., 2009 (Bessa et al., 2009). 
Map of PCS-TP was obtained from Kawakami Lab website 
(https://ztrap.nig.ac.jp/map2.html). pGL4.23-GW was obtained from Addgene 
(https://www.addgene.org/60323/). pRL-TK map is from the Promega: pRL Renilla 
Luciferase Control Reporter Vectors website: 
(https://worldwide.promega.com/products/luciferase-assays/genetic-reporter-vectors-and-
cell-lines/prl-renilla-luciferase-control-reporter-vectors/?catNum=E2231). Map of pUC19 
was obtained from Addgene (https://www.addgene.org/browse/sequence/74677/).  




















Appendix III: Primer list 
Appendix III Table.1:  Details of the primers used in this project 
Primer name Direction Sequence 
ZED insert confirmation 
mCNE1 forward AAAGGGAACAAAAGCTGGAG 
mCNE2 reverse AGTCGCTTCTCTTCGGTTGA 
pGL4.23-GW insert confirmation 
RVprimer3 forward CTAGCAAAATAGGCTGTCCC 








 reverse GTGTCAGGAAGGGAGGGGGAGGAACTTACACCT 
qRT-PCR primers 
Human GAPDH forward TGCACCACCAACTGCTTAGC 
















 reverse GGTTCTTCATGGCTGCGGTA 
Human ERG forward CGCAGAGTTATCGTGCCAGCAGAT 
 reverse CCATATTCTTTCACCGCCCACTCC 
Human GATA1 forward TTGCCACATCCCCAAGGCGG 
 reverse GGGGGAGGGGCTCTGAGGTC 
Human KLF1 forward TGACTTCCTCAAGTGGTGGC 
 reverse GGTGAGGAGGAGATCCAGGT 












 reverse AGGATGTGCGTGCGTGTGTA 
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Appendix IV: Prediction of G-quadruplexes 
During my master’s work the sequence of +24 Runx1 mouse regulatory region was 
obtained using forward (AAAGGGAACAAAAGCTGGAG) and reverse primers 
(AGTCGCTTCTCTTCGGTTGA). Despite multiple attempts and different primers, the region 
was never sequenced the full way through. When compared back to the mm9 +24 regulatory 
element sequence sent by Dr. Motomi Osato, it was noted that the sequences stopped in the 
same place every time. The online tool QGRS mapper was used to predict if there was a G-
quadruplex structure (Kikin et al., 2006). The Osato +24 mouse regulatory region sequence is 
shown below. The area that could not be sequenced is underlined, the probable G-quadruplex 
is highlighted in yellow. The most likely G-quadruplex is GGTGGGGGTGG, reverse 
complement CCACCCCCACC. C rich residues could also be forming i-motifs, However these 

























When the overlapping sequence data was examined, a small chunk of sequence is 
unable to be read (underlined area). Two predicted quadruplex structures sit either side of the 














Appendix V: Sequencing report 
Libraries were demultiplexed by Otago Genomics Facility (OGF). A summary of the 
sequencing for this project is below. The sequencing metrics are within Illumina's performance 






Appendix VI: Publication 
Some of the results from Chapter 3 contributed to Marsman, J., Thomas, A., Osato, M., 
O'Sullivan, J. M., & Horsfield, J. A. (2017). A DNA contact map for the mouse Runx1 gene 
identifies novel haematopoietic enhancers. Scientific Reports, 7, 13347 
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A DNA Contact Map for the Mouse 
Runx1 Gene Identifies Novel 
Haematopoietic Enhancers
Judith Marsman1, Amarni Thomas1, Motomi Osato2,3, Justin M. O’Sullivan  4,5  
& Julia A. Horsfield  1,5
The transcription factor Runx1 is essential for definitive haematopoiesis, and the RUNX1 gene is 
frequently translocated or mutated in leukaemia. Runx1 is transcribed from two promoters, P1 and P2, 
to give rise to different protein isoforms. Although the expression of Runx1 must be tightly regulated 
for normal blood development, the mechanisms that regulate Runx1 isoform expression during 
haematopoiesis remain poorly understood. Gene regulatory elements located in non-coding DNA 
are likely to be important for Runx1 transcription. Here we use circular chromosome conformation 
capture sequencing to identify DNA interactions with the P1 and P2 promoters of Runx1, and the 
previously identified +24 enhancer, in the mouse multipotent haematopoietic progenitor cell line HPC-
7. The active promoter, P1, interacts with nine non-coding regions that are occupied by transcription 
factors within a 1 Mb topologically associated domain. Eight of nine regions function as blood-specific 
enhancers in zebrafish, of which two were previously shown to harbour blood-specific enhancer activity 
in mice. Interestingly, the +24 enhancer interacted with multiple distant regions on chromosome 16, 
suggesting it may regulate the expression of additional genes. The Runx1 DNA contact map identifies 
connections with multiple novel and known haematopoietic enhancers that are likely to be involved in 
regulating Runx1 expression in haematopoietic progenitor cells.
Runx1 is a key regulator of haematopoietic development. Deletion of Runx1 in mouse embryos is lethal in embry-
onic stage (E) 12.5 due to the complete absence of definitive blood cell progenitors accompanied by extensive 
haemorrhaging1,2. Runx1 is crucial for haematopoietic stem cell (HSC) emergence and maintenance during 
development3, since conditional ablation of Runx1 in adult mice results in HSC exhaustion4. In acute myeloid 
leukaemia (AML) and myelodysplastic syndrome, RUNX1 function is frequently altered through mutations or 
translocations5, resulting in dysregulation of its target genes. While mutations directly affecting the RUNX1 pro-
tein are common in leukaemia, mutations in regulatory elements that affect RUNX1 expression remain enigmatic. 
As yet unidentified mutations in regulatory elements, such as enhancers, could alter Runx1 expression, resulting 
in abnormal haematopoiesis.
Runx1 is transcribed from two promoters, P1 and P2, to give rise to different protein isoforms6. Expression of 
these isoforms is tightly controlled during haematopoiesis. At the onset of mouse haematopoiesis (E7.5), preced-
ing the generation of HSCs, expression of the P2 isoform(s) is predominant7,8. P1 is expressed soon after P2, and 
its expression is synchronised with the generation of HSCs7,9. P1 expression is predominant in the mouse fetal 
liver, the main site of definitive haematopoietic stem/progenitor cell (HSPC) development from E12.5 onward9.
Regulatory elements, such as enhancers, can control the expression of genes via long-range chromatin interactions10. 
One previously identified Runx1 enhancer is located 24 kb downstream of the P1 transcriptional start site11,12. 
The +24 enhancer (also known as the +2313, or the +23.512 enhancer) is active in HSCs that express Runx1 dur-
ing mouse embryogenesis11–13. The human equivalent of the +24 enhancer (+32 kb downstream of P1) directly 
contacts the promoters of RUNX1 in leukaemia cell lines14. In addition to the +24 enhancer, putative regulatory 
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elements for RUNX1 have been identified upstream of RUNX1-P1 and between P1 and P2; however, whether they 
directly contact the RUNX1 promoters has not been investigated15,16.
Here we used circular chromosome conformation capture sequencing (4C-seq) to identify regulatory ele-
ments that interact with an active Runx1 P1 promoter, versus an inactive P2 promoter. While Hi-C provides 
genome-wide contact profiles, and Capture Hi-C enriches for interactions with preselected genomic features 
(usually promoters), 4C-seq can generate very high resolution contact profiles from ‘baits’ of particular interest17. 
Therefore, 4C-seq can yield richer information about a selected genomic region than Hi-C or Capture Hi-C. 
HPC-7 is a well characterised mouse HSPC line with genomic annotations, including transcription factor (TF) 
binding, histone modifications and chromatin accessibility18–20. 4C-seq in HPC-7 cells identified nine haemato-
poietic enhancers that interact with the P1 promoter and +24 enhancer, and that are occupied by haematopoietic 
TFs. Four of these were previously identified, three of which were functionally tested and two out of the three 
showed activity during mouse haematopoiesis15. Here we assessed the activity of all nine enhancers in zebrafish, 
and show that eight are active in zebrafish haematopoiesis. Further, the +24 enhancer was highly interactive 
both within a topologically associated domain (TAD) harbouring Runx1, as well as with loci outside the TAD. 
Collectively, our results point to the formation of a local ‘active chromatin hub’ controlling Runx1 expression in 
haematopoietic cells.
Results
We first confirmed that P1 is actively expressed in HPC-7 cells, while P2 is silent (Supplementary Fig. S1). 4C-seq 
in HPC-7 cells using the P1 and P2 promoters and the +24 enhancer as ‘baits’ identified genomic interactions 
at Runx1 (Fig. 1a). Bait locations were designed taking into account cohesin and CTCF binding sites near both 
promoters and the +24 enhancer. 4C baits were designed to regions of interest (P1, +24, P2), allowing for com-
parison of interactions between the active P1 promoter and inactive P2 promoter, with secondary baits located at 
nearby cohesin/CTCF (cc) binding sites (P1cc, +24cc, P2cc) (Fig. 1a).
4C-seq in HPC-7 cells confirms the presence of a 1.1 Mb domain harbouring Runx1. For each 
bait, two replicate 4C-seq libraries and one control library were sequenced. Reads were predominantly located 
within a 1.1 Mb region surrounding the Runx1 gene (Fig. 1b,c), representing a TAD harbouring Runx1. From 
visual inspection of the contact profile (Fig. 1b,c), domain boundaries appear to be present at the Cbr1/Setd4 
genes upstream of Runx1, and Clic6 downstream (Fig. 1b). A comparison with existing Hi-C data from mouse 
embryonic stem cells, mouse CH12 (erythroleukaemia) cells, human GM12878 (lymphoblastoid), human 
K562 (myeloid leukaemia) and human IMR90 (foetal lung) cells revealed that TAD boundaries are conserved, 
and that our 4C data is consistent with existing Hi-C data (Supplementary Fig. S2). Most P1 and +24 interac-
tions take place upstream of the Runx1 gene (Fig. 1b,c). In contrast, there are fewer upstream interactions from 
P2, while downstream interactions are retained (Fig. 1b,c). There are no other coding genes within the Runx1 
domain; however, three inactive non-coding genes19, Mir802 and the long non-coding RNAs 1810053B23Rik and 
1700029J03Rik, are located near the upstream border of the TAD.
Interactions from ‘cc’ baits (cohesin/CTCF binding sites) were similar to their nearby corresponding baits at 
P1, +24 and P2 (Fig. 1b). We investigated whether significant interactions for the ‘cc’ baits have more overlap with 
other cohesin or CTCF binding sites than for the non ‘cc’ baits, but did not find any difference (data not shown). 
The ‘cc’ baits may be too close to the corresponding P1, P2 and +24 baits to resolve unique interactions, although 
they are separated by at least one restriction fragment.
Chromatin interactions anchored by the Runx1 P1 and P2 promoters and +24 enhancer. Most 
of the significant interactions for P1, P2 and the +24 enhancer occur within the 1.1 Mb domain (Fig. 1b). There 
are ~40–50 significant interactions for P1cc/P1 baits, ~60–75 for +24/+24cc baits, and ~30 for P2/P2cc baits 
(Fig. 1d). Strikingly, the +24 enhancer in particular forms many significant interactions outside the Runx1 
domain (Fig. 1b,d). Many of these long-range interactions are with other genes or gene promoters on mouse chro-
mosome 16 (Fig. 2). Expression levels of these genes in human tissues according to Genotype-Tissue Expression 
(GTEx, https://www.gtexportal.org/home/)21 did not reveal obvious tissue-specific expression patterns. However, 
among the genes contacted by +24 are Erg, a haematopoietic TF, and Tiam1 (T-cell lymphoma invasion and 
metastasis 1), involved in cell adhesion and cell migration. These distant connections suggest that +24 may also 
regulate other haematopoietic genes in adjacent domains.
Identification of haematopoietic enhancers. We hypothesised that DNA connections formed from 
the active P1 promoter and the +24 enhancer may correspond to haematopoietic enhancers that regulate Runx1 
expression. To identify putative enhancers, we aligned significantly interacting sites with the occupancy of thirteen 
TFs involved in haematopoietic progenitor cell production; enhancer histone modifications and DNase I hyper-
sensitivity sites18–20; and conserved non-coding elements (CNE), which were identified based on comparative 
genomics alignment and retroviral integration site mapping to indicate potential DNaseI hypersensitive sites11. 
We note that the +24 enhancer binds all thirteen haematopoietic progenitor TFs in HPC-7 cells (Fig. 3).
We selected putative enhancers based on the binding of at least six TFs involved in haematopoietic progenitor 
cell development (Fig. 3), and the presence of a significant interaction directly at, or within 2 kb, of the TF binding 
cluster. Based on these criteria, we found eight other potential enhancers within the Runx1 domain that form con-
nections to the baits. These enhancers were named according to their distance from the P1 transcriptional start 
site: −371, −354, −327, −321, −303, −58, −48, and +110 (Fig. 3b). An additional interacting region at −368, 
a CNE, was located adjacent to a cluster of haematopoietic TFs (Fig. 3b). The +24 and +110 are also CNEs11. 
The putative enhancers either form distinct blocks upstream of Runx1-P1 (from −371 to −303 and −48 to −58), 
or fall between the P1 and P2 promoters (+24 and +110). Four out of nine of the identified putative enhancers 
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Figure 1. Runx1 interaction profile reflects the activity of the P1 and P2 promoters and the +24 enhancer. 
(a) Location of 4C baits at the mouse Runx1 gene (mm10). Baits are P1cc, P1, +24, +24cc, P2cc and P2; ‘cc’: 
cohesin and CTCF binding site. ChIP-seq data of Rad21 (blue) and CTCF (pink) in MEL and CH12 cells were 
obtained from ENCODE51 and in HPC-7 cells from18,19. Exons are in grey and the +24 enhancer is in green. (b) 
4C-seq profile (read per million normalised running mean of nine successive DpnII digestion fragments) for 
one replicate per bait with significant interactions (the top fifth percentile of interactions with a FDR of <0.01) 
that overlap in both replicates shown in a ~2.5 Mb region surrounding the Runx1 gene. The highest significant 
interactions (see Methods) are in red and other significant interactions in orange. Red dotted lines indicate the 
location of estimated domain boundaries. (c) Read distribution for both replicates of each bait. Line graphs 
represent the cumulative percentage of reads on chromosome 16 (y-axis) versus the distance from the bait 
(x-axis), shown in genomic coordinates on chromosome 16 (genome version mm10). The 0-value of each line 
indicates the location of each bait. (d) The number of significant interactions that overlap in both replicates 
inside (light grey) and outside (dark grey) the domain for each bait.
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(−327, −321, −58 and +110) were identified previously based on the binding of at least three blood TFs and the 
presence of a H3K27ac peak (denoting active chromatin) from a subset of the same HPC-7 datasets that we have 
used here15.
Eight out of nine putative enhancers (−371, −368, −354, −327, −321, −58, −48, and +110) form long-range 
interactions with the P1 promoter, the +24 enhancer, or both (Fig. 3b and Supplementary Table S1). The excep-
tion was −303, which does not interact with P1, but instead with the +24 and the P2 promoter. The +24 enhancer 
interacts promiscuously within the whole domain. Filtering at maximum stringency (see Methods) showed that 
the +24 enhancer connects to all putative enhancers and both Runx1 promoters (Fig. 3b). In contrast, the inac-
tive P2 promoter connects only to −303 and +24 (Fig. 3b and Supplementary Table S1). A specific interaction 
between +110 and P2 could not be resolved owing to a contiguous block of significant interactions throughout 
the short region between +110 and P2. A model of Runx1 interactions based on the 4C-seq results is shown in 
Fig. 4.
Long range chromatin interactions at haematopoietic enhancers. Long-range chromatin inter-
actions can be mediated by cohesin and CTCF22, and cohesin is involved in transcription regulation at active 
genes23. We found that four of the nine enhancer loci (in addition to the +24 enhancer) coincide with Rad21 
(cohesin) binding in the absence of CTCF (Fig. 3b and Supplementary Table S1). This is consistent with the idea 
that cohesin (but not necessarily CTCF) mediates local DNA-DNA interactions within TADs22. All Rad21 binding 
sites interacted with at least one ‘cc’ bait, therefore cohesin could mediate at least a subset of enhancer-promoter 
communication events in HPC-7 cells.
We compared the 4C interactions identified with recently published Capture Hi-C data in HPC-7 cells18 
(Supplementary Fig. S3). Capture Hi-C data was only available for interactions anchored at P1, and has a lower 
coverage and resolution than our 4C-seq study (an average of ~18,000 reads per promoter for Capture Hi-C with 
a 6-cutter, and over 1 million reads per bait for 4C-seq with a 4-cutter). The Capture Hi-C study in HPC-7 cells 
identified 15 P1-interacting regions that were reproduced in our study (Supplementary Fig. S3). All of these 
are upstream of Runx1-P1, and most are within the −368 to −303 enhancer cluster (Supplementary Fig. S3). 
Therefore, our study provides additional Runx1-anchored interactions that were not previously described as con-
nected to Runx1 promoters (enhancers −371, −48, −58 and +110).
Figure 2. Interactions of the Runx1 locus with other genes. Significant interactions that overlap with gene 
bodies or gene promoters (starting from 2 kb upstream of the gene transcriptional start site) are shown for the 
P1cc/P1 (a), +24/ +24cc (b) and P2cc/P2 baits (c) (assembly mm10).
www.nature.com/scientificreports/
5SCIeNTIfIC REPORTs | 7: 13347  | DOI:10.1038/s41598-017-13748-8
In vivo characterization of haematopoietic enhancers. Enhancer regions interacting with Runx1 
recruit haematopoietic TFs in HPC-7 cells, therefore we determined if these regions act as enhancers in vivo. Each 
of the putative enhancers was tested for the ability to drive tissue-specific GFP expression in zebrafish embryos. 
Eight out of nine drove GFP expression specifically in the intermediate cell mass and posterior blood island, 
which are sites of haematopoietic progenitor cell production at 20–24 hours post-fertilisation (hpf)24 (Fig. 5a,b 
and Supplementary Fig. S4). Two of these (−58 and +110) were previously shown to be active during mouse 
haematopoiesis15. The −303 enhancer also expressed GFP in keratinocytes, particularly after 24 hpf (Figs 5c, S4). 
Interestingly, −303 was the only enhancer identified that interacted with the P2 promoter of Runx1, rather than 
P1. Despite the occupancy of multiple haematopoietic TFs in HPC-7 cells, and the presence of similar TF binding 
motifs compared to the other enhancers (Fig. 3 and Supplementary Tables 1 and 2, we did not observe enhancer 
activity for −327, consistent with a previous study in mice15.
In summary, we have assigned in vivo function to multiple putative enhancers upstream of Runx1 that were 
previously identified in silico18. These regions not only drive haematopoietic expression, but also physically con-
nect with the Runx1-P1 promoter, lending confidence to the concept that they are bona fide regulators of Runx1 
transcription.
Figure 3. The active P1 promoter and +24 enhancer interact with clusters of haematopoietic transcription 
factor binding sites. Significant interactions within the domain for each bait are shown together with 
the reference genes (mm9), CNEs11, TF binding sites (green), Rad21 and CTCF binding sites (black), H3K27ac, 
H3K4me3 and DNaseI hypersensitivity sites in HPC-7 cells18–20. A 3 Mb region (a) and two zoomed-in views 
(b) are shown. Locations of TF binding clusters containing at least six TF binding sites at the same location, and 
a significant interaction directly at or within 2 kb of each cluster, are indicated by arrows and named according 
to their distance from the P1 transcriptional start site. See also Supplementary Fig. S3.
www.nature.com/scientificreports/
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Discussion
4C analysis in HPC-7 cells generated a high-resolution connectivity map of the genomic region harbouring 
Runx1, and confirmed previously identified upstream connections from P1 to putative regulatory elements18. 
Runx1 appears to be contained within a ~1 Mb chromatin domain, consistent with Hi-C analyses in other 
cell types25,26. We observed multiple connections both up- and downstream from all 4C-seq baits (Runx1-P1, 
Runx1-P2 and +24 enhancer). Significantly, there were many more upstream connections anchored by the active 
elements (Runx1-P1 and +24).
Surprisingly, the +24 enhancer forms many up- and downstream connections outside of the Runx1 TAD. 
These comprise up to one-third of all connections formed and include other haematopoietic genes, such as Tiam1 
downstream, and Erg upstream. Erg and Tiam1 dysregulation is associated with several tumor types, including 
AML and B- and T-cell lymphomas27,28. Strikingly, these genes are located over 2 Mb away from Runx1. These 
findings raise the interesting possibility that the +24 enhancer acts as a scaffold to recruit multiple promoters, 
enhancers and TFs over long distances in cis. Connections to +24 identified by our 4C-seq may point to the 
identity of some of these genes.
Our 4C-seq data identified multiple chromatin connections that intersect with some of the strongest indicators 
of upstream enhancers characterised by the binding of clusters of TFs and epigenetic modifications18,20. Eight out 
of nine of these DNA regions are able to drive haematopoietic expression in zebrafish, strongly suggesting an in 
vivo function. Although previous studies had identified transcriptional activity for a subset of these enhancers15, 
or an interaction with the P1 promoter for an overlapping subset18, no single prior study has shown that enhanc-
ers both interact with Runx1 promoters (and +24), and have transcriptional activity. Table 1 provides an overview 
of findings from these previous studies together with additional evidence from our study that connects spatial 
proximity with function. Two enhancers, termed −59 and +110, were previously shown to drive LacZ expression 
in mice15; these are equivalent to the −58 and +110 enhancers identified here. Our data show in addition that 
these regions are in contact with P1 and the +24 enhancer (Table 1). While the −327 enhancer has similar char-
acteristics as the other enhancers identified here, neither a previous study in mice15 nor our study identified any 
enhancer activity for it (Table 1). The −368, −354, −327, −321 and −303 enhancers were found to interact with 
P1 in a Capture Hi-C study in HPC-7 cells (Table 1). Our study confirms the presence of these interactions, and in 
addition, shows that these enhancers also interact with either the +24 enhancer or P2 (Table 1).
The −303 enhancer interacts with P2 rather than P1 and, in addition to being active in haematopoietic sites, 
it drives expression in keratinocytes, indicating that it could act in a complex that keeps P2 silent; and/or that it 
regulates expression of Runx1 in other tissues. Interestingly, Runx1 is actively expressed in mouse keratinocytes 
where it is important for hair follicle development29. Neuronal cells also express Runx130, and there may be addi-
tional regulatory elements that control Runx1 expression in a manner distinct from haematopoietic expression. 
In support of this idea, we previously determined that cohesin and CTCF influence runx1 expression in haemato-
poietic, but not neuronal cells, in zebrafish31,32.
Cohesin and CTCF organise chromatin structure and when present in combination, they appear to negatively 
correlate with the HSPC TFs in HPC-7 cells18. However, we observed a coincidence of cohesin subunit Rad21 bind-
ing in the absence of CTCF with four out of nine identified enhancers, as well as the +24 enhancer. This suggests 
that CTCF-independent cohesin mediates a subset of enhancer-promoter looping in combination with TFs. This 
interpretation is consistent with previously identified CTCF-independent functions for cohesin in genome organi-
zation and transcription33. Importantly, cohesin mutations are prevalent in AML and other myeloid malignancies34, 
and are categorised together with RUNX1 and spliceosome mutations in a genetic category that confers poor 
prognosis in AML5. Cohesin mutations led to increased chromatin accessibility of Runx1 as measured by 
ATAC-seq.35, raising the possibility that spatiotemporal regulation of Runx1 is cohesin-dependent in mouse and 
human, as was previously observed in zebrafish31.
Figure 4. Model of chromatin interactions based on Runx1 4C-seq. 4C-seq baits are shown in red and 
identified interacting enhancers in blue. P1 is active, and P2 is inactive. P1 interacts with −371, −368, −354, 
−327, −321, −58, −48, +24 and +110; +24 interacts with −371, −368, −354, −327, −321, −303, −58, −48, 
+110 and P2; and P2 interacts with −303 and +24.
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 4C-seq in HPC-7 cells has provided new high resolution connectivity data that sheds light on the genomic 
organization of Runx1, an important haematopoietic transcription factor. These data confirm and extend pre-
vious analyses (Table 1), and furthermore, provide insight into the function of enhancers that have potential to 
Figure 5. Putative mouse enhancers are active in haematopoietic regions in zebrafish. Whole mount 
representative lateral images of zebrafish embryos (20–24 hpf [a,b] and ~48 hpf [c]) that were injected with 
enhancer-GFP plasmids at the one-cell stage; left hand panels are merges with bright field, right hand panels 
are GFP fluorescence. (a) Negative control ZED plasmid shows zero (image) or non-specific fluorescence, 
while the positive control (+24) shows GFP expression in haematopoietic cells of the posterior blood island 
(red arrows) and intermediate cell mass (yellow arrows), which  represent primitive blood cells. (b) Enhancer 
activity of +110, −48, −58, −303, −321, −327, −354, −368, −371. GFP expression was observed in primitive 
haematopoietic cells of the posterior blood island (red arrows) and intermediate cell mass (yellow arrows). (c) 
The −303 enhancer also expressed GFP in keratinocytes (white arrows in b,c). The numbers in the right hand 
panels represent the number exhibiting the representative phenotype out of the total number of fluorescent 
embryos analysed. See also Supplementary Fig. S4.
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regulate Runx1 expression. The data presented here set the scene for functional analyses to precisely determine 
how Runx1 is regulated, including CRISPR/Cas9-mediated interference with enhancer activity. They also provide 
a rationale for screening patients with myeloproliferative disorders for mutations in enhancer regions.
Methods
Cell culture. HPC-7 cells were maintained at a density of 1–10 × 105 cells/mL in Iscove’s modified Dulbecco’s 
media (Gibco®) supplemented with 3.024 g/L sodium bicarbonate, 10% fetal bovine serum (Moregate, New 
Zealand), 10% stem cell factor conditioned media and 0.15 mM monothiolglycerol (Sigma-Aldrich) as previously 
described36. SCF-conditioned media was obtained from culturing BHK-MKL cells maintained in Dulbecco’s mod-
ified Eagle media (Sigma-Aldrich) supplemented with 3.5 g/L glucose, 3.7 g/L Sodium Bicarbonate and 10% FBS.
4C-seq library preparation. 4C library preparation was performed as previously described37 with modi-
fications. Three libraries were generated, two replicates (passage 8 and passage 10 cells) and one control (a 1:1 
mix of both replicates for which the first ligation step was omitted). Cells were cross-linked in 2% formaldehyde, 
5% FBS and 1x PBS for 10 minutes at room temperature while rotating. Formaldehyde was quenched with a final 
concentration of 125 mM glycine for 5 minutes on ice while inverting several times. Cell pellets were washed twice 
with ice-cold 1x PBS.
Nuclei were harvested by lysing the cell pellets in ice-cold lysis buffer (10 mM Tris pH 8.0, 10 mM NaCl, 
0.2% NP-40, protease inhibitors) for 10 minutes on ice. Nuclei were then resuspended in 1.2x DpnII restriction 
buffer (New England Biolabs) and 0.3% SDS and incubated for 1 hour at 37 °C while shaking. Triton X-100 
was then added to a final concentration of 1.8% and the reaction was left at 37 °C while shaking for another 
hour. Chromatin was digested with 800 U of DpnII overnight at 37 °C while shaking. DpnII was inactivated 
by adding SDS to a final concentration of 1.3% and incubating at 65 °C for 20 minutes. Nuclei were diluted 
into a volume of 7 mL containing 1.01x T4 DNA ligase buffer (Life Technologies) and Triton-X100 at a final 
concentration of 1% and incubated at 37 °C for 1 hour. Ligations were carried out with 100 U of T4 ligase (Life 
Technologies) for 4.5 hours at 16 °C and 30 minutes at room temperature while shaking. For control libraries, 
ligase was omitted. Samples were proteinase K treated and reverse-crosslinked overnight at 65 °C. Samples 
were then treated with RNase A at 37 °C for 30 minutes. DNA was purified by phenol/chloroform extraction 
and ethanol precipitated.
A second digestion was performed with 25 U of BfaI (New England Biolabs) for P1 and P2 baits or MseI (New 
England Biolabs) for +24 baits in restriction buffer overnight at 37 °C while shaking. Restriction was inactivated 
by adding SDS to a final concentration of 1.3% and incubating at 65 °C for 20 minutes. A second ligation was 
performed in the same way as the first ligation, except that ligations were incubated overnight. DNA was purified 
with two phenol/chloroform extractions and one chloroform extraction followed by ethanol precipitation. DNA 
Enhancer location 
relative to P1 (kb)
Interactions identified by other 
studies Previous functional validation Findings from our study
−371 — None
Interacts with +24 and P1. Enhancer 
activity in hematopoietic sites in 20–24 hpf 
zebrafish embryos.
−368 Interacts with P1 in HPC-7 cells (Capture Hi-C by Wilson et al.)18 None
Interacts with +24 and P1. Enhancer 
activity in hematopoietic sites in 20–24 hpf 
zebrafish embryos.
−354 Interacts with P1 in HPC-7 cells (Capture Hi-C by Wilson et al.)18 None
Interacts with +24 and P1. Enhancer 
activity in hematopoietic sites in 20–24 hpf 
zebrafish embryos.
−327 Interacts with P1 in HPC-7 cells (Capture Hi-C by Wilson et al.)18 No enhancer activity in mice (Schutte et al.)
15 Interacts with +24 and P1. No enhancer 
activity in zebrafish.
−321 Interacts with P1 in HPC-7 cells (Capture Hi-C by Wilson et al.)18
Identified, but not tested for enhancer activity 
(Schutte et al.)15
Interacts with +24 and P1. Enhancer 
activity in hematopoietic sites in 20–24 hpf 
zebrafish embryos.
−303 Interacts with P1 in HPC-7 cells (Capture Hi-C by Wilson et al.)18 None
Interacts with +24 and P2. Enhancer 
activity in hematopoietic sites in 20–24 hpf 
zebrafish embryos and in keratinocytes 
from 20 hpf.
−58 —
Haematopoietic enhancer activity in E11.5 
transgenic mice and luciferase enhancer 
activity in 416B cells (Schutte et al.)15
Interacts with +24 and P1. Enhancer 
activity in hematopoietic sites in 20–24 hpf 
zebrafish embryos.
−48 — None
Interacts with +24 and P1. Enhancer 
activity in hematopoietic sites in 20–24 hpf 
zebrafish embryos.
+24
Interacts with P1 and P2 in 
human leukaemia cell lines (3 C 
by Markova et al.)14
Haematopoietic enhancer activity in mouse 
and zebrafish development and luciferase 
enhancer activity in 416B cells (Nottingham et 
al., 2009, Ng et al., 2010, Schutte et al.)11,12,15
Interacts with P1 and P2. Enhancer 
activity in hematopoietic sites in 20–24 hpf 
zebrafish embryos.
+110 —
Haematopoietic enhancer activity in E11.5 
transgenic mice and luciferase enhancer 
activity in 416B cells (Schutte et al.)15
Interacts with P1. Enhancer activity in 
hematopoietic sites in 20–24 hpf zebrafish 
embryos.
Table 1. Previous findings on enhancers and new findings from this study.
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concentrations were measured using a Qubit® 3.0 Fluorometer (Life Technologies) and Qubit® double-stranded 
DNA (dsDNA) High Sensitivity Assay kit (Life Technologies).
For each bait, a total of 1 μg of DNA was amplified by PCR using Q5® High-Fidelity DNA Polymerase (New 
England Biolabs). Bait primer sequences are listed in Supplementary Table S3. PCR products were purified 
using the QIAquick PCR Purification kit (QIAGEN). DNA concentrations were measured using a Qubit® 3.0 
Fluorometer and average fragment size by the 2100 Bioanalyser (Agilent Technologies) using a High Sensitivity 
DNA Kit (Agilent Technologies). Amplicons from the six different baits were mixed equally based on the concen-
tration, average fragment size and ratio of demultiplexed 4C baits obtained from an initial MiSeq run. Libraries 
were prepared with Prep2SeqTM DNA Library Prep Kit from IlluminaTM (Affymetrix) and TruSeq® adaptors 
(Illumina). Libraries were mixed equimolarly and sequenced as 125 bp paired-end reads on two IlluminaTM HiSeq 
2500 lanes by New Zealand Genomics Limited.
4C-seq data analysis. 4C-seq data was analysed in command-line and the R statistical environment38, and 
visualised using the University of California, Santa Cruz (UCSC) genome browser (http://genome.ucsc.edu/) 
with mouse assemblies mm9 or mm1039,40, or with the R package ggplot241. Baits were demultiplexed based on 
bait primer sequences up to and including the digestion site using a custom awk script, allowing 0 mismatches. 
Only read pairs that had the forward and reverse bait sequences in the correct orientation were selected. Adapter 
sequences, bait sequences up to but excluding the digestion site, and bases with a Phred quality score under 20 
were then trimmed from the reads, using the fastq-multx, fastq-mcf and cleanadaptors v1.24 tools42,43. Quality of 
reads was assessed using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/)44.
Reads with a minimum length of 30 bp were mapped to the mm10 reference genome using Bowtie145, allow-
ing 0 mismatches. Mapped reads were assigned to DpnII digestion fragments using fourSig46. The following reads 
were removed from the files: 1) self-ligated reads, 2) uncut reads (fragments adjacent to baits), and 3) reads at 
fragments that have at least 1 read in the control (non-ligated) library. The running mean was calculated from the 
sum of read counts from nine successive fragments, which was obtained using fourSig46, and was read per million 
normalised.
Significant interaction calling was performed using the R package fourSig with the following settings: window 
size of 3, 1000 iterations, fdr of 0.01, fdr.prob of 0.05 (which selects the top fifth percentile of interactions with 
a FDR of <0.01), and only included mappable fragments46. Significant interactions were called for two regions: 
1) the whole of chr16, and 2) from chr16:92,250,000-93,635,000 (within the domain). Significant interactions in 
both replicates were overlapped using the bedIntersect tool from UCSC47.
In the fourSig package, significant interactions can be categorised into three categories: 1) interactions that 
are significant after the reads from the fragment with the highest read count is removed, 2) interactions that are 
significant when the fragment with the highest read count is averaged to the read counts of the neighbouring frag-
ments, and 3) interactions that are significant only when all fragment read counts are included46. For this study, 
only category 1 and 2 interactions that overlap between both replicates were included, as they are more likely 
to represent true interactions (because they span multiple fragments), and were previously shown to be more 
reproducible between replicates than single-fragment interactions46. Furthermore, we distinguished category 1 
interactions that overlap between both replicates from other category 1 and 2 interactions by colouring them red 
and orange, respectively, to visualise the most significant interactions. For conversion from assembly mm10 to 
mm9, the liftOver tool from UCSC was used (http://genome.ucsc.edu/)47. Gene annotations used in Figures are 
UCSC reference genes.
Zebrafish enhancer assay. Runx1 regulatory regions were amplified from HPC-7 gDNA or from 
I-SceI-zhsp70 plasmid containing the −368, +24 and +110 sequences11 (primer sequences are in Supplementary 
Table S3), and cloned into the zebrafish enhancer detection vector48. Plasmid purifications were performed with 
the NucleoSpin® Plasmid or NucleoBond® Xtra Midi prep kits (Machery-Nagel). Primers amplified the TF 
binding peak +/− 200 bp, except for −321 which (due to a repetitive region) did not have a 200-bp extension 
on the 3′ end. The −368, +24 and +110 fragments are 471, 529 and 579 bp, respectively11. A mixture of 30 pg 
vector DNA and 120 pg Tol2 transposase mRNA49 was injected into 1-cell zebrafish embryos. Embryos were 
imaged at 20–24 or ~48 hpf using a Leica M205FA stereomicroscope with a DFC490 camera and LAS software 
(Leica Microsystems), images were processed using Adobe Photoshop. Zebrafish were maintained as described 
previously50 and zebrafish handling and procedures were carried out in accordance with the Otago Zebrafish 
Facility Standard Operating Procedures. The University of Otago Animal Ethics Committee approved all zebraf-
ish research under approval AEC 48/11.
Identification of conserved non-coding elements. Mouse conserved non-coding elements (mCNEs) 
were identified as described previously11.
ChIP-seq, Capture Hi-C and DNase I hypersensitivity data. Occupancy of the transcription factors 
Erg, Fli1, Scl, Runx1, Gata2, E2A, Ldb1, Lyl1, Lmo2, Gfi1b, Meis1, Myb, phospho-Stat1, Pu.1, Stat3, Eto2, Cebp-α, 
Cebp-β, Elf1, Nfe2, p53, cMyc, Egr1, E2f4, cFos, Mac and Jun; Rad21 and CTCF; H3K27ac and H3K4me3; DNase 
I hypersensitivity sites; and Capture Hi-C data in HPC-7 cells was obtained from previously published data18–20. 
Rad21, Smc3 and CTCF chromatin immunoprecipitation sequencing (ChIP-seq) data in MEL and CH12 cells 
were obtained from ENCODE51.
Availability of data. The 4C-seq dataset is accessible through GEO Series accession number GSE86994 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc = GSE86994).
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Appendix VII: RUNX1 regulatory region Hg38 
coordinates 
Appendix VII Table 1:  Hg38 Genome coordinates for regulatory regions 
Regulatory region location 
relative to P1 (kb) 












m-42 Not conserved between humans and mice 




m+181 Not conserved between humans and mice 




Appendix VIII: 4C data processing 
The 4C sequencing libraries were prepared from 4C material, each containing PCR 
products amplified by bait specific primer pairs. The read counts were determined from the 
original sequencing library counts given by Otago Genomics Facility (Appendix VIII Table 1). 
The baits were demultiplexed by Dr. William Schierding (University of Auckland). The 
number of reads that demultiplexed to baits within each library was also determined (Appendix 
VIII Table 1).  
Appendix VIII Table 1:  Read counts before and after primer demultiplexing 




4533_16 K562 WT DMSO 1 11,747,923 3,973,768 
4533_17 K562 WT DMSO 2 6,124,022 3,218,192 
4533_18 K562 WT DMSO 3 4,231,900 2,511,463 
4533_19 Control K562 WT DMSO 2,854,280 1,395,817 
4533_20 K562 WT 12h PMA 1 4,568,245 3,389,303 
4533_21 K562 WT 12h PMA 2 6,851,198 1,672,071 
4533_22 K562 WT 12h PMA 3 4,223,579 1,999,157 
4533_23 K562 WT 72h PMA 1 6,349,712 4,105,424 
4533_24 K562 WT 72h PMA 2 2,934,889 2,094,222 
4533_25 K562 WT 72h PMA 3 4,357,508 2,707,894 
4533_26 Control K562 WT 72 PMA 3,087,335 1,844,770 
4533_27 K562 -/- DMSO 1 3,948,820 2,712,143 
4533_28 K562 -/- DMSO 2 4,173,877 2,528,795 
4533_29 K562 -/- DMSO 3 7,181,545 3,739,103 
4533_30 Control K562 -/- DMSO 31,255,638 92,067 
4533_31 K562 -/- 12h PMA 1 7,077,762 3,115,038 
4533_32 K562 -/- 12h PMA 2 8,657,941 3,624,719 
4533_33 K562 -/- 12h PMA 3 3,914,040 2,136,044 
4533_34 K562 -/- 72h PMA 1 6,648,572 3,795,374 
4533_35 K562 -/- 72h PMA 2 6,463,080 3,398,746 
4533_36 K562 -/- 72h PMA 3 23,085,885 3,480,265 
4533_37 Control K562 -/- 72 PMA 4,041,648 2,265,435 
 
After demultiplexing of primers, the reverse sequenced reads were mapped to a reduced 
genome based on the primary RE used in the first digestion (Dpn II). The majority of RUNX1 
+24 reads aligned to the reduced genome. Appendix VIII Figure 1 and 2 have very similar read 
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numbers. The quality evaluation  compares the read distributions to determine if a replicate is 
high enough quality to be included in the 4C interaction analysis (Appendix VIII Figure 3). 
RUNX1 +24  
 
Appendix VIII Figure 1: RUNX1 +24 demultiplexed read count.  




Appendix VIII Figure 2: RUNX1 +24 Mapped read count.  





Appendix VIII Figure 3: RUNX1 +24 4C quality evaluation.  
The coverage of fragments that had more than one read present within 0.1 mb on either side of the bait was 
plotted against the percentage of reads in cis over total. 4C data of WT 12 DMSO (light blue), WT 12 PMA 
(blue), WT 72 PMA (dark blue), STAG2 12 DMSO (yellow), STAG2 12 PMA (orange), STAG2 72 PMA (red) 
is plotted. Three points, corresponding to replicate 1, 2 and 3 are presented for each condition. Grey dotted lines 
indicate cut-off point for good quality data.  
 
Appendix IX: WT 12 DMSO interaction peaks 
Table of all the statistically significant interactions with RUNX1 +24 in WT 12 DMSO 
cells  
WT 12 DMSO cis significant interactions 
Appendix IX Table 1: WT 12 DMSO cis interactions 
Chromosome location (Chr21) 







Chromosome location (Chr21) 































WT 12 DMSO near-bait significant interactions 
Appendix IX Table 2: WT 12 DMSO near-bait interactions 
Chromosome location (Chr21) 































Chromosome location (Chr21) 


































Chromosome location (Chr21) 


































Chromosome location (Chr21) 


































Chromosome location (Chr21) 



























Appendix X: Trans interaction peaks 
The trans interactions of RUNX1 +24 could not be significantly investigated using 4C-
ker. The 4Cker analysis showed bands that spanned across large areas of the various 
chromosomes the trans interactions that could be detected, I looked at the raw read peaks across 
the genome (Appendix IX Figure 1). Based on peaks that contained reads in 2 or more 
replicates I detected three trans interactions (Appendix IX Figure 2-4). All peaks were in 
intergenic regions and contained minimal ENCODE annotations.  
  
Appendix X Figure 1: RUNX1 +24 trans chromosome 1 reads.  






Appendix X Figure 2: RUNX1 +24 chr 1 trans interactions.  
UCSC genome browser snapshot of normalised read count showing reads from all three replicates highlighting 





Appendix X Figure 3: RUNX1 +24 chr 3 trans interactions.  
UCSC genome browser snapshot of normalised read count showing reads from all three replicates highlighting 





Appendix X Figure 4: RUNX1 +24 chr 9 trans interactions.  
UCSC genome browser snapshot of normalised read count showing reads from all three replicates highlighting 





Appendix XI: List of significant changes (cis) 
Lists of all the statistically significant cis changes between conditions  
WT cis significant changes during differentiation 
Appendix XI Table 1: Differentially decreased cis interactions in WT 12 h PMA cells compared to WT 12 
h DMSO K562 cells 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
16193679 16290033 -8.0131141 0.00497879 
39852633 39906157 -7.8384879 0.00978024 
 
Appendix XI Table 2: Differentially decreased cis interactions in WT 72 h PMA cells compared to WT 12 
h DMSO K562 cells 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
22876545 23117188 -7.4296378 0.00362255 
24372136 24630993 -5.7785282 0.00383509 
28570440 28782508 -7.895935 0.00817325 
31223207 31350841 -8.8622479 0.00193125 
34626170 34659645 -6.4021928 0.00554615 
34861883 34886153 -6.2869926 0.00584545 
38065170 38088150 -7.50213 0.00211092 
39302647 39354164 -7.8347453 0.00178676 
43171342 43273433 -6.5989095 0.00645605 




WT and STAG2 cis comparisons 
Appendix XI Table 3: Differentially decreased cis interactions in STAG2 12h DMSO cells compared to 
WT 12h DMSO K562 cells 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
15789630 15905266 4.93016724 0.00656758 
16193679 16290033 -5.6375836 0.00465524 
16337170 16447658 4.39988775 0.00144947 
26749583 26912507 6.04072918 0.00276931 
30766929 30848918 6.02534263 0.00029361 
30975222 31069884 3.84968539 0.00943295 
34232784 34274588 5.95696286 0.00150594 
34738802 34767851 3.99116934 0.00827214 
34965396 34986172 4.06506145 0.0074603 
35064266 35082455 -5.5186585 0.00780053 
38065170 38088150 -5.1459938 0.00711804 
38099808 38123104 3.88469303 0.00595205 
38111456 38134838 5.55176215 0.00821735 
38790145 38825524 4.39693366 0.00587422 
39225824 39276819 4.59711214 0.00883934 
39251322 39302562 4.68523129 0.00971659 
39379992 39431602 5.13275693 0.0034974 
39561223 39613465 5.48301289 0.00504078 
40092657 40145586 5.52330128 0.00367745 
40383991 40437879 4.6125032 0.00692396 
41082235 41192923 -6.659979 0.00036723 
41137579 41253995 -6.518779 0.00213839 
42327921 42467118 4.93843987 0.00575986 
44546192 44629845 4.3041222 0.00671446 




Appendix XI Table 4: Differentially decreased cis interactions in STAG2 12 h PMA cells compared to WT 
12 h PMA K562 cells 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
36516987 36518381 8.83443992 00.0023261 
 
Appendix XI Table 5: Differentially decreased cis interactions in STAG2 72 h PMA cells compared to WT 
72 h PMA K562 cells 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
17658804 17929142 8.77960408 3.54E-05 
17795376 18062908 5.99772569 0.00353314 
18653456 18833421 5.86735877 0.00232339 
22762987 22996867 6.37260654 0.00782695 
22876545 23117188 10.0927403 1.21E-05 
26749583 26912507 8.04883755 0.00207552 
27308690 27428828 7.25476493 0.00509219 
27367527 27490129 7.74087843 0.00509219 
27426968 27553290 8.28178011 0.00214456 
28570440 28782508 8.32963928 0.00275066 
28997265 29212346 6.8981528 0.00358326 
29427589 29629288 6.36801489 0.00379672 
30646160 30726999 6.42810586 0.00190139 
31826262 31999444 4.97135124 0.00939023 
32513939 32620098 5.65073304 0.00866759 
33094489 33156981 4.74896145 0.00866759 
34169753 34211768 7.7060914 0.00015066 
34943785 34965232 7.39162623 0.0010998 
34954679 34975784 6.62312295 0.00399488 
37516547 37524058 5.84397019 0.00095948  
37520302 37527914 5.92987926 0.00232339 
37535840 37543879 8.92597012 0.00015066 
37720265 37734202 8.49654733 0.00315786 
 
304 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
38755847 38789797 5.92670113 0.00296832 
39431609 39483268 5.62911118 0.00855271 
40198325 40251084 5.08928081 0.00207552 
41812481 41960561 6.81246138 0.00351648 
43821554 43904818 7.13610776 0.00388488 
44313418 44387118 6.5161103 0.00156909 
44927619 45009217 6.82470303 0.00866759 
46067813 46187451 6.81361389 0.00263408 
46127632 46249867 7.68983358 0.00052257 
47058514 47214415 6.88001354 0.00124792 
47136465 47289912 5.62989411 0.00233245 





Appendix XII: List of significant changes (near-bait) 
Lists of all the statistically significant near-bait changes between conditions  
WT near-bait significant changes during differentiation 
Appendix XII Table 1: Differentially connected near-bait interactions in WT 12 h PMA cells compared to 
WT 12 h DMSO K562 cells 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
35474191 35488395 -8.9377799 0.00013656 
36278644 36280049 6.80655514 0.00194086 
36332447 36333601 -7.6163228 0.00154466 
36352605 36353690 8.07237223 0.00044141 
36366550 36367612 6.76625148 0.00046604 
36406427 36407599 8.25342937 5.34E-07 
36410566 36411762 7.97117671 1.17E-05 
36420971 36422856 7.47613931 0.00204346 
36517085 36518628 -7.8123099 0.00337409 
 
Appendix XII Table 2: Differentially connected near-bait interactions in WT 72 h PMA cells compared to 
WT 12 h DMSO K562 cells 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
36278644 36280049 -8.4916179 0.00011101 
36324230 36325417 -9.7177426 8.72E-05 
36326010 36327189 -9.9312191 1.98E-06 
36349329 36350423 -5.0850069 0.00025395 
36351516 36352604 -6.4430378 0.00243444 
36352061 36353147 -6.4430378 0.00243444 
36352605 36353690 -9.8028067 2.51E-05 
36353690 36354773 -10.007951 8.07E-06  
36357470 36358544 -11.333388 2.69E-13 
 
306 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
36366550 36367612 -8.4053431 2.59E-05 
36375572 36376634 -11.252854 2.29E-13 
36377697 36378762 -10.717736 6.58E-10 
36379295 36380362 -12.360236 5.70E-15 
36379828 36380896 -4.8535823 2.15E-05 
36380361 36381430 -3.9254633 0.00055942 
36380895 36381965 -4.0813855 0.00262689 
36383573 36384648 -3.5709246 0.00168646 
36384110 36385187 -12.034618 6.48E-15 
36384648 36385726 -10.183231 3.33E-06 
36387347 36388434 -5.9110333 8.45E-07 
36390068 36391163 -6.9307593 1.69E-11 
36390614 36391712 -3.8287182 0.00154049 
36391711 36392813 -13.697569 9.54E-21 
36392261 36393366 -13.781015 9.54E-21 
36393365 36394474 -10.689796 1.86E-12 
36393918 36395030 -11.706035 8.92E-16 
36394473 36395587 -11.160013 7.62E-14 
36395028 36396145 -8.4361378 1.20E-05 
36395586 36396705 -12.292107 8.92E-16 
36396144 36397266 -12.317332 3.42E-16 
36397827 36398958 -17.523158 1.40E-35 
36399523 36400657 -12.06068 1.38E-18 
36400090 36401227 -11.753278 5.96E-16 
36400658 36401798 -3.7399723 0.00119426 
36401228 36402371 -12.495422 8.92E-16 
36401799 36402945 -13.775696 1.32E-20 
36402372 36403521 -8.2326817 6.06E-12 
36403523 36404678 -4.7434083 5.04E-06 
36404100 36405259 -3.3574145 0.00265467 
36405261 36406426 -5.5279129 2.50E-06 
 
307 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
36405843 36407012 -11.666767 7.09E-14 
36406427 36407599 -9.8620529 3.89E-08 
36407013 36408189 -9.4757263 8.22E-07 
36410566 36411762 -9.6137529 7.05E-07 
36412365 36413572 -10.271704 1.98E-06 
36412969 36414179 -5.4552266 0.00954996 
36420971 36422225 -9.2193533 0.00014574 
36421598 36422856 -9.2193533 0.00014574 
36427314 36428599 -10.593799 3.32E-09 
36465477 36466854 -9.4216804 8.20E-06 
36479385 36480795 -4.1398039 0.00622221 
36508664 36510185 -8.5117676 0.00151198 
36598256 36600012 -5.3745211 0.00237202 
37108487 37112215 5.94585879 0.0068571 
 
 
WT and STAG2 near-bait comparisons 
Appendix XII Table 3: Differentially connected near-bait interactions in STAG2 12 h DMSO cells 
compared to WT 12 h DMSO K562 cells 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
35442448 35454754 5.14667346 0.00604543 
35488228 35503117 7.20660582 6.37E-05 
35510591 35526316 5.13712908 0.00958697 
35600268 35616837 5.63045291 0.00190404 
35608619 35625055 5.39764041 0.00313695 
35686013 35699118 5.05439121 0.00336181 
35692775 35705461 6.00241513 0.00036696 
35699325 35711598 5.92593227 0.00511254 
35734347 35744470 4.69026964 0.00330434 
35739543 35749398 4.87776795 0.00739212 
 
308 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
35903813 35913177 6.16813376 0.0003288 
35922480 35931468 5.15510497 0.00202299 
35979513 35986245 4.15306452 0.00272369 
36120292 36122672 -5.0846932 0.00165723 
36123862 36126228 -6.3081783 0.00204766 
36125047 36127409 -6.3378073 0.00217929 
36126230 36128589 5.37656029 0.00055046 
36127411 36129767 5.44025738 0.00532178 
36156784 36159142 -5.9130815 0.00347325 
36157963 36160322 -4.9202346 0.00236422 
36215926 36218078 5.72381578 0.00143193 
36238267 36240133 5.10258129 0.00313695 
36243806 36245595 -7.2643134 2.92E-05 
36253381 36255044 -5.5051643 0.00051481 
36261516 36263082 5.54363525 0.00201202 
36264639 36266171 -4.6884026 0.00198188 
36265409 36266933 -4.6884026 0.00198188 
36266175 36267691 7.33095815 2.50E-05 
36271428 36272893 -6.5493485 0.00012837 
36277225 36278641 -8.5036482 6.15E-07 
36277936 36279346 -8.5019255 7.48E-09 
36279349 36280749 -6.1583448 0.00133455 
36280051 36281446 -7.2873161 5.50E-06 
36280751 36282141 -8.5801776 1.12E-09 
36281449 36282833 -8.9300293 1.04E-10 
36282836 36284211 -5.7549271 0.00062342 
36288291 36289632 -6.526985 8.70E-05 
36290969 36292295 -4.543678 0.00052385 
36292958 36294274 5.09197601 0.00514143 
36293617 36294930 -6.0870697 8.83E-06 
36294275 36295584 -6.0372376 0.00018546 
 
309 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
36305857 36307115 -7.33992 5.14E-05 
36313951 36315177 -7.1939107 1.38E-05 
36314565 36315788 -8.4854587 3.55E-10 
36316400 36317616 -6.0665073 0.00091451 
36317009 36318223 -7.5011631 7.10E-06 
36317617 36318829 -6.6905219 0.00020166 
36324230 36325417 -6.4434308 0.00219053 
36326010 36327189 -6.7090075 0.00020387 
36328367 36329537 -6.1060016 0.00101977 
36328953 36330121 -6.8940376 0.00025188 
36329538 36330704 -5.8264151 0.00098554 
36331867 36333024 -6.3782038 0.00173938 
36333602 36334752 -7.5083462 3.30E-05 
36335327 36336470 -7.6558644 5.77E-06 
36335900 36337041 -7.9329818 1.75E-09 
36337042 36338179 -6.6785373 0.00186816 
36337611 36338746 -5.3144725 0.00281319 
36338180 36339312 -4.119617 0.00606764 
36338747 36339877 -5.0564483 0.00087849 
36339878 36341004 -5.4894373 0.00023521 
36340442 36341565 -5.1490454 0.00109411 
36341005 36342126 -5.5925002 0.00243223 
36341566 36342686 -5.4010668 0.00219053 
36343803 36344915 -6.9091289 0.00063124 
36346578 36347680 -5.7559427 2.67E-05 
36347130 36348230 -5.6191847 0.00011139 
36347681 36348780 -5.9721228 7.62E-05 
36348231 36349329 -6.7553451 5.15E-06 
36348781 36349876 -8.3451442 5.28E-08 
36349329 36350423 -7.2373471 1.21E-08 
36353148 36354232 -7.6190587 2.98E-08 
 
310 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
36353690 36354773 -6.7603357 0.00052385 
36357470 36358544 -8.2201229 5.59E-10 
36358545 36359617 -5.0586849 0.00053423 
36361223 36362291 -6.3245385 0.00018379 
36361757 36362824 -7.7342382 5.85E-07 
36363358 36364423 -4.2037648 0.00842511 
36367613 36368674 -5.3934605 0.00532178 
36368143 36369205 -7.6240911 1.65E-07 
36368674 36369735 -7.8172476 1.57E-08 
36369205 36370266 -6.0627492 0.0004902 
36370796 36371857 -7.1648961 7.03E-07 
36371327 36372388 -7.1668825 6.26E-07 
36375572 36376634 -8.1453593 5.00E-10 
36376103 36377166 -9.3578651 5.39E-14 
36376634 36377698 -8.6138615 3.31E-10 
36377166 36378230 -7.2504001 8.36E-07 
36377697 36378762 -7.5580953 4.60E-07 
36378230 36379295 -8.4133492 1.87E-09 
36378762 36379828 -9.1784314 2.31E-12 
36379295 36380362 -9.2348118 1.02E-11 
36379828 36380896 -9.6763744 6.47E-14 
36380361 36381430 -2.6218818 0.00652073 
36380895 36381965 -3.3237615 0.00243029 
36381430 36382501 -5.9783881 0.00249267 
36382500 36383573 -5.7246547 0.00453991 
36383036 36384111 -8.4451345 2.92E-11 
36383573 36384648 -9.2083949 6.67E-14 
36384110 36385187 -8.9215142 1.54E-11 
36384648 36385726 -6.9420433 0.00025483 
36386806 36387890 -8.5415748 3.55E-10 
36387347 36388434 -9.0233909 1.55E-11 
 
311 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
36387890 36388978 -8.8873084 1.85E-11 
36388433 36389523 -7.9683448 1.95E-08 
36388977 36390069 -6.9327362 2.49E-06 
36389522 36390615 -8.2426883 3.30E-09 
36390068 36391163 -9.9377838 7.34E-15 
36390614 36391712 -9.6751239 3.60E-14 
36391162 36392262 -9.0775585 9.77E-12 
36391711 36392813 -10.61135 2.95E-17 
36392261 36393366 -10.689834 2.95E-17 
36393365 36394474 -7.5904273 4.51E-09 
36393918 36395030 -8.6248651 2.98E-12 
36394473 36395587 -8.0668095 2.29E-10 
36395028 36396145 -5.2569823 0.0015807 
36395586 36396705 -9.1849292 2.02E-12 
36396144 36397266 -9.2193345 6.15E-13 
36396704 36397829 -9.0894818 8.09E-14 
36397265 36398393 -8.967531 6.11E-12 
36400090 36401227 -8.675502 1.80E-12 
36400658 36401798 -9.2692792 7.93E-14 
36401228 36402371 -9.378327 2.02E-12 
36401799 36402945 -5.038744 7.61E-08 
36402372 36403521 -3.5759767 0.00187333 
36403523 36404678 -9.3643406 4.72E-14 
36404100 36405259 -10.122268 6.08E-17 
36404680 36405841 -9.1409659 2.10E-11 
36405261 36406426 -8.2309386 4.38E-10 
36405843 36407012 -8.5509922 1.38E-10 
36407013 36408189 3.99025471 0.00241178 
36408190 36409373 -7.4028371 1.83E-08 
36409375 36410564 -5.8642315 0.00036696 
36409969 36411162 -6.3031778 5.49E-05 
 
312 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
36412365 36413572 -7.0352108 0.00016797 
36412969 36414179 -7.7426722 1.46E-05 
36414790 36416010 -4.6024336 0.00552198 
36415400 36416624 -7.9606583 3.87E-08 
36416012 36417240 -8.2026183 5.28E-08 
36416626 36417857 -6.4008285 1.11E-06 
36417242 36418476 -7.2248679 3.94E-07 
36417859 36419097 -8.6052284 3.53E-10 
36418478 36419719 -9.0721955 2.10E-11 
36425395 36426671 -6.1071262 0.00045891 
36426033 36427312 -3.2468646 0.00427006 
36426673 36427955 -5.5419205 1.03E-07 
36427314 36428599 -7.4220256 1.58E-06 
36427956 36429244 -7.2037424 6.20E-07 
36428600 36429891 -7.6476059 5.36E-09 
36429246 36430539 -6.7768232 2.50E-05 
36432493 36433799 -5.4958363 0.00874461 
36433146 36434455 -6.6494338 0.00223817 
36433800 36435112 -6.8541375 0.00085553 
36441738 36443074 -5.8566927 0.00652073 
36443075 36444413 -5.9206517 0.00249267 
36446428 36447774 7.39577926 2.96E-05 
36447775 36449123 -6.6516338 4.41E-06 
36449124 36450475 -5.6525322 0.00666041 
36449799 36451151 -5.6819926 0.00326723 
36455222 36456582 -5.9937473 0.00190552 
36455902 36457263 -4.5299829 0.00652073 
36464790 36466165 -6.4190745 0.00010023 
36465477 36466854 -6.1987382 0.00070554 
36468234 36469615 -5.8512261 0.00088366 
36468924 36470307 -6.8216637 1.71E-06 
 
313 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
36469616 36471000 -6.8430583 7.69E-07 
36470308 36471694 -7.453335 1.17E-07 
36471001 36472388 -7.582741 2.40E-06 
36471694 36473083 -6.7916012 0.0001583 
36474478 36475874 -9.0531798 5.21E-13 
36475176 36476573 -7.7620541 1.05E-06 
36476574 36477976 4.5685569 0.0094656 
36482213 36483633 -6.0956116 0.00219053 
36482923 36484346 -6.1011021 0.00196216 
36483634 36485060 -7.5770118 3.59E-05 
36484347 36485775 -8.8197034 1.55E-11 
36485061 36486492 -4.1300057 0.00056245 
36489374 36490822 -4.6474085 0.00292553 
36499642 36501131 -5.0309972 0.00810328 
36501880 36503377 -5.8853815 0.00109411 
36507905 36509423 -5.2677341 0.00433536 
36510186 36511710 4.20340063 0.00745852 
36547820 36549434 -5.0367016 0.00268999 
36548627 36550243 -6.1675094 3.01E-05 
36549435 36551053 -5.6311423 0.00690644 
36551054 36552676 -6.0681017 0.0046105 
36569979 36571652 -5.8495268 0.00299595 
36575859 36577549 -8.1808458 8.61E-10 
36586087 36587810 5.45802724 0.00225476 
36599134 36600892 -7.70849 0.00071704 
36613306 36615093 -6.6973562 1.05E-06 
36639644 36641497 4.98883571 0.00388645 
36643358 36645221 6.65546515 0.00076291 
36644289 36646155 4.44734443 0.00452901 
36675275 36677141 6.26116299 0.00199485 
36678070 36679930 4.12581365 0.00954415 
 
314 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
36681781 36683630 5.27931924 0.00840389 
36689136 36690961 -6.0643028 0.0065149 
36690048 36691870 -6.2983822 0.00056685 
36692776 36694589 -6.5063716 0.00100762 
36699984 36701773 -5.0619114 0.00491749 
36700879 36702664 -5.3418691 0.00359391 
36707985 36709750 -5.6312265 0.00214273 
36716767 36718514 -6.0836102 0.00242154 
36720257 36721999 4.76772143 0.00383356 
36760629 36762445 6.69185046 6.37E-05 
36769828 36771700 -5.4890296 0.00539627 
36770764 36772642 -5.0261707 0.00831542 
36780318 36782271 5.18649867 0.00453307 
36817180 36819432 5.41118856 0.00788438 
36820565 36822832 4.62864398 0.0055187 
36830832 36833128 3.91908454 0.00316182 
36833129 36835428 6.36933438 0.00084076 
36834279 36836579 7.26272323 8.89E-05 
36838884 36841188 4.91703132 0.00840389 
36845802 36848109 -5.5795055 0.00055954 
36861965 36864276 5.4450722 0.00057203 
36863120 36865432 5.94395026 0.00075854 
36880462 36882777 5.11807537 0.00104606 
36895580 36897926 3.31146263 0.00889445 
36896753 36899103 4.04485602 0.00281761 
36905029 36907416 4.68161925 0.00606764 
36915906 36918366 4.73789359 0.0032947 
36917136 36919606 4.96756688 0.00784981 
36958414 36961325 4.74411509 0.00074215 
36959870 36962799 5.84583263 0.00204766 
36981249 36984462 4.96011295 0.00056245 
 
315 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
36982856 36986093 5.03870752 0.00056245 
36991078 36994449 4.9324713 0.00491749 
37008653 37012362 4.85873578 0.00382578 
37028134 37032277 6.1739032 0.00104737 
37030206 37034396 5.79386359 0.00225476 
37032301 37036541 6.74526785 0.00074215 
37034421 37038710 5.82107512 0.00222416 
37036565 37040905 5.76476449 0.00064035 
37038735 37043124 5.90300992 0.00011139 
37043150 37047640 4.45955355 0.00235656 
37052283 37056975 5.01655284 0.00666041 
37095061 37100368 5.23676744 0.00434717 
37103038 37108370 5.31556159 0.00195862 
37105704 37111038 5.79920985 0.00054327 
37159176 37163807 4.10587535 0.00840389 
37170498 37174877 7.33275151 4.41E-06 
37172687 37177018 5.49103364 0.00612315 
37174853 37179137 5.24234056 0.00313695 
37181212 37185366 5.85259436 0.00105398 
37195362 37199276 4.48212577 0.00190552 
37222017 37225778 5.30380422 0.00634469 
37237127 37240932 6.31057776 0.00142198 
37256273 37260121 6.2641119 0.00062633 
37258197 37262045 6.06703571 0.00217929 
37260121 37263969 6.10036762 0.00109411 
37317455 37321316 5.98073692 0.00022105 
37319385 37323257 5.83117255 0.00190552 
37325210 37329115 6.6395281 5.82E-05 
37356988 37360994 5.84564246 0.00074215 
37358991 37362993 5.94765868 0.00165723 
37382680 37386536 5.32308698 0.00195583 
 
316 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
37384608 37388447 5.56009357 0.00199325 
 
Appendix XII Table 4: Differentially connected near-bait interactions in STAG2 12 h PMA cells 
compared to WT 12 h PMA K562 cells 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
35474191 35488395 8.88363712 0.00039423 
36329538 36330704 -7.104548 0.00325246 
36517085 36518628 8.07291617 0.00534208 
 
Appendix XII Table 5: Differentially connected near-bait interactions in STAG2 72 h PMA cells 
compared to WT 72 h PMA K562 cells 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  
Start  End 
35616930 35633181 6.39080745 0.00248597 
35820274 35829140 5.5848525 0.00097742 
35824675 35833604 5.60497619 0.002314 
35861078 35870515 5.67484009 0.00573638 
35865777 35875254 6.38202372 0.00294739 
36037368 36041588 5.93157339 0.00653349 
36085729 36088522 5.19853978 2.60E-05 
36087139 36089905 3.82433892 0.00644468 
36095322 36097948 5.91682845 0.00492169 
36103113 36105633 5.99928094 0.00569621 
36126230 36128589 5.74903532 0.00151667 
36212646 36214832 6.07280288 0.00314296 
36230511 36232484 4.39631305 0.00082114 
36231504 36233463 5.13758583 0.0092545 
36245601 36247365 4.08172618 0.00950164 
36246489 36248241 4.13413137 0.00769454 
 
317 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  
Start  End 
36247371 36249111 3.68908087 0.00950164 
36255049 36256690 4.35292358 0.00644468 
36255874 36257506 4.11377844 0.00961065 
36264639 36266171 -6.0507818 0.00031558 
36265409 36266933 -6.0507818 0.00031558 
36277936 36279346 -6.3021965 0.00037603 
36278644 36280049 11.6729562 1.33E-09 
36280751 36282141 3.78712369 0.0070179 
36281449 36282833 3.48142505 0.00992013 
36290302 36291632 2.88412113 0.00779809 
36293617 36294930 4.04452087 0.0011826 
36294275 36295584 4.6285964 0.00333127 
36296890 36298187 -5.8193993 0.0048044 
36321841 36323037 3.32492625 0.00601396 
36326010 36327189 9.70851274 6.56E-06 
36329538 36330704 -5.3848816 0.00813909 
36353690 36354773 9.46576918 4.07E-05 
36357470 36358544 10.7800466 6.46E-11 
36358008 36359081 -6.1100997 0.0006696 
36358545 36359617 -5.509932 0.00471123 
36359081 36360153 4.41661147 0.00242101 
36359617 36360688 3.72348938 0.00011918 
36368143 36369205 -5.3552475 0.00242101 
36375572 36376634 10.5041155 7.68E-11 
36378230 36379295 -5.9803434 0.00038571 
36378762 36379828 -6.2605281 4.97E-05 
36379828 36380896 -4.7731068 0.00242101 
36380895 36381965 3.59887114 0.00569621 
36384110 36385187 10.3846842 1.70E-10 
36386806 36387890 -5.2050704 0.00189496 
36387890 36388978 -7.26707 3.12E-06 
 
318 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  
Start  End 
36388433 36389523 -7.0197525 2.31E-05 
36389522 36390615 3.71566016 0.00693617 
36390614 36391712 -5.8030608 0.00010992 
36391162 36392262 -5.3553286 0.00091074 
36396704 36397829 -6.1154249 1.69E-05 
36397265 36398393 -5.9315806 0.00011918 
36400658 36401798 -5.4946701 0.00018284 
36401799 36402945 9.67500252 8.95E-10 
36403523 36404678 -4.5884313 0.002314 
36404100 36405259 -6.7406599 1.60E-06 
36405261 36406426 4.97333288 4.59E-05 
36408190 36409373 -6.8682933 6.56E-06 
36409375 36410564 4.14902314 0.00961065 
36412365 36413572 9.90821104 8.81E-06 
36412969 36414179 5.19516829 0.006363 
36415400 36416624 -5.3966426 0.002314 
36417242 36418476 3.55214792 0.00964533 
36418478 36419719 -7.3674023 3.66E-06 
36427314 36428599 8.28077489 2.02E-05 
36438413 36439740 6.19923091 0.00355447 
36439076 36440405 5.34938019 0.00781592 
36447101 36448448 3.42138535 0.00964533 
36447775 36449123 3.57663208 0.00973886 
36462046 36463416 5.37629124 0.00091074 
36466854 36468233 4.03332205 0.00678425 
36467544 36468924 4.03332205 0.00678425 
36468924 36470307 -5.051629 0.00303796 
36470308 36471694 3.53892576 0.00955617 
36473780 36475175 4.22259507 0.00195782 
36474478 36475874 3.02786348 0.00781592 
36476574 36477976 7.73871874 0.00086778 
 
319 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  
Start  End 
36483634 36485060 -5.6762586 0.00949249 
36525620 36527182 -5.0371467 0.0098543 
36548627 36550243 3.83613999 0.00674913 
36564157 36565814 -5.8356448 0.00350161 
36564985 36566644 -5.6011714 0.002314 
36574173 36575858 3.91851685 0.0048044 
36576704 36578397 4.09421663 0.00569621 
36581802 36583511 4.57197733 0.00781592 
36583512 36585226 -5.8699908 0.00294739 
36598256 36600012 6.96899254 1.69E-05 
36599134 36600892 8.45991798 0.0005704 
36613306 36615093 4.45512151 0.00042992 
36624088 36625898 4.88082738 0.00813909 
36624993 36626806 5.09223372 0.00189172 
36626807 36628624 3.59833853 0.00779809 
36627716 36629535 3.92259217 0.0098543 
36638718 36640569 5.23900589 0.00950164 
36639644 36641497 5.30117871 0.00781592 
36654596 36656478 6.9292274 0.0008546 
36728951 36730687 4.62761545 0.00314296 
36729819 36731555 4.37422906 0.00775817 
36735029 36736767 9.11645074 0.0001077 
36739379 36741122 4.39342681 0.00346245 
36756124 36757918 5.238339 0.00779809 
36777412 36779341 3.42447573 0.00798702 
36786243 36788249 3.67964767 0.00678425 
36787246 36789261 3.86273218 0.00632354 
36810491 36812704 5.61215239 0.002314 
36845802 36848109 5.854747 0.0001077 
36846955 36849263 5.16856943 3.66E-06 
36848109 36850417 3.85732002 0.00035811 
 
320 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  
Start  End 
36853880 36856189 -5.2477179 0.00973886 
36885096 36887417 5.06153769 0.00964533 
36895580 36897926 4.68289553 0.00156111 
36896753 36899103 4.72151154 0.00314296 
36911032 36913456 4.01547479 0.00709354 
36933626 36936251 4.86453523 0.00272994 
36934938 36937577 5.12703258 0.00248597 
37056999 37061790 5.78297835 0.00747781 
37059395 37064233 6.08828716 0.00242101 
37061814 37066698 5.31314356 0.00813909 
37084541 37089766 6.46491345 0.002314 
37087154 37092404 6.25238487 0.00091074 
37113699 37119014 5.88738966 0.00303796 
37116357 37121658 5.63425786 0.00967932 
37170498 37174877 4.73204438 0.00882689 
37187383 37191422 4.94111543 0.00781592 
37199264 37203129 7.52992906 0.00015582 
37205031 37208841 4.95470397 0.00758695 
37212613 37216380 5.08057016 6.35E-05 
37214497 37218259 5.81850888 0.00082114 
37246671 37250505 9.29052153 1.69E-05 
37263969 37267814 6.15339897 0.00314296 
37283130 37286944 5.57851522 0.00272994 
37302154 37305960 5.87814043 0.00346245 
37305962 37309776 3.96493041 0.00604611 
37307869 37311688 4.63176966 0.00011918 
37309778 37313604 4.43627766 0.00426435 
37313608 37317450 5.33377368 0.00398626 
37315529 37319381 5.18200797 0.00781592 
37346971 37350974 7.54451589 0.00069152 
37348973 37352979 6.87174577 0.00729703 
 
321 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  
Start  End 
37374884 37378805 5.53180004 0.00346245 
Appendix XIII: List of gene connections 
To investigate which genes may be co-regulated with RUNX1, interactions occurring 
with other genes were identified. Gene interaction analysis identifies a connection with an 
overlap in the same genomic region as a gene, and does not necessarily reflect an interaction 
with a promoter or exon of a gene.  
Appendix XIII Table 1: List of gene connecting to RUNX1 +24 connections in each condition 
WT 12 D WT 12 P WT 72 P STAG2 12 
D  








































AP001630.5 AP000282.3 AF129075.5 AP000688.1
5 
HLCS CLIC6 
BACE2 AP000320.6 AF246928.1 AP000705.6 HMGN1 DSCAM 
BRWD1 AP000474.1 AGPAT3 AP000705.7 IL10RB DSCR4 
BRWD1-
AS1 





AL109761.5 AP000959.2 KCNE2 H2AFZP1 
BRWD1-IT1 AP000688.1
4 
AP000255.6 AP001136.2 LINC00160 HMGN1 
 
322 
WT 12 D WT 12 P WT 72 P STAG2 12 
D  
STAG2 12 P STAG2 72 P 
CBR1 AP000688.2
9 
AP000318.2 AP001412.1 LINC01426 KCNE1 
CLIC6 AP000695.4 AP000320.6 AP001628.6 LINC01436 KCNE1B 
DSCR3 AP000696.2 AP000322.5
3 
AP003900.6 MIR548X LINC00160 
DSCR4 AP000705.6 AP000477.2 ATP5J MIR548XH
G 
LINC00205 
GAPDHP16 AP000705.7 AP000477.3 BAGE2 MORC3 LINC00315 

















BRWD1 SETD4 LINC01668 
IFNAR2 AP001610.5 AP000695.6 C21orf62-
AS1 
SYNJ1 MIR5692B 
IL10RB AP001619.2 AP001042.1 CBR3-AS1 Y_RNA MIR99A 
IL10RB-
AS1 
AP001619.3 AP001437.1 CLIC6 LOC100506
403 
MIR99AHG 
LCA5L AP003900.6 AP001469.5 CRYZL1 RUNXOR MIRLET7C 
LINC00159 ATP5J AP001469.7 CYCSP41 AF015720.3 NDUFV3 





BACH1 AP001625.4 DOPEY2 CH507-
396I9.3 
POFUT2 
MIR3197 BAGE2 AP001625.5 DSCR3 CMP21-
97G8.2 
RNU6-113P 
MIR5692B BRWD1 AP001625.6 DSCR4 KCNE1 SCAF4 
PDE9A BTF3L4P1 ATP5J DSCR8 KCNE1B SETD4 
PDXK BTF3P6 BACH1 DYRK1A RCAN1 SNORA81 
PKNOX1 BX322557.1
0 
BRWD1 ERG RUNX1-IT1 SOD1 
PLAC4 C2CD2 BRWD1-IT1 EZH2P1 
 
TRAPPC10 
POLR2CP1 CBR1 BTF3L4P1 FAM207A 
 
WDR4 









RAD23BLP CLDN14 C2CD2 GABPA 
 
RUNXOR 
RBMX2P1 CLDN17 CBR1 GART 
 
AF015720.3 










WT 12 D WT 12 P WT 72 P STAG2 12 
D  







RNU6-992P DOPEY2 CLDN14 IL10RB 
 
RUNX1-IT1 






SETD4 DSCR3 CXADR ITSN1 
  
TIMM9P2 DYRK1A DSCAM JAM2 
  
USP25 ERG DYRK1A KCNE2 
  
WRB EVA1C ERG KRTAP10-
10 
  
Y_RNA EZH2P1 ETS2 KRTAP10-
11 
  
AF015720.3 FAM3B EVA1C KRTAP10-6 
  




GABPA FDX1P2 KRTAP10-8 
  
LINC01426 GART GABPA KRTAP10-9 
  
RCAN1 GRIK1 GAPDHP14 LCA5L 
  
RPL34P3 HLCS GAPDHP16 LINC00114 
  
SMIM11A HLCS-IT1 GRIK1 LINC00160 
  




IMMTP1 HLCS LINC01424 
  
RUNXOR ITSN1 HMGN1 LINC01547 
  
 
























KRTAP12-1 KCNJ15 MIR6508 
  
 













LINC00160 KRTAP10-2 NRIP1 
  
 
LINC00205 KRTAP10-3 PFKL 
  
 




WT 12 D WT 12 P WT 72 P STAG2 12 
D  
STAG2 12 P STAG2 72 P 
 
LINC00315 KRTAP10-5 PRDM15 
  
 
LINC00334 KRTAP10-6 PSMG1 
  
 
LINC00649 KRTAP10-7 PTTG1IP 
  
 
LINC01426 KRTAP10-8 RCAN1 
  
 
LINC01436 KRTAP10-9 RIPK4 
  
 
LINC01684 LINC00160 RNF6P1 
  
 















MIR155HG LINC01436 RPL3P1 
  
 
MIR3197 LSS RRP1B 
  
 
MORC3 LTN1 RSPH1 
  
 
MRPL39 MAP3K7CL RWDD2B 
  
 
















NRIP1 MRPS6 SMIM11A 
  
 
OLIG2 OLIG2 SMIM11B 
  
 








POFUT2 PIGP SUMO3 
  
 
PRDM15 POLR2CP1 TIAM1 
  
 
PSMG1 RCAN1 TPTE 
  
 
RN7SL163P RIMKLBP1 TSPEAR 
  
 
RNA5SP489 RN7SL163P TTC3 
  
 















RNU6-696P RPL12P9 VN1R7P 
  
 









WT 12 D WT 12 P WT 72 P STAG2 12 
D  


















RPL23P2 SAMSN1 KCNE1 
  
 
RPL34P3 SCAF4 LINC00310 
  
 
RPL39P40 SETD4 LINC01426 
  
 
RPSAP64 SLC37A1 MIR802 
  
 
RWDD2B SMIM11A MRPS6 
  
 












   
 
SMIM11B TTC3 
   
 
SNORA3 U3 
   
 
SNORA62 USP16 
   
 
SNORA80A WRB 
   
 
SRSF9P1 Y_RNA 
   
 
TIAM1 ZBTB21 








   
 
TSPEAR AF015720.3 
   
 
TTC3 C21orf140 













   
 
URB1 MIR802 
   
 
URB1-AS1 RPS20P1 
   
 
USP16 RUNX1 
   
 
VN1R7P SLC5A3 
   
 
Y_RNA SNORA11 




    
 
RUNXOR 
    
 
AP000318.2 
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WT 12 D WT 12 P WT 72 P STAG2 12 
D  




    
 
C21orf140 
















    
 
KCNE1 
    
 
RCAN1 
    
 
RPS5P2 
    
 
SLC5A3 
    
 
RUNX1-IT1 





Appendix XIV: List of significant changes STAG2 12 
DMSO compared STAG2 72 PMA 
Appendix XIV Table 1: Differential cis interactions in STAG2 72 h PMA cells compared to STAG2 12 h 
DMSO K562 cells 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
16193679 16290033 5.86391632 0.00342781 
16287686 16392414 -4.8616436 0.00409359 
16337170 16447658 -6.2817559 0.00012778 
22535850 22765112 -5.3708546 0.00321359 
22876545 23117188 5.43274265 0.00202892 
23369288 23626457 -5.6528021 0.00375885 
23878355 24124540 5.05342004 0.00364158 
24761799 25024643 6.15905653 0.00200644 
32389417 32510405 4.90346805 0.00474697 
32513939 32620098 4.80628151 0.00831305 
33218357 33277752 -4.894004 0.00644409 
33999313 34042381 4.99233029 0.0072539 
34253734 34295441 -4.5073628 0.00819366 
34643232 34676058 -5.6689901 0.00199124 
35143611 35160271 -5.7105858 0.00205897 
35152010 35168532 -5.8140152 0.00203572 
35160337 35176727 -5.8371813 0.00382979 
35232484 35247888 -5.8832819 0.00186227 
35240230 35255545 -5.9020399 0.00219482 
35300676 35315394 -6.3841202 0.00031727 
35308065 35322722 -7.0977311 0.00049094 
35436900 35450845 -5.4020436 0.00279414 
35443887 35457803 -5.7110624 0.00808936 
35478603 35492364 -6.1583276 0.00397153 
35485500 35499228 -7.3015989 0.00041831 
 
328 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
35506094 35519714 -5.6341086 0.00993049 
35784920 35794816 4.30548294 0.00509029 
35823560 35832710 4.42665524 0.00753341 
35832755 35841723 5.20170137 0.00913565 
35859255 35867690 8.36421118 6.47E-06 
35880124 35888128 -5.3281192 0.00847348 
35903755 35911258 -5.2503345 0.00664818 
36021891 36026806 -6.535467 0.0020892 
36052207 36056497 6.36072775 0.00183374 
36074896 36078750 6.26158833 0.00049999 
36078768 36082551 6.79553391 0.00253267 
36097095 36100555 -5.3974861 0.00744211 
36103984 36107328 4.6414395 0.00806999 
36105670 36108987 4.80922853 0.00076676 
36107342 36110631 4.92457287 0.00813439 
36109000 36112262 3.82601073 0.00829254 
36112275 36115485 5.15725287 0.00445428 
36113893 36117077 6.39617859 0.00122301 
36115497 36118656 6.28087387 0.00227957 
36117089 36120223 5.47469903 0.0007658 
36118668 36121778 5.74373025 0.00023888 
36120235 36123321 4.29131238 0.00397123 
36124863 36127878 7.69970523 0.00031408 
36157164 36159733 5.31664623 0.00466991 
36178077 36180394 -6.4238107 0.00442351 
36182697 36184962 6.33079209 0.0010642 
36183836 36186089 4.35662179 0.00424197 
36194887 36197021 6.2781405 0.00149473 
36200196 36202277 4.9283002 0.00932299 
36213393 36215346 8.73987292 5.24E-06 
36216323 36218250 -6.0057821 0.00371672 
 
329 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
36243603 36245303 7.23413186 0.00012512 
36250339 36251990 6.41840825 0.00232423 
36253634 36255261 4.29466569 0.00520545 
36255264 36256880 6.54826795 3.05E-06 
36256075 36257685 6.7786123 1.28E-06 
36257688 36259287 -5.7516519 0.0022048 
36266370 36267913 -5.4044968 0.00522296 
36267144 36268682 -5.5749242 0.00318493 
36269452 36270976 -6.1952272 0.00042122 
36270979 36272494 5.24954146 8.02E-05 
36271738 36273249 5.05029119 0.00466991 
36278479 36279951 9.11879907 4.07E-08 
36279217 36280685 9.10568924 1.27E-08 
36280687 36282148 9.96475177 2.53E-11 
36281420 36282876 10.0030672 2.11E-11 
36282150 36283603 7.2543056 5.17E-05 
36282878 36284327 7.267999 2.71E-05 
36287208 36288634 5.4507541 0.0009367 
36287923 36289346 5.48484313 0.00103209 
36289348 36290764 -5.3562441 0.00474829 
36290765 36292175 6.16887781 7.97E-07 
36291472 36292878 8.49998497 9.96E-10 
36293581 36294976 9.48666016 1.69E-11 
36294280 36295673 9.42356641 4.13E-09 
36305263 36306608 7.78796024 0.00024295 
36309954 36311281 7.00839478 7.71E-05 
36311282 36312604 3.874062 0.00903138 
36311944 36313264 9.62390448 2.18E-10 
36313924 36315237 4.9712562 0.00731705 
36316548 36317852 6.15266037 0.00170019 
36317201 36318502 9.11561781 1.50E-09 
 
330 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
36317853 36319152 9.31437377 2.64E-07 
36321741 36323028 3.48271698 0.00296189 
36322386 36323671 5.0790562 0.0032143 
36324953 36326231 4.94922112 0.00085693 
36331937 36333195 6.78039204 0.0016612 
36333196 36334450 5.39157606 0.00498829 
36335078 36336327 9.16501077 1.40E-07 
36335703 36336952 8.22164842 4.77E-09 
36336952 36338198 8.75800874 1.10E-05 
36337576 36338819 8.33783655 6.32E-09 
36338198 36339441 3.92381229 0.00396733 
36338820 36340061 5.05953517 0.00189014 
36340062 36341300 6.38840711 6.78E-06 
36340682 36341919 6.09958357 0.00069069 
36341301 36342536 5.71437787 0.00202855 
36343771 36345001 7.75787409 0.00011951 
36346844 36348068 7.40707966 1.11E-07 
36347456 36348680 6.98617274 8.03E-07 
36348069 36349291 8.01430446 1.16E-07 
36348680 36349902 7.63758264 3.05E-06 
36349292 36350512 -4.1354402 0.00625147 
36352947 36354161 9.36897263 1.97E-10 
36353555 36354768 6.77679685 0.0008522 
36357190 36358398 8.10083758 6.32E-09 
36357795 36359002 -5.1152283 0.0021679 
36359002 36360208 6.20858216 9.77E-07 
36360811 36362014 5.65592073 0.00093715 
36361413 36362615 7.08985193 3.05E-06 
36363217 36364417 5.6998418 0.00062424 
36368612 36369807 7.96066213 7.07E-08 
36369210 36370405 7.79227784 5.41E-06 
 
331 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
36370405 36371599 6.98964564 2.43E-05 
36371003 36372196 8.48952557 4.77E-09 
36372196 36373389 -4.7126163 0.00681217 
36375178 36376369 7.97514 1.05E-08 
36375774 36376965 8.46543677 4.33E-10 
36376369 36377560 6.87164047 3.99E-06 
36376965 36378155 6.49272082 1.46E-05 
36377560 36378750 6.51577197 0.00051865 
36379940 36381129 7.76836353 1.83E-09 
36382913 36384101 8.19486754 1.83E-09 
36383507 36384695 8.70214754 7.00E-11 
36384101 36385289 7.88858675 3.34E-08 
36388853 36390041 8.66212113 5.90E-09 
36389447 36390636 8.76037028 9.96E-10 
36400743 36401934 7.95025266 4.13E-09 
36401339 36402530 5.74612908 0.00069069 
36403126 36404318 -6.0357879 0.00025132 
36404915 36406108 8.17048154 8.37E-09 
36405511 36406704 8.2239719 4.77E-09 
36407899 36409094 7.28607373 8.75E-06 
36409692 36410889 8.8601203 2.25E-08 
36410290 36411487 9.3885889 8.84E-08 
36412086 36413284 7.17619303 0.00012778 
36412685 36413884 8.01748321 9.23E-06 
36414484 36415685 5.86499505 0.0007024 
36416286 36417488 6.88736529 2.17E-05 
36416887 36418089 10.1733878 5.63E-13 
36417488 36418691 9.59154074 1.79E-10 
36425940 36427152 9.46629636 2.11E-11 
36426546 36427760 6.31447739 2.88E-08 
36427153 36428367 3.93077012 0.00822862 
 
332 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
36427760 36428975 6.59679415 6.53E-05 
36428367 36429583 7.65349876 1.40E-07 
36428975 36430192 7.26378089 1.10E-06 
36438757 36439987 6.91199385 0.00065793 
36439372 36440603 6.14925001 0.00924672 
36444930 36446170 4.71329953 0.00943458 
36447413 36448657 9.30726002 7.08E-10 
36448035 36449280 7.82083118 3.06E-05 
36454913 36456170 5.79710857 0.00306027 
36455542 36456800 6.12998107 0.00253267 
36460592 36461860 -6.8333284 0.00091342 
36469524 36470810 7.30008641 1.92E-07 
36470167 36471454 8.5845074 5.10E-09 
36470810 36472099 8.68900968 2.08E-07 
36474685 36475982 9.99750841 5.63E-13 
36475334 36476631 6.07165637 0.00049999 
36477933 36479237 6.63647668 0.0002694 
36484482 36485800 8.23693073 5.18E-06 
36485141 36486460 4.67621314 0.00031408 
36493775 36495114 -5.8752384 0.00266934 
36507315 36508686 5.44741229 0.00466335 
36508000 36509373 7.91544296 2.06E-05 
36525409 36526824 -5.4466584 0.00614928 
36526116 36527533 -5.4517141 0.00176164 
36527534 36528954 6.18594195 0.00418337 
36547749 36549219 6.62979028 0.00219296 
36548484 36549956 9.16765578 9.96E-10 
36552172 36553653 4.78145992 0.00044474 
36562621 36564128 6.40969238 0.00313258 
36564884 36566396 -4.6857336 0.00779839 
36567155 36568672 9.22163454 1.40E-07 
 
333 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
36567914 36569433 9.05790068 8.03E-07 
36568673 36570195 7.16735245 0.0015729 
36571722 36573251 -4.8063868 0.00855029 
36574785 36576321 3.51398395 0.00253267 
36575553 36577091 8.58721717 1.94E-08 
36576322 36577862 9.07635381 9.96E-10 
36577092 36578634 4.08026932 0.00253267 
36580956 36582508 4.44860024 0.00118968 
36581732 36583285 5.43783997 0.00051611 
36584065 36585624 5.19288271 0.00393797 
36594271 36595854 6.15128015 0.00160141 
36598238 36599831 5.36914918 0.00046146 
36599035 36600629 9.99934587 1.32E-06 
36609474 36611093 -4.3698555 0.00462971 
36612719 36614346 5.11568005 0.00397123 
36613532 36615161 9.58710989 1.69E-11 
36620074 36621719 5.03147673 0.00847348 
36625022 36626677 5.05492652 0.00065793 
36625849 36627507 4.03410268 0.00869538 
36629171 36630836 -7.003066 0.00091276 
36630003 36631671 -6.9765212 0.0007058 
36631672 36633343 -5.2309112 0.00349047 
36632508 36634181 -5.0187545 0.0068581 
36635020 36636700 3.92357996 0.00346738 
36635860 36637541 4.70853391 0.00589323 
36644310 36646011 -5.1397395 0.00534331 
36678230 36680011 -6.1696126 0.00065238 
36680012 36681798 -5.4258578 0.00152795 
36680905 36682693 -5.8357132 0.00152115 
36692611 36694428 8.50167259 2.29E-05 
36699911 36701747 5.08698912 0.00891689 
 
334 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
36700829 36702667 5.57415448 0.00397999 
36701748 36703588 5.27879921 0.00574901 
36708215 36710072 7.88117736 1.56E-05 
36711005 36712870 7.86184739 0.00085693 
36721336 36723230 9.67340601 1.30E-06 
36722283 36724180 7.52574543 0.00011951 
36737632 36739576 5.64719404 0.0033521 
36740553 36742506 8.81583236 1.11E-07 
36755374 36757378 5.10121704 0.00235956 
36760401 36762422 -6.4717096 0.0009367 
36761411 36763436 -6.7162771 6.46E-06 
36769564 36771619 6.72228717 0.00399923 
36785192 36787309 -5.2462769 0.00187615 
36793723 36795876 -6.4362647 0.00016942 
36803497 36805693 6.06936737 0.00025205 
36809012 36811232 9.17706758 4.08E-06 
36810122 36812348 8.86807383 5.75E-06 
36819097 36821364 -5.9229886 0.00024525 
36829396 36831713 -6.6250797 0.00085578 
36847072 36849476 3.19423968 0.00602858 
36853113 36855549 5.81392578 0.0073898 
36862945 36865433 -6.4243639 0.00175456 
36880669 36883253 -5.789861 0.00360003 
36915511 36918300 -5.4894569 0.00108972 
36938338 36941266 6.49251367 0.00022981 
36947191 36950174 6.6451659 0.00209437 
36951679 36954690 8.74416556 2.80E-07 
36957728 36960776 -4.267691 0.00693789 
36962314 36965390 5.81521445 0.00010327 
36963852 36966937 6.6754402 3.30E-05 
36973177 36976319 5.71456785 0.00410491 
 
335 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
36990714 36993959 -5.8539048 0.00393797 
36992337 36995591 -5.6809478 0.00545778 
37008816 37012162 -5.3731915 0.00642581 
37036116 37039601 -7.0225175 0.00051611 
37106625 37110350 -6.2762985 0.00160141 
37157395 37161183 5.53000647 0.00410395 
37187773 37191580 5.65172598 0.00093715 
37212576 37216405 4.03696126 0.0009367 
37245306 37249188 6.70840535 0.00035383 
37247247 37251133 6.7562262 0.00031408 
37376917 37381656 6.39608048 0.00034011 
37430352 37435904 -6.2005704 0.00083817 
37456313 37462375 -6.1134865 0.00932299 
37539859 37548012 -5.5442088 0.00334075 
37592907 37602638 6.7819362 0.0009367 
37634048 37645088 -4.2859502 0.00785999 
37674649 37687034 -5.2094426 0.00642581 
37865474 37884227 7.43317842 0.00011951 
38182100 38205843 6.36973826 0.00315036 
38426343 38451967 -6.075009 0.00175456 
38439155 38464954 -4.9213404 0.00473672 
38601369 38630247 -5.4469672 0.00837855 
38790145 38825524 -4.5339137 0.00832257 
38844384 38882175 -4.3926606 0.0076947 
39379992 39431602 -6.0661361 0.00202892 
39959632 40013021 7.35958173 0.00038437 
40383991 40437879 -5.9831322 0.00186227 
40521163 40578110 -6.1239067 0.00160141 
40549637 40607654 -7.4662199 3.51E-05 
41082235 41192923 5.30969732 0.00720145 
41960980 42110232 5.70041547 0.00511626 
 
336 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  End 
42327921 42467118 -5.3236343 0.0072539 
44313418 44387118 7.77763181 3.70E-06 
44588018 44672916 -4.6105679 0.00815263 
45203237 45280637 5.66002205 0.00410491 
 
Appendix XIV Table 2: Differential near-bait interactions in STAG2 72 h PMA cells compared to STAG2 
12 h DMSO K562 cells 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  
Start  End 
35436685 35448601 -6.0857456 0.00059104 
35442448 35454754 -6.2731354 0.00225731 
35448407 35461102 -5.3307194 0.00758347 
35460911 35474374 -5.4099975 0.00396781 
35474191 35488395 -6.6574472 0.00021416 
35481117 35495673 -6.5801675 0.00070013 
35488228 35503117 -7.5036046 0.00015947 
35510591 35526316 -5.794641 0.00682029 
35758987 35768060 -5.2165839 0.00436163 
35820274 35829140 3.92392103 0.00762037 
35903813 35913177 -5.522952 0.00277216  
35917872 35926974 -5.7170437 0.00574955 
35922480 35931468 -6.113011 0.00110525 
36018477 36023451 -5.7857828 0.00392621 
36021017 36025886 -6.7927842 0.00064853 
36039518 36043657 -6.1093502 0.00451839 
36053474 36057119 5.74975949 0.00063965 
36067476 36070695 8.09423417 3.10E-05 
36073869 36076922 5.75049924 0.00332039 
36078448 36081394 6.09584481 0.00765344 
36097958 36100545 -5.8280405 0.00249966 
 
337 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  
Start  End 
36106893 36109371 8.88047564 6.43E-07 
36108138 36110604 8.41167605 7.90E-06 
36111836 36114270 5.79605247 0.0008147 
36113058 36115482 4.50555696 0.00858253 
36114274 36116689 5.70466809 0.00362316 
36117896 36120289 4.91532515 0.00054761 
36119096 36121482 5.09296712 0.0005213 
36120292 36122672 8.16806929 9.78E-08 
36121485 36123860 3.52660994 0.00623036 
36123862 36126228 6.83826906 0.00081453 
36125047 36127409 7.17074017 0.00050799 
36157963 36160322 4.70290259 0.00407907 
36178044 36180403 -6.5938745 0.00186164 
36182762 36185114 5.77498867 0.00250278 
36183939 36186289 3.78948919 0.0093649 
36209319 36211537 6.65970543 0.00332039 
36212646 36214832 5.17999525 0.00343304 
36213745 36215920 4.60367943 0.00623036 
36215926 36218078 -6.2287521 0.00162394 
36243806 36245595 6.03604449 0.00077209 
36253381 36255044 6.4051837 4.04E-05 
36255049 36256690 5.40118095 5.45E-05 
36255874 36257506 6.13577976 4.78E-06 
36257511 36259122 -6.071433 0.0005773 
36261516 36263082 -5.5745924 0.00440467 
36266175 36267691 -5.693073 0.00186164 
36266936 36268445 -5.8929383 0.00092378 
36269199 36270685 -4.7459043 0.00396781 
36271428 36272893 7.39629365 1.32E-05 
36278644 36280049 8.47626445 2.67E-07 
36279349 36280749 5.88273561 0.00229365 
 
338 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  
Start  End 
36280751 36282141 9.32271791 9.28E-11 
36281449 36282833 9.35755075 5.57E-11 
36282143 36283523 6.57986117 0.00012543 
36282836 36284211 6.59308126 7.17E-05 
36288291 36289632 8.41409446 2.34E-07 
36290969 36292295 4.93437188 0.00015032 
36293617 36294930 8.87598018 5.57E-11 
36294275 36295584 8.73704516 2.01E-08 
36296239 36297539 -4.9893355 0.00789699 
36296890 36298187 -4.8207939 0.00789699 
36314565 36315788 7.49896603 7.50E-08 
36316400 36317616 5.93787377 0.00130598 
36317009 36318223 7.64886122 5.92E-06 
36317617 36318829 8.6586326 7.12E-07 
36321841 36323037 2.85880135 0.00530882 
36322440 36323634 4.47423164 0.00624517 
36326010 36327189 6.48630118 0.00040072 
36331867 36333024 6.10489364 0.00279432 
36333602 36334752 5.22177302 0.00589405 
36335327 36336470 8.61424774 3.23E-07 
36335900 36337041 8.53667475 1.96E-10 
36337042 36338179 8.08807553 0.00012543 
36337611 36338746 5.3259128 0.00297428 
36339878 36341004 6.67090109 5.25E-06 
36340442 36341565 4.41760746 0.00624517 
36341005 36342126 5.29524101 0.00458437 
36341566 36342686 5.04193019 0.00472812 
36343803 36344915 6.01427329 0.00340964 
36346578 36347680 6.91611197 3.18E-07 
36347130 36348230 6.51125992 5.99E-06 
36348231 36349329 7.41012673 6.09E-07 
 
339 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  
Start  End 
36348781 36349876 7.07821381 8.52E-06 
36353148 36354232 8.71656398 3.22E-10 
36353690 36354773 6.2181543 0.00160582 
36357470 36358544 7.66678156 1.93E-08 
36358008 36359081 -5.798246 0.00022941 
36359081 36360153 5.45257467 2.37E-05 
36361223 36362291 5.91568037 0.00057599 
36361757 36362824 5.96298918 0.00024763 
36368674 36369735 6.1916237 2.00E-05 
36369205 36370266 7.16297674 2.76E-05 
36370796 36371857 7.9559838 4.25E-08 
36371327 36372388 7.95799941 3.91E-08 
36372388 36373449 -5.0616276 0.00231887 
36375572 36376634 7.39662037 4.22E-08 
36376103 36377166 7.9155326 4.23E-10 
36376634 36377698 7.20737095 3.50E-07 
36377166 36378230 6.00247042 9.26E-05 
36381430 36382501 6.25125031 0.00167117 
36383036 36384111 7.58060482 7.62E-09 
36383573 36384648 8.19239228 9.17E-11 
36384110 36385187 7.27158077 1.01E-07 
36388977 36390069 8.04050851 4.58E-08 
36389522 36390615 8.18851773 9.50E-09 
36402372 36403521 -3.3526677 0.00615 
36402947 36404099 -6.4052802 5.56E-05 
36404680 36405841 7.07708111 6.41E-07 
36405261 36406426 7.67635857 1.65E-08 
36407013 36408189 -6.0414894 0.00012123 
36409375 36410564 8.16295853 2.63E-07 
36409969 36411162 8.58969704 1.89E-08 
36412365 36413572 6.67171768 0.00045194 
 
340 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  
Start  End 
36412969 36414179 7.48261385 3.87E-05 
36414790 36416010 5.19805826 0.00169526 
36416012 36417240 6.47370689 4.25E-05 
36416626 36417857 8.32922355 1.96E-10 
36417242 36418476 8.93449959 3.22E-10 
36417859 36419097 8.70673298 4.23E-10 
36425395 36426671 6.48656042 0.0001889 
36426033 36427312 3.57574031 0.00163044 
36426673 36427955 5.26153509 7.12E-07 
36427314 36428599 5.10900159 0.00187829 
36427956 36429244 7.04581518 1.63E-06 
36428600 36429891 7.15848213 1.01E-07 
36429892 36431189 -5.9821829 0.00141003 
36438413 36439740 5.99517147 0.00297428 
36439076 36440405 6.23445205 0.00130598 
36446428 36447774 -5.7569719 0.00197578 
36447101 36448448 4.89204718 1.31E-05 
36447775 36449123 8.79337306 7.24E-10 
36455222 36456582 5.4545644 0.00504532 
36460677 36462045 -7.0332119 0.0002511 
36469616 36471000 6.74924793 1.63E-06 
36470308 36471694 7.98815314 2.01E-08 
36471001 36472388 8.00746203 7.12E-07 
36474478 36475874 9.60736861 1.17E-13 
36475176 36476573 5.68780928 0.0007157 
36481504 36482922 -5.8163104 0.00162394 
36484347 36485775 8.59528198 1.52E-10 
36485061 36486492 3.8841857 0.00132208 
36493739 36495204 -6.1089012 0.00074837 
36507148 36508663 5.26009344 0.00630545 
36507905 36509423 7.34675317 4.36E-05 
 
341 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  
Start  End 
36513242 36514775 -5.3173362 0.00395153 
36516314 36517855 -5.5017113 0.00467387 
36520951 36522503 -5.0549633 0.00674828 
36525620 36527182 -5.9381324 0.00050799 
36529533 36531103 -5.2801418 0.00162394 
36537423 36539010 -5.510789 0.00049537 
36538217 36539806 -5.2311225 0.00605158 
36547820 36549434 6.90041921 2.56E-05 
36548627 36550243 8.56415831 3.08E-09 
36549435 36551053 8.4001037 3.10E-05 
36551865 36553489 4.07906958 0.00112378 
36564157 36565814 -5.3641166 0.00220175 
36564985 36566644 -5.5645765 0.00050915 
36566645 36568309 8.87079792 3.00E-06 
36567477 36569143 8.44738811 3.57E-06 
36571653 36573330 -5.0946442 0.00277375 
36575015 36576703 2.89255552 0.00485284 
36575859 36577549 9.23549274 3.18E-11 
36576704 36578397 3.36271086 0.00769729 
36580949 36582655 3.66835445 0.00352294 
36581802 36583511 4.64640089 0.00160582 
36598256 36600012 4.60675253 0.00126352 
36599134 36600892 9.27003353 3.57E-05 
36609742 36611522 -5.0781173 0.00030496 
36612414 36614199 -6.4072496 0.00079017 
36613306 36615093 9.02751731 5.57E-11 
36615989 36617781 -5.1702582 0.00498024 
36617782 36619578 5.98150753 0.00140614 
36624993 36626806 4.22364429 0.00234029 
36628625 36630448 -7.2845038 0.00034806 
36629536 36631361 -7.3250371 0.00023556 
 
342 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  
Start  End 
36631362 36633192 -5.386783 0.00028369 
36632277 36634110 -5.2554689 0.00229365 
36635950 36637793 3.72955132 0.00432525 
36644289 36646155 -5.4874679 0.00201106 
36645222 36647089 -5.7016239 0.00455515 
36663073 36664956 -6.1681355 0.00220175 
36678070 36679930 -5.9626629 0.00093922 
36679928 36681783 -6.3506823 6.52E-05 
36680855 36682707 -6.4303147 0.0002511 
36681781 36683630 -5.8688247 0.00575549 
36692776 36694589 7.82142793 5.81E-05 
36693683 36695492 -4.2375019 0.0092254 
36700879 36702664 4.90280398 0.00861558 
36710630 36712389 7.35556765 0.00067607 
36711509 36713267 7.26403527 0.00171581 
36721128 36722869 9.0055117 2.52E-06 
36734160 36735898 -4.5910204 0.00809055 
36749016 36750781 -6.8938244 5.59E-05 
36755229 36757019 4.44296764 0.00348182 
36756124 36757918 8.00306112 1.79E-05 
36760629 36762445 -6.8698039 0.00022941 
36761537 36763358 -7.1788108 2.34E-07 
36764276 36766112 5.80709303 0.00407907 
36769828 36771700 6.11400191 0.00186684 
36770764 36772642 5.66022215 0.00272098 
36774541 36776448 4.68783611 0.00156114 
36785244 36787241 -5.7724043 0.00021416 
36793363 36795435 -6.8419092 3.79E-06 
36794399 36796481 -6.1091525 0.00200109 
36801784 36803931 5.77163822 0.00433589 
36803935 36806100 5.34462276 0.00182957 
 
343 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  
Start  End 
36809388 36811594 8.14513954 6.21E-05 
36810491 36812704 4.52197815 0.00407907 
36811597 36813817 -4.3276266 0.00634438 
36829685 36831979 -7.1834139 5.23E-05 
36838884 36841188 -5.5325229 0.00652333 
36845802 36848109 10.2038466 5.57E-11 
36846955 36849263 2.65570785 0.00758347 
36863120 36865432 -6.7298954 0.00057648 
36867743 36870055 5.59197015 0.00506037 
36876991 36879304 -6.1757115 0.00017592 
36880462 36882777 -6.1215596 0.00056329 
36902651 36905026 -6.0752014 0.00498024 
36912244 36914677 -6.6823463 0.00103827 
36915906 36918366 -5.6577655 0.00187829 
36947079 36949855 5.96104556 0.00452362 
36948467 36951259 6.78019674 0.0004733 
36958414 36961325 -5.2806253 0.00051959 
36962808 36965773 5.01921642 0.00058573 
36964290 36967274 5.59505943 0.00045611 
36973386 36976488 7.34270572 6.52E-05 
36991078 36994449 -6.363725 0.00112452 
36992763 36996164 -5.6514451 0.0034993 
37008653 37012362 -5.7851037 0.0020801 
37043150 37047640 -6.4945969 0.00013199 
37045395 37049936 -4.1547449 0.00943078 
37097715 37103034 -4.5778842 0.00451839 
37105704 37111038 -4.6751958 0.00650289 
37134665 37139771 6.31946179 0.00049537 
37187383 37191422 4.83341234 0.00257763 
37212613 37216380 3.51274477 0.00163945 
37229550 37233329 6.17766054 0.00200687 
 
344 
Chromosome location (Chr21) log2FoldChange Adjusted p value 
Start  
Start  End 
37246671 37250505 6.06968467 0.00092378 
37256273 37260121 -6.2127862 0.00179831 
37360992 37364988 4.59646079 0.00856585 
37376844 37380751 5.86772378 0.00112378 
37380743 37384617 -5.7182386 0.00630545 
 
